

[illegible]

Db 1141 TTAATGTTTATTATTGTAAGACATTAATTATTAAGAAATGGTTATTATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGGTAATCTTAAGAAATTTGAGGTACTACAGATTTTCAAACT 1260
Db 1201 TTTCTAATCTGCTGTAAGGTAATCTTAAGAAATTTGAGGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATATACCACTCTGCTGTTCTTTAGTGAATAACAATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATATACCACTCTGCTGTTCTTTAGTGAATAACAATAAACTCT 1320
QY 1321 GAATTAAGACTC 1333
Db 1321 GAATTAAGACTC 1333

RESULT 184
US-10-020-445A-321
; Sequence 321, Application US/10020445A
; Publication No. US20030198994A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C74
; CURRENT APPLICATION NUMBER: US/10/020.445A
; CURRENT FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078004
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078936
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079689
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079920
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/079923
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: 60/080105
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080107
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080194
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080327
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080328
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080333
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080334
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/081070
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081049
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081071
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081195
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081952
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081838
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082568
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/062569
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/062704
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/062804
; PRIOR FILING DATE: 1998-04-22

```

; PRIOR APPLICATION NUMBER: 60/082700
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082797
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/082796
; PRIOR FILING DATE: 1998-04-23
; PRIOR APPLICATION NUMBER: 60/083336
; PRIOR FILING DATE: 1998-04-27
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/083392
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083495
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083496
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083499
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083545
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083554
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083558
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083559
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083500
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/083742
; PRIOR FILING DATE: 1998-04-30
; PRIOR APPLICATION NUMBER: 60/084366
; PRIOR FILING DATE: 1998-05-05
; PRIOR APPLICATION NUMBER: 60/084414
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084639
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084640
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084598
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084643
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085582
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085700
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085689
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085580
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085573
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697
; PRIOR APPLICATION NUMBER: 60/085697

Query Match 100.0%; Score 1333; DB 15; Length 1333;

Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCACGGTCCGATGGGGTTCAGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCACGGTCCGATGGGGTTCAGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTTCGCCCATTTGGCCACATTTAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTTCGCCCATTTGGCCACATTTAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACCAAGTGAATACCCCTGTAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAGAAATCCTATAGACCAAGTGAATACCCCTGTAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCACGCTTCTTCTGTCATGTTTCTTTGTGACAGAGTGGCTTACACTGG 240
DB 181 CCTCATCCACGCTTCTTCTGTCATGTTTCTTTGTGACAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
DB 241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
QY 301 TGGCCCGAGGACTCTATGACCCCTACCAACCATCATGATGACATATTTAGCATATTTGTA 360
DB 301 TGGCCCGAGGACTCTATGACCCCTACCAACCATCATGATGACATATTTAGCATATTTGTA 360
QY 361 GAAGGAGGATGGTGCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAGGATGGTGCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAAACAAACACAGAGAAATTTGGTCCAGTAAAT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAAACAAACACAGAGAAATTTGGTCCAGTAAAT 480
QY 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGTCCCTGCAAGAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGTCCCTGCAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTCTTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTCTTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTAAATGGTAT 660
DB 601 TTTTGTCTTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTAAATGGTAT 660
QY 661 TACGTATAAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTTGACATTC 720
DB 661 TACGTATAAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTTGACATTC 720
QY 721 TTAAGGAAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGAACTTCTAGGCTCATTTTGGTTTCTTCTTCTTCTTCTTCTTCTTCT 840
DB 781 GAAGCTTTTGTATAGAACTTCTAGGCTCATTTTGGTTTCTTCTTCTTCTTCTTCTTCTTCT 840
QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
DB 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
QY 901 TGGGAAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATATATATATATATATATATAT 960
DB 901 TGGGAAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATATATATATATATATATATATAT 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTGGCTTGAATATATATCCCTGATATATATATATATATAT 1020
DB 961 AAAAATAAAGCGGGAATTTTCCCTTGGCTTGAATATATATATATATATATATATATATATAT 1020
QY 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAAATAATATCTTGTAAATTTCTTAAGGATA 1080
DB 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAAATAATATCTTGTAAATTTCTTAAGGATA 1080
```

Db	1021	GAGAGATTTCCCATATTTCCATACGAGTAATAATATACCTGCTTTAAATCTTTAAGCATAT	1080
Qy	1081	AGTAAACATGATATAAAAAATATATGCTGAATTACTTGTGAAGAATGCATTTAAAGCTATT	1140
Db	1081	AGTAAACATGATATAAAAAATATATGCTGAATTACTTGTGAAGAATGCATTTAAAGCTATT	1140
Qy	1141	TTAAATCTGTTTTTATTTGTGAAGACATTACTTTATTAAGAAATTTGGTTATTATGCTTACTG	1200
Db	1141	TTAAATCTGTTTTTATTTGTGAAGACATTACTTTATTAAGAAATTTGGTTATTATGCTTACTG	1200
Qy	1201	TTCTAAATCTGGTGTAAAGGTATTCTTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT	1260
Db	1201	TTCTAAATCTGGTGTAAAGGTATTCTTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT	1260
Qy	1261	GAATGAGAGAAATGATATACCATCTCTGTTGCTTTAGTTCGATACAAATAAACTCT	1320
Db	1261	GAATGAGAGAAATGATATACCATCTCTGTTGCTTTAGTTCGATACAAATAAACTCT	1320
Qy	1321	GAATTAAGACTC	1333
Db	1321	GAATTAAGACTC	1333

RESULT 185

US-10-013-924A-321

/ Sequence 321, Application US/10013924A

/ Publication No. US20030199021A1

/ GENERAL INFORMATION:

/ APPLICANT: Ashkenazi, Avi

/ APPLICANT: Baker Kevin P.

/ APPLICANT: Botstein, David

/ APPLICANT: Desnoyers, Luc

/ APPLICANT: Eaton, Dan

/ APPLICANT: Ferrara, Napoleon

/ APPLICANT: Filvaroff, Ellen

/ APPLICANT: Fong, Sherman

/ APPLICANT: Gao, Wei-Qiang

/ APPLICANT: Gerber, Hanspeter

/ APPLICANT: Gerritsen, Mary E.

/ APPLICANT: Goddard, Audrey

/ APPLICANT: Godowski, Paul J.

/ APPLICANT: Grimaldi, J. Christopher

/ APPLICANT: Hurney, Austin L.

/ APPLICANT: Hillan, Kenneth J.

/ APPLICANT: Kljavin, Ivar J.

/ APPLICANT: Kuo, Sophia S.

/ APPLICANT: Napier, Mary A.

/ APPLICANT: Pan, James;

/ APPLICANT: Paoni, Nicholas F.

/ APPLICANT: Roy, Margaret Ann

/ APPLICANT: Shelton, David L.

/ APPLICANT: Stewart, Timothy A.

/ APPLICANT: Tumas, Daniel

/ APPLICANT: Williams, P. Mickey

/ APPLICANT: Wood, William I.

/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

/ TITLE OF INVENTION: Acids Encoding the Same

/ FILE REFERENCE: P2630P1C76

/ CURRENT APPLICATION NUMBER: US/10/013,924A

/ CURRENT FILING DATE: 2002-12-10

/ PRIOR APPLICATION NUMBER: 09/918595

/ PRIOR FILING DATE: 2001-07-30

/ PRIOR APPLICATION NUMBER: 60/062250

/ PRIOR FILING DATE: 1997-10-17

/ PRIOR APPLICATION NUMBER: 60/064249

/ PRIOR FILING DATE: 1997-11-03

/ PRIOR APPLICATION NUMBER: 60/065311

/ PRIOR FILING DATE: 1997-11-13

/ PRIOR APPLICATION NUMBER: 60/066364

/ PRIOR FILING DATE: 1997-11-21

/ PRIOR APPLICATION NUMBER: 60/077450

/ PRIOR FILING DATE: 1998-03-10

/ PRIOR APPLICATION NUMBER: 60/077632

Db 781 GAAGCTTTTGTATAGGAACTTTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
QY 841 TTATATAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTAAAAATGTATATCTGACTAG 900
Db 841 TTATATAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTAAAAATGTATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGTTTCCCTCATCTGTCATGTCGATGATATATATGGATACATTTTAC 960
Db 901 TGGGAAACCTTCATGGTTTCCCTCATCTGTCATGTCGATGATATATATGGATACATTTTAC 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCAATGAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCAATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAAATATATCTTCTTTAATTTCTTAAGCATTA 1080
Db 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAAATATATCTTCTTTAATTTCTTAAGCATTA 1080
QY 1081 AGTAAACATGATATAAATAATATATCTGTAATTTACTTTGTGAAGAAATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATCTGTAATTTACTTTGTGAAGAAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTTTTTATTTTGTAAAGCAATTAATTAATAAGAAATGGTTATATCTTACTG 1200
Db 1141 TTAATATGTTTTTATTTTGTAAAGCAATTAATTAATAAGAAATGGTTATATCTTACTG 1200
QY 1201 TTCTAATCTGGTGTAAAGGTAATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGGTGTAAAGGTAATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGTAAACCATCTCTGCTTCTTTAGTGCATTAACAATAAATACTCT 1320
Db 1261 GAATGAGAGAAATTTGTAAACCATCTCTGCTTCTTTAGTGCATTAACAATAAATACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 186

US-10-017-084A-321
; Sequence 321, Application US/10017084A
; Publication No. US20030203402A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; Acids Encoding the Same

; FILE REFERENCE: P2630P1C66
; CURRENT APPLICATION NUMBER: US/10/017,084A
; CURRENT FILING DATE: 2002-04-30
; Prior application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-084A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCACGCGTCCGATGGCGTTCAAGTTCGCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCACGCGTCCGATGGCGTTCAAGTTCGCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGTCTATCTTCTTTCGCAATTTGGCAATATATAGCATTTGATAGCTGAAGAC 120
Db 61 CACTGCCGCGTCTATCTTCTTTCGCAATTTGGCAATATATAGCATTTGATAGCTGAAGAC 120
QY 121 TGATTAAGAAGTCTCTATAGACAGTGTAAATACCTGTAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTAAGAAGTCTCTATAGACAGTGTAAATACCTGTAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGAATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGAATGAG 300
QY 301 TGGCCGAGGACTCTATGACCCCTACAACTCATCATGATGACATATTTCTAGCATATTTGCA 360
Db 301 TGGCCGAGGACTCTATGACCCCTACAACTCATCATGATGACATATTTCTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTGCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGGTGCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACAAACACAGAAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGTGAGCTCTTAGAACAAACACAGAAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGAGTCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGAGTCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTTAT 660
QY 661 TACGTATAAATTAATAAATAATGATTAATCTGCTGTTGTGACAGGTTTGAATCTGCATTC 720
Db 661 TACGTATAAATTAATAAATAATGATTAATCTGCTGTTGTGACAGGTTTGAATCTGCATTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATCTGCTCTAGTACATTG 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATCTGCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGAACTCTGAGGCTCAATTTGGTTTCAATGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGAACTCTGAGGCTCAATTTGGTTTCAATGAAACAGTATCTAA 840
QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATCTGACTAG 900
Db 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATCTGACTAG 900

Db 841 TTATAAATTAGCTGTAGATATACAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
QY TGGGAACCTTCATGGTTTCCTCATCTGTCTGATGATATATATGATATATGATATATAC 960
Db TGGGAACCTTCATGGTTTCCTCATCTGTCTGATGATATATATGATATATGATATATAC 960
QY AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATGATATAT 1020
Db AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATGATATAT 1020
QY 1021 GAGAGATTTCCATATTTCCATGAGAGTAATAATATATCTGCTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATGAGAGTAATAATATATCTGCTTAAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATCTGCTTAAATTTCTTAAGCATA 1140
Db 1081 AGTAAACATGATATAAATAATATATCTGCTTAAATTTCTTAAGCATA 1140
QY 1141 TTAATGCTGTTTATTTTGAAGCATTTACTTAAAGAAATTTGTTTATATGCTTACTG 1200
Db 1141 TTAATGCTGTTTATTTTGAAGCATTTACTTAAAGAAATTTGTTTATATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGTATATACCTCTGCTGTTTCTTTAGTGCAATATATATATCTCT 1320
Db 1261 GAATGAGAGAAATTTGTATATACCTCTGCTGTTTCTTTAGTGCAATATATATATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 187

US-10-017-085A-321
; Sequence 321, Application US/10017085A
; Publication No. US20030204055A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C73
; CURRENT APPLICATION NUMBER: US/10/017, 085A
; CURRENT FILING DATE: 2002-04-30
; Prior Application removed - File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-085A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCACCGCTCCGATGCGGTTTCAGTTGCGGCGCTTCTGCTACATGCTGCGGCTGCTGCT 60
Db 1 GCCCACCGCTCCGATGCGGTTTCAGTTGCGGCGCTTCTGCTACATGCTGCGGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTGGCCATTGCGCAATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTTGGCCATTGCGCAATATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTAACAAGATCCTATAGACCAAGTGTAAATACCTCGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTAACAAGATCCTATAGACCAAGTGTAAATACCTCGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTGTGCGAGCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTGTGCGAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGGATGATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGGATGATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCGAGATTTAGCATATTTGCA 360
Db 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCGAGATTTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGTTGCAAAATTAGCTTTTATCTTCTAGCATTTTTTACCTATATGG 420
Db 361 GAAGGAAGGATGTTGCAAAATTAGCTTTTATCTTCTAGCATTTTTTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACACACACAGAGAAATTTGCTCAAGTAA 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACACACACAGAGAAATTTGCTCAAGTAA 480
QY 481 GCATGCAAAAAGCCACCAATGAAAGGATTTCTTCCAGCAAGATCCCTGTCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAATGAAAGGATTTCTTCCAGCAAGATCCCTGTCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATATAAGATTTTAAATGTTAT 660
Db 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATATAAGATTTTAAATGTTAT 660
QY 661 TAGGTATTAATTAATATAAATGATTTACCTCTGCTGTTGAGCAGGTTGAACTTGCACTTC 720
Db 661 TAGGTATTAATTAATATAAATGATTTACCTCTGCTGTTGAGCAGGTTGAACTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTA 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTA 780
QY 781 GAAGCTTTTGTATTAAGAACTTTGAGGCTCATTTTGGTTCATTTGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATTAAGAACTTTGAGGCTCATTTTGGTTCATTTGAAACAGTATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGCTCTTCTGATGAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGCTCTTCTGATGAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGTTTCCTCATCTGTCTGATGAAGTGAATGATATATCTGACTAG 960

Db 901 TGGGAAACTTCATGGGTTTCTCATCTGTGATGATGATATATATGATGATATATAC 960
QY 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATCCATGAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATCCATGAAT 1020
QY 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAAATATATATCTTGAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAAATATATATCTTGAATTTCTTAAGCATA 1080
QY 1081 AGTAACATGATATAAATAATATATATGCTGAATTTACTTTGTAAGAAATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAATAATATATGCTGAATTTACTTTGTAAGAAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTTTATTTATTTGAAGACATTTACTTATTAAGAAATGGTTATTTATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTATTTGAAGACATTTACTTATTAAGAAATGGTTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGTTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGTTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAAATTTGTAACCATCTGCTGTTCTTTAGTCAATACAAATAAACTCT 1320
Db 1261 GAATGAGAAATTTGTAACCATCTGCTGTTCTTTAGTCAATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 188

US-10-013-916A-321
; Sequence 321, Application US/10013916A
; Publication No. US20030206915A1

GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630PIC79
; CURRENT APPLICATION NUMBER: US/10/013,916A
; CURRENT FILING DATE: 2002-04-30
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-013-916A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCGTTACGTTTCGCGGCTTCTCTACATGCTCGCGCTGCTGCT 60
Db 1 GCCACGCGTCCGATGGCGTTACGTTTCGCGGCTTCTCTACATGCTCGCGCTGCTGCT 60
QY 61 CACTCGCGCGCTCANTCTTCTTCCCATTTGGCACATTTAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTCGCGCGCTCANTCTTCTTCCCATTTGGCACATTTAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGATCCCTATAGACAGTGAATCCCTTGAATCCCTTGTACTCCCAAGTA 180
Db 121 TGATTACAAGATCCCTATAGACAGTGAATCCCTTGAATCCCTTGTACTCCCAAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCACTGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCACTGAG 300
QY 301 TGGCCCGAGACTCTATGACCCCTACCAACCATCATGAATGAGATATTTAGCATATTTG 360
Db 301 TGGCCCGAGACTCTATGACCCCTACCAACCATCATGAATGAGATATTTAGCATATTTG 360
QY 361 GAAGGAAGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAACAACAACAACAACAACA 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAACAACAACAACAACAACA 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTTTAAATAAGCACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTTTAAATAAGCACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGAAAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGAAAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGATATAATTAATATAAATGATTAATCTCTGTGTTGACAGGTTTGAACCTTCATTC 720
Db 661 TACGATATAATTAATATAAATGATTAATCTCTGTGTTGACAGGTTTGAACCTTCATTC 720
QY 721 TTAAGGAACAGCCATAATCCCTGATGATGATTAATTAATGATGATGATGATGATGAT 780
Db 721 TTAAGGAACAGCCATAATCCCTGATGATGATTAATTAATGATGATGATGATGATGAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTGTTTCAATTTTAAACAGATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTGTTTCAATTTTAAACAGATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGTGTCTTCTGATGAAGTGAATGATGATGATGATGAT 900
Db 841 TTATAAATAGCTGTAGATATCAGTGTCTTCTGATGAAGTGAATGATGATGATGATGAT 900
QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGTCATGATGATGATGATGATGATGAT 960
Db 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGTCATGATGATGATGATGATGATGAT 960
QY 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATCCATGAAT 1020

Db 961 AAAAAAAGCGGAATTTCCCTCGCTTGGAATATATATCCCTGTATATTCATGAAT 1020
 Qy 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTTGTCTTTAATCTTAAGCATA 1080
 Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTTGTCTTTAATCTTAAGCATA 1080
 Qy 1081 AGTAACATGATATAAATAATATCTGCTGAATATCTTGTGAAGAATGCAATTAAGCTATT 1140
 Db 1081 AGTAACATGATATAAATAATATCTGCTGAATATCTTGTGAAGAATGCAATTAAGCTATT 1140
 Qy 1141 TTAATGTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATGCTTATTAAGCTTACTG 1200
 Db 1141 TTAATGTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATGCTTATTAAGCTTACTG 1200
 Qy 1201 TTCTAATCTGCTGTAAGGTATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
 Db 1201 TTCTAATCTGCTGTAAGGTATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
 Qy 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGCTTCTTCTTGTAGTGAATACAAATAAACTCT 1320
 Db 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGCTTCTTCTTGTAGTGAATACAAATAAACTCT 1320
 Qy 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 189

US-10-143-026B-321
 ; Sequence 321, Application US/10143026B
 ; Publication No US20030207803A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Baker Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnovers, Luc
 ; APPLICANT: Eaton, Dan
 ; APPLICANT: Ferrara, Napoleon
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Kuo, Sophia S.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James;
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Shelton, David L.
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE OF INVENTION: Acids Encoding the Same
 ; FILE REFERENCE: P26301C58
 ; CURRENT APPLICATION NUMBER: US/10/143, 026B
 ; CURRENT FILING DATE: 2003-05-09
 ; PRIOR APPLICATION NUMBER: 09/918585
 ; PRIOR FILING DATE: 2001-07-30
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/064249
 ; PRIOR FILING DATE: 1997-11-03
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066364

; PRIOR FILING DATE: 1997-11-21
 ; PRIOR APPLICATION NUMBER: 60/077450
 ; PRIOR FILING DATE: 1998-03-10
 ; PRIOR APPLICATION NUMBER: 60/077632
 ; PRIOR FILING DATE: 1998-03-11
 ; PRIOR APPLICATION NUMBER: 60/077641
 ; PRIOR FILING DATE: 1998-03-11
 ; PRIOR APPLICATION NUMBER: 60/077649
 ; PRIOR FILING DATE: 1998-03-11
 ; PRIOR APPLICATION NUMBER: 60/077791
 ; PRIOR FILING DATE: 1998-03-12
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 624
 ; SEQ ID NO 321
 ; LENGTH: 1333
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-10-143-026B-321
 Query Match 100.0%; Score 1333; DB 16; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 1.8e-303;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GCCCAGCGCTCCGATGGCGTTACGTTGCGGGCTTCTGCTACATGCTGCGCTGCTGCT 60
 Db 1 GCCCAGCGCTCCGATGGCGTTACGTTGCGGGCTTCTGCTACATGCTGCGCTGCTGCT 60
 Qy 61 CACTGGCGCTCATCTTCTTCCCATTTGGCCATTTATAGCATTTGATGAGCTGAAGAC 120
 Db 61 CACTGGCGCTCATCTTCTTCCCATTTGGCCATTTATAGCATTTGATGAGCTGAAGAC 120
 Qy 121 TGATTACAAGATCCCTATAGACCAGTGTATACCCGTAATCCCTGTTACTTCCAGAGTA 180
 Db 121 TGATTACAAGATCCCTATAGACCAGTGTATACCCGTAATCCCTGTTACTTCCAGAGTA 180
 Qy 181 CCTCATCCAGCGTTTCTTCTGCTCATGTTTCTTGTGACAGAGAGTGGCTTACACTGGG 240
 Db 181 CCTCATCCAGCGTTTCTTCTGCTCATGTTTCTTGTGACAGAGAGTGGCTTACACTGGG 240
 Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACAGGTATGAG 300
 Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACAGGTATGAG 300
 Qy 301 TGGCCAGGACTCTATGACCCCTACCAACCATCATGAATGACAGATATTTCTAGCATATTGTCA 360
 Db 301 TGGCCAGGACTCTATGACCCCTACCAACCATCATGAATGACAGATATTTCTAGCATATTGTCA 360
 Qy 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGG 420
 Db 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGG 420
 Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
 Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
 Qy 481 GCATGCAAAAAGCCCAAAATGAAGGATTTATCCAGCAAGATCTCTGCTCCAGAGTAGC 540
 Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTATCCAGCAAGATCTCTGCTCCAGAGTAGC 540
 Qy 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTTTTAAATGTTTCCACAT 600
 Qy 601 TTTTGTCTTGTGAAGACGTTTCTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
 Db 601 TTTTGTCTTGTGAAGACGTTTCTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
 Qy 661 TAGGTATAAATTAATAAATGATTACCTCTGGTGTGTCACAGGTTTGAACCTTGCACTTC 720
 Db 661 TAGGTATAAATTAATAAATGATTACCTCTGGTGTGTCACAGGTTTGAACCTTGCACTTC 720
 Qy 721 TTAAGGAACAGCAATATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
 Db 721 TTAAGGAACAGCAATATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780

;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600

;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCAGCGTCCGATGGGTTTCAGTTTCGGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAGCGTCCGATGGGTTTCAGTTTCGGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

Qy 61 CACTGCGCGCTCATCTTCTTCGCCATTTCGCACATTATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCGCCATTTCGCACATTATAGCATTTGATGAGCTGAAGAC 120

Qy 121 TGATTACAAGAAATCCTATAGACACAGTGTAAATACCCCTTGTAATCCCTCCAGAGTA 180
Db 121 TGATTACAAGAAATCCTATAGACACAGTGTAAATACCCCTTGTAATCCCTCCAGAGTA 180

Qy 181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTCAGCAGAGTGCTTACCTGGG 240
Db 181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTCAGCAGAGTGCTTACCTGGG 240

Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGTACAGTGTAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGTACAGTGTAG 300

Qy 301 TGGCCAGGACTCTATGACCCCTACAACCATCATGAATGCAGATATTTAGCATATTGTCA 360
Db 301 TGGCCAGGACTCTATGACCCCTACAACCATCATGAATGCAGATATTTAGCATATTGTCA 360

Qy 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420

Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAAACACACAGAAATGGTCCAGTAAAT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAAACACACAGAAATGGTCCAGTAAAT 480

Qy 481 GCATGCAAAAAGCCCAAAATGAAGGATTCATTCAGCAAGATTCCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTCATTCAGCAAGATTCCTGTCCAGAGTAGC 540

Qy 541 CTGTGGAAATCTGATCAGTACTTTTAAATAAGTCTCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAAATCTGATCAGTACTTTTAAATAAGTCTCTCTTATTTTAAATGTTTCCACAT 600

Qy 601 TTTTGTGTGGAAAGACTGTTTTCATATGTTTATCTACATGAAGATTTTAAATGTTAT 660
Db 601 TTTTGTGTGTGGAAAGACTGTTTTCATATGTTTATCTACATGAAGATTTTAAATGTTAT

361	Db	GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCAATTTTTTTTACTACTATATGG	420
421	QY	CATGATCTATCTTTTGGTGCAGCTCTTAGAAACAACACAGAGAAGAAATCGTCAGTTAAGT	480
421	Db	CATGATCTATCTTTTGGTGCAGCTCTTAGAAACAACACAGAGAAGAAATCGTCAGTTAAGT	480
481	QY	GCATGCAAAAAGCCACCAAAATGAAGGGATCTATCCAGCAAGATCCTGCCAAGAGTAGC	540
481	Db	GCATGCAAAAAGCCACCAAAATGAAGGGATCTATCCAGCAAGATCCTGCCAAGAGTAGC	540
541	QY	CTGTGGAACTCGATCAGTTACTTTAAAAAAAGACTCTTATTTTAAATGTTTCCACAT	600
541	Db	CTGTGGAACTCGATCAGTTACTTTAAAAAAAGACTCTTATTTTAAATGTTTCCACAT	600
601	QY	TTTTTGCTTGTGAAAAGACTGTTTTCAVATGTTATATCTCAGATAAAGATTTTTAAATGGPAT	660
601	Db	TTTTTGCTTGTGAAAAGACTGTTTTCAVATGTTATATCTCAGATAAAGATTTTTAAATGGPAT	660
661	QY	TACGTATAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACATTC	720
661	Db	TACGTATAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACATTC	720
721	QY	TTAAGGAACAGCCATAATCCTCTCAATGATGCATAAATTAATGCTGACTGTCCTAGTACATTG	780
721	Db	TTAAGGAACAGCCATAATCCTCTCAATGATGCATAAATTAATGCTGACTGTCCTAGTACATTG	780
781	QY	GAAGCTTTTGTTTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA	840
781	Db	GAAGCTTTTGTTTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA	840
841	QY	TTATAAATTAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAATGATATCTGCAGTAG	900
841	Db	TTATAAATTAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAATGATATCTGCAGTAG	900
901	QY	TGGGAAACTTCATGGGGTTTCCTCATCTGTCATGTCGATGATATATATATGGATACATTAC	960
901	Db	TGGGAAACTTCATGGGGTTTCCTCATCTGTCATGTCGATGATATATATATGGATACATTAC	960
961	QY	AAAAATAAAAGCGGGAAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT	1020
961	Db	AAAAATAAAAGCGGGAAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT	1020
1021	QY	GAGAGATTTCCCATATTTCCATCAGAGTAATAATATACCTTGCTTTAAATTTCTTAAAGCAT	1080
1021	Db	GAGAGATTTCCCATATTTCCATCAGAGTAATAATATACCTTGCTTTAAATTTCTTAAAGCAT	1080
1081	QY	AGTAAACATGATATAAAAATATATGCTGAAATTAATCTGTGAAGAAATGCATTTAAAGCTATT	1140
1081	Db	AGTAAACATGATATAAAAATATATGCTGAAATTAATCTGTGAAGAAATGCATTTAAAGCTATT	1140
1141	QY	TTAAATGTGTTTTTATTTGTAAGACATTAATTTTAAAGAAATTTGGTTTATTTGCTTACTG	1200
1141	Db	TTAAATGTGTTTTTATTTGTAAGACATTAATTTTAAAGAAATTTGGTTTATTTGCTTACTG	1200
1201	QY	TTCTAATCTGGTGAAGGTATTTCTTAAAGAAATTTGCAGGTACTATACAGATTTTCAAAACT	1260
1201	Db	TTCTAATCTGGTGAAGGTATTTCTTAAAGAAATTTGCAGGTACTATACAGATTTTCAAAACT	1260
1261	QY	GAATGAGAAAAATTGTATTAACCATCCTGCTGTTTCTTTTAGTGCATATACAAATAAACTCT	1320
1261	Db	GAATGAGAAAAATTGTATTAACCATCCTGCTGTTTCTTTTAGTGCATATACAAATAAACTCT	1320
1321	QY	GAATTTAAGACTC	1333
1321	Db	GAATTTAAGACTC	1333

```

1  ; APPLICANT: Baker Kevin P.
2  ; APPLICANT: Botstein, David
3  ; APPLICANT: Desnoyers, Luc
4  ; APPLICANT: Eaton, Dan
5  ; APPLICANT: Ferrara, Napoleon
6  ; APPLICANT: Filvaroff, Ellen
7  ; APPLICANT: Fong, Sherman
8  ; APPLICANT: Gao, Wei-Qiang
9  ; APPLICANT: Gerber, Hanspeter
10 ; APPLICANT: Gerritsen, Mary E.
11 ; APPLICANT: Goddard, Audrey
12 ; APPLICANT: Godowski, Paul J.
13 ; APPLICANT: Grimaldi, J. Christopher
14 ; APPLICANT: Gurney, Austin L.
15 ; APPLICANT: Hillan, Kenneth J.
16 ; APPLICANT: Kijavlin, Ivar J.
17 ; APPLICANT: Kuo, Sophia S.
18 ; APPLICANT: Napier, Mary A.
19 ; APPLICANT: Pan, James;
20 ; APPLICANT: Paoni, Nicholas F.
21 ; APPLICANT: Roy, Margaret Ann
22 ; APPLICANT: Shelton, David L.
23 ; APPLICANT: Stewart, Timothy A.
24 ; APPLICANT: Tumas, Daniel
25 ; APPLICANT: Williams, P. Mickey
26 ; APPLICANT: Wood, William I.
27 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
28 ; FILE REFERENCE: P2630PIC56
29 ; CURRENT APPLICATION NUMBER: US/10/162,522A
30 ; CURRENT FILING DATE: 2002-10-10
31 ; PRIOR APPLICATION NUMBER: 09/918585
32 ; PRIOR FILING DATE: 2001-07-30
33 ; PRIOR APPLICATION NUMBER: 60/062250
34 ; PRIOR FILING DATE: 1997-10-17
35 ; PRIOR APPLICATION NUMBER: 60/064249
36 ; PRIOR FILING DATE: 1997-11-03
37 ; PRIOR APPLICATION NUMBER: 60/065311
38 ; PRIOR FILING DATE: 1997-11-13
39 ; PRIOR APPLICATION NUMBER: 60/066364
40 ; PRIOR FILING DATE: 1997-11-21
41 ; PRIOR APPLICATION NUMBER: 60/077450
42 ; PRIOR FILING DATE: 1998-03-10
43 ; PRIOR APPLICATION NUMBER: 60/077632
44 ; PRIOR FILING DATE: 1998-03-11
45 ; PRIOR APPLICATION NUMBER: 60/077641
46 ; PRIOR FILING DATE: 1998-03-11
47 ; PRIOR APPLICATION NUMBER: 60/077649
48 ; PRIOR FILING DATE: 1998-03-11
49 ; PRIOR APPLICATION NUMBER: 60/077791
50 ; PRIOR FILING DATE: 1998-03-12
51 ; REMAINING PRIOR Application data removed - See File Wrapper or PALM.
52 ; NUMBER OF SEQ ID NOS: 624
53 ; SEQ ID NO 321
54 ; LENGTH: 1333
55 ; TYPE: DNA
56 ; ORGANISM: Homo sapiens
57 US-10-162-522A-321

```

RESULT 192
US-10-162-522A-321
; Sequence 321, Application US/10162522A
; Publication No. US20030215908A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi

121 TGATTACAAAGATCTATAGACGAGTGTATACCTGATCCCTCTCTACTCCAGAGTA 180
181 CCTCATCCAGGCTTTCTTCTGTGTGTCATGTTCTTTTGTGAGCAGAGTGGCTTACACAGGG 240
181 CCTCATCCAGGCTTTCTTCTGTGTGTCATGTTCTTTTGTGAGCAGAGTGGCTTACACAGGG 240
241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACACAGGTGATGAG 300
241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACACAGGTGATGAG 300
301 TGGCCCGAGCTCTATGACCTTACAAACCATCATGATGACAGATATTTCTAGCATATTTGCA 360
301 TGGCCCGAGCTCTATGACCTTACAAACCATCATGATGACAGATATTTCTAGCATATTTGCA 360
361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTCTATATGG 420
361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTCTATATGG 420
421 CATGATCTATGTTTGGTGGCTCTTAGAACACACACAGAGAAATTTGTCAGTTAAGT 480
421 CATGATCTATGTTTGGTGGCTCTTAGAACACACACAGAGAAATTTGTCAGTTAAGT 480
481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGCAAGTAGC 540
481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGCAAGTAGC 540
541 CTGTGGAATCTGATCAGTTTAAATGATGCTCTTATTTTAAATGTTTCCACAT 600
541 CTGTGGAATCTGATCAGTTTAAATGATGCTCTTATTTTAAATGTTTCCACAT 600
601 TTTTGTGTTGGAAAGCTGTTTCAATGTTATCTAGATTAAGATTTTAAATGTTT 660
601 TTTTGTGTTGGAAAGCTGTTTCAATGTTATCTAGATTAAGATTTTAAATGTTT 660
661 TACGTATAAATTAATATAAATGATTAACCTCTGTTGTGACAGTTTGAACCTTGCATTC 720
661 TACGTATAAATTAATATAAATGATTAACCTCTGTTGTGACAGTTTGAACCTTGCATTC 720
721 TTAAGGAACAGCCATATCTCTGAATGATCATTATCTGATGATGATGATGATGATGATG 780
721 TTAAGGAACAGCCATATCTCTGAATGATCATTATCTGATGATGATGATGATGATGATG 780
781 GAAGCTTTTGTATAGAACTTTAGGCTCAATTTGGTCTTCAATGAAACAGTATCTAA 840
781 GAAGCTTTTGTATAGAACTTTAGGCTCAATTTGGTCTTCAATGAAACAGTATCTAA 840
841 TTATAAATTAGCTGTAGATATCAGTGTCTTCTGATGATGATGATGATGATGATGATG 900
841 TTATAAATTAGCTGTAGATATCAGTGTCTTCTGATGATGATGATGATGATGATGATG 900
901 TGGGAACCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 960
901 TGGGAACCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 960
961 AAAAAATAAAGCGGAATTTTCCCTTCGCTGATATATATATATATATATATATATAT 1020
961 AAAAAATAAAGCGGAATTTTCCCTTCGCTGATATATATATATATATATATATATATAT 1020
1021 GAGAGATTTCCCATATTTCCATCAGATTAATATATATATATATATATATATATATAT 1080
1021 GAGAGATTTCCCATATTTCCATCAGATTAATATATATATATATATATATATATATATAT 1080
1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGAAATGATTAAGCTATT 1140
1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGAAATGATTAAGCTATT 1140
1141 TTAATGTGTTTTTATTTGTAAGACATTAATTAAGAAATGCTTTTATATATGCTTACTG 1200
1141 TTAATGTGTTTTTATTTGTAAGACATTAATTAAGAAATGCTTTTATATATGCTTACTG 1200
1201 TTCTAAATCTGTTAAAGGATTTCTTAAAGAAATTTGACAGGATTTTCAAAACT 1260
1201 TTCTAAATCTGTTAAAGGATTTCTTAAAGAAATTTGACAGGATTTTCAAAACT 1260

1261 GAATGAGAGAAATTTCTATACCATCTCTGTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
1261 GAATGAGAGAAATTTCTATACCATCTCTGTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
1321 GAAATTAAGACTC 1333
1321 GAAATTAAGACTC 1333

RESULT 193

US-10-013-923A-321
; Sequence 321, Application US/10013923A

; Publication No: US20030216305A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C87
; CURRENT FILING DATE: 2001-10-25
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens

US-10-013-923A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0;

QY 1 GCCCAGCGCTCGAGTGGCGTTCCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGCTCGAGTGGCGTTCCAGTTCCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCACTCTTCTCGCCATTGGCAGATATATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCACTCTTCTCGCCATTGGCAGATATATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTAACAAGATCCCTATAGACAGGTGTAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTAACAAGATCCCTATAGACAGGTGTAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGCTCATGTTTCTTTTGTGACAGAGTGGCTTACATGGG 240

Db 181 CCTCATCCACGCTTTCTTCTGTGTCACTTTCTTGTGCAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAACAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAACAGTATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATCAGATATTTAGCATATTTGTCA 360
Db 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATCAGATATTTAGCATATTTGTCA 360
QY 361 GAAGGAGAGTGGTCAAAATAGCTTTTAACTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAGAGTGGTCAAAATAGCTTTTAACTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTAGAAACACACACAGAGAAATGGTCCAGTAAAT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTAGAAACACACACAGAGAAATGGTCCAGTAAAT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGTAGC 540
QY 541 CTGTGGATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATAATGATTAACCTCTGTGTTGACAGGTTTGAACCTTGACTTC 720
Db 661 TACGTATAAATTAATAAATAATGATTAACCTCTGTGTTGACAGGTTTGAACCTTGACTTC 720
QY 721 TTAAGGACACGCCATATCCCTGTAATGATGATTAATTAATGACTGCTCCTAGTACATG 780
Db 721 TTAAGGACACGCCATATCCCTGTAATGATGATTAATTAATGACTGCTCCTAGTACATG 780
QY 781 GAAGCTTTGTTTATAGAACTTTGAGGCTCATTTTGGTTCATTTGAACAGATCTAA 840
Db 781 GAAGCTTTGTTTATAGAACTTTGAGGCTCATTTTGGTTCATTTGAACAGATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAAACTTTCATGAGTTTCTCTCATCTGCTATGCTGATATATATGATATCTTAC 960
Db 901 TGGGAAACTTTCATGAGTTTCTCTCATCTGCTATGCTGATATATATGATATCTTAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATGCTATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATGCTATGAAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGATATATATATATATATATATATATATATAT 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGATATATATATATATATATATATATATATAT 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGTAAGATGATATATATATAT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGTAAGATGATATATATATAT 1140
QY 1141 TTAATATGTTTATTTGTAAGACATTTACTTTAAGAAATTTGTTTATATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTGTAAGACATTTACTTTAAGAAATTTGTTTATATGCTTACTG 1200
QY 1201 TTCTAATCTGTTGTAAGATTTCTTAAAGATTTGAGGTAATGATATATATATATAT 1260
Db 1201 TTCTAATCTGTTGTAAGATTTCTTAAAGATTTGAGGTAATGATATATATATATATAT 1260
QY 1261 GAATGAGAGAAAATGATATACCATCTGCTGTTTCTTCTAGTGAATACATATATAT 1320
Db 1261 GAATGAGAGAAAATGATATACCATCTGCTGTTTCTTCTAGTGAATACATATATATAT 1320

QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 194

US-10-013-925A-321
; Sequence 321, Application US/10013925A
; Publication No. US20030216560A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630F1C83
; CURRENT APPLICATION NUMBER: US/10/013,925A
; CURRENT FILING DATE: 2002-05-03
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-013-925A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGCGGTTACGTTCCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
Db 1 GCCACGCGTCCGATGCGGTTACGTTCCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCCCATTTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCCCATTTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAATCCTATAGACAGAGTGAATACCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAGAATCCTATAGACAGAGTGAATACCTGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTTCTTCTGCTGCTATGTTTCTTGTGAGAGAGTGGCTTACCTGGG 240
Db 181 CCTCATCCAGCTTTCTTCTGCTGCTATGTTTCTTGTGAGAGAGTGGCTTACCTGGG 240
QY 241 TCTCAATATGCCCTCTTGTGCTATCATATTTGGAGGTATATGATAGACAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGTGCTATCATATTTGGAGGTATATGATAGACAGTATGAG 300

Db 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATGAGTACACAGTGTGAG 300
QY 301 TGGCCAGAGCTCTATGACCCCTACCAACCATCATGAATGACATATCTTAGCATATTTGCA 360
Db 301 TGGCCAGAGCTCTATGACCCCTACCAACCATCATGAATGACATATCTTAGCATATTTGCA 360
QY 361 GAAGCAAGAGTGTGCAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGCAAGAGTGTGCAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAATTTGTCTCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAATTTGTCTCAGTTAAGT 480
QY 481 GCATCAAAAGCCACCAATGAAGGATTTCTATCAGCAAGATCCTGTCCAGAGTAGC 540
Db 481 GCATCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTCATGAGTTTCTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTCATGAGTTTCTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAGAGCTTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTTGTGGAAGAGCTTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGACTTC 720
Db 661 TACGTATAAATTAATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGACTTC 720
QY 721 TTAAGCAACAGCATAATCTCTGATGATGATTAATTAATGATGCTCTAGTACATG 780
Db 721 TTAAGCAACAGCATAATCTCTGATGATGATTAATTAATGATGCTCTAGTACATG 780
QY 781 GAAGCTTTGTTTATAGGAAGCTTTGAGGCTCATTTTGGTTTCATGAAGAGTATCTAA 840
Db 781 GAAGCTTTGTTTATAGGAAGCTTTGAGGCTCATTTTGGTTTCATGAAGAGTATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTCTTCTGATGAGTGAAGTGAATGATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTCTTCTGATGAGTGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAACCTTCACTGTTTCTCATCTGTCATGTCATGATTAATATATGATGATATTTAC 960
Db 901 TGGGAACCTTCACTGTTTCTCATCTGTCATGTCATGATTAATATATGATGATATTTAC 960
QY 961 AAAAATAAAGGGGAATTTCCCTTCCTTGAATATATATCCCTGTATATTTGATGAT 1020
Db 961 AAAAATAAAGGGGAATTTCCCTTCCTTGAATATATATCCCTGTATATTTGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAATTTCTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAATTTCTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGCTTTTATTTCTAGACATTAATTTATTAAGAAATTTGGTTATATGCTTACTG 1200
Db 1141 TTAATATGCTTTTATTTCTAGACATTAATTTATTAAGAAATTTGGTTATATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGATTTCTTAAAGATTTTGCAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGATTTCTTAAAGATTTTGCAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAAATTTGATAAATCAATCCTGCTGTTCTTCTAGTGAATATAAATAAATCTCT 1320
Db 1261 GAATGAGAAATTTGATAAATCAATCCTGCTGTTCTTCTAGTGAATATAAATAAATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 195

US-10-013-927A-321

; Sequence 321, Application US/10013927A

; Publication No. US20030216561A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Baker Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan

; APPLICANT: Ferrara, Napoleon

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Kuo, Sophia S.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James;

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: ROY, Margaret Ann

; APPLICANT: Shelton, David L.

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tunas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P26301C88

; CURRENT APPLICATION NUMBER: US/10/013, 927A

; CURRENT FILING DATE: 2001-10-25

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 624

; SEQ ID NO 321

; LENGTH: 1333

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-013-927A-321

Query Match

Best Local Similarity 100.0%; Score 1333; DB 16; Length 1333;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAACGCTCCGATGGCGTTTCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAACGCTCCGATGGCGTTTCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCCGCTCATCTTCTTCGCCATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCCGCTCATCTTCTTCGCCATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTAAGAATCTTATAGACCAAGTGAATACCTGAAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTAAGAATCTTATAGACCAAGTGAATACCTGAAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCACGCTTCTTCTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGCTTCTTCTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATGAGTACACAGTGTGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATGAGTACACAGTGTGAG 300
QY 301 TGGCCAGAGCTCTATGACCCCTACCAACCATCATGAATGATATCTTAGCATATTTGCA 360

```
Db 301 TGGCCAGGAGCTCTATGACCCCTACCAACCATCATGATGCAGATATCTTAGCATATTGTCA 360
Qy 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTGAACAACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTGAACAACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCCAAAATGAAGGATCTTATCCAGAGATCCTGTCCAAGATAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATCTTATCCAGAGATCCTGTCCAAGATAGC 540
Qy 541 CTGTGGAATCTGATCAGTACTTTTAAAGAAAGTCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTTTAAAGAAAGTCTCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTCTGTTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTCTGTTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATATAAATGATTACCTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGTATAAATTAATATAAATGATTACCTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
Qy 721 TTAAGGAACAGCCATAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780
Db 721 TTAAGGAACAGCCATAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780
Qy 781 GAAGCTTTGTTTATAGGAACCTTGTAGGCTCATTTTGGTTCATTTGTTGTTGTTGTTGTTG 840
Db 781 GAAGCTTTGTTTATAGGAACCTTGTAGGCTCATTTTGGTTCATTTGTTGTTGTTGTTGTTG 840
Qy 841 TTATAAATAGCTGTAGATATCAGCTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
Db 841 TTATAAATAGCTGTAGATATCAGCTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
Qy 901 TGGGAACCTCATGGGTTTCTCATCTGTCATGTCGATGATGATGATGATGATGATGATGATG 960
Db 901 TGGGAACCTCATGGGTTTCTCATCTGTCATGTCGATGATGATGATGATGATGATGATGATG 960
Qy 961 AAAAAATAGGCGGGAATTTTCCCTCGCTGATATTTATCCCTGATATTTGATGATGATGAT 1020
Db 961 AAAAAATAGGCGGGAATTTTCCCTCGCTGATATTTATCCCTGATATTTGATGATGATGAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATCTTAAGCATAT 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATCTTAAGCATAT 1080
Qy 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTGTGAAGATGATGATGATGATGATGAT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTGTGAAGATGATGATGATGATGATGAT 1140
Qy 1141 TTAATATGTTTATTTGTAAGACATCTTATTAAGAAATGGTATATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTGTAAGACATCTTATTAAGAAATGGTATATGCTTACTG 1200
Qy 1201 TTCTAATCTGGTGAAGATATCTTAAGAAATTTGCGGTTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGATATCTTAAGAAATTTGCGGTTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGTAACCATCTCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACCATCTCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 196
US-10-145-093A-321
```

Sequence 321, Application US/10145093A
Publication No. US20040005312A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Deanoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Geritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C48
CURRENT APPLICATION NUMBER: US/10/145,093A
PRIORITY FILING DATE: 2001-10-18
PRIORITY FILING DATE: 2001-07-30
PRIORITY FILING DATE: 2001-07-30
PRIORITY FILING DATE: 1997-10-17
PRIORITY FILING DATE: 1997-10-17
PRIORITY FILING DATE: 1997-11-03
PRIORITY FILING DATE: 1997-11-03
PRIORITY FILING DATE: 1997-11-13
PRIORITY FILING DATE: 1997-11-13
PRIORITY FILING DATE: 1997-11-21
PRIORITY FILING DATE: 1997-11-21
PRIORITY FILING DATE: 1998-03-10
PRIORITY FILING DATE: 1998-03-10
PRIORITY FILING DATE: 1998-03-11
PRIORITY FILING DATE: 1998-03-11
PRIORITY FILING DATE: 1998-03-11
PRIORITY FILING DATE: 1998-03-11
PRIORITY FILING DATE: 1998-03-11
PRIORITY FILING DATE: 1998-03-12
PRIORITY FILING DATE: 1998-03-12
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 624
SEQ ID NO 321
LENGTH: 1333
TYPE: DNA
ORGANISM: Homo sapiens
US-10-145-093A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303; Mismatches 0; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCACAGGCTCCGATGGGTTTACGCTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCT 60
Db 1 GCCACAGGCTCCGATGGGTTTACGCTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCT 60
Qy 61 CACTGCCGCTCATCTTCTTCTGCGCATTTGCGACATTTAGCATTTGATGAGCTGAAGAC 120

Db 61 CACTGCCGGCTCATCTCTTGGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
Qy 121 TGANTCAAGAATCCTATAGACAGTGAATACCCCTGTAATCCCTTGTACTCCCAAGATA 180
Db 121 TGAATCAAGAATCCTATAGACAGTGAATACCCCTGTAATCCCTTGTACTCCCAAGATA 180
Qy 181 CCTCATCCAGCTTCTCTCTGTGTCATCTTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCAGCTTCTCTCTGTGTCATCTTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Qy 301 TGGCCCAAGACTCTATGACCCCTACCAACATCATGATGAGATGAGATATTTAGCATATTTGCA 360
Db 301 TGGCCCAAGACTCTATGACCCCTACCAACATCATGATGAGATGAGATATTTAGCATATTTGCA 360
Qy 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAATTTGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAGCCACCAATGAAGGATCTTATCCAGCAGATCTCTGTCGAAGTAGC 540
Db 481 GCATGCAAAAGCCACCAATGAAGGATCTTATCCAGCAGATCTCTGTCGAAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTTCTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTTCTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATATAAATGATTAATCTCTGGTGGTGACAGGTTGAACTTGCACTTC 720
Db 661 TACGTATAAATTAATATAAATGATTAATCTCTGGTGGTGACAGGTTGAACTTGCACTTC 720
Qy 721 TTAAGGAACAGCAATAATCCTCTGATGATGATTAATTAATCTGCTGCTAGTACATTTG 780
Db 721 TTAAGGAACAGCAATAATCCTCTGATGATGATTAATTAATCTGCTGCTAGTACATTTG 780
Qy 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTGGTTTCATTTGGAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTGGTTTCATTTGGAACAGTATCTAA 840
Qy 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAGTGAATGATATATCTGACTAG 900
Qy 901 TGGGAACCTTCAATGGTTTCTCTCATCTGTCATGATGATTAATGATGATGATGATGATG 960
Db 901 TGGGAACCTTCAATGGTTTCTCTCATCTGTCATGATGATTAATGATGATGATGATGATG 960
Qy 961 AAAATAAAGGGGAATTTCCCTTCCCTGCAATATATATCCCTGATATGATGATGATGAT 1020
Db 961 AAAATAAAGGGGAATTTCCCTTCCCTGCAATATATATCCCTGATATGATGATGATGATG 1020
Qy 1021 GAGAGATTTCCCATATTTCCCATGAGTAAATAATATATCTGCTTTAAATCTTAAGCATTA 1080
Db 1021 GAGAGATTTCCCATATTTCCCATGAGTAAATAATATATCTGCTTTAAATCTTAAGCATTA 1080
Qy 1081 AGTAAACATGATATAAATAATATATGCTGATTAATCTTGTGAAGATGCAATTTAAAGTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGATTAATCTTGTGAAGATGCAATTTAAAGTATT 1140
Qy 1141 TTAATATGTTTTTATTTGATAGACATTAATCTTATTAAGAAATGGTTATATGCTTACTG 1200
Db 1141 TTAATATGTTTTTATTTGATAGACATTAATCTTATTAAGAAATGGTTATATGCTTACTG 1200

RESULT 197

US-10-013-919A-321
; Sequence 321, Application US/10013919A
; Publication No. US20040005657A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C85
; CURRENT APPLICATION NUMBER: US/10/013,919A
; CURRENT FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624

```
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-013-919A-321

Query Match      100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCACGCGTCCGATGGCGTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCACGCGTCCGATGGCGTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

Qy 61 CACTGCCGCGTCACTTCTTCGCGCATTTGGCCATATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGTCACTTCTTCGCGCATTTGGCCATATATAGCATTTGATGAGCTGAAGAC 120

Qy 121 TGATTACAAGAACTCTATAGACCACTGTAATACCTGTAATCCCTTGCTACCTCCAGAGTA 180
Db 121 TGATTACAAGAACTCTATAGACCACTGTAATACCTGTAATCCCTTGCTACCTCCAGAGTA 180

Qy 181 CCTCATCCACGCTTCTTCTGTCGTCATGTTCTTTGTCGACGAGTGCGCTTACACTGGG 240
Db 181 CCTCATCCACGCTTCTTCTGTCGTCATGTTCTTTGTCGACGAGTGCGCTTACACTGGG 240

Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCACTGATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCACTGATGAG 300

Qy 301 TGGCCCAAGACTCTATGACCCCTAGCAATCATGATGATGATGATGATGATGATGATGATG 360
Db 301 TGGCCCAAGACTCTATGACCCCTAGCAATCATGATGATGATGATGATGATGATGATGATG 360

Qy 361 GAAGAAGAGTGGTGCAAAATGAGTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGAAGAGTGGTGCAAAATGAGTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420

Qy 421 CATGATCATGTTTGGTGAGCTCTTAGAACAACACACAGAGAGTGGTCCAGTTAAGT 480
Db 421 CATGATCATGTTTGGTGAGCTCTTAGAACAACACACAGAGAGTGGTCCAGTTAAGT 480

Qy 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTCTCAAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTCTCAAGAGTAGC 540

Qy 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600

Qy 601 TTTTGTGTTGGAAGACTGTTTTCATATGTTATATCTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTGTTGGAAGACTGTTTTCATATGTTATATCTCAGATAAGATTTTAAATGGTAT 660

Qy 661 TACGTATAAAATTAATAAAATGATTAATCTCTGGTGGTTGACAGGTTTGAACCTGCACAT 720
Db 661 TACGTATAAAATTAATAAAATGATTAATCTCTGGTGGTTGACAGGTTTGAACCTGCACAT 720

Qy 721 TTAAGGAACAGCCATATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780
Db 721 TTAAGGAACAGCCATATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780

Qy 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTTTCATTGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTTTCATTGAAACAGATATCTAA 840

Qy 841 TTATAAATAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
Db 841 TTATAAATAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900

Qy 901 TGGGAACTTCATGGGTTTCTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTC 960
Db 901 TGGGAACTTCATGGGTTTCTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTC 960
```

RESULT 198
US-10-232-226-119
; Sequence 119, Application US/10232226
; Publication No. US2004006206A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C110
; CURRENT APPLICATION NUMBER: US/10/232,226
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/052287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246


```
; SEQ ID NO 119
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-232-226-119

Query Match      100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGCTCCGATGGGGTTCACGTTGCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
DB 1 GCCACGGCTCCGATGGGGTTCACGTTGCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60

QY 61 CACTCGGGCTCATCTTCTTCCGCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTCGGGCTCATCTTCTTCCGCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCTGAAATCCCTTGTAATCCCAAGATA 180
DB 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCTGAAATCCCTTGTAATCCCAAGATA 180

QY 181 COTCATCCAGCTTCTTCTGCTGTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACACTGG 240
DB 181 COTCATCCAGCTTCTTCTGCTGTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300

QY 301 TGGCCCGAGGACTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCCGAGGACTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360

QY 361 GAAGGAAGATGGTGGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCATATGG 420
DB 361 GAAGGAAGATGGTGGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCATATGG 420

QY 421 CATGATCTATGTTTGGTGGCTCTTAGACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGGCTCTTAGACACACACAGAGAAATGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCTGTCCAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGGAAGACGTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACGTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGCTATAAATTAATAAATAGTATCTCTGTTGTTGACAGGTTTGAACCTTGCACCTTC 720
DB 661 TAGCTATAAATTAATAAATAGTATCTCTGTTGTTGACAGGTTTGAACCTTGCACCTTC 720

QY 721 TTAAGGAACAGCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAACAGCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 780

QY 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTGTTTCAATGGAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTGTTTCAATGGAACAGTATCTAA 840

QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATATCTGACTAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATATCTGACTAG 900

QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
DB 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
```

```

; SEQ ID NO 119
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-232-226-119

Query Match      100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGCTCCGATGGGGTTCACGTTGCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
DB 1 GCCACGGCTCCGATGGGGTTCACGTTGCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60

QY 61 CACTCGGGCTCATCTTCTTCCGCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTCGGGCTCATCTTCTTCCGCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCTGAAATCCCTTGTAATCCCAAGATA 180
DB 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCTGAAATCCCTTGTAATCCCAAGATA 180

QY 181 COTCATCCAGCTTCTTCTGCTGTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACACTGG 240
DB 181 COTCATCCAGCTTCTTCTGCTGTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300

QY 301 TGGCCCGAGGACTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCCGAGGACTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360

QY 361 GAAGGAAGATGGTGGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCATATGG 420
DB 361 GAAGGAAGATGGTGGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCATATGG 420

QY 421 CATGATCTATGTTTGGTGGCTCTTAGACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGGCTCTTAGACACACACAGAGAAATGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCTGTCCAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGGAAGACGTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACGTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGCTATAAATTAATAAATAGTATCTCTGTTGTTGACAGGTTTGAACCTTGCACCTTC 720
DB 661 TAGCTATAAATTAATAAATAGTATCTCTGTTGTTGACAGGTTTGAACCTTGCACCTTC 720

QY 721 TTAAGGAACAGCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAACAGCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 780

QY 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTGTTTCAATGGAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTGTTTCAATGGAACAGTATCTAA 840

QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATATCTGACTAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATATCTGACTAG 900

QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
DB 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
```

```

; Sequence 321, Application US/10013920A
; Publication No. US20040006219A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630FIC78
; CURRENT APPLICATION NUMBER: US/10/013,920A
; CURRENT FILING DATE: 2001-10-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
```

Matches	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1	GCCACAGCGTCGATGGCGGTT	CAGGTT	CAGGTCGCGGCCCTTC	GTCTACATGCTGGCGCTGCTGCT	60		
Db	1	GCCACAGCGTCGATGGCGGTT	CAGGTT	CAGGTCGCGGCCCTTC	GTCTACATGCTGGCGCTGCTGCT	60		
QY	61	CAC TGCCGCGCTCATCTCTCTTCG	CCATT	TGGCATTATAGCATATAGCATTT	TGATGAGCTGAAGAC	120		
Db	61	CAC TGCCGCGCTCATCTCTCTTCG	CCATT	TGGCATTATAGCATATAGCATTT	TGATGAGCTGAAGAC	120		
QY	121	TGATTACAAGAACTCTATAGACCAGT	GTAA	TACCCTGAATCCCTCTGTACTCC	CAGAGTA	180		
Db	121	TGATTACAAGAACTCTATAGACCAGT	GTAA	TACCCTGAATCCCTCTGTACTCC	CAGAGTA	180		
QY	181	CCTCATCCAGCTTCTCTCTGTGTG	TCATGTT	TTGTGACAGAGTGGCTTAC	TGCGG	240		
Db	181	CCTCATCCAGCTTCTCTCTGTGTG	TCATGTT	TTGTGACAGAGTGGCTTAC	TGCGG	240		
QY	241	TCTCAATATGCCCTCTCTGGCATAT	CAATAT	TGGAGGTATATGATAGACAC	CAGTATGAG	300		
Db	241	TCTCAATATGCCCTCTCTGGCATAT	CAATAT	TGGAGGTATATGATAGACAC	CAGTATGAG	300		
QY	301	TGGCCCAAGACTATAGCCCTCA	CAACCAT	CATGAATGCAGATATCT	TAGCATATTTGCA	360		
Db	301	TGGCCCAAGACTATAGCCCTCA	CAACCAT	CATGAATGCAGATATCT	TAGCATATTTGCA	360		
QY	361	GAAGGAAGGATGGTCAAAATAGCT	TTTTTA	TCITCTAGCATTTTTTTT	TACCTATATGG	420		
Db	361	GAAGGAAGGATGGTCAAAATAGCT	TTTTTA	TCITCTAGCATTTTTTTT	TACCTATATGG	420		
QY	421	CATGATCTATGTTTTGGTGGAGCT	CTTAGA	CAACACAGAAAGATTTGGT	CCAGTTAAGT	480		
Db	421	CATGATCTATGTTTTGGTGGAGCT	CTTAGA	CAACACAGAAAGATTTGGT	CCAGTTAAGT	480		
QY	481	GCATGCAAAAGCCACCAATGAG	GGGATTT	CTCCAGCAAGATCTCTGT	CCAGAGTAGC	540		
Db	481	GCATGCAAAAGCCACCAATGAG	GGGATTT	CTCCAGCAAGATCTCTGT	CCAGAGTAGC	540		
QY	541	CTGTGGAATCTGATCAGTTACT	TTTAA	AAAAATGACTCCTTTATTTT	TAAATGTTTCCACAT	600		
Db	541	CTGTGGAATCTGATCAGTTACT	TTTAA	AAAAATGACTCCTTTATTTT	TAAATGTTTCCACAT	600		
QY	601	TTTTGCTGTGGAAGACTGTTTT	CATAT	GTGTATCTCAGATAAAGAT	TTTTAAATGCTAT	660		
Db	601	TTTTGCTGTGGAAGACTGTTTT	CATAT	GTGTATCTCAGATAAAGAT	TTTTAAATGCTAT	660		
QY	661	TAGGTATAAATTAATATAAAAT	GATTAC	CTCTGGTGTGACAGGTTTGA	ACTTGCATCTTC	720		
Db	661	TAGGTATAAATTAATATAAAAT	GATTAC	CTCTGGTGTGACAGGTTTGA	ACTTGCATCTTC	720		
QY	721	TTAAGGAACAGCCATAATCTCT	CAATG	ATGTCATTAATCTGACTGT	CCTAGTACATG	780		
Db	721	TTAAGGAACAGCCATAATCTCT	CAATG	ATGTCATTAATCTGACTGT	CCTAGTACATG	780		
QY	781	GAAGCTTTTGTATTAGAACTTG	TAGGGCT	CATTTTTGGTTTCATTGAAA	CAGTATCTAA	840		
Db	781	GAAGCTTTTGTATTAGAACTTG	TAGGGCT	CATTTTTGGTTTCATTGAAA	CAGTATCTAA	840		
QY	841	TTATAAATTAGCTGTAGATAT	CAGGTGCT	GTGATGAGTGAATGTA	TATCTGACTAG	900		
Db	841	TTATAAATTAGCTGTAGATAT	CAGGTGCT	GTGATGAGTGAATGTA	TATCTGACTAG	900		
QY	901	TGGGAAACTTTCATGGGTTTCT	CTCAT	CTGTGATGCGATGATATAT	TATGGATACATTAC	960		
Db	901	TGGGAAACTTTCATGGGTTTCT	CTCAT	CTGTGATGCGATGATATAT	TATGGATACATTAC	960		
QY	961	AAAAATAAAAAGCGGGAAATTTT	CCCTT	TCGCTTGAATATATCCCT	GTATATTCATGAAT	1020		
Db	961	AAAAATAAAAAGCGGGAAATTTT	CCCTT	TCGCTTGAATATATCCCT	GTATATTCATGAAT	1020		

US-10-230-130-119

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACACAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAGAAATCCTATAGACACAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCACGGCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGGCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGCAAGTATGAG 300
Db 241 TCTCAATATGCCCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGCAAGTATGAG 300

QY 301 TGGCCGAGGACTATGACCTTACACATCATGATGAGTACATATCTAGCATATTTGCA 360
Db 301 TGGCCGAGGACTATGACCTTACACATCATGATGAGTACATATCTAGCATATTTGCA 360

QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTCTATATGG 420
Db 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTCTATATGG 420

QY 421 CATGATCTAATGTTTGGTGAAGCTTTAGAACACACACACAGAGAATTTGCTCCAGTAA 480
Db 421 CATGATCTAATGTTTGGTGAAGCTTTAGAACACACACACAGAGAATTTGCTCCAGTAA 480

QY 481 GCATGCAAAAGCCACCAATGAAGGATCTTATCCAGCAAGATCTGTCGCAAGTAGC 540
Db 481 GCATGCAAAAGCCACCAATGAAGGATCTTATCCAGCAAGATCTGTCGCAAGTAGC 540

QY 541 CTGTGGAATCTCATAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCACAT 600
Db 541 CTGTGGAATCTCATAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCACAT 600

QY 601 TTTTGTCTTGGAAGACCTGTTTTCATATGTTATATCTAGATAAGAAATTTAAATGGTAT 660
Db 601 TTTTGTCTTGGAAGACCTGTTTTCATATGTTATATCTAGATAAGAAATTTAAATGGTAT 660

QY 661 TAGCTATAAATTAATAAATGATTAACCTCTGGTGTTCACAGGTTTGAACCTGCACTTC 720
Db 661 TAGCTATAAATTAATAAATGATTAACCTCTGGTGTTCACAGGTTTGAACCTGCACTTC 720

QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATGACTGCTCTAGTACATG 780
Db 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATGACTGCTCTAGTACATG 780

QY 781 GAAGCTTTTGTATAGGAACCTGTTAGGCTCATTTTGGTTCATTTGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTGTTAGGCTCATTTTGGTTCATTTGAACAGATATCTAA 840

QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTAAATGATATCTGACTAG 900
Db 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTAAATGATATCTGACTAG 900

QY 901 TGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATGACATTTAC 960
Db 901 TGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATGACATTTAC 960

QY 961 AAAAATAAAGCGGGAATTTCCCTTCGTTGAATATTTATCCCTGATATTTGCATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTCCCTTCGTTGAATATTTATCCCTGATATTTGCATGAAT 1020
```

RESULT 201

US-10-119-480-119
; Sequence 119, Application US/10119480
; Publication No. US20040087769A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PL1
; CURRENT APPLICATION NUMBER: US/10/119,480
; CURRENT FILING DATE: 2002-04-09
; NUMBER OF SEQ ID NOS: 246
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 119
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-119-480-119

Query Match 100.0%; Score 1333; DB 17; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACACAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAGAAATCCTATAGACACAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCACGGCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGGCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240
```

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTATGAG 300
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTATGAG 300
Db |||||
QY 301 TGGCCAGGACTATGACCCCTACAAACCATCATGAATGACAGATATTTAGCATATTTGCA 360
Db |||||
QY 301 TGGCCAGGACTATGACCCCTACAAACCATCATGAATGACAGATATTTAGCATATTTGCA 360
Db |||||
QY 361 GAAGGAAGGTGTCGAATAGCTTTTATCTCTAGCATTTTCTACTACCTATATGG 420
Db |||||
QY 361 GAAGGAAGGTGTCGAATAGCTTTTATCTCTAGCATTTTCTACTACCTATATGG 420
Db |||||
QY 421 CATGATCATGTTTGTGTGAGCTCTTAGAACAAACACACAGAGAATTCCTCCAGTTAGT 480
Db |||||
QY 421 CATGATCATGTTTGTGTGAGCTCTTAGAACAAACACACAGAGAATTCCTCCAGTTAGT 480
Db |||||
QY 481 GCATGCAAAAAGCCAAATGAAGGATTTCTATCCAGCAAGATCCTGTCAGAGTAGC 540
Db |||||
QY 481 GCATGCAAAAAGCCAAATGAAGGATTTCTATCCAGCAAGATCCTGTCAGAGTAGC 540
Db |||||
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 601 TTTTGTGTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Db |||||
QY 601 TTTTGTGTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Db |||||
QY 661 TACGTATTAATTAATAAATGATTAATCTCTGTTGTTGACAGGTTTGAATGCACTTC 720
Db |||||
QY 661 TACGTATTAATTAATAAATGATTAATCTCTGTTGTTGACAGGTTTGAATGCACTTC 720
Db |||||
QY 721 TTAAGGAACAGCCATTAATCTGATGATTAATTAATCTGATGATGATTAATCTGATGAT 780
Db |||||
QY 721 TTAAGGAACAGCCATTAATCTGATGATTAATTAATCTGATGATGATTAATCTGATGAT 780
Db |||||
QY 781 GAAGCTTTGTTTATAGGAATCTGTTAGGGCTCAATTTGTTTCAATGAACAGATATCTAA 840
Db |||||
QY 781 GAAGCTTTGTTTATAGGAATCTGTTAGGGCTCAATTTGTTTCAATGAACAGATATCTAA 840
Db |||||
QY 841 TTTAATATGATCTGATGATTAATCTGATGATTAATCTGATGATGATTAATCTGATGAT 900
Db |||||
QY 841 TTTAATATGATCTGATGATTAATCTGATGATTAATCTGATGATGATTAATCTGATGAT 900
Db |||||
QY 901 TGGGAAACTTCATGAGGTTTCTCTCATCTGATGATTAATCTGATGATTAATCTGATGAT 960
Db |||||
QY 901 TGGGAAACTTCATGAGGTTTCTCTCATCTGATGATTAATCTGATGATTAATCTGATGAT 960
Db |||||
QY 961 AAAAAAAGCGGGAATTTTCCCTTCCCTGGAATATATATCCCTGATATATGATGAT 1020
Db |||||
QY 961 AAAAAAAGCGGGAATTTTCCCTTCCCTGGAATATATATCCCTGATATATGATGAT 1020
Db |||||
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTGTTTATTTCTTAAGCAT 1080
Db |||||
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTGTTTATTTCTTAAGCAT 1080
Db |||||
QY 1081 AGTAAACATGATATAAATAATATATCTGATGATTAATCTGATGATTAATCTGATGAT 1140
Db |||||
QY 1081 AGTAAACATGATATAAATAATATATCTGATGATTAATCTGATGATTAATCTGATGAT 1140
Db |||||
QY 1141 TTAATGTTTATTTGTAAGCAATTAATTAATTAAGAAATGTTTATTAATGTTTACTG 1200
Db |||||
QY 1141 TTAATGTTTATTTGTAAGCAATTAATTAATTAAGAAATGTTTATTAATGTTTACTG 1200
Db |||||
QY 1201 TTTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATGATGATGATTTTCAAACT 1260
Db |||||
QY 1201 TTTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATGATGATGATTTTCAAACT 1260
Db |||||
QY 1261 GAATGAGAGAAATTTGATTAACATCTCTGCTGTTCTTTAGTGCATATCAATAAACTCT 1320
Db |||||
QY 1261 GAATGAGAGAAATTTGATTAACATCTCTGCTGTTCTTTAGTGCATATCAATAAACTCT 1320
Db |||||

QY 1321 GAAATTAAGACTC 1333
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||

RESULT 202

US-09-822-846-396
; Sequence 396, Application US/09822846
; Publication No. US20030027139A1
; GENERAL INFORMATION:
; APPLICANT: Jacobs, Kenneth
; APPLICANT: McCoy, John M.
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; APPLICANT: Evans, Cheryl
; APPLICANT: Merberg, David
; APPLICANT: Treacy, Maurice
; APPLICANT: Agostino, Michael J.
; APPLICANT: Steinger II, Robert J.
; APPLICANT: Bowman, Michael R.
; APPLICANT: Spaulding, Vikki
; APPLICANT: Wong, Gordon G.
; APPLICANT: Clark, Hilary
; APPLICANT: Fecthel, Kim
; APPLICANT: Howes, Steven H.
; APPLICANT: Resnick, Richard J.
; APPLICANT: Gulukota, Kamalakar
; APPLICANT: Graham, James R.
; APPLICANT: Genetics Institute, Inc.
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING NOVEL SECRETED PROTEINS
; FILE REFERENCE: GIN 6400
; CURRENT APPLICATION NUMBER: US/09/822,846
; CURRENT FILING DATE: 2001-03-29
; PRIOR APPLICATION NUMBER: 60/195,605
; PRIOR FILING DATE: 2000-04-06
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 396
; LENGTH: 1432
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-822-846-396

Query Match 99.1%; Score 1321.4; DB 10; Length 1432;
Best Local Similarity 99.5%; Pred. No. 1e-300;
Matches 1325; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 3 CCAGCGTCCGATGGGCTTACGTTCCGGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 62
Db 102 CCTCCCGAGCCATGGCGTTACGTTCCGGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 161
QY 63 CTGCGCGCTCATCTTCTTCCCATTTGGCACATTATAGCATTTGATGAGCTGAAGACTG 122
Db 162 CTGCGCGCTCATCTTCTTCCCATTTGGCACATTATAGCATTTGATGAGCTGAAGACTG 221
QY 123 ATTACAAGATCTTATAGACCCAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTACC 182
Db 222 ATTACAAGATCTTATAGACCCAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTACC 281
QY 183 TCATCCAGCTTCTTCTGCTGATGTTCTTTGTGAGCAGAGTGGCTTACACTGGGTC 242
Db 282 TCATCCAGCTTCTTCTGCTGATGTTCTTTGTGAGCAGAGTGGCTTACACTGGGTC 341
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGTG 302
Db 342 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGTG 401
QY 303 GCCCAGGACTTATGACCCCTACACCATCATGATGATGATGATTTCTAGCATATTTGTGAGA 362
Db 402 GCCCAGGACTTATGACCCCTACACCATCATGATGATGATGATTTCTAGCATATTTGTGAGA 461
QY 363 AGGAGAGATGGTGAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCA 422
Db |||||

Db 462 AGGAAGGATGGTGCARAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGGCA 521
QY 423 TGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAAATTTGGTCCAGTTAAGTGC 482
Db 522 TGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAAATTTGGTCCAGTTAAGTGC 581
QY 483 ATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAGATCCCTGTCACAGATAGCT 542
Db 582 ATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAGATCCCTGTCACAGATAGCT 641
QY 543 GTGAATCTGATCAGTTACTTTAAAAAATGACTCTTATTTTAAATGTTTCCACATTT 602
Db 642 GTGAATCTGATCAGTTACTTTAAAAAATGACTCTTATTTTAAATGTTTCCACATTT 701
QY 603 TTGCTTTGTGAAAGACTGTTTCTATGTTATCTCAGATAAAGATTTAAATGGTATTA 662
Db 702 TTGCTTTGTGAAAGACTGTTTCTATGTTATCTCAGATAAAGATTTTAAATGGTATTA 761
QY 663 CGTATAAATTTATATAAATGATTACTCTGTTGTTGACAGGTTTGAACCTTCACCTCTT 722
Db 762 CGTATAAATTTATATAAATGATTACTCTGTTGTTGACAGGTTTGAACCTTCACCTCTT 821
QY 723 AAGGAACAGCCATAATCTCTGAATGATGATTAATTAATGATGATGATGATGATGATG 782
Db 822 AAGGAACAGCCATAATCTCTGAATGATGATTAATTAATGATGATGATGATGATGATG 881
QY 783 AGCTTTTGTGTAAGAACTTTGAGGCTCATTTTGGTTTCAATGAAACAGTATCTAAT 842
Db 882 AGCTTTTGTGTAAGAACTTTGAGGCTCATTTTGGTTTCAATGAAACAGTATCTAAT 941
QY 843 ATAAATTTAGCTGTAGATATCAGTGCTCTGATGATGATGATGATGATGATGATGATG 902
Db 942 ATAAATTTAGCTGTAGATATCAGTGCTCTGATGATGATGATGATGATGATGATGATG 1001
QY 903 GGAATCTTCATGGTTTCTCATCTGATGATGATGATGATGATGATGATGATGATGATG 962
Db 1002 GGAATCTTCATGGTTTCTCATCTGATGATGATGATGATGATGATGATGATGATGATG 1061
QY 963 AATAAAGGCGGAAATTTCCCTGCTGATGATGATGATGATGATGATGATGATGATGATG 1022
Db 1062 AATAAAGGCGGAAATTTCCCTGCTGATGATGATGATGATGATGATGATGATGATGATG 1121
QY 1023 GAGATTTCCATATTTCCATCAGAGTAAATAATATATCTGTTTAAATCTTAAGCATAAG 1082
Db 1122 GAGATTTCCATATTTCCATCAGAGTAAATAATATATCTGTTTAAATCTTAAGCATAAG 1181
QY 1083 TAAACATGATATAAATAATATCTGATGATGATGATGATGATGATGATGATGATGATG 1142
Db 1182 TAAACATGATATAAATAATATCTGATGATGATGATGATGATGATGATGATGATGATG 1241
QY 1143 AAATGTTTATTTTATTTGTAAGACATTAATTTTAAAGAAATTTGTTTATGTTTACTGTT 1202
Db 1242 AAATGTTTATTTTATTTGTAAGACATTAATTTTAAAGAAATTTGTTTATGTTTACTGTT 1301
QY 1203 CTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGTAATGATGATGATGATGATGATG 1262
Db 1302 CTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGTAATGATGATGATGATGATGATG 1361
QY 1263 ATGAGAGAAATTTGATACCAATCTGCTGTTCTTTAGTGAATGATGATGATGATGATG 1322
Db 1362 ATGAGAGAAATTTGATACCAATCTGCTGTTCTTTAGTGAATGATGATGATGATGATG 1421
QY 1323 AATTAAGACTC 1333
Db 1422 AATTAAGACTC 1432

RESULT 203

US-10-044-477-2

; Sequence 2, Application US/10044477

; Publication No. US2002010342A1

; GENERAL INFORMATION:

; APPLICANT: Hillman, Jennifer L.

Corley, Neil C.
Shah, Purvi
TITLE OF INVENTION: HUMAN CORNICHOX PROTEIN
NUMBER OF SEQUENCES: 3
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/044,477
FILING DATE: 10-Jan-2002
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/09/365,705
FILING DATE: 02-Aug-1999
APPLICATION NUMBER: US/08/950,168
FILING DATE: 14-Oct-1997
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0401 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-855-0555
TELEFAX: 650-845-4166
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 1391 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: BLADNOT04
CLONE: 1318847
SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-044-477-2

Query Match 98.8%; Score 1316.8; DB 14; Length 1391;
Best Local Similarity 99.5%; Pred. No. 1.2e-299;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 3 CCACGCGTCCGATGGCGTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 62
Db 63 CTCTCCAGCATGGCGTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 122
QY 63 CTGCGCGCTCATCTTCTTCCGCAATTTGGCAATTTATAGCATTTGATGAGCTGAAGACTG 122
Db 123 CTGCGCGCTCATCTTCTTCCGCAATTTGGCAATTTATAGCATTTGATGAGCTGAAGACTG 182
QY 123 ATTACAGAACTCTATAGACCAAGTGTATACCCGTAATCCCTTGTACTCCAGATACC 182
Db 183 ATTACAGAACTCTATAGACCAAGTGTATACCCGTAATCCCTTGTACTCCAGATACC 242
QY 183 TCATCCAGCTTCTTCTGCTCATGTTTCTTTGGCAGAGAGTGGCTTACACTGGGTC 242
Db 243 TCATCCAGCTTCTTCTGCTCATGTTTCTTTGGCAGAGAGTGGCTTACACTGGGTC 302
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAGTG 302
Db 303 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAGTG 362
QY 303 GCCCAGGACTTATGACCCCTACCAACCATCATGAATGAGATATTTCTAGCATATTTGTGAGA 362
Db 363 GCCCAGGACTTATGACCCCTACCAACCATCATGAATGAGATATTTCTAGCATATTTGTGAGA 422
QY 363 AGGAAGGATGGTGCATAATTTAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGGCA 422

Db 423 AGGAAGGATGTCGCAAAATAGCTTTTATCTCTAGCAATTTTCTACCTATATGCA 482
QY 423 TGATCTATGTTTGGTGAAGCTTTAGAACACACACAGAGAAATGGTCCAGTAAAGTGC 482
Db 483 TGATCTATGTTTGGTGAAGCTTTAGAACACACACAGAGAAATGGTCCAGTAAAGTGC 542
QY 483 ATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTCTGTCACAGAGTAGCCT 542
Db 543 ATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTCTGTCACAGAGTAGCCT 602
QY 543 GTGGAATCTGATCAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTT 602
Db 603 GTGGAATCTGATCAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTT 662
QY 603 TTGCTTGTGGAAGAGCTCTTTTATGCTTATCTCAGATAAGATTTTAAATGTTATTA 662
Db 663 TTGCTTGTGGAAGAGCTCTTTTATGCTTATCTCAGATAAGATTTTAAATGTTATTA 722
QY 663 CGTATAAATTAATAAATGATTAACCTCTGCTGTGTGACAGTTTGAACCTTGCATCTCT 722
Db 723 CGTATAAATTAATAAATGATTAACCTCTGCTGTGTGACAGTTTGAACCTTGCATCTCT 782
QY 723 AAGGAACAGCCATTAATCTCTGAATGATGCTTAATTAATGCTGCTCCTAGTACATTTGA 782
Db 783 AAGGAACAGCCATTAATCTCTGAATGATGCTTAATTAATGCTGCTCCTAGTACATTTGA 842
QY 783 AGCTTTTGTATAGGAAGCTTTGAGGCTCAATTTGGTCTTCAATTTGAACAGATCTAAT 842
Db 843 AGCTTTTGTATAGGAAGCTTTGAGGCTCAATTTGGTCTTCAATTTGAACAGATCTAAT 902
QY 843 ATAAATAGCTGTAGATATCAGGCTCTCTGATGAAGTGAATAATGATATCTGCTAGTGTG 902
Db 903 ATAAATAGCTGTAGATATCAGGCTCTCTGATGAAGTGAATAATGATATCTGCTAGTGTG 962
QY 903 GGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATATGATGATACATTTACA 962
Db 963 GGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATATGATGATACATTTACA 1022
QY 963 AAATAAAGAGGGGAATTTTCCCTTCGCTTGAATATATCTGCTTAAATCTTTAAGCAATGA 1022
Db 1023 AAATAAAGAGGGGAATTTTCCCTTCGCTTGAATATATCTGCTTAAATCTTTAAGCAATGA 1082
QY 1023 GAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTAAATCTTTAAGCAATGA 1082
Db 1083 GAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTAAATCTTTAAGCAATGA 1142
QY 1083 TAAACATGATATAAATAATATGCTGAATTAATCTGTCGAAGATGCAATTTAAAGCTATTTT 1142
Db 1143 TAAACATGATATAAATAATATGCTGAATTAATCTGTCGAAGATGCAATTTAAAGCTATTTT 1202
QY 1143 AAATGCTGTTTATTTGTAAGACATTAATTAATTAAGAAATTTGTTATGCTTACTGTT 1202
Db 1203 AAATGCTGTTTATTTGTAAGACATTAATTAATTAAGAAATTTGTTATGCTTACTGTT 1262
QY 1203 CTAACTGCTGTTAAAGTATTTCTTAAGAAATTTGAGGTAATTAAGAAATTTGTTATGCTTACTGTT 1262
Db 1263 CTAACTGCTGTTAAAGTATTTCTTAAGAAATTTGAGGTAATTAAGAAATTTGTTATGCTTACTGTT 1322
QY 1263 ATGAGCAAAATTTGTAATACCATCTGCTGTTCTTTAGTGAATATAAATAAATCTGTA 1322
Db 1323 ATGAGCAAAATTTGTAATACCATCTGCTGTTCTTTAGTGAATATAAATAAATCTGTA 1382
QY 1323 AAATTAAGA 1330
Db 1383 AAATTAAGA 1390

RESULT 204
US-09-729-835-34
; Sequence 34, Application US/09729835
; Patent No. US20010016647A1
; GENERAL INFORMATION:

; APPLICANT: Ruben et al.
; TITLE OF INVENTION: 29 Human Secreted Proteins
; FILE REFERENCE: P2015P1
; CURRENT APPLICATION NUMBER: US/09/729,835
; CURRENT FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: 09/257,179
; PRIOR FILING DATE: 1999-02-25
; PRIOR APPLICATION NUMBER: 60/056,270
; PRIOR FILING DATE: 1997-08-29
; PRIOR APPLICATION NUMBER: 60/056,271
; PRIOR FILING DATE: 1997-08-29
; PRIOR APPLICATION NUMBER: 60/056,247
; PRIOR FILING DATE: 1987-08-29
; PRIOR APPLICATION NUMBER: 60/056,073
; PRIOR FILING DATE: 1997-08-29
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 34
; LENGTH: 1404
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (36)
; OTHER INFORMATION: n equals a,t,g, or c
US-09-729-835-34

Query Match 98.8%; Score 1316.4; DB 9; Length 1404;
Best Local Similarity 99.5%; Pred. No. 1.5e-299;
Matches 1320; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 3 CCACGCGCTCCGATGGCGCTTACGCTTCGGGCGCTTCTGCTACATGCTGGCGCTGCTGCTCA 62
Db 52 CCTCCCCAGCGATGGCGCTTCAOGTTCCGCGCTTCTGCTACATGCTGGCGCTGCTGCTCA 111
QY 63 CTGCGCGCTCATCTTCTTCCGCCATTTGGACATTTATAGCATTTTGTAGAGCTGAAGACTG 122
Db 112 CTGCGCGCTCATCTTCTTCCGCCATTTGGACATTTATAGCATTTTGTAGAGCTGAAGACTG 171
QY 123 ATTACAAGATTCCTATAGACCCAGTGTAAATACCTCGAATCCCTTGTACTCCAGAGTACC 182
Db 172 ATTACAAGATTCCTATAGACCCAGTGTAAATACCTCGAATCCCTTGTACTCCAGAGTACC 231
QY 183 TCATCCAGCTTCTTCTGCTGCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 242
Db 232 TCATCCAGCTTCTTCTGCTGCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 291
QY 243 TCAATATGCCCCCTTCTGCGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAGTG 302
Db 292 TCAATATGCCCCCTTCTGCGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAGTG 351
QY 303 GCCCAGGACTCTATGACCCCTACAAACATCATGAATGAATGAGTAGACCATGATGAGTG 362
Db 352 GCCCAGGACTCTATGACCCCTACAAACATCATGAATGAATGAGTAGACCATGATGAGTG 411
QY 363 AGGAAGATGCTGCAATTAAGCTTTTATCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 422
Db 412 AGGAAGATGCTGCAATTAAGCTTTTATCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 471
QY 423 TGATCTATGTTTGGTGAAGCTCTTAGAACAAACACAGAGAAATTTGCTCCAGTTAAGTGC 482
Db 472 TGATCTATGTTTGGTGAAGCTCTTAGAACAAACACAGAGAAATTTGCTCCAGTTAAGTGC 531
QY 483 ATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCACAGAGTAGCCT 542
Db 532 ATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCACAGAGTAGCCT 591
QY 543 GTGGAATCTGATCAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTT 602
Db 592 GTGGAATCTGATCAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTT 651
QY 603 TTGCTTGTGGAAGAGCTGTTTTCATATGTTATGCTCAGATAAGATTTTAAATGTTATTA 662

Db 652 TTGCTTGTGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTATTA 711
QY 663 CGTATAAATTAATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTCTT 722
Db 712 CGTATAAATTAATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTCTT 771
QY 723 AAGGACAGCCATATCCCTCGAATGATGATTAATCTAGCTGTCTAGTACATGGA 782
Db 772 AAGGACAGCCATATCCCTCGAATGATGATTAATCTAGCTGTCTAGTACATGGA 831
QY 783 AGCTTTTGTATTAGAACTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCAATT 842
Db 832 AGCTTTTGTATTAGAACTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCAATT 891
QY 843 ATAAATAGCTGTAGATACAGTGTCTCTGATGAAGTGAATAATGATATCTAGTAG 902
Db 892 ATAAATAGCTGTAGATACAGTGTCTCTGATGAAGTGAATAATGATATCTAGTAG 951
QY 903 GGAAACTTTCATGGTTTCCCTCATCTGTCATGTCGATGATTAATATGATATGATACAA 962
Db 952 GGAAACTTTCATGGTTTCCCTCATCTGTCATGTCGATGATTAATATGATATGATACAA 1011
QY 963 AAATAAAGAGCGGAATTTTCCCTTGGCTTGAATATATCCCTGATATATGATACAA 1022
Db 1012 AAATAAAGAGCGGAATTTTCCCTTGGCTTGAATATATCCCTGATATATGATACAA 1071
QY 1023 GAGATTTCCATATTTCCATCAGATGATTAATATATCTTGTCTTAACTTAAAGCATAG 1082
Db 1072 GAGATTTCCATATTTCCATCAGATGATTAATATATCTTGTCTTAACTTAAAGCATAG 1131
QY 1083 TAAACATGATATAAATAATATGCTGAATTAATCTGTAAGATGATTAATGATATTTT 1142
Db 1132 TAAACATGATATAAATAATATGCTGAATTAATCTGTAAGATGATTAATGATATTTT 1191
QY 1143 AAATGTGTTTATTTGTAAGACATTAATTAATTAAGAAATTTGTTATGCTTACTGTT 1202
Db 1192 AAATGTGTTTATTTGTAAGACATTAATTAATTAAGAAATTTGTTATGCTTACTGTT 1251
QY 1203 CTAACTCGTGTAAAGGTTTCTTAAGAAATTTGCAAGTACAGATTTTCAAACTGA 1262
Db 1252 CTAACTCGTGTAAAGGTTTCTTAAGAAATTTGCAAGTACAGATTTTCAAACTGA 1311
QY 1263 ATGAGAGAAATTTGTAAGAAATTTGCAAGTACAGATTTTCAAACTGA 1322
Db 1312 ATGAGAGAAATTTGTAAGAAATTTGCAAGTACAGATTTTCAAACTGA 1371
QY 1323 AATTA 1328
Db 1372 AATTA 1377

RESULT 205

US-10-373-809-34

; Sequence 34, Application US/10373809
; Publication No. US20040023260A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: 29 Human Secreted Proteins
; FILE REFERENCE: PZ015P1
; CURRENT APPLICATION NUMBER: US/10/373,809
; PRIORITY FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: US/09/729,835
; PRIORITY FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: 09/257,179
; PRIORITY FILING DATE: 1999-02-25
; PRIOR APPLICATION NUMBER: 60/056,270
; PRIORITY FILING DATE: 1997-08-29
; PRIOR APPLICATION NUMBER: 60/056,271
; PRIORITY FILING DATE: 1997-08-29
; PRIOR APPLICATION NUMBER: 60/056,247
; PRIORITY FILING DATE: 1997-08-29
; PRIOR APPLICATION NUMBER: 60/056,073
; PRIORITY FILING DATE: 1997-08-29

; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 34
; LENGTH: 1404
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (36)
; OTHER INFORMATION: n equals a,t,g, or c
US-10-373-809-34

Query Match

Best Local Similarity 98.8%; Score 1316.4; DB 17; Length 1404;

Matches 1320; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 3 CCACGCGTCCGATGCGTTCAGCTTCGGGGCTTCTGCTACATGCTGCGGCTGCTGCTCA 62
Db 52 CCTCCCGAGCCATGCGGTTACGTTTCGGGGCTTCTGCTACATGCTGCGGCTGCTGCTCA 111
QY 63 CTGCGCGCTCATCTTCTTCCGCCATTTGGCACATTTATAGCATTTGATGAGCTGAAGACTG 122
Db 112 CTGCGCGCTCATCTTCTTCCGCCATTTGGCACATTTATAGCATTTGATGAGCTGAAGACTG 171
QY 123 ATTACAGAAATCTTATAGACAGTGAATACCCCTGAATCCCTTGTACTCCACAGATGACC 182
Db 172 ATTACAGAAATCTTATAGACAGTGAATACCCCTGAATCCCTTGTACTCCACAGATGACC 231
QY 183 TCATCCAGCTTCTTCTGCTCATGTTCTTGTGACAGAGTGGCTTACACTGGGTC 242
Db 232 TCATCCAGCTTCTTCTGCTCATGTTCTTGTGACAGAGTGGCTTACACTGGGTC 291
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGTATATGATAGACAGTGAAGTGTG 302
Db 292 TCAATATGCCCTCTTGGCATATCATATTTGGAGTATATGATAGACAGTGAAGTGTG 351
QY 303 GCCAGAGCTCTATGACCCCTACACCATCATGAATGACAGATATCTAGCATTTGTCTAGA 362
Db 352 GCCAGAGCTCTATGACCCCTACACCATCATGAATGACAGATATCTAGCATTTGTCTAGA 411
QY 363 AGGAAGGATGTCGAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGCA 422
Db 412 AGGAAGGATGTCGAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGCA 471
QY 423 TGAATCTATGTTTGTGAGCTCTTAGAACAACAACAAGAAATTTGTCAGTTAAAGTGC 482
Db 472 TGAATCTATGTTTGTGAGCTCTTAGAACAACAACAAGAAATTTGTCAGTTAAAGTGC 531
QY 483 ATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGAGATCCCTGTCAGAGTAGGCT 542
Db 532 ATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGAGATCCCTGTCAGAGTAGGCT 591
QY 543 GTGGAATCTGATCAGTTTACTTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACATTT 602
Db 592 GTGGAATCTGATCAGTTTACTTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACATTT 651
QY 603 TTGCTTGTGGAAGAGCTGTTTTCATATGTTATATCTCAGATAAAGATTTAAATGCTATTA 662
Db 652 TTGCTTGTGGAAGAGCTGTTTTCATATGTTATATCTCAGATAAAGATTTAAATGCTATTA 711
QY 663 CGTATAAATTAATAAATGATTAACCTCTGCTGCTGTCAGAGGTTTGAACCTTCTT 722
Db 712 CGTATAAATTAATAAATGATTAACCTCTGCTGCTGTCAGAGGTTTGAACCTTCTT 771
QY 723 AAGGAACAGCCATTAATCTCTGATGATGATTAATTAATTAATGATGATTAATTAATGGA 782
Db 772 AAGGAACAGCCATTAATCTCTGATGATGATTAATTAATTAATGATGATTAATTAATGGA 831
QY 783 AGCTTTTGTATTAGAACTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCAATT 842
Db 832 AGCTTTTGTATTAGAACTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCAATT 891
QY 843 ATAAATAGCTGTAGATATCAGGTTGCTTCTGATGAAGTGAATAATGATATCTGACTAGTG 902

Db 1261 TAACCATCTCGTGTCTTCTTAGTGAATACATCAATAAACTCTGAATTAAGACTC 1315

RESULT 207

US-09-822-846-249
; Sequence 249, Application US/09822846
; Publication No. US20030027139A1

GENERAL INFORMATION:

; APPLICANT: Jacobs, Kenneth
; APPLICANT: McCoy, John M.
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; APPLICANT: Evans, Cheryl
; APPLICANT: Merberg, David
; APPLICANT: Treacy, Maurice
; APPLICANT: Agostino, Michael J.
; APPLICANT: Steining II, Robert J.
; APPLICANT: Bowman, Michael R.
; APPLICANT: Spaulding, Vikki
; APPLICANT: Wong, Gordon G.
; APPLICANT: Clark, Hilary
; APPLICANT: Fechtel, Kim
; APPLICANT: Howes, Steven H.
; APPLICANT: Resnick, Richard J.
; APPLICANT: Gulukota, Kamalakara
; APPLICANT: Graham, James R.
; APPLICANT: Genetics Institute, Inc.
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING NOVEL SECRETED PROTEINS
; FILE REFERENCE: GIN 6400
; CURRENT APPLICATION NUMBER: US/09/822,846
; CURRENT FILING DATE: 2001-03-29
; PRIOR APPLICATION NUMBER: 60/195,605
; PRIOR FILING DATE: 2000-04-06
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 249
; LENGTH: 2916
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-822-846-249

Query Match 97.6%; Score 1301.4; DB 10; Length 2916;

Best Local Similarity 99.8%; Pred. No. 8e-296;

Matches 1313; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY	16	GGCGTTACGTTCCGGCGCTCTGCTACATGCTGGCGCTGCTCCTACCTGCGCGCTCAT	75
Db	1	GGCGTTACGTTCCGGCGCTCTGCTACATGCTGGCGCTGCTCCTACCTGCGCGCTCAT	60
QY	76	CTTCTTGGCCATTTGGCACAATATAGCAATTTGATGAGCTGAAGACTGATTACAAGATCC	135
Db	61	CTTCTTGGCCATTTGGCACAATATAGCAATTTGATGAGCTGAAGACTGATTACAAGATCC	120
QY	136	TATAGACGAGTATACCTGAATCCCTTGTACTCCAGAGTACCTCATCCAGCTTT	195
Db	121	TATAGACGAGTATACCTGAATCCCTTGTACTCCAGAGTACCTCATCCAGCTTT	180
QY	196	CTTCTGTGTCATGTTCTTTTGTGACAGAGTGGCTTACACTGGGTCTCAATATGCCCT	255
Db	181	CTTCTGTGTCATGTTCTTTTGTGACAGAGTGGCTTACACTGGGTCTCAATATGCCCT	240
QY	256	CTTGGCATATCATTTTGGAGGTATATAGTAGACCAAGCTGATGAGTGGCCAGGACTCTA	315
Db	241	CTTGGCATATCATTTTGGAGGTATATAGTAGAGCCAGTGATGAGTGGCCAGGACTCTA	300
QY	316	TGACCTTACAACCATCATCAATGAGATATTTAGCAATTTCTCAGAAGAGGATGGTG	375
Db	301	TGACCTTACAACCATCATCAATGAGATATTTAGCAATTTCTCAGAAGAGGATGGTG	360
QY	376	CAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCATCATCTATGTTTT	435
Db	361	CAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCATCATCTATGTTTT	420

QY	436	GGTGAAGCTCTTAGAACAACAACAACAAGAAATTTGGTCCAGTTAAGTGCATGAAAAAGCCA	495
Db	421	GGTGAAGCTCTTAGAACAACAACAACAAGAAATTTGGTCCAGTTAAGTGCATGAAAAAGCCA	480
QY	496	CCAAATGAAGGATTTCTATCCAGCAAGATCTGTCCCAAGAGTAGCTCTGGAATCTGATC	555
Db	481	CCAAATGAAGGATTTCTATCCAGCAAGATCTGTCCCAAGAGTAGCTCTGGAATCTGATC	540
QY	556	AGTTACTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACATTTTGTCTGTGAAA	615
Db	541	AGTTACTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACATTTTGTCTGTGAAA	600
QY	616	GACTGTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTATTACGTATAAATTAAT	675
Db	601	GACTGTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTATTACGTATAAATTAAT	660
QY	676	ATAAATGATTAACCTCTGCTGTGACAGTTTGAACCTTCTTAAGGAACAGCCAT	735
Db	661	ATAAATGATTAACCTCTGCTGTGACAGTTTGAACCTTCTTAAGGAACAGCCAT	720
QY	736	AATCCTCTGAATGATGCAATTAATTACTGACTGTCTCTAGTACATTTGAAAGCTTTTCTTAT	795
Db	721	AATCCTCTGAATGATGCAATTAATTACTGACTGTCTCTAGTACATTTGAAAGCTTTTCTTAT	780
QY	796	AGGAATTTGTAGGCTCATTTTGGTTTCATTTGAACAGTATCTAATTAATTAAGCTGT	855
Db	781	AGGAATTTGTAGGCTCATTTTGGTTTCATTTGAACAGTATCTAATTAATTAAGCTGT	840
QY	856	AGATATCAGGTGCTTCTGATGAAGTAAATGTATATCTGACTAGTGGGAACCTTCATGG	915
Db	841	AGATATCAGGTGCTTCTGATGAAGTAAATGTATATCTGACTAGTGGGAACCTTCATGG	900
QY	916	GTTTCCTCATCTGCTGATGATGATTAATATATGATGATCAATTTACAAAATTAAGAGCG	975
Db	901	G-TTTCCTCATCTGCTGATGATGATTAATATATGATGATCAATTTACAAAATTAAGAGCG	959
QY	976	GAAATTTTCCCTTCGCTTGAATATATCCCTGTATATTCATGCAATGAGAGATTTCCCAT	1035
Db	960	GAAATTTTCCCTTCGCTTGAATATATCCCTGTATATTCATGCAATGAGAGATTTCCCAT	1019
QY	1036	TTTCCATCAGAGTAAATAATATACCTGCTTTAAATTTTAAAGCATAAGTAAACATGATATA	1095
Db	1020	TTTCCATCAGAGTAAATAATATACCTGCTTTAAATTTTAAAGCATAAGTAAACATGATATA	1079
QY	1096	AAATATATCTGATGATTTCTGCAAGTATGCAATTAAGCTATTTTAAATGTGTTTTTA	1155
Db	1080	AAATATATCTGATGATTTCTGCAAGTATGCAATTTAAAGCTATTTTAAATGTGTTTTTA	1139
QY	1156	TTTGTAAAGACATTAATTAAGAAATTTGGTTATTTATGCTTCTTAAATCTGCTGT	1215
Db	1140	TTTGTAAAGACATTAATTAAGAAATTTGGTTATTTATGCTTCTTAAATCTGCTGT	1199
QY	1216	AAAGTATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAACTGAATGAGAGAAAT	1275
Db	1200	AAAGTATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAACTGAATGAGAGAAAT	1259
QY	1276	GTAATACCATCTCTGCTGTCTTCTTAGTGCATACATTAATTAAGCTCTGAAATTAAGA	1330
Db	1260	GTAATACCATCTCTGCTGTCTTCTTAGTGCATACATTAATTAAGCTCTGAAATTAAGA	1314

RESULT 208

US-09-814-353-20379
; Sequence 20379, Application US/09814353
; Publication No. US20030165831A1

GENERAL INFORMATION:

; APPLICANT: Thompson, Pamela
; APPLICANT: Lee, John
; APPLICANT: Lillie, James
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR
; TITLE OF INVENTION: IDENTIFICATION, ASSESSMENT, PREVENTION, AND
; TITLE OF INVENTION: THERAPY OF OVARIAN CANCER
; FILE REFERENCE: MRI-006B

CURRENT APPLICATION NUMBER: US/09/814,353
CURRENT FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: US 60/191,031
PRIOR FILING DATE: 2000-03-21
PRIOR APPLICATION NUMBER: US 60/207,124
PRIOR FILING DATE: 2000-05-25
PRIOR APPLICATION NUMBER: US 60/211,940
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: US 60/216,820
PRIOR FILING DATE: 2000-07-07
PRIOR APPLICATION NUMBER: US 60/220,661
PRIOR FILING DATE: 2000-07-25
PRIOR APPLICATION NUMBER: US 60/257,672
PRIOR FILING DATE: 2000-12-21
NUMBER OF SEQ ID NOS: 22037
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 20379
LENGTH: 1640
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: 1, 1640
OTHER INFORMATION: n = A,T,C or G
US-09-814-353-20379

Query Match 90.7%; Score 1209.4; DB 10; Length 1640;
Best Local Similarity 97.7%; Pred. No. 2.7e-274;
Matches 1301; Conservative 0; Mismatches 21; Indels 9; Gaps 7;
3 CCACGGCTCCGATGGCGCTTCAAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCTCA 62
127 COTCCCCAGCCATGGCGTTCAGTTGCGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 186
63 CTGGCGGCTCATCTTCTTGGCGCTTGGCGCTTGGCGCTTGGCGCTTGGCGCTGAGACTG 122
187 CTGGCGGCTCATCTTCTTGGCGCTTGGCGCTTGGCGCTTGGCGCTTGGCGCTGAGACTG 246
123 ATTACAGAGATCCATAGACAGGATGTAATCCCTGATCCCTGATCCCTGATCCCTGATCC 182
247 ATTACAGAGATCCATAGACAGGATGTAATCCCTGATCCCTGATCCCTGATCCCTGATCC 306
183 TCATCCAGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 242
307 TCATCCAGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 366
243 TCATATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 302
367 TCATATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 426
303 GCCCAGGACTCTATGACCTACACCATCATGAATGAGATGCTGCTGCTGCTGCTGCTGCTGCT 362
427 GCCCAGGACTCTATGACCTACACCATCATGAATGAGATGCTGCTGCTGCTGCTGCTGCTGCT 486
363 AGGAAGGATGGTCAAAATAGCTTTTATCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 422
487 AGGAAGGATGGTCAAAATAGCTTTTATCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 546
423 TGATCTATGTTTGGTGGCTCTTAGAACACACACACACACACACACACACACACACACACAC 482
547 TGATCTATG-TTTGGTGGCTCTTAGAACACACACACACACACACACACACACACACACACAC 605
483 ATGCAAAAGCCACCAATGAGGATTTCTATCCAGCAAGATCTGCTGCTGCTGCTGCTGCTGCT 542
606 ATGCAAAAGCCACCAATGAGGATTTCTATCCAGCAAGATCTGCTGCTGCTGCTGCTGCTGCT 665
543 GTGGAATCTGATCAGTTACTTTTAAATAAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 602
666 GTGGAATCTGATCAGTTACTTTTAAATAAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 724
603 TTGCTGCTGGAAGACTGTTTCTATGTTATGTTATGTTATGTTATGTTATGTTATGTTATGTTA 662
725 TTGCTGCTGGAAGACTGTTTCTATGTTATGTTATGTTATGTTATGTTATGTTATGTTATGTTA 784

QY 663 CGTATAAATAATAATAAATGATTAACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 722
Db 785 CGTATAAATAATAATAAATGATTAACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 844
QY 723 AAGGAACAGCCATTAATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 782
Db 845 -AGGAACAGCCATTAATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 901
QY 783 AGCTTTTGTATAGGAACCTTGTAGGCTCAATTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 842
Db 902 AGC-TTGGTTTATAGGAACCTTGTAGGCTCAATTT--GGTTTCAAGAACAGTATCTAA-T 957
QY 843 ATAAATTAGCTGTAGATATCAAGTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 902
Db 958 ATAAATGAGCTGAAGATATCAAGTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1017
QY 903 GGAACCTTCATGGGTTTCCCTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 962
Db 1018 GGAACCTTCATGGGTTTCCCTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1077
QY 963 AAATAAAAGCGGGAATTTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCT 1022
Db 1078 AAATAAAAGCGGGAATTTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCT 1137
QY 1023 GAGATTTCCCATATTTCCCATCAGAGTAATAAATACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1082
Db 1138 GAGATTTCCCATATTTCCCATCAGAGTAATAAATACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1197
QY 1083 TAAACATGATATAAAATATATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1142
Db 1198 TAAACATGATATAAAATATATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1257
QY 1143 AAATGCTGTTTTTATTTGTAAGACATTTACTTTATTAAGAAATTTGGTTATTTATGCTTACTGTT 1202
Db 1258 AAATGCTGTTTTTATTTGTAAGACATTTACTTTATTAAGAAATTTGGTTATTTATGCTTACTGTT 1317
QY 1203 CTATCTGGTGGTAAAGGTAATCTTAAGAAATTTGCGAGTACTACAGATTTTCAAAACTGA 1262
Db 1318 CTATCTGGTGGTAAAGGTAATCTTAAGAAATTTGCGAGTACTACAGATTTTCAAAACTGA 1377
QY 1263 ATGAGAGAAAATGTATAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1322
Db 1378 ATGAGAGAAAATGTATAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1437
QY 1323 AATTAGACTC 1333
Db 1438 AATTAGACTC 1448

Search completed: June 14, 2004, 20:34:02
Job time : 651 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 14, 2004, 16:06:22 ; Search time 3773 Seconds
(without alignments)
10550.301 Million cell updates/sec

Title: US-09-978-298A-321
Perfect score: 1333
Sequence: 1 gccacgcgtccgatggcgt.....aaactctgaattaagactc 1333

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 27513289 segs, 14931090276 residues

Total number of hits satisfying chosen parameters: 1

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%

Maximum Match 100%

Listing first 65000 summaries

Database :

EST:*

1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_htc:*
9: gb_est1.*
10: gb_est2.*
11: gb_htc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rod:*
26: em_gss_phg:*
27: em_gss_vrl:*
28: gb_gss1.*
29: gb_gss2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	1290.4	96.8	1394	11	AF070654 Homo sapi

ALIGNMENTS

RESULT 1
AF070654

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

MEDLINE

PUBMED

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

AF070654 1394 bp mRNA linear HTC 21-NOV-2002
Homo sapiens cornichon protein mRNA, complete cds.

AF070654.1 GI:4454683

HTC.

Homo sapiens (human)

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 1394)

Zhang, Q.H., Ye, M., Wu, X.Y., Ren, S.X., Zhao, M., Zhao, C.J., Fu, G.,

Shen, Y., Fan, H.Y., Lu, G., Zhong, M., Xu, X.R., Han, Z.G., Zhang, J.W.,

Tao, J., Huang, Q.H., Zhou, J., Hu, G.X., Gu, J., Chen, S.J. and Chen, Z.

Cloning and functional analysis of cDNAs with open reading frames

for 300 previously undefined genes expressed in CD34+ hematopoietic

stem/progenitor cells

Genome Res. 10 (10), 1546-1560 (2000)

20499367

11042152

2 (bases 1 to 1394)

Fu, G., Ye, M., Zhang, Q., Zhou, J., Wu, J., Shen, Y., Kan, L., He, K.,

Gu, B., Chen, S., Mao, M. and Chen, Z.

Human cornichon gene

Unpublished

3 (bases 1 to 1394)

Fu, G.

Direct Submission

Submitted (05-JUN-1998) Shanghai Institute of Hematology, Shanghai

Second Medical University, Rui-Jin Hospital, 197 Rui-Jin Road II,

Shanghai 200025, P. R. China

Location/Qualifiers

1. .1394

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

57. .491

/codon_start=1

/product="cornichon protein"

/protein_id="AAD20960.1"

/db_xref="GI:4454684"

/translation="MAPFAAFVYMLALLTAALIFPAIWHIAFDELKTYKNPIDQ

CNTLNPLVLEPLIHAFVCFVFLGLNMLPLAYHINRYMSRPMVMSGSLYD

PTTMMADILAYCKEGWCKLAFYLLAFFYLYGMIYLVSS"

ORIGIN

Query Match 96.8%; Score 1290.4; DB 11; Length 1394;
Best Local Similarity 99.0%; Pred. No. 9.1e-291;
Matches 1320; Conservative 0; Mismatches 11; Indels 3; Gaps 2;

Qy 3 CCACGCGTCGATGGCGTTCACGTTCCGCGCTTCTGCTACATGCTGGCGTGTCTGCTCA 62

Db 46 CCTCCCGACCATGGCGTTACGTTCCGCGCTTCTGCTACATGCTGGCGTGTCTGCTCA 105

Qy 63 CTGCGCGCTCATCTTCTTCGCCATTGGGCACATATAGCATTTGATGAGCTGAAGACTG 122

Db 106 CTGCGCGCTCATCTTCTTCGCCATTGGGCACATATAGCATTTGATGAGCTGAAGACTG 165

Qy 123 ATTACAGATCCCTATAGACAGTGTATACCTGATCCCTGATCCCTGATCCCTGATCC 182

Db 166 ATTACAGATCCCTATAGACAGTGTATACCTGATCCCTGATCCCTGATCCCTGATCC 225

Qy 183 TCATCCACGCTTCTTCTGCTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGGGTC 242

Db 226 TCATCCACGCTTCTTCTGCTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGGGTC 285

Qy 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGATG 302

Db 286 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGATG 345

Search completed: June 14, 2004, 18:56:00
Job time : 3775 secs

```
QY 303 GCCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTCTTAGCATATTGTCAGA 362
Db 346 GCCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTCTTAGCATATTGTCAGA 405
QY 363 AGGAAGGATGGTGCAAAATAGCTTTTATCTTCTTAGCATTTTCTTACTACCTATATGCA 422
Db 406 AGGAAGGATGGTGCAAAATAGCTTTTATCTTCTTAGCATTTTCTTACTACCTATATGCA 465
QY 423 TGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGTGC 482
Db 466 TGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGTGC 525
QY 483 ATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGCCT 542
Db 526 ATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGCCT 585
QY 543 GTGGAATCTGATCAGTTAC-TTTAAAAAATGACTCCTTA--TTTTTTTAAATGTTTCCACA 599
Db 586 GTGGAATCTGATCAGTTACTTTTAAAAATGACTCCTTAATTTTTTAAATGTTTCCACA 645
QY 600 TTTTGGCTTTGGAAAGACTGTTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTA 659
Db 646 TTTTGGCTTTGGAAAGACTGTTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTA 705
QY 660 TTACGTATAAATTAATATAAATGATTACCTCTGCTGTTGACAGGTTTGAAGTTGCACTT 719
Db 706 TTACGTATAAATTAATATAAATGATTACCTCTGCTGTTGACAGGTTTGAAGTTGCACTT 765
QY 720 CTTAAGGAACGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTGTCCTAGTACATT 779
Db 766 CTTAAGGAACGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTGTCCTAGTACATT 825
QY 780 GGAAGCTTTGTTTATAGAACTTTGAGGGCTCATTTGGTTTCATTTGAAAACAGTATCTA 839
Db 826 GGAAGCTTTGTTTATAGAACTTTGAGGGCTCATTTGGTTTCATTTGAAAACAGTATCTA 885
QY 840 ATTATAAATAGCTGTAGATATCAGGTCTCTGATGAAGTGAATAATGTTATATCTGACTA 899
Db 886 ATTATAAATAGCTGTAGATATCAGGTCTCTGATGAAGTGAATAATGTTATATCTGACTA 945
QY 900 GTGGAAAACCTCATGGGTTTCCATCTGTCATGTCGATGATTAATATATGATGATACATTTA 959
Db 946 GTGGAAAACCTCATGGGTTTCCATCTGTCATGTCGATGATTAATATATGATGATACATTTA 1005
QY 960 CAAAATTAAGACGGGAATTTTCCCTTGGCTTGAATATATCCCTGTATATTGCAATGAA 1019
Db 1006 CAAAATTAAGACGGGAATTTTCCCTTGGCTTGAATATATCCCTGTATATTGCAATGAA 1065
QY 1020 TGAGAGATTTCCATATTTCCATCAGAGTAATAAATAATATACCTGCTTTAATTTCTTAAGCAT 1079
Db 1066 TGAGAGATTTCCATATTTCCATCAGAGTAATAAATAATATACCTGCTTTAATTTCTTAAGCAT 1125
QY 1080 AAGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGAATGCAATTAAGCTPAT 1139
Db 1126 AAGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGAATGCAATTTAAAGCTPAT 1185
QY 1140 TTTTAAATGTTTATTTTATTTGAAGACATTTACTTATTAAGAAATGGTTATTTATGCTTACT 1199
Db 1186 TTTTAAATGTTTATTTTATTTGAAGACATTTACTTATTAAGAAATGGTTATTTATGCTTACT 1245
QY 1200 GTTCTAATCTGGTGTAAAGGTATTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAAC 1259
Db 1246 GTTCTAATCTGGTGTAAAGGTATTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAAC 1305
QY 1260 TGAATGAGAGAAAATTTGTTATATACCATCTGCTGTTCTTTTAGTGCATACAAATAAACTC 1319
Db 1306 TGAATGAGAGAAAATTTGTTATATACCATCTGCTGTTCTTTTAGTGCATACAAATAAACTC 1365
QY 1320 TGAATTAAGACTC 1333
Db 1366 TGAATTAAGACTC 1379
```

US-09-257-179-63

Query Match 100.0%; Score 784; DB 4; Length 145;
 Best Local Similarity 100.0%; Pred. No. 4.7e-79;
 Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MAFTFAAFCVNLALLLTAALIFFAIWHIIAFDELKTDYKNPIDOCNTLNPLVLPYLIHA	60
DB	1	MAFTFAAFCVNLALLLTAALIFFAIWHIIAFDELKTDYKNPIDOCNTLNPLVLPYLIHA	60
QY	61	FFCVMFCAAEWLTGLNMPLLAYHIWYMSRPVMSGPLYDPTIMNADILAYCOKEGW	120
DB	61	FFCVMFCAAEWLTGLNMPLLAYHIWYMSRPVMSGPLYDPTIMNADILAYCOKEGW	120
QY	121	CKLAFYLLAFFYYLYGMIYVLVSS	144
DB	121	CKLAFYLLAFFYYLYGMIYVLVSS	144

Search completed: June 14, 2004, 20:38:01
 Job time : 33 secs

RESULT 6
US-09-671-325-327
; TITLE OF INVENTION: DIAGNOSIS OF LUNG CANCER
; FILE REFERENCE: 210121.478C9
; CURRENT APPLICATION NUMBER: US/09/614,124B
; CURRENT FILING DATE: 2001-07-11
; NUMBER OF SEQ ID NOS: 1668
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-614-124B-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
DB 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
QY 61 FFCVMFLCAEWLTGLNMPLLAYHWRVMSRPVMSGGLYDPTTMMNADILAYCOKEGW 120
DB 61 FFCVMFLCAEWLTGLNMPLLAYHWRVMSRPVMSGGLYDPTTMMNADILAYCOKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYLVSS 144

RESULT 6
US-09-671-325-327
; Sequence 327, Application US/09671325
; Patent No. 6667154
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedwick, Tom
; APPLICANT: Carter, Darriack
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; APPLICANT: Fan, Liqun
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; FILE REFERENCE: 210121.478C12
; CURRENT APPLICATION NUMBER: US/09/671,325
; CURRENT FILING DATE: 2000-09-26
; NUMBER OF SEQ ID NOS: 1825
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-671-325-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
DB 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
QY 61 FFCVMFLCAEWLTGLNMPLLAYHWRVMSRPVMSGGLYDPTTMMNADILAYCOKEGW 120
DB 61 FFCVMFLCAEWLTGLNMPLLAYHWRVMSRPVMSGGLYDPTTMMNADILAYCOKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYLVSS 144

RESULT 7
US-09-589-184-327
; Sequence 327, Application US/09589184
; Patent No. 6686447
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedwick, Tom
; APPLICANT: Carter, Darriack
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; APPLICANT: Retter, Marc
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND
; FILE REFERENCE: 210121.478C8
; CURRENT APPLICATION NUMBER: US/09/589,184
; CURRENT FILING DATE: 2000-06-05
; NUMBER OF SEQ ID NOS: 827
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-589-184-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
DB 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
QY 61 FFCVMFLCAEWLTGLNMPLLAYHWRVMSRPVMSGGLYDPTTMMNADILAYCOKEGW 120
DB 61 FFCVMFLCAEWLTGLNMPLLAYHWRVMSRPVMSGGLYDPTTMMNADILAYCOKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYLVSS 144

RESULT 8
US-09-257-179-63
; Sequence 63, Application US/09257179
; Patent No. 6410709
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; FILE REFERENCE: P2015P1
; CURRENT APPLICATION NUMBER: US/09/257,179
; CURRENT FILING DATE: 1999-02-25
; EARLIER APPLICATION NUMBER: PCT/US98/17709
; EARLIER FILING DATE: 1998-08-27
; EARLIER APPLICATION NUMBER: 60/056,270
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,271
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,247
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,073
; EARLIER FILING DATE: 1997-08-29
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 63
; LENGTH: 145
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (145)
; OTHER INFORMATION: Xaa equals stop translation

CURRENT APPLICATION DATA:
APPLICANT: US/09/365,705
FILING DATE: 02-Aug-1999
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/950,168
FILING DATE: 14-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0401 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-855-0555
TELEFAX: 650-845-4166
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 144 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: BLADNOT04
CLONE: 1318847
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-365-705-1

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAFTFAFCYMLALLTAAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
Db 1 MAFTFAFCYMLALLTAAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
Qy 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
Db 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
Qy 121 CKLAFYLLAFFYLYGMIVLVSS 144
Db 121 CKLAFYLLAFFYLYGMIVLVSS 144

RESULT 3

US-09-702-705-327
Sequence 327, Application US/09702705
Patent No. 6504010
GENERAL INFORMATION:
APPLICANT: Wang, Tongtong
APPLICANT: Bangur, Chaitanya S.
APPLICANT: Lodes, Michael A.
APPLICANT: Fanger, Gary
APPLICANT: Vedwick, Tom
APPLICANT: Carter, Darrick
APPLICANT: Retter, Marc
APPLICANT: Mannion, Jane
APPLICANT: Fan, Liqun
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
FILE REFERENCE: 210121.478C14
CURRENT APPLICATION NUMBER: US/09/702,705
CURRENT FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 1833
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 327
LENGTH: 144
TYPE: PRT
ORGANISM: Homo sapiens
US-09-702-705-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAFTFAFCYMLALLTAAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
Db 1 MAFTFAFCYMLALLTAAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
Qy 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
Db 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
Qy 121 CKLAFYLLAFFYLYGMIVLVSS 144
Db 121 CKLAFYLLAFFYLYGMIVLVSS 144

RESULT 4

US-09-736-457-327
Sequence 327, Application US/09736457
Patent No. 6509448
GENERAL INFORMATION:
APPLICANT: Wang, Tongtong
APPLICANT: Bangur, Chaitanya S.
APPLICANT: Lodes, Michael A.
APPLICANT: Fanger, Gary
APPLICANT: Vedwick, Tom
APPLICANT: Carter, Darrick
APPLICANT: Retter, Marc
APPLICANT: Mannion, Jane
APPLICANT: Fan, Liqun
APPLICANT: Wang, AiJun
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
FILE REFERENCE: 210121.478C15
CURRENT APPLICATION NUMBER: US/09/736,457
CURRENT FILING DATE: 2000-12-13
NUMBER OF SEQ ID NOS: 1864
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 327
LENGTH: 144
TYPE: PRT
ORGANISM: Homo sapiens
US-09-736-457-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAFTFAFCYMLALLTAAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
Db 1 MAFTFAFCYMLALLTAAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
Qy 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
Db 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
Qy 121 CKLAFYLLAFFYLYGMIVLVSS 144
Db 121 CKLAFYLLAFFYLYGMIVLVSS 144

RESULT 5

US-09-614-124B-327
Sequence 327, Application US/09614124B
Patent No. 6630574
GENERAL INFORMATION:
APPLICANT: Wang, Tongtong
APPLICANT: Bangur, Chaitanya S.
APPLICANT: Lodes, Michael A.
APPLICANT: Fanger, Gary
APPLICANT: Vedwick, Tom
APPLICANT: Carter, Darrick
APPLICANT: Retter, Marc
APPLICANT: Mannion, Jane
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 14, 2004, 20:34:06 ; Search time 31 Seconds
(without alignments)
239.811 Million cell updates/sec

Title: US-09-978-298A-322
Perfect score: 784
Sequence: 1 MAFTFAFCYMLALLTAAL.....FYLLAFFYLYGMIVLVSS 144

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database :
1: /cgn2_6/ptodata/2/iaa/5A COMB.pcp.*
2: /cgn2_6/ptodata/2/iaa/5B COMB.pcp.*
3: /cgn2_6/ptodata/2/iaa/6A COMB.pcp.*
4: /cgn2_6/ptodata/2/iaa/6B COMB.pcp.*
5: /cgn2_6/ptodata/2/iaa/PCTUS COMB.pcp.*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pcp.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	784	100.0	144	2	US-08-950-168-1
2	784	100.0	144	4	US-09-365-705-1
3	784	100.0	144	4	US-09-702-705-327
4	784	100.0	144	4	US-09-736-457-327
5	784	100.0	144	4	US-09-614-124B-327
6	784	100.0	144	4	US-09-671-325-327
7	784	100.0	144	4	US-09-589-184-327
8	784	100.0	145	4	US-09-257-179-63

ALIGNMENTS

RESULT 1
US-08-950-168-1
; Sequence 1, Application US/08950168
; Patent No. 5968744
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Corley, Neil C.
; APPLICANT: Shah, Purvi
; TITLE OF INVENTION: HUMAN CORNICHON PROTEIN
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto

STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/950,168
FILING DATE: Herewith
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0401 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-855-0555
TELEFAX: 650-845-4166
TELEX:
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 144 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: BLADNOT04
CLONE: 1318847
US-08-950-168-1
Query Match 100.0%; Score 784; DB 2; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAFTFAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTLNPLVLYLHA 60
DB 1 MAFTFAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTLNPLVLYLHA 60
QY 61 FFCVMFLCAEWLTGLNMPLLAYHWYMSRPMVSGPLYDPTTINADILAYCOKEG 120
DB 61 FFCVMFLCAEWLTGLNMPLLAYHWYMSRPMVSGPLYDPTTINADILAYCOKEG 120
QY 121 CKLAFYLLAFFYLYGMIVLVSS 144
DB 121 CKLAFYLLAFFYLYGMIVLVSS 144
RESULT 2
US-09-365-705-1
; Sequence 1, Application US/09365705
; Patent No. 6348576
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Corley, Neil C.
; APPLICANT: Shah, Purvi
; TITLE OF INVENTION: HUMAN CORNICHON PROTEIN
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 14, 2004, 16:02:21 ; Search time 5327 Seconds
(without alignments)
10845.929 Million cell updates/sec

Title: US-09-978-298a-321
Perfect score: 1333
Sequence: 1 gccacgcgtccgtagcggt.....aaactctgaaattaagactc 1333

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database :

GenEmbl.*
1: gb_ba.*
2: gb_htg.*
3: gb_in.*
4: gb_om.*
5: gb_ov.*
6: gb_pat.*
7: gb_ph.*
8: gb_pl.*
9: gb_pr.*
10: gb_ro.*
11: gb_sts.*
12: gb_sy.*
13: gb_un.*
14: gb_vi.*
15: em_ba.*
16: em_fun.*
17: em_hum.*
18: em_in.*
19: em_mu.*
20: em_om.*
21: em_or.*
22: em_ov.*
23: em_pat.*
24: em_ph.*
25: em_pl.*
26: em_ro.*
27: em_sts.*
28: em_un.*
29: em_vi.*
30: em_htg_hum.*
31: em_htg_inv.*
32: em_htg_other.*
33: em_htg_mus.*
34: em_htg_pln.*
35: em_htg_rod.*
36: em_htg_mam.*
37: em_htg_vrt.*
38: em_sy.*
39: em_htgo_hum.*
40: em_htgo_mus.*
41: em_htgo_other.*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1333	100.0	1333	6	AX358866 Sequence
2	1333	100.0	1333	6	AX362359 Sequence
3	1333	100.0	1333	6	AX454416 Sequence
4	1333	100.0	1333	6	AX490894 Sequence
5	1333	100.0	1333	6	AX538136 Sequence
6	1333	100.0	1333	9	AX358635 Homo sapi
7	1321.4	99.1	1378	6	BD194411 Secretary
8	1316.8	98.8	1391	6	AR080257 Sequence
9	1316.8	98.8	1391	6	AR194401 Sequence
10	1316.4	98.8	1404	6	BD266710 29 human
11	1316.4	98.8	1404	6	AR216209 Sequence
12	1313.4	98.5	1325	6	BD231887 Bone marr
13	1311.8	98.4	1321	6	BD127279 Primer fo
14	1311.8	98.4	1321	9	AK074781 Homo sapi
15	1296.2	97.2	1396	9	AF031379 Homo sapi
16	1279.4	96.0	1398	9	AF104398 Homo sapi

ALIGNMENTS

RESULT 1
AX358866
LOCUS AX358866 1333 bp DNA linear PAT 13-FEB-2002
DEFINITION Sequence 119 from Patent WO0193983.
ACCESSION AX358866
VERSION AX358866.1 GI:18675334
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Baker,K.P., Desnoyers,L., Gerritsen,M.E., Goddard,A.,
Godowski,P.J., Grimaldi,J.C., Gurney,A.L., Smith,V., Stephan,J.P.,
Watanabe,C.K. and Wood,W.I.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: WO 0193983-A 119 13-DEC-2001;
Genentech Inc. (US)
FEATURES
source Location/Qualifiers
1. 1333
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGCGTTCACGTTGCGGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGCGTTCACGTTGCGGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCGCCATTGGCCACATTATACATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTCGCCATTGGCCACATTATACATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGATCCTATACACACAGTGTAAATACCTGAATCCCTGTCTACTCCAGAGTA 180
DB 121 TGATTACAAGATCCTATACACACAGTGTAAATACCTGAATCCCTGTCTACTCCAGAGTA 180
QY 181 CCTCATCACGCTTCTTCATGTCATGTTCTTTGTGTCAGACAGTGGCTTACACTGGG 240

Pred. No. is the number of results predicted by chance to have a

Db 181 CCTCATCCACGGCTTCTCTGTCATGTTCTTTTGTGACGACAGTGGCTTACACTGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
Qy 301 TGGCCACGAGACTCTATGACCCCTACACCATCATGATGATGAGTATCTAGCATATGTCA 360
Db 301 TGGCCACGAGACTCTATGACCCCTACACCATCATGATGATGAGTATCTAGCATATGTCA 360
Qy 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATTTTATCTAGCATATGAG 420
Db 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATTTTATCTAGCATATGAG 420
Qy 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACCAACACACAGAAGAATTTGGTCCAGTAA 480
Db 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACCAACACACAGAAGAATTTGGTCCAGTAA 480
Qy 481 GCATGCAAAAGCCCAATGAAGGATCTATCCAGCAAGATCTGTCAGAGTAGG 540
Db 481 GCATGCAAAAGCCCAATGAAGGATCTATCCAGCAAGATCTGTCAGAGTAGG 540
Qy 541 CTGTGGAATCTGATCAGTACTTTTAAATAAGTACTCTTATTTTAAATGTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTTTAAATAAGTACTCTTATTTTAAATGTTCCACAT 600
Qy 601 TTTTGGTGTGGAAGACTGTTTTCATGTTATGTTATCTAGTAAAGATTTTAAATGTTAT 660
Db 601 TTTTGGTGTGGAAGACTGTTTTCATGTTATGTTATCTAGTAAAGATTTTAAATGTTAT 660
Qy 661 TAGGTATAATTAATAAATGATTAACCTCTGCTGTCACAGGTTTGAACCTTGCACTTC 720
Db 661 TAGGTATAATTAATAAATGATTAACCTCTGCTGTCACAGGTTTGAACCTTGCACTTC 720
Qy 721 TTAAGGAAACAGCATATCTCTGAATGATGCAATTAATTAAGTACTGCTAGTACATG 780
Db 721 TTAAGGAAACAGCATATCTCTGAATGATGCAATTAATTAAGTACTGCTAGTACATG 780
Qy 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCATTTTGGTTCATTGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCATTTTGGTTCATTGAAACAGTATCTAA 840
Qy 841 TTATAAATTAAGTGTAGATCAGGTCTTCTGATGAAGTGAATAATCTGACTAG 900
Db 841 TTATAAATTAAGTGTAGATCAGGTCTTCTGATGAAGTGAATAATCTGACTAG 900
Qy 901 TGGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGATACATTTAC 960
Db 901 TGGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGATACATTTAC 960
Qy 961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATATATCCCTGTATATTCGATGAAT 1020
Db 961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATATATCCCTGTATATTCGATGAAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTAAATTTCTTAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTAAATTTCTTAAGCAT 1080
Qy 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTTGTGAAGAAATCATTTAAAGCTAT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTTGTGAAGAAATCATTTAAAGCTAT 1140
Qy 1141 TTAATCTGTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTATATGCTTACTG 1200
Db 1141 TTAATCTGTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTATATGCTTACTG 1200
Qy 1201 TTCTAATCTGGTGAAGTATTTCTTAAGAAATTTGCAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGTATTTCTTAAGAAATTTGCAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGTATACCAATCTCTGCTGTTTCTTTAGTGCATATACATTAATCTCT 1320
Db 1261 GAATGAGAGAAATTTGTATACCAATCTCTGCTGTTTCTTTAGTGCATATACATTAATCTCT 1320

Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 2
AX362359 1333 bp DNA linear PAT 15-FEB-2002
LOCUS Sequence 119 from Patent WO0208288.
DEFINITION
ACCESSION AX362359
VERSION AX362359.1 GI:18694637
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Baker, K.P., Desnoyers, L., Gerritsen, M.E., Goddard, A.,
Godowski, P.J., Grimaldi, J.C., Gurney, A.L., Smith, V., Stephan, J.P.,
Watanabe, C.K. and Wood, W.I.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: WO 0208288-A 119 31-JAN-2002;
Genentech, Inc. (US)
FEATURES
source location/Qualifiers
1..1333
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCCAGCGTCCGATGGGTTCCACGTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAGCGTCCGATGGGTTCCACGTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
Qy 61 CACTGCCGCGCTCATCTTCTCGCCATTTGGCACATTAATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTCGCCATTTGGCACATTAATAGCATTTGATGAGCTGAAGAC 120
Qy 121 TGATTACAGAATCTCTATAGACAGCTGAATACCCCTGAATCCCTTGTTACTCCAGAGTA 180
Db 121 TGATTACAGAATCTCTATAGACAGCTGAATACCCCTGAATCCCTTGTTACTCCAGAGTA 180
Qy 181 CCTCATCCACGCTTTCTTCTGTCATGTTCTTTGTGACGACAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGCTTTCTTCTGTCATGTTCTTTGTGACGACAGTGGCTTACACTGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
Qy 301 TGGCCACGAGACTCTATGACCCCTACACCATCATGATGATGAGTATCTAGCATATGTCA 360
Db 301 TGGCCACGAGACTCTATGACCCCTACACCATCATGATGATGAGTATCTAGCATATGTCA 360
Qy 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATTTTATCTAGCATATGAG 420
Db 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATTTTATCTAGCATATGAG 420
Qy 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACCAACACACAGAAGAATTTGGTCCAGTAA 480
Db 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACCAACACACAGAAGAATTTGGTCCAGTAA 480
Qy 481 GCATGCAAAAGCCCAATGAAGGATCTATCCAGCAAGATCTGTCAGAGTAGG 540
Db 481 GCATGCAAAAGCCCAATGAAGGATCTATCCAGCAAGATCTGTCAGAGTAGG 540
Qy 541 CTGTGGAATCTGATCAGTACTTTTAAATAAGTACTCTTATTTTAAATGTTTCCACAT 600

Db 541 CTGTGNAATCGATCAGTACTTAAATAATGATCCTCTATTTTAAAGTTTCCCAT 600
Qy 601 TTTTGTCTGTGGAAGAACTGTTTCATATGATTAATCTAGATTAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGAACTGTTTCATATGATTAATCTAGATTAAGATTTTAAATGGTAT 660
Qy 661 TAGCTATAAATTAATAAATAATGATTAATCTAGATTAAGATTTTAAATGGTAT 720
Db 661 TAGCTATAAATTAATAAATAATGATTAATCTAGATTAAGATTTTAAATGGTAT 720
Qy 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATCTAGATTAAGATTTTAAATGGTAT 780
Db 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATCTAGATTAAGATTTTAAATGGTAT 780
Qy 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTGGTTTCAATTAAGAGATTTTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTGGTTTCAATTAAGAGATTTTAA 840
Qy 841 TTAATAAATAGCTGATGATTAATCTAGATTAAGATTTTAAATGGTAT 900
Db 841 TTAATAAATAGCTGATGATTAATCTAGATTAAGATTTTAAATGGTAT 900
Qy 901 TGGGAACCTTCAATGATTAATCTAGATTAAGATTTTAAATGGTAT 960
Db 901 TGGGAACCTTCAATGATTAATCTAGATTAAGATTTTAAATGGTAT 960
Qy 961 AAAAATAAAGCGGGAATTTTCCCTTCCCTGATTAATCTAGATTAAGATTTTAAATGGTAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCCCTGATTAATCTAGATTAAGATTTTAAATGGTAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATGATTAATCTAGATTAAGATTTTAAATGGTAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATGATTAATCTAGATTAAGATTTTAAATGGTAT 1080
Qy 1081 AGTAAACATGATTAATAAATAATGATTAATCTAGATTAAGATTTTAAATGGTAT 1140
Db 1081 AGTAAACATGATTAATAAATAATGATTAATCTAGATTAAGATTTTAAATGGTAT 1140
Qy 1141 TTAATGTTTATTTGTAAGATTAATCTAGATTAAGATTTTAAATGGTAT 1200
Db 1141 TTAATGTTTATTTGTAAGATTAATCTAGATTAAGATTTTAAATGGTAT 1200
Qy 1201 TTTCTAATCTGTGTGTAAGATTAATCTAGATTAAGATTTTAAATGGTAT 1260
Db 1201 TTTCTAATCTGTGTGTAAGATTAATCTAGATTAAGATTTTAAATGGTAT 1260
Qy 1261 GAATGAGAGAAAATGTAATAAATGATTAATCTAGATTAAGATTTTAAATGGTAT 1320
Db 1261 GAATGAGAGAAAATGTAATAAATGATTAATCTAGATTAAGATTTTAAATGGTAT 1320
Qy 1321 GAATTTAAGACTC 1333
Db 1321 GAATTTAAGACTC 1333

RESULT 3
AX454416
LOCUS AX454416 1333 bp DNA linear PAT 06-JUL-2002
DEFINITION Sequence 1 from Patent WO0208284.
ACCESSION AX454416
VERSION AX454416.1 GI:21713832
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Baker, K.P., Ferrara, N., Gerber, H., Gerritsen, M.E., Goddard, A.,
Goddard, P.J., Gurney, A.L., Hillan, K.J., Marsters, S.A., Pan, J.,
Paoni, N.F., Stephan, J.P., Watanabe, C.K., Williams, P.M., Wood, W.I.
and Ye, W.
TITILE Compositions and methods for the diagnosis and treatment of

disorders involving angiogenesis
Patent: WO 0208284-A 1 31-JAN-2002;
Genentech, Inc. (US); Baker, Kevin P. (US); Ferrara, Napoleone
(US); Gerber, Hanspeter (US); Gerritsen, Mary E. (US); Goddard,
Audrey (US); Godowski, Paul J. (US); Gurney, Austin L. (US);
Hillan, Kenneth J. (US); Marsters, Scot A. (US); Pan, James (US);
Paoni, Nicholas F. (US); Stephan, Jean-Philippe F. (US);
Watanabe, Colin K. (US); Williams, P. Mickey (US); Wood, William
I. (US)

FEATURES
source
1. .1333
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCACGCGTCCGATGCGGTTTCAGGTTCCGCGGCTTCTGCTACATGCTGGCGTGTGCT 60
Db 1 GCCACGCGTCCGATGCGGTTTCAGGTTCCGCGGCTTCTGCTACATGCTGGCGTGTGCT 60
Qy 61 CACTGCCGCGTCACTCTTCTGCGCATTTGGCCATTTAGCATTTATAGCATTTGATGAGTGAAGAC 120
Db 61 CACTGCCGCGTCACTCTTCTGCGCATTTGGCCATTTAGCATTTATAGCATTTGATGAGTGAAGAC 120
Qy 121 TGAATTAAGAATCCTATAGACAGTGTATACCTGAATCCCTCTGATCTCCAGAGTA 180
Db 121 TGAATTAAGAATCCTATAGACAGTGTATACCTGAATCCCTCTGATCTCCAGAGTA 180
Qy 181 CCTCATCCAGCTTCTTCTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACATGGG 240
Db 181 CCTCATCCAGCTTCTTCTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACATGGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATAGTAGACAGGTGATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATAGTAGACAGGTGATGAG 300
Qy 301 TGGCCAGGACTCTATGACCTTACCAACATCAATGAATGTCAGATATTTAGCATTTGTCA 360
Db 301 TGGCCAGGACTCTATGACCTTACCAACATCAATGAATGTCAGATATTTAGCATTTGTCA 360
Qy 361 GAGGAGAGTGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTACCTATATGG 420
Db 361 GAGGAGAGTGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTACCTATATGG 420
Qy 421 CATGATCTATGTTTGTGTGAGCTCTTAGAACAAACACACAGAGAAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGTGTGAGCTCTTAGAACAAACACACAGAGAAATTTGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGAGAGATCCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGAGAGATCCTGTCCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTAAATTTTAAATTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTAAATTTTAAATTTTCCACAT 600
Qy 601 TTTTGTCTGTGGAAGAGTCTTTTTCATATGTTTACTCAGATTAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGAGTCTTTTTCATATGTTTACTCAGATTAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATAAATAATGATTAATCTGCTGTGTGTCAGAGTTTGAACCTTCCACTTC 720
Db 661 TACGTATAAATTAATAAATAATGATTAATCTGCTGTGTGTCAGAGTTTGAACCTTCCACTTC 720
Qy 721 TTAAGGACAGCCATAATCCTCTGAATGATGATTAATCTAGATTAAGATTTTAAATGGTAT 780
Db 721 TTAAGGACAGCCATAATCCTCTGAATGATGATTAATCTAGATTAAGATTTTAAATGGTAT 780
Qy 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTGGTTTCAATTAAGAGATTTTAA 840

```
Db      781  |||||GAGCCTTTGTTTATAGGAACCTTGAGGGCTCAATTTGGTTTCATGGAACGATCTAA 840
Qy      841  TTATAAATTAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATGATATCTGACTAG 900
Db      841  TTATAAATTAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATGATATCTGACTAG 900
Qy      901  TGGGAACCTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGGATATCTTAC 960
Db      901  TGGGAACCTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGGATATCTTAC 960
Qy      961  AAAAATAAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGATATATGATGAAT 1020
Db      961  AAAAATAAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGATATATGATGAAT 1020
Qy      1021  GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAAATCTTAAGCATA 1080
Db      1021  GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAAATCTTAAGCATA 1080
Qy      1081  AGTAAACATGATATAAAAATATATCTGCTGAATTTCTGTGAAGATGCAATTAAGCTAAT 1140
Db      1081  AGTAAACATGATATAAAAATATATCTGCTGAATTTCTGTGAAGATGCAATTAAGCTAAT 1140
Qy      1141  TTAATATGCTTTTATTTGTAAGACATTTCTTATTAAGAAATGCTTATATGCTTACTG 1200
Db      1141  TTAATATGCTTTTATTTGTAAGACATTTCTTATTAAGAAATGCTTATATGCTTACTG 1200
Qy      1201  TTCTAATCTGGTGGTAAAGGATTTCTTAAGAAATTTGCGGTTACTACAGATTTTCAAACT 1260
Db      1201  TTCTAATCTGGTGGTAAAGGATTTCTTAAGAAATTTGCGGTTACTACAGATTTTCAAACT 1260
Qy      1261  GAATCAGAGAAATTTGTATACCATCTGCTCTCTTTAGTGCAATCAATAAATCTCT 1320
Db      1261  GAATCAGAGAAATTTGTATACCATCTGCTCTCTTTAGTGCAATCAATAAATCTCT 1320
Qy      1321  GAAATTAAGACTC 1333
Db      1321  GAAATTAAGACTC 1333

RESULT 4
AX490894
LOCUS      1333 bp      DNA      linear      PAT 16-AUG-2002
DEFINITION Sequence 1 from Patent WO200690.
ACCESSION AX490894
VERSION    AX490894.1 GI:22323784
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Baker, K.P., Ferrara, N., Gerber, H., Gertsen, M.E., Goddard, A.,
            Godowski, P.J., Gurney, A.L., Hillan, K.J., Marsters, S.A., Pan, J.,
            Paoni, N.F., Stephan, J.P., Watanabe, C.K., Williams, P.M., Wood, W.I.
            and Ye, W.
TITLE      Compositions and methods for the diagnosis and treatment of
            disorders involving angiogenesis
JOURNAL    Patent: WO 0200690-A 1 03-JAN-2002;
            Genentech, Inc. (US)
FEATURES   Location/Qualifiers
            source          1..1333
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"

ORIGIN
Query Match      100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 GCCCACGCGTCGATGGGCTTCAAGTTCCGGGCTTCTGCTACATGCTGGGCTGTGCT 60
61  CACTGCCGCGCTCATCTTTCGGCCATTTGGCAATTTATAGCATTTGATGAGCTGAAGAC 120
61  CACTGCCGCGCTCATCTTTCGGCCATTTGGCAATTTATAGCATTTGATGAGCTGAAGAC 120
121  TGATTACAAGAATCCTATAGACACAGTGTAAATACCTCGAATCCCTCTGCTACCTCCAGAGTA 180
121  TGATTACAAGAATCCTATAGACACAGTGTAAATACCTCGAATCCCTCTGCTACCTCCAGAGTA 180
181  CCTCATCCAGCTTTCTTCTGTGTCATGTTTCTTTGTGTCAGACAGAGTGGCTTACATGGG 240
181  CCTCATCCAGCTTTCTTCTGTGTCATGTTTCTTTGTGTCAGACAGAGTGGCTTACATGGG 240
241  TCTCAATATGCCCTCTTTCGATATCATATTTGAGGATATATGATGATGAGTGGATGAG 300
241  TCTCAATATGCCCTCTTTCGATATCATATTTGAGGATATATGATGATGAGTGGATGAG 300
301  TGGCCAGGACTCTATGACCCCTACCAACATCATGAATGCAGATATTTCTAGCATATTTGCA 360
301  TGGCCAGGACTCTATGACCCCTACCAACATCATGAATGCAGATATTTCTAGCATATTTGCA 360
361  GAAGGAAGGATGGTGCAAAATGAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 420
361  GAAGGAAGGATGGTGCAAAATGAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 420
421  CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTAAAT 480
421  CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTAAAT 480
481  GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCGAAGTATGC 540
481  GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCGAAGTATGC 540
541  CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
541  CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
601  TTTTCTGTTGGAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
601  TTTTCTGTTGGAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
661  TACGTATAAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTGCACCTC 720
661  TACGTATAAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTGCACCTC 720
721  TTAAGGAACAGCCATAAATCCTCTGAATGATGCAATTAATTAATGATGATGATGATG 780
721  TTAAGGAACAGCCATAAATCCTCTGAATGATGCAATTAATTAATGATGATGATGATG 780
781  GAAGCTTTTGTATAGGAACCTTGAGGCTCATTTGGTTGTTGTTGTTGTTGTTGTTGTTG 840
781  GAAGCTTTTGTATAGGAACCTTGAGGCTCATTTGGTTGTTGTTGTTGTTGTTGTTGTTG 840
841  TTATAAATTAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATGATATCTGACTAG 900
841  TTATAAATTAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATGATATCTGACTAG 900
901  TGGGAACCTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGGATATCTTAC 960
901  TGGGAACCTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGGATATCTTAC 960
961  AAAAATAAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGATATATGATGAAT 1020
961  AAAAATAAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGATATATGATGAAT 1020
1021  GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAAATCTTAAGCATA 1080
1021  GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAAATCTTAAGCATA 1080
1081  AGTAAACATGATATAAAAATATATCTGCTGAATTTCTGTGAAGATGCAATTAAGCTAAT 1140
1081  AGTAAACATGATATAAAAATATATCTGCTGAATTTCTGTGAAGATGCAATTAAGCTAAT 1140
```

1141 TTTAAATGTTGTTTATTTGTAAGACATTAATTAAAGAAATGTTGTTATTTATGCTTACTG 1200
1141 TTTAAATGTTGTTTATTTGTAAGACATTAATTAAAGAAATGTTGTTATTTATGCTTACTG 1200
1201 TTCTAAATCTGTTGTTAAAGGTTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAAACT 1260
1201 TTCTAAATCTGTTGTTAAAGGTTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAAACT 1260
1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTCTTTAGTGTGCAATACATAAAACTCT 1320
1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTCTTTAGTGTGCAATACATAAAACTCT 1320
1321 GAAATTAAGACTC 1333
1321 GAAATTAAGACTC 1333

RESULT 5
AX538136
LOCUS AX538136 1333 bp DNA linear PAT 23-NOV-2002
DEFINITION Sequence 321 from Patent BP1241179.
ACCESSION AX538136
VERSION AX538136.1 GI:25270261
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Wood, W. I., Goddard, A., Gurney, A., Yuan, J., Baker, K. P. and Chen, J.
TITLE Human cornichon-like protein and nucleic acids encoding it
JOURNAL Patent: EP 1241179-A 321 18-SEP-2002;
Genentech, Inc. (US)
FEATURES
source 1. .1333
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGCGTTCAAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGCGTTCAAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGTCACTCTTTCGCCATTTGGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGTCACTCTTTCGCCATTTGGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACCAAGTGAATACCCCTGAATCCCTTGTTACTCCCAAGATA 180
DB 121 TGATTACAAGAAATCCTATAGACCAAGTGAATACCCCTGAATCCCTTGTTACTCCCAAGATA 180
QY 181 CCTCATCAAGCTTCTTCTGTCATGCTTTCTTGTGTCAGAGTGGCTTCACTGGG 240
DB 181 CCTCATCAAGCTTCTTCTGTCATGCTTTCTTGTGTCAGAGTGGCTTCACTGGG 240
QY 241 TCTCAATATGCCCTCTTTCGGCATATCATATTTGGAGGTATATGATAGCAGTGTATGAG 300
DB 241 TCTCAATATGCCCTCTTTCGGCATATCATATTTGGAGGTATATGATAGCAGTGTATGAG 300
QY 301 TGGCCAGGACTCTATAGACCCCTACAAACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCAGGACTCTATAGACCCCTACAAACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
QY 361 GAAGGAAGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAAGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420

QY 421 CATGATCTATGTTTGGTGGCTCTTTAGAACACACACAGAAATTTGGTCCAGTTAACT 480
DB 421 CATGATCTATGTTTGGTGGCTCTTTAGAACACACACAGAAATTTGGTCCAGTTAACT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTAAGTCTTTTAAAAAAGTCTCCTTAATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTAAGTCTTTTAAAAAAGTCTCCTTAATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGTGGAAGAGTCTGTTTTCATATGCTTACTCAGATAAAGATTTTAAATGTTAT 660
DB 601 TTTTGTCTTGTGGAAGAGTCTGTTTTCATATGCTTACTCAGATAAAGATTTTAAATGTTAT 660
QY 661 TAGGTATAAATTAATATAAATGATTAACCTCTGTGTGTGACAGGTTTGAACCTTGCACATC 720
DB 661 TAGGTATAAATTAATATAAATGATTAACCTCTGTGTGTGACAGGTTTGAACCTTGCACATC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATGATGCTGCTCTAGTACATG 780
DB 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATGATGCTGCTCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAAGTCTGTTAGGGCTCATTTTGGTTCATTTCGAAAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAAGTCTGTTAGGGCTCATTTTGGTTCATTTCGAAAACAGTATCTAA 840
QY 841 TTATAAATTAAGTCTAGATATCAGGTCCTCTGATGAAGTGAATGATAATCTGATCTAG 900
DB 841 TTATAAATTAAGTCTAGATATCAGGTCCTCTGATGAAGTGAATGATAATCTGATCTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGATGCTGATGATGATATATGATGATATATAC 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGATGCTGATGATATATATATGATGATATATAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
DB 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGATATAAATAATCTGCTTTAATTTCTTAAGCATATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGATATAAATAATCTGCTTTAATTTCTTAAGCATATA 1080
QY 1081 AGTAAAACATGATATAAATAATATATCTGCTGCTGATGATGATGATGATGATGATGAT 1140
DB 1081 AGTAAAACATGATATAAATAATATATCTGCTGCTGATGATGATGATGATGATGATGAT 1140
QY 1141 TTAATGTTTGTATTTTAAAGACATTAATTAAGAAATTTGTTTATTTATGCTTACTG 1200
DB 1141 TTAATGTTTGTATTTTAAAGACATTAATTAAGAAATTTGTTTATTTATGCTTACTG 1200
QY 1201 TTCTAAATCTGTTGTTAAAGGTTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAAACT 1260
DB 1201 TTCTAAATCTGTTGTTAAAGGTTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTCTTTAGTGTGCAATACATAAAACTCT 1320
DB 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTCTTTAGTGTGCAATACATAAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 6
AX538635
LOCUS AX538635 1333 bp mRNA linear PRI 03-OCT-2003
DEFINITION Homo sapiens clone DN23330 CNIL (UNQ155) mRNA, complete cds.
ACCESSION AX538635
VERSION AX538635.1 GI:37182391
KEYWORDS FLI CDNA.
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 1333)
 Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,
 Chen,J., Chow,B., Chuai,C., Crowley,C., Currell,B., Deuel,B.,
 Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E.,
 Heidens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,
 Lee,J., Lewis,J., Liao,D., Mark,M., Robbie,E., Sanchez,C.,
 Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V.,
 Stinson,J., Vagts,A., Vanden.R., Watanabe,C., Wieand,D., Woods,K.,
 Xie,M.H., Yansura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,
 Goddard,A., Wood,W.I. and Godowski,P.
 The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
 Effort to Identify Novel Human Secreted and Transmembrane Proteins:
 A Bioinformatics Assessment
 Genome Res. 13 (10), 2265-2270 (2003)
 12975309
 2 (bases 1 to 1333)
 Clark,H.F.
 Direct Submission
 Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
 Inc., 1 DNA Way, South San Francisco, CA 94080, USA
 Location/Qualifiers
 1..1333
 /organism="Homo sapiens"
 /mol_type="mrna"
 /db_xref="taxon:9606"
 /clone="DNA2330"
 1..1333
 /locus_tag="UNQ155"
 14..448
 /locus_tag="UNQ155"
 /note="PRO181"
 /codon_start=1
 /product="CNIL"
 /protein_id="AA089898.1"
 /db_xref="GI:3718232"
 /translation="MAFTPAFCYMLALLLFAFWHLLIAFDEKTDYKNPIDQ
 CNTLPLVPEYLHAFVCFMFLCAEWLTGLNPLLAYHWRVMSRPVMSGPLGD
 PTTIMNADILAYCQEGWCKLAFYLLAFYYLYGMIVLVSS"
 ORIGIN
 Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-283; Mismatches 0; Indels 0; Gaps 0;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCTTCTGCTACATCGTGGCGTGGCTGCT 60
 DB 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCTTCTGCTACATCGTGGCGTGGCTGCT 60
 QY 61 CACTGCGGCGTCACTCTTCTGCGCAATTTGGCAATATAGCAATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCGGCGTCACTCTTCTGCGCAATTTGGCAATATAGCAATTTGATGAGCTGAAGAC 120
 QY 121 TGATTAACAAGATCCCTATAGACAGAGTAAATCCCTGAATCCCTTGATCTCCACAGATA 180
 DB 121 TGATTAACAAGATCCCTATAGACAGAGTAAATCCCTGAATCCCTTGATCTCCACAGATA 180
 QY 181 CTTCAATCCAGCTTTCTTCTGTCATGTTTCTTTGTCAGCAGAGTGGCTTACACTGGG 240
 DB 181 CTTCAATCCAGCTTTCTTCTGTCATGTTTCTTTGTCAGCAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTACAGTATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTACAGTATGAG 300
 QY 301 TGGCCAGGACTCTATGACCTCAACCATCATGAATGACATATTTCTAGCATATTTGTCA 360
 DB 301 TGGCCAGGACTCTATGACCTCAACCATCATGAATGACATATTTCTAGCATATTTGTCA 360
 QY 361 GAAGGAGGATGGTGAAATTAGCTTTTATCTTCTAGCATATTTTCTTACTTACCTATATGG 420

DB 361 GAAGGAGGATGGTGAAATTAGCTTTTATCTTCTAGCATATTTTCTTACTTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAAAATGAAGGATTCATCCAGCAGAGATCCCTGCCAAGATGAC 540
 DB 481 GCATGCAAAAAGCCACCAAAATGAAGGATTCATCCAGCAGAGATCCCTGCCAAGATGAC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTCTGTGGAAGACAGTCTTTTATATGATTAATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTGTCTGTGGAAGACAGTCTTTTATATGATTAATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TAGCTATTAATTAATTAATTAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGACATTC 720
 DB 661 TAGCTATTAATTAATTAATTAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGACATTC 720
 QY 721 TTAAGGAAACAGCCATAATCTCTGAATGATGATTAATCTGACTGTCTAGTACATTTG 780
 DB 721 TTAAGGAAACAGCCATAATCTCTGAATGATGATTAATCTGACTGTCTAGTACATTTG 780
 QY 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTGTGACAGGTTTGAACCTTGACATTC 840
 DB 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTGTGACAGGTTTGAACCTTGACATTC 840
 QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATTAATCTGACTAG 900
 DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATTAATCTGACTAG 900
 QY 901 TGGGAAACTTTCATGGGTTTCTCATCTCATGTCGATGATTAATATATGATGATTAATTTAC 960
 DB 901 TGGGAAACTTTCATGGGTTTCTCATCTCATGTCGATGATTAATATATGATGATTAATTTAC 960
 QY 961 AAAATAAAGCGGGAATTTCCCTTCGTTGAATATATATCCCTGATATTTGATGATGAT 1020
 DB 961 AAAATAAAGCGGGAATTTCCCTTCGTTGAATATATATCCCTGATATTTGATGATGAT 1020
 QY 1021 GAGAGATTTCCATATTTCCATCAGATAAATAATATATCTTCTTAAATTTCTTAAGCATA 1080
 DB 1021 GAGAGATTTCCATATTTCCATCAGATAAATAATATATCTTCTTAAATTTCTTAAGCATA 1080
 QY 1081 AGTAAACATGATATAAATAATATATCTGTAATTAATCTGTAAGATGCAATTTAAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAATAATATATCTGTAATTAATCTGTAAGATGCAATTTAAAGCTATT 1140
 QY 1141 TTAATGTTTATTTTATTTGTAAGACATTTCTTAAAGATTTTGCAGGTACTACAGATTTTCAAACT 1200
 DB 1141 TTAATGTTTATTTTATTTGTAAGACATTTCTTAAAGATTTTGCAGGTACTACAGATTTTCAAACT 1200
 QY 1201 TTTCTAATCTGGTGTGTAAGGATTTCTTAAAGATTTTGCAGGTACTACAGATTTTCAAACT 1260
 DB 1201 TTTCTAATCTGGTGTGTAAGGATTTCTTAAAGATTTTGCAGGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAATTTGATTAACCTGCTGCTGCTTCTTTAGTGGCAATACATAAACTCT 1320
 DB 1261 GAATGAGAGAAATTTGATTAACCTGCTGCTGCTTCTTTAGTGGCAATACATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333

RESULT 7
 BD194411
 LOCUS
 DEFINITION
 Secretory proteins and polynucleotides encoding the same.
 BD194411
 ACCESSION
 BD194411.1 GI:33004152

1378 bp DNA linear PAT 17-JUL-2003

KEYWORDS JP 2002509722-A/6.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1378)
 AUTHORS Jacobs, K., McCoy, J. M., Lavallie, E. R., Racie, L. A. C., Evans, C.,
 Merberg, D., Treacy, M., Agostino, M. J., and Il, R. J. S.
 TITLE Secretory proteins and polynucleotides encoding the same
 JOURNAL Patent: JP 2002509722-A 6 02-APR-2002;
 GENETICS INSTITUTE INC
 COMMENT OS Homo sapiens (human)
 PN JP 2002509722-A/6
 PD 02-APR-2002
 PF 30-MAR-1999 JP 2000541293
 PR 31-MAR-1998 US 60/080110, 29-MAR-1999 US 09/280591 PI
 KENNETH JACOBS, JOHN M MCCOY, EDWARD R LAVALLIE, LISA A COLLINS PI
 RACIE,
 PI CHERYL EVANS, DAVID MERBERG, MAURICE TREACY, MICHAEL J AGOSTINO,
 PC C12N15/09, C07K14/00, C07K14/435, C12N5/10, C12N15/00, PC
 C12N5/00
 CC Secretory proteins and polynucleotides encoding the same FH
 Key Location/Qualifiers
 FT source 1..1378
 FT /organism="Homo sapiens (human)".
 FEATURES source
 1..1378
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 ORIGIN
 Query Match 99.1%; Score 1321.4; DB 6; Length 1378;
 Best Local Similarity 99.5%; Pred. No. 3.4e-280;
 Matches 1325; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 3 CCACGCGTCCGATGCGGTTCAGTTCGGCGCTTCTGCTACATGCTGGCGTCTGCTCA 62
 DB 33 CTCCTCCAGCCAGTGGCGTTCAGTTCGGCGCTTCTGCTACATGCTGGCGTCTGCTCA 92
 QY 63 CTGCGCGCTCATCTCTTCTGCGCATTTGGCAGATTTAGCATTTGATGAGCTGAAGACTG 122
 DB 93 CTGCGCGCTCATCTCTTCTGCGCATTTGGCAGATTTAGCATTTGATGAGCTGAAGACTG 152
 QY 123 ATTCAAGAACTTATAGACAGGTATACCTGAATCCCTGATCCCTGATCCAGAGTACC 182
 DB 153 ATTCAAGAACTTATAGACAGGTATACCTGAATCCCTGATCCCTGATCCAGAGTACC 212
 QY 183 TCATCCAGCTTCTCTGCTGTCATGTTCTGTCAGTTCGTCAGAGTGGCTTACACTGGGTC 242
 DB 213 TCATCCAGCTTCTCTGCTGTCATGTTCTGTCAGTTCGTCAGAGTGGCTTACACTGGGTC 272
 QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTATAGTACAGCATGATG 302
 DB 273 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTATAGTACAGCATGATG 332
 QY 303 GCCCAGGACTCTATGACCTCAACCAATCAATGCAATGTCAGATTTCTAGCATTTGTCAGA 362
 DB 333 GCCCAGGACTCTATGACCTCAACCAATCAATGCAATGTCAGATTTCTAGCATTTGTCAGA 392
 QY 363 AGGAAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTAGCATTTTCTAGCATTTG 422
 DB 393 AGGAAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTAGCATTTTCTAGCATTTG 452
 QY 423 TGATCTATGTTTTGGTGAAGCTTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 482
 DB 453 TGATCTATGTTTTGGTGAAGCTTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 512
 QY 483 ATGCCAAAGCCACCAATGAAGGATTTCTATCCAGCAGATCTCTGTCAGAGTACGCT 542
 DB 513 ATGCCAAAGCCACCAATGAAGGATTTCTATCCAGCAGATCTCTGTCAGAGTACGCT 572

QY 543 GTGGAATCTGATCAGTTACTTTTAAATAATGACTCTCTTATTTTAAATGTTTCCACATTT 602
 DB 573 GTGGAATCTGATCAGTTACTTTTAAATAATGACTCTCTTATTTTAAATGTTTCCACATTT 632
 QY 603 TTGCTCTGTGAAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGTTTAA 662
 DB 633 TTGCTCTGTGAAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGTTTAA 692
 QY 663 CGTATAAATTAATAAATAAAGATTACCTCTGCTGTTGACAGGTTTGAACCTTGCATCTTT 722
 DB 693 CGTATAAATTAATAAATAAAGATTACCTCTGCTGTTGACAGGTTTGAACCTTGCATCTTT 752
 QY 723 AAGGAACGACCATATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTAATTA 782
 DB 753 AAGGAACGACCATATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTAATTA 812
 QY 783 AGCTTTTGTGTTTATAGGAACCTTGTAGGGCTCAATTTTGGTTTTCATTTGAAACAGTATCTAAT 842
 DB 813 AGCTTTTGTGTTTATAGGAACCTTGTAGGGCTCAATTTTGGTTTTCATTTGAAACAGTATCTAAT 872
 QY 843 ATAAATAGCTGTAGATATCAGGTGCTTCTGATGAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA 902
 DB 873 ATAAATAGCTGTAGATATCAGGTGCTTCTGATGAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA 932
 QY 903 GGAAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAATTAATTA 962
 DB 933 GGAAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAATTAATTA 992
 QY 963 AAATAAAGCGGGAATTTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTAATTAAT 1022
 DB 993 AAATAAAGCGGGAATTTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTAATTAAT 1052
 QY 1023 GAGATTTCCCATATTTCCATCAGAGTAAATAATACTGCTTTAAATTTCTTAAGCATTAAG 1082
 DB 1053 GAGATTTCCCATATTTCCATCAGAGTAAATAATACTGCTTTAAATTTCTTAAGCATTAAG 1112
 QY 1083 TAAACATCATATAAATAATATATGCTGAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1142
 DB 1113 TAAACATCATATAAATAATATATGCTGAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1172
 QY 1143 AAATGTGTTTTTATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1202
 DB 1173 AAATGTGTTTTTATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1232
 QY 1203 CTAATCTGCTGTAAGGTTTCTTAAGAAATTCAGGTTCTACAGATTTTTCBAAACTGA 1262
 DB 1233 CTAATCTGCTGTAAGGTTTCTTAAGAAATTCAGGTTCTACAGATTTTTCBAAACTGA 1292
 QY 1263 ATGAGAGAAATTTGTATAAACCATCTGCTGTTTCTTTAGTCAATACATATAAATACTCTGA 1322
 DB 1293 ATGAGAGAAATTTGTATAAACCATCTGCTGTTTCTTTAGTCAATACATATAAATACTCTGA 1352
 QY 1323 AATTAAGACTC 1333
 DB 1353 AATTAAGACTC 1363
 RESULT 8
 AR080257
 LOCUS Sequence 2 from patent US 5968744.
 DEFINITION AR080257
 ACCESSION AR080257
 VERSION AR080257.1 GI:10006992
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 1391)
 AUTHORS Hillman, J. L., Corley, N. C. and Shah, P.
 TITLE Human cornichon molecule
 JOURNAL Patent: US 5968744-A 2 19-OCT-1999;
 FEATURES Location/Qualifiers
 1..1391 source

```
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match          98.8%; Score 1316.8; DB 6; Length 1391;
Best Local Similarity 99.5%; Pred. No. 3.5e-279;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 CCACGGTCCGATGAGGCTTCAGGTTCCGGGCGCTTCCTGCTACATGCTGGCGCTGCTCA 62
DB 63 CTTCCCGACCATGCGGTTTCAGTTTCGGGCGCTTCCTGCTACATGCTGGCGCTGCTCA 122
QY 63 CTGCGCGCTCATCTTTCTGGCATTTGGCATTATGACATTATAGCATTTGATGAGCTGAAGACTG 122
DB 123 CTGCGCGCTCATCTTTCTGGCATTTGGCATTATGACATTATAGCATTTGATGAGCTGAAGACTG 182
QY 123 ATTCAAGAATCCTATAGACCATGTAATACCTGTAATCCCTGTAATCCCTGTAATCCCGAGTACC 182
DB 183 ATTCAAGAATCCTATAGACCATGTAATACCTGTAATCCCTGTAATCCCGAGTACC 242
QY 183 TCATCCACGCTTCTTCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTC 242
DB 243 TCATCCACGCTTCTTCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTC 302
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGGTATATGAGGTATATGAGGTATATG 302
DB 303 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGGTATATGAGGTATATGAGGTATATG 362
QY 303 GCCCAGGACTCTATGACCTCAACCATCATGAATGCAGATATCTAGCATATTTGTGAGA 362
DB 363 GCCCAGGACTCTATGACCTCAACCATCATGAATGCAGATATCTAGCATATTTGTGAGA 422
QY 363 AGGAGGATGGCAAAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTTCTAGCATTTTCT 422
DB 423 AGGAGGATGGTSCAAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTTCTAGCATTTTCT 482
QY 423 TCATCTATGTTTGTGAGTCTCTAGAACACACACAGAGAAATGGTCCAGTTAAGTGC 482
DB 483 TGATCTATGTTTGTGAGTCTCTAGAACACACACAGAGAAATGGTCCAGTTAAGTGC 542
QY 483 ATGCAAAAGCCACCAATGAGGAGTCTATCCAGCAAGATCTCTGTCACAGAGTAGCCT 542
DB 543 ATGCAAAAGCCACCAATGAGGAGTCTATCCAGCAAGATCTCTGTCACAGAGTAGCCT 602
QY 543 GTGGATCTGATCAGTCTATCTTAAATAAAGTCTCTTATTTTAAATGTTTCCCATTT 602
DB 603 GTGGATCTGATCAGTCTATCTTAAATAAAGTCTCTTATTTTAAATGTTTCCCATTT 662
QY 603 TTGCTTGTGGAAGACTGTTTTCATATGTTATCTAGATAAAGATTTTAAATGGTATTA 662
DB 663 TTGCTTGTGGAAGACTGTTTTCATATGTTATCTAGATAAAGATTTTAAATGGTATTA 722
QY 663 CGTATAAATTAATAAATGATTAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 722
DB 723 CGTATAAATTAATAAATGATTAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 782
QY 723 AAGGACAGCATAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 782
DB 783 AAGGACAGCATAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 842
QY 783 AGCTTTTGTGTTAAGGAACTTGTAGGCTCATTTTGGTTCATTTGATGAAACAGTATCTAAT 842
DB 843 AGCTTTTGTGTTAAGGAACTTGTAGGCTCATTTTGGTTCATTTGATGAAACAGTATCTAAT 902
QY 843 ATAAATAGCTGATGATATCAGGTGCTTCTGATGATGATGATGATGATGATGATGATGATGATGATG 902
DB 903 ATAAATAGCTGATGATATCAGGTGCTTCTGATGATGATGATGATGATGATGATGATGATGATGATG 962
QY 903 GGAACCTTCATGGGTTTCTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 962
DB 963 GGAACCTTCATGGGTTTCTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 1022
QY 963 AAATAAAGAGGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGATATTTAGCATATTTGTCAGA 1022
```

```
Db 1023 AAATAAAGAGGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGATATTTATGATGAATGA 1082
QY 1023 GAGATTTCCCATATTTTCCATCAGAGTAATAATATATCTGCTTTAAATTTCTTAAGCATGAAG 1082
Db 1083 GAGATTTCCCATATTTTCCATCAGAGTAATAATATATCTGCTTTAAATTTCTTAAGCATGAAG 1142
QY 1083 TAACATGATATAAATAATATATCTGCTTTAAATTTCTTAAGCATGAAG 1142
Db 1143 TAACATGATATAAATAATATATCTGCTTTAAATTTCTTAAGCATGAAG 1202
QY 1143 AAATGCTGTTTATTTTGAAGACATTTACTTATTAAGAAATTTGGTATTTATCTTACTGTT 1202
Db 1203 AAATGCTGTTTATTTTGAAGACATTTACTTATTAAGAAATTTGGTATTTATCTTACTGTT 1262
QY 1203 CTAACTCGTGGTAAAGTATTTTAAGAAATTTGAGTACTACAGATTTTCAAAACTGA 1262
Db 1263 CTAACTCGTGGTAAAGTATTTTAAGAAATTTGAGTACTACAGATTTTCAAAACTGA 1322
QY 1263 ATGAGAGAAATTTGATAAACCCTGCTGTTTCTTTAGTGCATACATAAATAAATCTGA 1322
Db 1323 ATGAGAGAAATTTGATAAACCCTGCTGTTTCTTTAGTGCATACATAAATAAATCTGA 1382
QY 1323 AATTAAGA 1330
Db 1383 AATTAAGA 1390

RESULT 9
AR194401
LOCUS AR194401 1391 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2 from patent US 6348576.
ACCESSION AR194401
VERSION AR194401.1 GI:20240993
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 1391)
AUTHORS Hillman, J.L., Corley, N.C. and Shah, P.
TITLE Human cornichon molecule
JOURNAL Patent: US 6348576-A 2 19-FEB-2002;
FEATURES
Location/Qualifiers
1..1391
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 98.8%; Score 1316.8; DB 6; Length 1391;
Best Local Similarity 99.5%; Pred. No. 3.5e-279;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 CCACGGTCCGATGAGGCTTCAGGTTCCGGGCGCTTCCTGCTACATGCTGGCGCTGCTCA 62
DB 63 CTTCCCGACCATGCGGTTTCAGTTTCGGGCGCTTCCTGCTACATGCTGGCGCTGCTCA 122
QY 63 CTGCGCGCTCATCTTTCTGGCATTTGGCATTATGACATTATAGCATTTGATGAGCTGAAGACTG 122
DB 123 CTGCGCGCTCATCTTTCTGGCATTTGGCATTATGACATTATAGCATTTGATGAGCTGAAGACTG 182
QY 123 ATTCAAGAATCCTATAGACCATGTAATACCTGTAATCCCTGTAATCCCTGTAATCCCGAGTACC 182
DB 183 ATTCAAGAATCCTATAGACCATGTAATACCTGTAATCCCTGTAATCCCGAGTACC 242
QY 183 TCATCCACGCTTCTTCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTC 242
DB 243 TCATCCACGCTTCTTCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTC 302
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGGTATATGAGGTATATGAGGTATATG 302
DB 303 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGGTATATGAGGTATATGAGGTATATG 362
QY 303 GCCCAGGACTCTATGACCTCAACCATCATGAATGCAGATATCTAGCATATTTGTGAGA 362
DB 363 GCCCAGGACTCTATGACCTCAACCATCATGAATGCAGATATCTAGCATATTTGTGAGA 422
QY 363 AGGAGGATGGCAAAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTTCTAGCATTTTCT 422
DB 423 AGGAGGATGGTSCAAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTTCTAGCATTTTCT 482
QY 423 TCATCTATGTTTGTGAGTCTCTAGAACACACACAGAGAAATGGTCCAGTTAAGTGC 482
DB 483 TGATCTATGTTTGTGAGTCTCTAGAACACACACAGAGAAATGGTCCAGTTAAGTGC 542
QY 483 ATGCAAAAGCCACCAATGAGGAGTCTATCCAGCAAGATCTCTGTCACAGAGTAGCCT 542
DB 543 ATGCAAAAGCCACCAATGAGGAGTCTATCCAGCAAGATCTCTGTCACAGAGTAGCCT 602
QY 543 GTGGATCTGATCAGTCTATCTTAAATAAAGTCTCTTATTTTAAATGTTTCCCATTT 602
DB 603 GTGGATCTGATCAGTCTATCTTAAATAAAGTCTCTTATTTTAAATGTTTCCCATTT 662
QY 603 TTGCTTGTGGAAGACTGTTTTCATATGTTATCTAGATAAAGATTTTAAATGGTATTA 662
DB 663 TTGCTTGTGGAAGACTGTTTTCATATGTTATCTAGATAAAGATTTTAAATGGTATTA 722
QY 663 CGTATAAATTAATAAATGATTAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 722
DB 723 CGTATAAATTAATAAATGATTAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 782
QY 723 AAGGACAGCATAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 782
DB 783 AAGGACAGCATAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 842
QY 783 AGCTTTTGTGTTAAGGAACTTGTAGGCTCATTTTGGTTCATTTGATGAAACAGTATCTAAT 842
DB 843 AGCTTTTGTGTTAAGGAACTTGTAGGCTCATTTTGGTTCATTTGATGAAACAGTATCTAAT 902
QY 843 ATAAATAGCTGATGATATCAGGTGCTTCTGATGATGATGATGATGATGATGATGATGATGATGATG 902
DB 903 ATAAATAGCTGATGATATCAGGTGCTTCTGATGATGATGATGATGATGATGATGATGATGATGATG 962
QY 903 GGAACCTTCATGGGTTTCTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 962
DB 963 GGAACCTTCATGGGTTTCTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 1022
QY 963 AAATAAAGAGGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGATATTTAGCATATTTGTCAGA 1022
```

```
Db 363 GCCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATCTAGCATATGTCAGA 422
Qy 363 AGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATATTTTATCTAGCATATGTCAGA 422
Db 423 AGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATATTTTATCTAGCATATGTCAGA 482
Qy 423 TGATCTATGTTTGTGTAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGTGC 482
Db 483 TGATCTATGTTTGTGTAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGTGC 542
Qy 483 ATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCCTGTCCAGAGTAGCT 542
Db 543 ATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCCTGTCCAGAGTAGCT 602
Qy 543 GTGGGAATCTGATCAGTACTTAAAGAAAGTACCTTATTTTAAAGTCTTCAATTT 602
Db 603 GTGGGAATCTGATCAGTACTTAAAGAAAGTACCTTATTTTAAAGTCTTCAATTT 662
Qy 603 TTGCTTGTGGAAGACTGTTTCAATATGTTATCTCAGATAAGATTTTAAATGCTATTA 662
Db 663 TTGCTTGTGGAAGACTGTTTCAATATGTTATCTCAGATAAGATTTTAAATGCTATTA 722
Qy 663 CGTATAAATTAATAAAGATTAACCTCTGCTGTGTGACAGGTTTGAACCTTCACTTCT 722
Db 723 CGTATAAATTAATAAAGATTAACCTCTGCTGTGTGACAGGTTTGAACCTTCACTTCT 782
Qy 723 AAGGAACAGCCATAATCTCTCAATGATGATGATGATGATGATGATGATGATGATGAT 782
Db 783 AAGGAACAGCCATAATCTCTCAATGATGATGATGATGATGATGATGATGATGATGAT 842
Qy 783 AGCTTTTGTATAGGAAGCTGTAGGCTCATTTTGGTTTCAATGATGATGATGATGATGAT 842
Db 843 AGCTTTTGTATAGGAAGCTGTAGGCTCATTTTGGTTTCAATGATGATGATGATGATGAT 902
Qy 843 ATAAATAGCTGTAGATATCAGTGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 902
Db 903 ATAAATAGCTGTAGATATCAGTGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 962
Qy 903 GGAACCTTCATGGGTTTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 962
Db 963 GGAACCTTCATGGGTTTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 1022
Qy 963 AAATAAAGCGGGAATTTTCCCTTCTGATGATGATGATGATGATGATGATGATGATGAT 1022
Db 1023 AAATAAAGCGGGAATTTTCCCTTCTGATGATGATGATGATGATGATGATGATGATGAT 1082
Qy 1023 GAGATTTCCCATATTTCCATCAGAGTAAATATATATATATATATATATATATATATAT 1082
Db 1083 GAGATTTCCCATATTTCCATCAGAGTAAATATATATATATATATATATATATATATAT 1142
Qy 1083 TAAACATGATATAAATAATATATATATATATATATATATATATATATATATATATATAT 1142
Db 1143 TAAACATGATATAAATAATATATATATATATATATATATATATATATATATATATATAT 1202
Qy 1143 AAATGTGTTTATTTGTAAGACATTAATTAAGAAATTTGTTTATATATATATATATATAT 1202
Db 1203 AAATGTGTTTATTTGTAAGACATTAATTAAGAAATTTGTTTATATATATATATATATAT 1262
Qy 1203 CTAATCTGGTGAAGTATTTTAAGAAATTTGAGAGTATTAAGAAATTTGAGAGTATTAAG 1262
Db 1263 CTAATCTGGTGAAGTATTTTAAGAAATTTGAGAGTATTAAGAAATTTGAGAGTATTAAG 1322
Qy 1263 ATGAGAGAAATTTGTAAGAAATTTGAGAGTATTAAGAAATTTGAGAGTATTAAGAAAT 1322
Db 1323 ATGAGAGAAATTTGTAAGAAATTTGAGAGTATTAAGAAATTTGAGAGTATTAAGAAAT 1382
Qy 1323 AAATTAAGA 1330
Db 1383 AAATTAAGA 1390
```

RESULT 10

BD266710
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

BD266710 1404 bp DNA Linear PAT 17-JUL-2003
29 human secreted proteins.
BD266710
BD266710.1 GI:33076478
JP 2002532054-A/33.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1404)
Ruben, S.M., Rosen, C.A., Fan, P., Kyaw, H. and Wei, Y.F.
29 human secreted proteins
Patent: JP 2002532054-A 33 02-OCT-2002;
HUMAN GENOME SCIENCES INC
OS Homo sapiens (human)
PN JP 2002532054-A/33
PD 02-OCT-2002
PF 27-AUG-1998 JP 2000507689
PR 29-AUG-1997 US 60/056073, 29-AUG-1997 US 60/056271 PR
29-AUG-1997 US 60/056270, 29-AUG-1997 US 60/056247 PI STEVEN
M RUBEN, CRAIG A ROSEN, PING FAN, HLA KYAW, YING FEI WEI PC
C12N15/09, A61K38/00, A61K48/00, A61P15/00, A61P17/00, A61P37/00, PC
C07K14/52,
PC C07K16/24, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12P21/08 PC
, C12Q1/68, G01N33/15,
PC G01N33/50, C12N15/00, A61K37/02, C12N5/00
CC n equals a,t,g, or c
FH Key Location/Qualifiers
FT source 1..1404
/organism="Homo sapiens (human)"

REFERENCE
AUTHORS
TITLE
JOURNAL

COMMENT

FEATURES
source

ORIGIN

Query Match 98.8%; Score 1316.4; DB 6; Length 1404;
Best Local Similarity 99.5%; Pred. No. 4.3e-279;
Matches 1320; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```
Qy 3 CCACGGTCCGATGGGTTACGTTCCGGGCTTCTGCTACATGCTGGCGTCTGCTCA 62
Db 52 CTTCCAGCATGGGTTACGTTCCGGGCTTCTGCTACATGCTGGCGTCTGCTCA 111
Qy 63 CTGCGGCGCTCATCTTCTGCGCATTTGGCACATTTAGCATTTGATGAGTGAAGACTG 122
Db 112 CTGCGGCGCTCATCTTCTGCGCATTTGGCACATTTAGCATTTGATGAGTGAAGACTG 171
Qy 123 ATTCAAGAATCTTATAGA CAGGTAAATACCTGAAATCCCTTGTACTCCAGAGTACC 182
Db 172 ATTCAAGAATCTTATAGA CAGGTAAATACCTGAAATCCCTTGTACTCCAGAGTACC 231
Qy 183 TCATCCAGCTTTCTTCTGTCATGTTCTTTGTGCGAGGAGTGGCTTACACTGGGTC 242
Db 232 TCATCCAGCTTTCTTCTGTCATGTTCTTTGTGCGAGGAGTGGCTTACACTGGGTC 291
Qy 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAGTG 302
Db 292 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAGTG 351
Qy 303 GCCCAGGACTTATGACCCCTACCAATCATGATGAGTATTTCTAGCATATTTGTGTCAGA 362
Db 352 GCCCAGGACTTATGACCCCTACCAATCATGATGAGTATTTCTAGCATATTTGTGTCAGA 411
Qy 363 AGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATATTTTACTATATATGCA 422
Db 412 AGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATATTTTACTATATATGCA 471
Qy 423 TGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 482
Db 472 TGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 531
```

483 ATGCACCAAGCCACCAATGAGGATCTCTATCCAGCAAGATCCTGTCGAGAGTAGCCT 542
Db
532 ATGCACCAAGCCACCAATGAGGATCTCTATCCAGCAAGATCCTGTCGAGAGTAGCCT 591
QY 543 GTGGAATCTGATCAGTTACTTTAAATAAGACTCTTATTTTAAATGTTTCCACATTT 602
Db 592 GTGGAATCTGATCAGTTACTTTAAATAAGACTCTTATTTTAAATGTTTCCACATTT 651
QY 603 TTGCTGTGGAAGACTGTTTTCATATGTTATCTAGATAAAGATTTAAATGGTATTA 662
Db 652 TTGCTGTGGAAGACTGTTTTCATATGTTATCTAGATAAAGATTTAAATGGTATTA 711
QY 663 CGTATAAATAATATAAATGATTACCTCTGAGTGTGACAGGTTGACCTGACATCTTT 722
Db 712 CGTATAAATAATATAAATGATTACCTCTGAGTGTGACAGGTTGACCTGACATCTTT 771
QY 723 AAGGAACAGCCATTAATCTCTGAATGATGCAATTAATTAAGTCTGCTAGTACATTGGA 782
Db 772 AAGGAACAGCCATTAATCTCTGAATGATGCAATTAATTAAGTCTGCTAGTACATTGGA 831
QY 783 AGCTTTTGTATAGGAACCTGTAGGCTCAATTTGGTTTCANTGAAAACAGTATCTAAT 842
Db 832 AGCTTTTGTATAGGAACCTGTAGGCTCAATTTGGTTTCANTGAAAACAGTATCTAAT 891
QY 843 ATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATATGATACAA 902
Db 892 ATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATATGATACAA 951
QY 903 GGAACTCTGAGGTTTCCCTCACTCTGATGATGATGATGATGATGATGATGATGATGAT 962
Db 952 GGAACTCTGAGGTTTCCCTCACTCTGATGATGATGATGATGATGATGATGATGATGAT 1011
QY 963 AAATAAAGAGCGGAATTTTCCCTTCGCTTGAATATATATATATATATATATATATAT 1022
Db 1012 AAATAAAGAGCGGAATTTTCCCTTCGCTTGAATATATATATATATATATATATATAT 1071
QY 1023 GAGATTTCACATATTTCCATCAGAGTAATAAATAATATATATATATATATATATATAT 1082
Db 1072 GAGATTTCACATATTTCCATCAGAGTAATAAATAATATATATATATATATATATATAT 1131
QY 1083 TAAACATGATATAAATAAT 1142
Db 1132 TAAACATGATATAAATAAT 1191
QY 1143 AAATGTTTATTTTGTAGACATTTACTTATTAAGAAATTTGGTTATATATATATATAT 1202
Db 1192 AAATGTTTATTTTGTAGACATTTACTTATTAAGAAATTTGGTTATATATATATATAT 1251
QY 1203 CTAATCTGTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACTGA 1262
Db 1252 CTAATCTGTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACTGA 1311
QY 1263 ATGAGAGAAATTTGATACCACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1322
Db 1312 ATGAGAGAAATTTGATACCACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1371
QY 1323 AATTA 1328
Db 1372 AATTA 1377

RESULT 11
LOCUS AR216209
DEFINITION Sequence 34 from patent US 6410709.
ACCESSION AR216209
VERSION AR216209.1 GI:23314573
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1404)

AUTHORS
TITLE
JOURNAL
FEATURES

source

ORIGIN

Query Match

Best Local Similarity 98.8%; Score 1316.4; DB 6; Length 1404;

Matches 1320; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Ruben, S.M., Rosen, C.A., Fan, P., Kyaw, H. and Wei, Y.-F.
Cornichon-like protein
Patent: US 6410709-A 34 25-JUN-2002;
Location/Qualifiers

1. 1404
/organism="unknown"
/mol_type="genomic DNA"

QY 3 CCAAGCGTCCGATGGGCTTCACTGCGGCGCTTCTGCTACATGCTGCGGCTGCTGCTCA 62
Db 52 CTTCCCGAGCATGGGCTTCACTGCGGCGCTTCTGCTACATGCTGCGGCTGCTGCTCA 111
QY 63 CTGCGGCGCTCATCTCTCTTCTGCGCATTTGGCAATTAATAGCATTTGATGAGTGAAGCTG 122
Db 112 CTGCGGCGCTCATCTCTCTTCTGCGCATTTGGCAATTTAGCATTTGATGAGTGAAGCTG 171
QY 123 ATTACAAGAAATCTATAGACCAAGTGTAAATCCCTGAATCCCTTGTACTTCCAGAGTACC 182
Db 172 ATTACAAGAAATCTATAGACCAAGTGTAAATCCCTGAATCCCTTGTACTTCCAGAGTACC 231
QY 183 TCATCCAGCTTCTTCTGCTGCTCACTGTTTCTTGTGCGAGCAGAGTGGCTTACACTGGGTC 242
Db 232 TCATCCAGCTTCTTCTGCTGCTCACTGTTTCTTGTGCGAGCAGAGTGGCTTACACTGGGTC 291
QY 243 TCAATATGCCCCCTTGGCATATCATTTTGGAGGTATATAGTATAGACCAAGTGAAGTGTG 302
Db 292 TCAATATGCCCCCTTGGCATATCATTTTGGAGGTATATAGTATAGACCAAGTGAAGTGTG 351
QY 303 GCCCAGGACTCTATCAACCTCAACCATCATCAATGAGATATTTAGTATAGTATAGTATAGT 362
Db 352 GCCCAGGACTCTATCAACCTCAACCATCATCAATGAGATATTTAGTATAGTATAGTATAGT 411
QY 363 AGGAAGGATGTCGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTAGCTATATATATATAT 422
Db 412 AGGAAGGATGTCGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTAGCTATATATATATAT 471
QY 423 TGATCTATGTTTGTGAGCTCTTGAACAACAACAACAACAACAACAACAACAACAACAACA 482
Db 472 TGATCTATGTTTGTGAGCTCTTGAACAACAACAACAACAACAACAACAACAACAACAACA 531
QY 483 ATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCGAGAGTAGCCT 542
Db 532 ATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCGAGAGTAGCCT 591
QY 543 GTGGAAATCTGATCAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCCACTTT 602
Db 592 GTGGAAATCTGATCAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCCACTTT 651
QY 603 TTGCTGTGGAAGACTGTTTTCATATGTTATCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 662
Db 652 TTGCTGTGGAAGACTGTTTTCATATGTTATCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 711
QY 663 CGTATAAATAATATAAATGATTACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 722
Db 712 CGTATAAATAATATAAATGATTACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 771
QY 723 AAGGAACAGCCATTAATCTCTGAATGATGCAATTAATTAAGTCTGCTAGTACATTGGA 782
Db 772 AAGGAACAGCCATTAATCTCTGAATGATGCAATTAATTAAGTCTGCTAGTACATTGGA 831
QY 783 AGCTTTTGTATAGGAACCTGTAGGCTCAATTTGGTTTCANTGAAAACAGTATCTAAT 842
Db 832 AGCTTTTGTATAGGAACCTGTAGGCTCAATTTGGTTTCANTGAAAACAGTATCTAAT 891
QY 843 ATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATATATATATATAT 902
Db 892 ATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATATATATATATAT 951

QY	903	GGAACCTTCATGGGTTTCCTCATCTGTCATGTCGATGATATATATGATACATTACAA	963
DB	952	GGAACCTTCATGGGTTTCCTCATCTGTCATGTCGATGATATATGATACATTACAA	1011
QY	963	AAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCGATGAATGA	1022
DB	1012	AAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCGATGAATGA	1071
QY	1023	GAGATTTCCCATATTTTCCATCAGAGTAAATAATATCTTGTGAAGAAATGCATTTAAAGCATAAG	1082
DB	1072	GAGATTTCCCATATTTTCCATCAGAGTAAATAATATCTTGTGAAGAAATGCATTTAAAGCATAAG	1131
QY	1083	TAAACATGATATAAAATATATATGCTGAATTAATCTTGTGAAGAAATGCATTTAAAGCATTTT	1142
DB	1132	TAAACATGATATAAAATATATATGCTGAATTAATCTTGTGAAGAAATGCATTTAAAGCATTTT	1191
QY	1143	AAATGCTGTTTTTATTTGTAAGACATTAATTAAGAAATGGTTATATATGCTTTACGTT	1202
DB	1192	AAATGCTGTTTTTATTTGTAAGACATTAATTAAGAAATGGTTATATATGCTTTACGTT	1251
QY	1203	CTAATCTGCTGCTAAAGATTAATCTTAAGAAATTTTCAGGTAATCTAAGAAATTTCAAACTGA	1262
DB	1252	CTAATCTGCTGCTAAAGATTAATCTTAAGAAATTTTCAGGTAATCTAAGAAATTTCAAACTGA	1311
QY	1263	ATGAGAGAAATTTGTAAGACATTAATTAAGAAATGGTTATATATGCTTTACGTT	1322
DB	1312	ATGAGAGAAATTTGTAAGACATTAATTAAGAAATGGTTATATATGCTTTACGTT	1371
QY	1323	AAATTA 1328	
DB	1372	AAATTA 1377	
RESULT 12			
LOCUS	BD231887	1325 bp DNA linear	PAT 17-JUL-2003
DEFINITION	Bone marrow secreted proteins and polynucleotides.		
ACCESSION	BD231887		
VERSION	BD231887.1	GI:33041657	
KEYWORDS	JP 2002511231-A/1.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
TITLE	Lin.H. and Cao.L.		
JOURNAL	Bone marrow secreted proteins and polynucleotides		
COMMENT	Patent: JP 2002511231-A 1 16-APR-2002;		
	CHIRON CORP		
	OS	Homo sapiens (human)	
	PN	JP 2002511231-A/1	
	PD	16-APR-2002	
	PF	18-DEC-1998 JP 2000526635	
	PR	30-DEC-1997 US 60/068959, 24-SEP-1998 US 60/101603 PR	
	30-SEP-1998 US 60/102540		
	PI	HAISHAN LIN, LI CAO	
	PC	C12N15/09, A61K38/00, A61P43/00, C07K14/47, C07K16/18, C12N5/10, PC	
		C12Q1/68,	
	PC	C12N15/00, A61K37/02, C12N5/00	
	CC	Bone marrow secreted proteins and polynucleotides FH	Key
	FT	source	
	FT	1. .1325	
FEATURES	Location/Qualifiers		
source	1. .1325		
	/organism="Homo sapiens"		
	/mol_type="genomic DNA"		
	/db_xref="taxon:9606"		
ORIGIN			
Query Match	98.5%; Score 1313.4; DB 6; Length 1325;		
Best Local Similarity	99.9%; Pred. No. 2e-278;		
Matches 1314; Conservative	0; Mismatches 1; Indels 0; Gaps 0;		


```

QY 1272 AATTGTATACCACTCTGCTGTTCTTTAGTGCATACATAAATACTCTGAATT 1326
Db |||||||
1267 AATTGTATACCACTCTGCTGTTCTTTAGTGCATACATAAATACTCTGAATT 1321
|||||

RESULT 14
AK074781
LOCUS Homo sapiens cDNA FLJ90300 fis, clone NT2RP2000533, highly similar
DEFINITION to Homo sapiens cornichon protein mRNA.
ACCESSION AK074781
VERSION AK074781.1 GI:22760452
KEYWORDS oligo capping; fis (full insert sequence).
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Isogai,T., Ota,T., Nishikawa,T., Hayashi,K., Otsuki,T.,
Sugiyama,T., Suzuki,Y., Nagai,K., Sugano,S., Iehli,S.,
Kawai-Hio,Y., Saito,K., Yamamoto,J., Wakamatsu,A., Nakamura,Y.,
Kojima,S., Nagahari,K., Masuho,Y., Ono,T., Okano,K., Yoshikawa,Y.,
Aotsuka,S., Sasaki,N., Hattori,A., Okumura,K., Iwayanagi,T. and
Ninomiya,K.
TITLE NEDO human cDNA sequencing project
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1321)
AUTHORS Isogai,T. and Otsuki,T.
TITLE Direct Submission
JOURNAL Submitted (25-MAR-2002) Takao Isogai, Helix Research Institute,
Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan
(E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)
COMMENT NEDO human cDNA sequencing project supported by Ministry of
Economy, Trade and Industry of Japan; cDNA full insert sequencing:
Research Association for Biotechnology; cDNA library construction:
Institute of Medical Science, University of Tokyo, Laboratory of
Genome Structure, Human Genome Center; cDNA 5'- & 3'-end one pass
sequencing and clone selection: Helix Research Institute (supported
by Japan Key Technology Center etc.).
FEATURES
source
1. 1321
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="NT2RP2000533"
/cell_line="NT2"
/cell_type="teratocarcinoma"
/clone_lib="NT2RP2"
/note="cloning vector: pME18FL3-mRNA from NT2 neuronal
precursor cells after 2-weeks retinoic acid (RA)
induction"

ORIGIN
Query Match 98.4%; Score 1311.8; DB 9; Length 1321;
Best Local Similarity 99.8%; Pred. NO. 4.4e-278;
Matches 1313; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 12 CGATGGCGTTTCACGTTCCGGCGCTTCTGCTACATCGTGGCGTGTGCTGCTACTGCGGCG 71
Db |||||||
7 CCATGGCGTTTCACGTTCCGGCGCTTCTGCTACATCGTGGCGTGTGCTGCTACTGCGGCG 66
|||||

QY 72 TCATCTCTTCGCGCATTTGGCACAATTATAGCATTTGATGAGCTGAAGACTGATTACAGA 131
Db |||||||
67 TCATCTCTTCGCGCATTTGGCACAATTATAGCATTTGATGAGCTGAAGACTGATTACAGA 126
|||||

QY 132 ATCTCTATAGACAGTGTAATCCCTGAATCCCTTGTAATCCCTGTAATCCCTGTAATCCCTG 191
Db |||||||
127 ATCTCTATAGACAGTGTAATCCCTGAATCCCTTGTAATCCCTGTAATCCCTGTAATCCCTG 186
|||||

QY 192 CTTTCTCTGCTGTGTCATGTTCTTTGTCAGCAGAGTGGCTTTACATGCTGGTCTCAATATGC 251
Db |||||||
187 CTTTCTCTGCTGTGTCATGTTCTTTGTCAGCAGAGTGGCTTTACATGCTGGTCTCAATATGC 246
|||||

```

```

QY 252 CCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAGTGAAGTGGCCCGAGGAC 311
Db |||||||
247 CCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAGTGAAGTGGCCCGAGGAC 306
|||||

QY 312 TCTATGACCCCTCAACCAATCATGATGAGATATTTCTAGCATATTTGTTCAGAGGAGGAT 371
Db |||||||
307 TCTATGACCCCTCAACCAATCATGATGAGATATTTCTAGCATATTTGTTCAGAGGAGGAT 366
|||||

QY 372 GGTGCAAAATAGCTTTTATCTTCTAGCAATTTTTTACTTACCTATATATGCGCATGCTATG 431
Db |||||||
367 GGTGCAAAATAGCTTTTATCTTCTAGCAATTTTTTACTTACCTATATATGCGCATGCTATG 426
|||||

QY 432 TTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGTCAGTTAAGTGCATGCAAAA 491
Db |||||||
427 TTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGTCAGTTAAGTGCATGCAAAA 486
|||||

QY 492 GCCACCAATGAAGGAGATTTATCCAGCAAGATCTCTGCCAAGAGTAGGCTCTGGAATCT 551
Db |||||||
487 GCCACCAATGAAGGAGATTTATCCAGCAAGATCTCTGCCAAGAGTAGGCTCTGGAATCT 546
|||||

QY 552 GATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTTTTTGTGTTG 611
Db |||||||
547 GATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTTTTTGTGTTG 606
|||||

QY 612 GAAACACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTATACGTATAAT 671
Db |||||||
607 GAAACACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTATACGTATAAT 666
|||||

QY 672 TAATAATAAATGATTACCTCTGGTTCACAGCTTTGAATTTGCACTTCTTAAAGAACAG 731
Db |||||||
667 TAATAATAAATGATTACCTCTGGTTCACAGCTTTGAATTTGCACTTCTTAAAGAACAG 726
|||||

QY 732 CCATTAATCTCTGAATGATGATTAATTAATTAATGATGATTAATTAATGATGATTAAT 791
Db |||||||
727 CCATTAATCTCTGAATGATGATTAATTAATTAATGATGATTAATTAATGATGATTAAT 786
|||||

QY 792 TTATAGGAATTTGTAAGGCTCATTTTGGTTTTCATTGGAACAGTACTAATTAATTAAT 851
Db |||||||
787 CTATAGGAATTTGTAAGGCTCATTTTGGTTTTCATTGGAACAGTACTAATTAATTAAT 846
|||||

QY 852 CTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAGTGGAACTTC 911
Db |||||||
847 CTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAGTGGAACTTC 906
|||||

QY 912 ATGGGTTTCCCTCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 971
Db |||||||
907 ATGGGTTTCCCTCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 966
|||||

QY 972 GCGGGAATTTCCCTCTGCTGTAATATTTATCCCTGTAATTTGATGATGATGATGATGAT 1031
Db |||||||
967 GCGGGAATTTCCCTCTGCTGTAATATTTATCCCTGTAATTTGATGATGATGATGATGAT 1026
|||||

QY 1032 CATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATTTTAAAGCATTAAGTAAACATGA 1091
Db |||||||
1027 CATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATTTTAAAGCATTAAGTAAACATGA 1086
|||||

QY 1092 TATAAATAATATGCTGAAATTTACTTGTGAAGATGCAATTAAGCATTTTAAATGTTT 1151
Db |||||||
1087 TATAAATAATATGCTGAAATTTACTTGTGAAGATGCAATTTAAAGCATTTTAAATGTTT 1146
|||||

QY 1152 TTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTTATTTAGTTTCTTAAATCTGG 1211
Db |||||||
1147 TTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTTATTTAGTTTCTTAAATCTGG 1206
|||||

QY 1212 TGGTAAAGGTATTTCTTAAGATTTTGCAGGTACTACAGATTTTCAAACTGAAGAGAA 1271
Db |||||||
1207 TGGTAAAGGTATTTCTTAAGATTTTGCAGGTACTACAGATTTTCAAACTGAAGAGAA 1266
|||||

QY 1272 AATTGTATACCACTCTGCTGTTCTTTAGTGCATACATAAATACTGAATTT 1326
Db |||||||
1267 AATTGTATACCACTCTGCTGTTCTTTAGTGCATACATAAATACTGAATTT 1321
|||||

```

RESULT 15
 AF031379 1396 bp mRNA linear PRI 27-MAY-1999
 DEFINITION Homo sapiens cornichon-like protein mRNA, complete cds.
 ACCESSION AF031379
 VERSION AF031379.1 GI:4894208
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 1396)
 RANDALL, J., SCHNIEDERS, B., SANDHOFF, K., VOLK, H.D., MILFORD, B. and
 GULLANS, S.R.
 The human homolog of Drosophila cornichon protein is differentially
 expressed in alloactivated T-cells
 Biochim. Biophys. Acta 1449 (3), 203-210 (1999)
 9227056
 PUBMED 10209299
 REFERENCE 2 (bases 83 to 1102)
 Utku, N., Bulwin, G.-C., Soren, B., Beato, F., Volk, H.D., Milford, B.L.
 and Gullans, S.R.
 Direct Submission
 Submitted (24-OCT-1997) Immunology, Charite, Schumannstr.20/21,
 Berlin 10098, Germany
 Location/Qualifiers
 1..1396
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /cell_type="lymphocytes"
 114..518
 /codon_start=1
 /product="cornichon-like protein"
 /protein_id="AAD32301.1"
 /db_xref="GI:4894208"
 /translation="MLALLLTAALIFPAIWHIIAFDELKTDYKNPIDQCNLTNPLVLP
 EYLIIHAFCCYMFICAAEAEWLTGLNPLLAYHIWRVMSRPVMSGPLGYDPTIMNADIL
 AYQREGKWLKLAFFYLAFVYLYGMIVLVSS"
 ORIGIN
 Query Match 97.2%; Score 1296.2; DB 9; Length 1396;
 Best Local Similarity 99.8%; Pred. No. 1.2e-274;
 Matches 1298; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 26 TTGCGGCGCTTCTGCTACAGCTGGCGCTGCTGCTCACTGCGCGCTCATCTTCTGCGC 85
 DB 96 TGGCGGCGCTTCTGCTACAGCTGGCGCTGCTGCTCACTGCGCGCTCATCTTCTGCGC 155
 QY 86 ATTGGCAGATTATAGCATTTGATGAGCTGAAGACTGATTAAGAATCCTATAGACCAG 145
 DB 156 ATTGGCAGATTATAGCATTTGATGAGCTGAAGACTGATTAAGAATCCTATAGACCAG 215
 QY 146 TGTATACCTGAATCCCTTCTGCTACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 205
 DB 216 TGTATACCTGAATCCCTTCTGCTACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 275
 QY 206 ATGTTTCTTTGTGACAGAGTGGCTTACACTGGGTCTCAATATGCGCTCTTGGCATAT 265
 DB 276 ATGTTTCTTTGTGACAGAGTGGCTTACACTGGGTCTCAATATGCGCTCTTGGCATAT 335
 QY 266 CATATTGGAGGTATATAGTAGACAGCTGATGAGTGGCCAGGACTCTATGACCCCTACA 325
 DB 336 CATATTGGAGGTATATAGTAGACAGCTGATGAGTGGCCAGGACTCTATGACCCCTACA 395
 QY 326 ACCATCATGATGACATATCTTACATATTTGTCAGAGGAGGATGGTGCATATAGCT 385
 DB 396 ACCATCATGATGACATATCTTACATATTTGTCAGAGGAGGATGGTGCATATAGCT 455
 QY 386 TTTTATCTTCTAGCAATTTTTTACTACCTATATGCGATGATCTATCTTTTGTGAGCTCT 445
 DB 456 TTTTATCTTCTAGCAATTTTTTACTACCTATATGCGATGATCTATGTTTGTGAGCTCT 515

QY 446 TAGAACACACACACAGAGAAATTGGTCCAGTAAGTGCATGCAAAAGCCACCAATGAAG 505
 DB 516 TAGAACACACACACAGAGAAATTGGTCCAGTAAGTGCATGCAAAAGCCACCAATGAAG 575
 QY 506 GGATTTCTATCCAGCAAGATCCTGCAAGAGTAGCTGTGGAATCTGATCAGTACTTTA 565
 DB 576 GGATTTCTATCCAGCAAGATCCTGCAAGAGTAGCTGTGGAATCTGATCAGTACTTTA 635
 QY 566 AAAAATGACTCCTTATTTTAAATGTTTCCACATTTTCTGCTGTGGAAGACTGTTTTC 625
 DB 636 AAAAATGACTCCTTATTTTAAATGTTTCCACATTTTCTGCTGTGGAAGACTGTTTTC 695
 QY 626 ATATGTTTACTCAGATAAAGATTTTAAATGTTTACGATTAATTAATTAATGAATGAT 685
 DB 696 ATATGTTTACTCAGATAAAGATTTTAAATGTTTACGATTAATTAATTAATGAATGAT 755
 QY 686 TACCTCTGGTGTGACAGGTTTGAACCTTCACATTTTGAAGACAGCCATAATCCCTCTGA 745
 DB 756 TACCTCTGGTGTGACAGGTTTGAACCTTCACATTTTGAAGACAGCCATAATCCCTCTGA 815
 QY 746 ATGATGCATTAATTAATGACTGTCTGCTAGTACATTTGGAAGCTTTTGTATAGGAATCTGT 805
 DB 816 ATGATGCATTAATTAATGACTGTCTGCTAGTACATTTGGAAGCTTTTGTATAGGAATCTGT 875
 QY 806 AGGCTCATTTTGGTTCATTTGAACAGATTAATTAATTAATTAATTAATTAATTAATTAAT 865
 DB 876 AGGCTCATTTTGGTTCATTTGAACAGATTAATTAATTAATTAATTAATTAATTAATTAAT 935
 QY 866 TGCTTCTGATGAAGTGAAGTATATCTGACTAGTGGGAAGCTTCCATGCTGTTTCTCAT 925
 DB 936 TGCTTCTGATGAAGTGAAGTATATCTGACTAGTGGGAAGCTTCCATGCTGTTTCTCAT 995
 QY 926 CTGCTATGCTGATTAATTAATGATATATGATATGATATGATATGATATGATATGATATG 985
 DB 996 CTGCTATGCTGATTAATTAATGATATATGATATGATATGATATGATATGATATGATATG 1055
 QY 986 TTGCTTTGAATATATCCCTGATATATGATATGATATGATATGATATGATATGATATGAT 1045
 DB 1056 TTGCTTTGAATATATCCCTGATATATGATATGATATGATATGATATGATATGATATGAT 1115
 QY 1046 AGTAATAAATATATCTGCTTTTAAATCTTAAGCATTAAGTAAACATGATATAAATAATATG 1105
 DB 1116 AGTAATAAATATATCTGCTTTTAAATCTTAAGCATTAAGTAAACATGATATAAATAATATG 1175
 QY 1106 CTGAATTTCTGGAAGAAATGCAATTAAGCTATTTTAAATGTTTATTTTATTTGTAAGAC 1165
 DB 1176 CTGAATTTCTGGAAGAAATGCAATTAAGCTATTTTAAATGTTTATTTTATTTGTAAGAC 1235
 QY 1166 ATTACTTTTAAAGAAATGCTTTTATTTATGCTTACTGTTCTTAATCTGTTGTAAGGTTTC 1225
 DB 1236 ATTACTTTTAAAGAAATGCTTTTATTTATGCTTACTGTTCTTAATCTGTTGTAAGGTTTC 1295
 QY 1226 TTAAGAAATTTGCAAGTACTACAGATTTTCAAACTGAATGAGAGAAAATTTGATTAACCAT 1285
 DB 1296 TTAAGAAATTTGCAAGTACTACAGATTTTCAAACTGAATGAGAGAAAATTTGATTAACCAT 1355
 QY 1286 CCTGCTGTTCTTTTGTAGTGAATACAAATAAACTCTGAAATT 1326
 DB 1356 CCTGCTGTTCTTTTGTAGTGAATACAAATAAACTCTGAAATT 1396

RESULT 16
 AF104398
 LOCUS
 DEFINITION Homo sapiens cornichon mRNA, complete cds.
 ACCESSION AF104398
 VERSION AF104398.1 GI:4063708
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AF104398 1398 bp mRNA linear PRI 28-DEC-1998
 Homo sapiens cornichon mRNA, complete cds.
 AF104398.1 GI:4063708

REFERENCE 1 (bases 1 to 1398)
 Plisov,S.Y., Ivanov,S.V., Lerman,M. and Perantoni,A.O.
 TITLE Direct Submission
 Submitted (04-NOV-1998) Laboratory of Comparative Carcinogenesis,
 JOURNAL National Cancer Institute, FCRDC, Bldg 538, Room 221, Frederick, MD
 21702, USA

FEATURES
 source
 1..1398
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="dbSTS:G38596"
 /db_xref="caxon:9606"
 /chromosome="14"
 /cell_line="786-0"
 /tissue type="clear cell carcinoma"
 57..491
 /note="expression elevated in dividing 786-0 cells
 compared with confluent 786-0 cells"
 /codon_start=1
 /product="cornichon"
 /protein_id="AAC98388.1"
 /db_xref="GI:4063709"
 /translation="MAFTEAFACVYMLALLLTAALIFFAIWHIIAFDELKDYKPIDQ
 CNTLNPLVPLYLHAFPCVNFCLCAEAWLTGLNPLLHAYHIWYMSRPVMSGPLXD
 PTTINADILAYCOREGWCKLAFYLLAFYYLYGMIVLVSS"

ORIGIN

Query Match 96.0%; Score 1279.4; DB 9; Length 1398;
 Best Local Similarity 98.9%; Pred. No. 5.9e-271;
 Matches 1320; Conservative 0; Mismatches 8; Indels 7; Gaps 3;
 Qy 3 CCACGGTCGATGCGGTTCAGTTCGGGCTTCTGTACATGCTGGCGTGTGCTCA 62
 Db 46 CTTCCCGAGCATGGCGTTCAGTTCGGGCTTCTGTACATGCTGGCGTGTGCTCA 105
 Qy 63 CTGCGGCTCATCTTCTTCCGCTTGGGCATTTGGGCATTTAGCATTTGATGAGCTG 122
 Db 106 CTGCGGCTCATCTTCTTCCGCTTGGGCATTTGGGCATTTAGCATTTGATGAGCTG 165
 Qy 123 ATTACAGAAATCCATAGACAGGTGTAATACCCGTAATCCCTGTACTCCAGAGTACC 182
 Db 166 ATTACAGAAATCCATAGACAGGTGTAATACCCGTAATCCCTGTACTCCAGAGTACC 225
 Qy 183 TCATCCAGCTTCTTCTGTCATGTTCTTGTGACAGAGTGGCTTACACTGGGTC 242
 Db 226 TCATCCAGCTTCTTCTGTCATGTTCTTGTGACAGAGTGGCTTACACTGGGTC 285
 Qy 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTATGATGAGTG 302
 Db 286 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTATGATGAGTG 345
 Qy 303 GCCCAGGACTCTATGACCTTACACCATCATGATGATGATGATGATGATGATGATG 362
 Db 346 GCCCAGGACTCTATGACCTTACACCATCATGATGATGATGATGATGATGATGATG 405
 Qy 363 AGAAGAGTGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCT 422
 Db 406 AGAAGAGTGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCT 465
 Qy 423 TGATCTATGTTTGTGAGCTCTTAGACACACACACAGAGAATTTGTCAGTTAAGTGC 482
 Db 466 TGATCTATGTTTGTGAGCTCTTAGACACACACACAGAGAATTTGTCAGTTAAGTGC 525
 Qy 483 ATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTCTCAAGAGTAGCCT 542
 Db 526 ATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTCTCAAGAGTAGCCT 585
 Qy 543 GTGGAATCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 602
 Db 586 GTGGAATCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 645
 Qy 603 TTGCTTGTGGAAGACTGTTT-CATATGTTATATCATGATAAGATTTAAATGGTATT 661

Db 646 TTGCTTGTGGAAGACTGTTTCCATATGTTATCTACTCAGATAAAGATTTTAAATGGTATT 705
 Qy 662 ACGTATAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTCTCT 721
 Db 706 ACGTATAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTCTCT 765
 Qy 722 TAAGGACAGCCATAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 781
 Db 766 TAAGGACAGCCATAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 825
 Qy 782 AAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGTGTTTCAATGAACAGTATCTAAT 841
 Db 826 AAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGTGTTTCAATGAACAGTATCTAAT 885
 Qy 842 TATATAATAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 901
 Db 886 TATATAATAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 945
 Qy 902 GGGAAACCTTCATGAGTTCCTCATCTGTCATGTCGATGATGATGATGATGATGATGATGATG 961
 Db 946 GGGAAACCTTCATGAGTTCCTCATCTGTCATGTCGATGATGATGATGATGATGATGATGATG 1005
 Qy 962 AAAAT-----AAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTCGAT 1016
 Db 1006 AAAATAAAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTCGAT 1065
 Qy 1017 GAATGAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTGTCTTAAAT-CTTAA 1075
 Db 1066 GAATGAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTGTCTTAAATTTAA 1125
 Qy 1076 GCATAAGTAAACATGATATAAAATATATCTGTAATTTCTTGTGAAGAAATGCAATTTAAAG 1135
 Db 1126 GCATAAGTAAACATGATATAAAATATATCTGTAATTTCTTGTGAAGAAATGCAATTTAAAG 1185
 Qy 1136 CTATTTTAAATGCTTTTTTATTTCTGAAGACATTTACTTTAAGAAATTTGGTTATATGCT 1195
 Db 1186 CTATTTTAAATGCTTTTTTATTTCTGAAGACATTTACTTTAAGAAATTTGGTTATATGCT 1245
 Qy 1196 TACTGTTCTAATCTGGTGTAAAGGTTATCTTAAGAAATTTGCGAGGTACTACAGATTTTCA 1255
 Db 1246 TACTGTTCTAATCTGGTGTAAAGGTTATCTTAAGAAATTTGCGAGGTACTACAGATTTTCA 1305
 Qy 1256 AAACCTGAATGAGAAATTTGTATAACCATCTCTGTTCTCTTTAGTGCATAAATAA 1315
 Db 1306 AAACCTGAATGAGAAATTTGTATAACCATCTCTGTTCTCTTTAGTGCATAAATAA 1365
 Qy 1316 ACTCTGAATTTAAGA 1330
 Db 1366 ACTNTGAATTTAAGA 1380

Search completed: June 14, 2004, 17:53:03
 Job time : 5333 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 14, 2004, 16:01:41 ; Search time 579 Seconds
(without alignments)
9780.394 Million cell updates/sec

Title: US-09-978-298A-321
Perfect score: 1333
Sequence: 1 gccacgcgcgcgatggcgt.....aaactctgaaattaagactc 1333

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 117

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%

Maximum Match 100%

Listing first 65000 summaries

Database : N_Geneseq_29Jan04.*

1: Geneseq1980s.*

2: Geneseq1990s.*

3: Geneseq2000s.*

4: Geneseq2001as.*

5: Geneseq2001bs.*

6: Geneseq2002as.*

7: Geneseq2003as.*

8: Geneseq2003bs.*

9: Geneseq2003cs.*

10: Geneseq2004s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	1333	100.0	1333	2	Aaz34164 Human PRO
2	1333	100.0	1333	3	Aaa88439 Antitumor
3	1333	100.0	1333	3	Aac78538 Human PRO
4	1333	100.0	1333	6	Abk33595 cDNA enco
5	1333	100.0	1333	6	AbL88072 Human PRO
6	1333	100.0	1333	6	AbL95561 Human ang
7	1333	100.0	1333	7	AcA66900 cDNA enco
8	1333	100.0	1333	7	AcA42697 Novel hum
9	1333	100.0	1333	7	AcD68652 Novel hum
10	1333	100.0	1333	7	AcA63732 Novel hum
11	1333	100.0	1333	7	AcA71896 Human sec
12	1333	100.0	1333	7	Abx92536 cDNA enco
13	1333	100.0	1333	7	AcA66277 Human cDN
14	1333	100.0	1333	7	AcA68556 Human PRO
15	1333	100.0	1333	8	AbT44285 Human PRO
16	1333	100.0	1333	8	ADA24860 Novel hum
17	1333	100.0	1333	8	AcD29878 Novel hum
18	1333	100.0	1333	8	ADA12521 Human cDN
19	1333	100.0	1333	8	AbT44568 Human PRO
20	1333	100.0	1333	8	AcD82235 Human sec
21	1333	100.0	1333	8	AcD29293 Novel hum
22	1333	100.0	1333	8	AbT43941 Human mem
23	1333	100.0	1333	8	ADB83609 Novel hum

24	1333	100.0	1333	8	ADB80715 Novel hum
25	1333	100.0	1333	8	ADB73256 Novel hum
26	1333	100.0	1333	8	ADB78338 Novel hum
27	1333	100.0	1333	9	ADB84986 Human PRO
28	1333	100.0	1333	9	ADB78092 Novel hum
29	1333	100.0	1333	9	ADB73827 Human PRO
30	1333	100.0	1333	9	ADB87158 Human PRO
31	1333	100.0	1333	9	ADB84740 Human PRO
32	1333	100.0	1333	9	ADB83855 Novel hum
33	1333	100.0	1333	9	ADB73010 Novel hum
34	1333	100.0	1333	9	ADB76543 Human PRO
35	1333	100.0	1333	9	ADB43969 Human cDN
36	1333	100.0	1333	9	ADC61729 Human cDN
37	1333	100.0	1333	9	ADC63693 Human cDN
38	1333	100.0	1333	9	ADC66793 Human cDN
39	1333	100.0	1333	9	ADC68917 Human cDN
40	1333	100.0	1333	9	ADC62977 Human cDN
41	1333	100.0	1333	9	ADC68042 Human cDN
42	1333	100.0	1333	9	ADC41362 Human cDN
43	1333	100.0	1333	9	ADC67417 Human cDN
44	1333	100.0	1333	9	ADC62353 Human cDN
45	1333	100.0	1333	9	ADC36848 Human PRO
46	1333	100.0	1333	9	ADC41986 Human PRO
47	1333	100.0	1333	9	ADC21838 Human PRO
48	1333	100.0	1333	9	ADC49869 Novel hum
49	1333	100.0	1333	9	ADC49068 Novel hum
50	1333	100.0	1333	9	ADC49585 Novel hum
51	1333	100.0	1333	9	ADC47446 Novel hum
52	1333	100.0	1333	9	ADC47191 Novel hum
53	1333	100.0	1333	9	ADC78066 Novel hum
54	1333	100.0	1333	9	ADD06301 Novel hum
55	1333	100.0	1333	9	ADD10290 Human sec
56	1333	100.0	1333	9	ADC77820 Novel hum
57	1333	100.0	1333	9	ADD11250 Human sec
58	1333	100.0	1333	9	ADD50783 Novel hum
59	1333	100.0	1333	9	ADD51029 Novel hum
60	1333	100.0	1333	9	ADD37043 Human sec
61	1333	100.0	1333	9	ADD50510 Human PRO
62	1333	100.0	1333	9	ADD50264 Human PRO
63	1333	100.0	1333	9	ADD51275 Novel hum
64	1333	100.0	1333	9	ADB49355 Human cDN
65	1333	100.0	1333	9	ADB35409 Human cDN
66	1333	100.0	1333	9	ADB16523 Human cDN
67	1333	100.0	1333	9	ADD73138 Human cDN
68	1333	100.0	1333	9	ADD72496 Human cDN
69	1333	100.0	1333	9	ADB17147 Human cDN
70	1333	100.0	1333	10	ADC48822 Novel hum
71	1333	100.0	1333	10	ADB20993 Novel hum
72	1333	100.0	1333	10	ADB505837 Human PRO
73	1333	100.0	1333	10	ADD75066 Human PRO
74	1333	100.0	1333	10	ADD75812 Novel hum
75	1333	100.0	1333	10	ADD85044 Novel hum
76	1333	100.0	1333	10	ADD86870 Novel hum
77	1333	100.0	1333	10	ADB20747 Novel hum
78	1333	100.0	1333	10	ADB39044 Novel hum
79	1333	100.0	1333	10	ADB05591 Human PRO
80	1333	100.0	1333	10	ADD73576 Human PRO
81	1333	100.0	1333	10	ADB48655 Human cDN
82	1333	100.0	1333	10	ADB78416 Novel hum
83	1333	100.0	1333	10	ADB41251 Human sec
84	1333	100.0	1333	10	ADB21239 Novel hum
85	1333	100.0	1333	10	ADB77354 Novel hum
86	1333	100.0	1333	10	ADB20501 Novel hum
87	1333	100.0	1333	10	ADD75566 Human PRO
88	1333	100.0	1333	10	ADD74082 Human PRO
89	1333	100.0	1333	10	ADD74328 Human PRO
90	1333	100.0	1333	10	ADD76058 Novel hum
91	1333	100.0	1333	10	ADB85550 Novel hum
92	1333	100.0	1333	10	ADB05099 Human PRO
93	1333	100.0	1333	10	ADD75312 Human PRO
94	1333	100.0	1333	10	ADD76856 Novel hum
95	1333	100.0	1333	10	ADD86624 Novel hum
96	1333	100.0	1333	10	ADD78092 Novel hum

97 1333 100.0 1333 10 ADE89756 Human cDN
 98 1333 100.0 1333 10 ADD77600 Novel hum
 99 1333 100.0 1333 10 ADD77846 Novel hum
 100 1333 100.0 1333 10 ADD85304 Novel hum
 101 1333 100.0 1333 10 ADD73836 Human PRO
 102 1333 100.0 1333 10 ADD74574 Human PRO
 103 1333 100.0 1333 10 ADD77102 Novel hum
 104 1333 100.0 1333 10 ADD85796 Novel hum
 105 1333 100.0 1333 10 ADE05345 Human PRO
 106 1333 100.0 1333 10 ADD74820 Human PRO
 107 1321.4 99.1 1378 2 AAX90853 cDNA clon
 108 1321.4 99.1 1432 6 ABK36005 cDNA sequ
 109 1316.8 98.8 1391 2 AAK30544 Human cor
 110 1316.8 98.8 1391 6 AAD31079 Human cor
 111 1316.8 98.8 1391 6 ABK91098 cDNA enco
 112 1316.4 98.8 1404 2 AAX30168 Human sec
 113 1313.4 98.5 1320 3 AAK36228 cDNA enco
 114 1311.8 98.4 1321 4 AAK94250 Human ful
 115 1301.4 97.6 2316 6 ABK35858 cDNA sequ
 116 1277.8 95.9 1398 7 ABX10419 DNA enco
 117 1195.4 89.7 1360 9 ADD78291 Human CGD

ALIGNMENTS

RESULT 1
 AAZ34164
 ID AAZ34164 standard; cDNA; 1333 BP.

XX AC AAZ34164;

XX DT 07-DEC-1999 (first entry)

XX DE Human PRO181 nucleotide sequence.

XX KW Human; PRO; EST; expressed sequence tag; PCR primer; hybridisation;
 KW probe; blood coagulation disorder; cancer; cellular adhesion disorder;
 KW secreted protein; transmembrane protein; ss.

XX OS Homo sapiens.

XX PN WO9946281-A2.

XX PD 16-SEP-1999.

XX PF 08-MAR-1999; 99WO-U6005028.

XX PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077841P.

PR 11-MAR-1998; 98US-0077649P.

PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.

PR 17-MAR-1998; 98US-00040220.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078910P.

PR 20-MAR-1998; 98US-0078936P.

PR 20-MAR-1998; 98US-0078939P.

PR 25-MAR-1998; 98US-0079294P.

PR 26-MAR-1998; 98US-0079656P.

PR 27-MAR-1998; 98US-0079663P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079728P.

PR 27-MAR-1998; 98US-0079786P.

PR 30-MAR-1998; 98US-0079920P.

PR 30-MAR-1998; 98US-0079923P.

PR 31-MAR-1998; 98US-0080105P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080165P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080328P.
 PR 01-APR-1998; 98US-0080333P.
 PR 01-APR-1998; 98US-0080334P.
 PR 08-APR-1998; 98US-0081049P.
 PR 08-APR-1998; 98US-0081070P.
 PR 08-APR-1998; 98US-0081071P.
 PR 09-APR-1998; 98US-0081195P.
 PR 09-APR-1998; 98US-0081203P.
 PR 09-APR-1998; 98US-0081229P.
 PR 15-APR-1998; 98US-0081817P.
 PR 15-APR-1998; 98US-0081838P.
 PR 15-APR-1998; 98US-0081952P.
 PR 15-APR-1998; 98US-0081953P.
 PR 21-APR-1998; 98US-0082568P.
 PR 21-APR-1998; 98US-0082569P.
 PR 22-APR-1998; 98US-0082700P.
 PR 22-APR-1998; 98US-0082704P.
 PR 22-APR-1998; 98US-0082804P.
 PR 23-APR-1998; 98US-0082767P.
 PR 23-APR-1998; 98US-0082796P.
 PR 27-APR-1998; 98US-0083336P.
 PR 28-APR-1998; 98US-0083322P.
 PR 29-APR-1998; 98US-0083392P.
 PR 29-APR-1998; 98US-0083495P.
 PR 29-APR-1998; 98US-0083496P.
 PR 29-APR-1998; 98US-0083499P.
 PR 29-APR-1998; 98US-0083500P.
 PR 29-APR-1998; 98US-0083545P.
 PR 29-APR-1998; 98US-0083554P.
 PR 29-APR-1998; 98US-0083558P.
 PR 29-APR-1998; 98US-0083559P.
 PR 30-APR-1998; 98US-0083742P.
 PR 05-MAY-1998; 98US-0084366P.
 PR 06-MAY-1998; 98US-0084414P.
 PR 07-MAY-1998; 98US-0084441P.
 PR 07-MAY-1998; 98US-0084598P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 07-MAY-1998; 98US-0084627P.
 PR 07-MAY-1998; 98US-0084637P.
 PR 07-MAY-1998; 98US-0084639P.
 PR 07-MAY-1998; 98US-0084640P.
 PR 07-MAY-1998; 98US-0084643P.
 PR 13-MAY-1998; 98US-0085323P.
 PR 13-MAY-1998; 98US-0085338P.
 PR 13-MAY-1998; 98US-0085339P.
 PR 15-MAY-1998; 98US-0085573P.
 PR 15-MAY-1998; 98US-0085579P.
 PR 15-MAY-1998; 98US-0085580P.
 PR 15-MAY-1998; 98US-0085582P.
 PR 15-MAY-1998; 98US-0085689P.
 PR 15-MAY-1998; 98US-0085697P.
 PR 15-MAY-1998; 98US-0085700P.
 PR 18-MAY-1998; 98US-0086023P.
 PR 22-MAY-1998; 98US-0086392P.
 PR 22-MAY-1998; 98US-0086414P.
 PR 22-MAY-1998; 98US-0086430P.
 PR 22-MAY-1998; 98US-0086486P.
 PR 28-MAY-1998; 98US-0087098P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 28-MAY-1998; 98US-0087208P.
 PR 30-JUL-1998; 98US-0094651P.
 PR 11-SEP-1998; 98US-0100038P.

(GETH) GRNENTECH INC.

Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;

WPI; 1999-551358/46.

P-PSDB; AAY41732.

New secreted and transmembrane polypeptides and their polynucleotides,
 useful for treating blood coagulation disorders, cancers and cellular

adhesion disorders.

Claim 2; Fig 128; 530pp; English.

The present invention describes and transmembrane polypeptides and their polynucleotides. The nucleotide sequences are useful as sources of probes, primers, for chromosome mapping, and for generation of antisense sequences. They can also be used to create transgenic animals. The proteins can be used to treat a variety of diseases and disorders, depending on their function. Diseases that may be treated include blood coagulation disorders, cancers and cellular adhesion disorders. They may also be used to raise antibodies. AA233891 to AA234338, and AA241685 to AA241774 represent polynucleotide and polypeptide sequence given in the exemplification of the present invention

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 2; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9,6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGTCGATGGCGCTTACGTTCCGCGCTTCTCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGTCGATGGCGCTTACGTTCCGCGCTTCTCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGGCTCATCTTCTCGCCATTGGCACATTATAGCATTTTGGAGCTGAAGAC 120
DB 61 CACTGCGGCTCATCTTCTCGCCATTGGCACATTATAGCATTTTGGAGCTGAAGAC 120
QY 121 TGATTAAGAATCTTATAGACAGTGTAATACCTTGAATCCCTTGTACTCCACAGATA 180
DB 121 TGATTAAGAATCTTATAGACAGTGTAATACCTTGAATCCCTTGTACTCCACAGATA 180
QY 181 CTTCTATCCAGCTTCTTCTGTCGATGTTCTTTGTGCGAGAGTGCTTACACTGGG 240
DB 181 CTTCTATCCAGCTTCTTCTGTCGATGTTCTTTGTGCGAGAGTGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTTCCGATATCATATTTGGAGGTATATGAGTACCACTGATGAG 300
DB 241 TCTCAATATGCCCTTCCGATATCATATTTGGAGGTATATGAGTACCACTGATGAG 300
QY 301 TGGCCAGGACTCTATGACCTTACACCATCATGATGATGATGATGATGATGATGATG 360
DB 301 TGGCCAGGACTCTATGACCTTACACCATCATGATGATGATGATGATGATGATGATG 360
QY 361 GAAGGAGAGTGGTGAATATGATGTTTATCTTCTAGCATTTTCTTCTTCTTCTTCT 420
DB 361 GAAGGAGAGTGGTGAATATGATGTTTATCTTCTTCTTCTTCTTCTTCTTCTTCT 420
QY 421 CATGATCTATGTTTGTGAGCTCTTGAACACACACAGAGATTTGCTTAACTTAACT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTGAACACACACAGAGATTTGCTTAACTTAACT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCGAAGTAGC 540
DB 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCGAAGTAGC 540
QY 541 CTGTGGAATCTGATGAGTACCTTTTAAATGATGCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATGAGTACCTTTTAAATGATGCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGAGCTTTTCTATGTTTATCTTCTTCTTCTTCTTCTTCTTCTT 660
DB 601 TTTTGTCTGTGGAAGAGCTTTTCTATGTTTATCTTCTTCTTCTTCTTCTTCTTCTT 660
QY 661 TAGGTAAATTAATATAAATGATTTACTCTGCTGTTGACAGGTTTGAACCTTGCACCTC 720
DB 661 TAGGTAAATTAATATAAATGATTTACTCTGCTGTTGACAGGTTTGAACCTTGCACCTC 720
QY 721 TTAAGGAAAGGCAATATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780
DB 721 TTAAGGAAAGGCAATATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780

QY 781 GAAGCTTTTGTATTATAGGAACTTGTAGGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATTATAGGAACTTGTAGGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
QY 841 TTATATAATAGCTGTAGATATCAGGTGCTTCTGATGAAAGTGAATGATATATCTGACTAG 900
DB 841 TTATATAATAGCTGTAGATATCAGGTGCTTCTGATGAAAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAAAGCTTCATGGGTTTCCCTCATCTGTCATGTCATGATGATGATGATGATGATGATG 960
DB 901 TGGGAAAGCTTCATGGGTTTCCCTCATCTGTCATGTCATGATGATGATGATGATGATGATG 960
QY 961 AAAAAATAAAAGCGGGAATTTTCCCTTCCCTTGAATATATATCCCTGATATGATGATGATG 1020
DB 961 AAAAAATAAAAGCGGGAATTTTCCCTTCCCTTGAATATATATCCCTGATATGATGATGATG 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATACTTCTTAAATTTCTTAAGCAATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATACTTCTTAAATTTCTTAAGCAATA 1080
QY 1081 AGTAAACATGATATAAAATATATATCTGTCATGTCATGTCATGTCATGTCATGTCATGTC 1140
DB 1081 AGTAAACATGATATAAAATATATATCTGTCATGTCATGTCATGTCATGTCATGTCATGTC 1140
QY 1141 TTAATATGTTTATTTTGAAGCAATTTTCCCTTCCCTTGAATATATATCCCTGATATGATGATG 1200
DB 1141 TTAATATGTTTATTTTGAAGCAATTTTCCCTTCCCTTGAATATATATCCCTGATATGATGATG 1200
QY 1201 TTCTAATCTGTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
DB 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
RESULT 2
AAA88439
ID AAA88439 standard; cDNA; 1333 BP.
XX
AC AAA88439;
XX
DT 09-JAN-2001 (first entry)
XX
DE Antitumour PRO181 cDNA clone DNA23330-1390.
XX
KW PRO181; antitumour; antiproliferative; human; cancer; therapy;
XX drug screening; ss.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 14..448
XX FT /*tag= a
XX FT sig_peptide 14..73
XX FT /*tag= b
XX FT mat_peptide 74..445
XX FT /*tag= c
XX
XX WO200053751-A1.
XX
XX 14-SEP-2000.
XX
XX 30-DEC-1999; 99WO-US031243.
XX
XX 08-MAR-1999; 99WO-US005028.
XX 29-MAR-1999; 99US-0126773P.
XX 20-JUL-1999; 99US-0144758P.

PR 08-SEP-1999; 99WO-US020594.
PR 20-DEC-1999; 99WO-US030999.
XX
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Napier MA, Wood WI;
XX WPI; 2000-594321/56.
DR P-PSDB; AAB19524.
XX
XX Novel PRO181 and PRO237 polypeptides useful for treating tumors including
PT cancers of breast, prostate, lung, leukemia in humans and for identifying
PT compounds capable of inhibiting growth of neoplastic cells.
XX
XX Claim 20; Fig 1; 107pp; English.
XX
XX The present sequence is that of cDNA clone DNR23330-1390 (ATCC 209775),
CC which includes an open reading frame coding for human PRO181 (see
CC AAB19524), a novel inhibitor of neoplastic cell growth. The cDNA was
CC isolated from a placenta cDNA library. The library was cloned into vector
CC pSST-AMY.0, a plasmid that has the yeast alcohol dehydrogenase (ADH)
CC promoter preceding the cDNA cloning sites and the mouse amylase sequence
CC (without the secretion signal). Yeast clones secreting amylase were
CC selected, and insert cDNA was amplified by PCR using primers (see
CC AAA88441-42) based on yeast ADH promoter and mouse amylase sequences. The
CC encoded protein shows significant sequence homology to cornichon protein.
CC The invention provides PRO181 and PRO237 (see AAB19525) polypeptides and
CC polynucleotides, vectors, host cells, methods for their production,
CC chimeric molecules and antibodies. Also claimed is a composition
CC comprising PRO181 or PRO237, or their agonists, useful for the treatment
CC of a tumour, especially breast cancer, ovarian cancer, renal cancer,
CC colorectal cancer, uterine cancer, prostate cancer, lung cancer, bladder
CC cancer, central nervous system cancer, melanoma and leukaemia. PRO181 and
CC PRO237 are also useful for treating neuronal, glial, astrocytal,
CC hypothalamic and other glandular, macrophagal, epithelial, stromal, and
CC blastocoele disorders and inflammatory, angiogenic and immunologic
CC disorders. They are useful for identifying agonists to PRO181 or PRO237
CC in drug screening and rational drug design
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 3; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GCCACGCGTCCGATGCGGCTTACGTTCCGGGCTTCTGCTACATGCTGGCGCTGCTGCT	60
DB	1		
QY	61	CACGCGCGCTCATCTTCTTCGCCATTGGCCACATTATAGCATTTGATGAGCTGAAGAC	120
DB	61		
QY	121	TGATTACAGAAATCTATAGACAGTGTATATACCTGAATCCCGTGTACTCCAGATGA	180
DB	121		
QY	181	CCTCATCCAGCTTCTTCTGTCGTCAGTTCTTTTGGCAGCAGTGGCTTACCTGGG	240
DB	181		
QY	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGACCGATGATG	300
DB	241		
QY	301	TGGCCGAGGACTCTATGACCTCAACCATCATGAATGCGAGATTTCTAGCATATTTGCA	360
DB	301		
QY	361	GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG	420
DB	361		

RESULT 3
AAC78538

ID AAC78538 standard; cDNA; 1333 BP.

XX

AC AAC78538;

XX

DT 08-FEB-2001 (first entry)

XX

QY	421	CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGTCAGTTAAGT	480
DB	421		
QY	481	GCATGCAAAAAGCCACCAATGAAGGGAATTTATCCAGCAAGATCCTGTCCAGAGTAGC	540
DB	481		
QY	541	CTGTGGAATCTGATCAGTTACTTTTAAATAAGTACCTTTTAAATGTTTCCACAT	600
DB	541		
QY	601	TTTTGCTGCTGGAAGAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGCTAT	660
DB	601		
QY	661	TACGTATAAATTAATATAAATGAATTAACCTCTGGTGTTCACAGGTTTGAACCTGCACTTC	720
DB	661		
QY	721	TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT	780
DB	721		
QY	781	GAGCTTTTGTATTATAGGAACCTTTAGGGCTCATTTTGGCTTTCAATTGAAACAGATATCTAA	840
DB	781		
QY	841	TTATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT	900
DB	841		
QY	901	TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATTAATTAATTAATTAATTAATTAAT	960
DB	901		
QY	961	AAAAATAAAGGCGGAAATTTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTAAT	1020
DB	961		
QY	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATACTTGTCTTTAATTTCTTAAGCATA	1080
DB	1021		
QY	1081	AGTAACATGATATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA	1140
DB	1081		
QY	1141	TTAAATGCTTTTATTTCTTAAGACATTAATTAATTAAGAAATTTGGTTATATGCTTACTG	1200
DB	1141		
QY	1201	TTCTATCTGGTGAAGTATTTCTTAAGATTTTCAGGTACTCAGATTTTCAAACT	1260
DB	1201		
QY	1261	GATGAGAGAAAATTTGTATAAACCCTCCTGCTGTTCTTTAGTGAATTAATAAATAAATAAATAA	1320
DB	1261		
QY	1321	GAAATTAAGACTC 1333	
DB	1321		

DE Human PRO181 (UNQ155) nucleotide sequence SEQ ID NO:321.
 XX
 KW Human; secreted protein; transmembrane protein; PRO; EST; cytosstatic;
 KW expressed sequence tag; detection; cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200053756-A2.
 XX
 PD 14-SEP-2000.
 XX
 XX 18-FEB-2000; 2000WO-US004341.
 XX
 XX 08-MAR-1999; 99WO-US005028.
 PR 12-MAR-1999; 99US-0123957P.
 PR 29-MAR-1999; 99US-0126773P.
 PR 21-APR-1999; 99US-0130232P.
 PR 28-APR-1999; 99US-0131445P.
 PR 14-MAY-1999; 99US-0134287P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 XX
 XX (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan MJ;
 PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tumas D, Williams PM, Wood WI;
 XX WPI; 2000-611443/58.
 DR P-PSDB; AAB44288.
 XX
 XX Novel PRO polypeptides and polynucleotides used in detection methods, to
 PT target bioactive molecules to specific cells, and to modulate cellular
 PT activities.
 XX
 PS Claim 2; Fig 128; 636pp; English.
 XX
 XX AAC78458 to AAC78599 represent polynucleotide and EST (expressed sequence
 CC tag) sequences which encode secreted or transmembrane PRO polypeptides.
 CC The PRO polynucleotides and polypeptides have cytosstatic activity. The
 CC polynucleotides and polypeptides can be used for detecting the presence
 CC of PRO polypeptides in samples, for linking bioactive molecules to cells
 CC and for modulating biological activities of cells, using the polypeptides
 CC for specific targeting. The polypeptide targeting can be used to kill the
 CC target cells, e.g. for the treatment of cancers. The polypeptide pairs
 CC provide specific targeting of bioactive molecules to cells. AAC78600 to
 CC AAC78987 represent PCR primers and probes used in the isolation of the
 CC PRO polynucleotide sequences
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 3; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GCCACGGCTCGATGGCGTTCAACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 1 GCCACGGCTCGATGGCGTTCAACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 61 CACTCCCGCGCTCATCTTCTTCCGCCATTTGGCAGATTAAGCAATTTGATGAGCTGAAGAC 120

QY 1201 TTCTAATCTGGTGGTAAAGGTAATCTTAAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1201 TTCTAATCTGGTGGTAAAGGTAATCTTAAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
QY 1261 GAAATGAGAGAAATTTGATTAACCATCTGCTGCTCTTTAGTGGCAATACATATAAACTCT 1320
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1261 GAAATGAGAGAAATTTGATTAACCATCTGCTGCTCTTTAGTGGCAATACATATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1321 GAAATTAAGACTC 1333
RESULT 4
ID ABK33595 standard; cDNA; 1333 BP.
XX
AC ABK33595;
XX
DT 08-MAY-2002 (first entry)
XX
DE cDNA encoding human PRO protein, Seq ID No 119.
XX
KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200208288-A2.
XX
ED 31-JAN-2002.
XX
PF 29-JUN-2001; 2001WO-US021066.
XX
PR 20-JUL-2000; 2000US-0219556P.
PR 25-JUL-2000; 2000US-0220585P.
PR 25-JUL-2000; 2000US-0220605P.
PR 25-JUL-2000; 2000US-0220607P.
PR 25-JUL-2000; 2000US-0220624P.
PR 25-JUL-2000; 2000US-0220638P.
PR 25-JUL-2000; 2000US-0220654P.
PR 25-JUL-2000; 2000US-0220666P.
PR 26-JUL-2000; 2000US-0220893P.
PR 28-JUL-2000; 2000WO-US020710.
PR 01-AUG-2000; 2000US-0227133P.
PR 22-AUG-2000; 2000US-0227133P.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 10-NOV-2000; 2000WO-US030873.
PR 28-NOV-2000; 2000US-0253646P.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2002-172001/22.
DR P-PSDB; AAU83651.
XX
PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumors such

as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor or liver tumor.
Claim 2; Fig 119; 359pp; English.
XX
CC The invention relates to one hundred and twenty two nucleic acids encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides encode human secreted proteins. The PRO nucleic acids, polypeptides, agonists and antagonists are useful for treating a PRO related disorder. The PRO polypeptides are useful for diagnosing tumors, especially lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor or liver tumor. The PRO polypeptides are useful for stimulating the proliferation of, or gene expression, in pericyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the release of tumour necrosis factor-alpha from human blood, for stimulating or inhibiting the proliferation of normal human dermal fibroblast cells. The PRO polypeptide may also be used as molecular weight markers and for tissue typing. The PRO nucleic acids have applications in molecular biology, including use as hybridisation probes, and in chromosome and gene mapping. ABK33536-ABK33657 represent human PRO protein coding sequences of the invention
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGGTTACGTTTCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 GCCACGCGTCCGATGGGTTACGTTTCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
QY 61 GACTGCGGCTCATCTTCTGCGCATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
61 GACTGCGGCTCATCTTCTGCGCATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAAGATCCTATAGACCACTGAATACCTGTAATCCCTTGCTACTCCAGAGTA 180
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
121 TGATTACAAAGATCCTATAGACCACTGAATACCTGTAATCCCTTGCTACTCCAGAGTA 180
QY 181 COTCATCCACGCTTTCTTCTGTCATGTTCTTTGTGTCAGAGTGGCTTACATGGG 240
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
181 COTCATCCACGCTTTCTTCTGTCATGTTCTTTGTGTCAGAGTGGCTTACATGGG 240
QY 241 TCTCAATATGCGGCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
241 TCTCAATATGCGGCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
QY 301 TGGCCCGAGGACTCTATGACCTTACCAACCATCATGATGAGATATTTCTAGCATATTGTCA 360
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
301 TGGCCCGAGGACTCTATGACCTTACCAACCATCATGATGAGATATTTCTAGCATATTGTCA 360
QY 361 GAAGAGAGGATGGTCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
361 GAAGAGAGGATGGTCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGGCTCTTAGAACCAACACACAGAGAAATTTGCTCCAGTTAACT 480
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
421 CATGATCTATGTTTGGTGGCTCTTAGAACCAACACACAGAGAAATTTGCTCCAGTTAACT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGGATTCTATCAGCAAGATCTGTCCAGAGTAGC 540
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
481 GCATGCAAAAAGCCCAAAATGAAGGGATTCTATCAGCAAGATCTGTCCAGAGTAGC 540
QY 541 CTGTGAATCTGATCAGTTACTTTTAAAAAATGATCTCTTTTAAATGTTTCCACAT 600
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
541 CTGTGAATCTGATCAGTTACTTTTAAAAAATGATCTCTTTTAAATGTTTCCACAT 600
QY 601 TTTTGGCTTGTGGAAGACGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
601 TTTTGGCTTGTGGAAGACGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGGTATAAATTAAATATAAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720

```

Db      661  |||||TACGTAATAATTAATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGACCTTC 720
Qy      721  TTAAGGAACAGCAATTAATCTCTGAATGATGATTAATTAATCTGCTGCTAGTCAATTTG 780
Db      721  TTAAGGAACAGCAATTAATCTCTGAATGATGATTAATTAATCTGCTGCTAGTCAATTTG 780
Qy      781  GAAGCTTTTGTATTAAGGAATCTGTAGGCTCAATTTTGGTTTCATTTGAAACAGTATCTAA 840
Db      781  GAAGCTTTTGTATTAAGGAATCTGTAGGCTCAATTTTGGTTTCATTTGAAACAGTATCTAA 840
Qy      841  TTATAAATAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATAATGATATATCTGACTAG 900
Db      841  TTATAAATAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATAATGATATATCTGACTAG 900
Qy      901  TGGGAACCTCATAGGTTTCCCTCATCTGTCATGTCGATGATATATATGATATGATATTTAC 960
Db      901  TGGGAACCTCATAGGTTTCCCTCATCTGTCATGTCGATGATATATATGATATGATATTTAC 960
Qy      961  AAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATGATGAT 1020
Db      961  AAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATGATGAT 1020
Qy      1021  GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATATCTGCTTTAATTTCTTAAGCATA 1080
Db      1021  GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATATCTGCTTTAATTTCTTAAGCATA 1080
Qy      1081  AGTAACATGATATAAATAATATCTGCTGATTAATCTGCTGATGATGATGATGATGATGAT 1140
Db      1081  AGTAACATGATATAAATAATATCTGCTGATTAATCTGCTGATGATGATGATGATGATGAT 1140
Qy      1141  TTAATGTTTGTATTAATGTAAGCATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
Db      1141  TTAATGTTTGTATTAATGTAAGCATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
Qy      1201  TTCTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGTAATGATGATGATGATGATGAT 1260
Db      1201  TTCTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGTAATGATGATGATGATGATGAT 1260
Qy      1261  GAATGAGAGAAATTTGATTAACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db      1261  GAATGAGAGAAATTTGATTAACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Qy      1321  GAATTAAGACTC 1333
Db      1321  GAATTAAGACTC 1333

```

RESULT 5

ABL88072

ID ABL88072 standard; cDNA; 1333 BP.

XX AC ABL88072;

XX DT 16-MAY-2002 (first entry)

XX DE Human PRO181 cDNA sequence SEQ ID NO:1.

XX Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
 KW vulnery; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
 KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;
 KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
 KW age-related macular degeneration; arterial restenosis; angina;
 KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;
 KW lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
 KW wound healing; chromosome mapping; gene mapping; gene; ss.

XX OS Homo sapiens.

XX PN WO200200690-A2.

XX XX 03-JAN-2002.

XX PD

PF 20-JUN-2001; 2001WO-US019692.
 XX 23-JUN-2000; 2000US-0213637P.
 PR 20-JUL-2000; 2000US-0219556P.
 PR 25-JUL-2000; 2000US-0220624P.
 PR 25-JUL-2000; 2000US-0220664P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 02-AUG-2000; 2000US-0222695P.
 PR 17-AUG-2000; 2000US-00643657.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 07-SEP-2000; 2000US-0230978P.
 PR 18-SEP-2000; 2000US-00664610.
 PR 18-SEP-2000; 2000US-00865350.
 PR 24-OCT-2000; 2000US-0242922P.
 PR 08-NOV-2000; 2000US-00709238.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 22-JAN-2001; 2001US-00767609.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US0066520.
 PR 01-MAR-2001; 2001WO-US0066520.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 25-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 30-MAY-2001; 2001US-00870574.
 PR 30-MAY-2001; 2001WO-US017443.
 PR 01-JUN-2001; 2001WO-US017800.
 XX (GETH) GENENTECH INC.

Baker KP, Ferrara N, Gerber H, Gerttsen ME, Goddard A;

Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;

Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;

WPI; 2002-090516/12.

P-PSDB; ABB84817.

One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 infarction), endothelial or angiogenic disorders in a mammal.

Claim 2; Fig 1; 565pp; English.

ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
 ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
 antiangiogenic, hypotensive, vulnery and antiarteriosclerotic
 activities, and can be used in gene therapy. The PRO polynucleotides,
 proteins, agonists and antagonists are useful for treating or diagnosing
 a cardiovascular, endothelial or angiogenic disorder in a mammal, e.g.
 cardiac hypertrophy, trauma, cancer, age-related macular degeneration,
 atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
 angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
 angiogenesis (such as breast carcinoma and liver carcinoma) and wound
 healing. The PRO polynucleotides have applications in molecular biology,
 including use as hybridisation probes, and in chromosome and gene
 mapping. ABL88259 to ABL88267 represent primers and probes used in the
 exemplification of the present invention

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 6; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGTCCGATGGCGTTTCACTGTCGGGCTTCTGCTACATGCTGGCGCTCTGCT 60
Db 1 GCCCAGCGTCCGATGGCGTTTCACTGTCGGGCTTCTGCTACATGCTGGCGCTCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTCGCCATTTGGCAGCATATAGACATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTCGCCATTTGGCAGCATATAGACATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACAGTGTAAATACCTGTAATCCCTGTAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAAGAAATCCTATAGACAGTGTAAATACCTGTAATCCCTGTAATCCCTTGTACTCCAGAGTA 180
QY 181 CTTCAATCCAGCGTTTCTTCTGTCGTGTCATGTTCTTCTGTCAGCAGAGTGGCTTACACTGG 240
Db 181 CTTCAATCCAGCGTTTCTTCTGTCGTGTCATGTTCTTCTGTCAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTATGAG 300
QY 301 TGGCCAGAGACTCTATGACCCCTACAACTATGATGAGTGAATGAGTGAATGAGTGAATGAGTGA 360
Db 301 TGGCCAGAGACTCTATGACCCCTACAACTATGATGAGTGAATGAGTGAATGAGTGAATGAGTGA 360
QY 361 GAAGGAGGATGTCGCAATTTAGCTTTTATCTTCTGTCAGTATTTTCTTACCTATATGG 420
Db 361 GAAGGAGGATGTCGCAATTTAGCTTTTATCTTCTGTCAGTATTTTCTTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTGAACAACACACAGAGAAATTTGTCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTGAACAACACACAGAGAAATTTGTCAGTTAAGT 480
QY 481 GCATGCAAAAGCCCAATGAGGATTTCTATCCAGCAAGATCTCTGTCAGAGTAGC 540
Db 481 GCATGCAAAAGCCCAATGAGGATTTCTATCCAGCAAGATCTCTGTCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTTCTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTTCTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGGAAGACAGCTGTTTTCATATGTTTATCTCAGATAAGAAATTTAAATGGTAT 660
Db 601 TTTTGTCTGGAAGACAGCTGTTTTCATATGTTTATCTCAGATAAGAAATTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAAATGATTTACCTCTGGTGTTCACAGGTTTGAACCTTGACCTTC 720
Db 661 TAGCTATAAATTAATAAATGATTTACCTCTGGTGTTCACAGGTTTGAACCTTGACCTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
QY 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTGTTTCATGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTGTTTCATGAAACAGTATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAGTGAAGTGAAGTGAAGTGAAGTGA 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAGTGAAGTGAAGTGAAGTGAAGTGA 900
QY 901 TGGGAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATATGATGATGATGATGAT 960
Db 901 TGGGAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATATGATGATGATGATGAT 960
QY 961 AAAAATAAAGCGGAAATTTCCCTTCGTTGATTAATTAATTAATTAATTAATTAATTAATTAAT 1020
Db 961 AAAAATAAAGCGGAAATTTCCCTTCGTTGATTAATTAATTAATTAATTAATTAATTAATTAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTGAATAATATATCTGCTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTGAATAATATATCTGCTTAAATTTCTTAAGCATA 1080

QY 1081 AGTAAACATGATATAAAATATATGCTGAATTTCTGTTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAAATATATGCTGAATTTCTGTTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTTGTTTATTTTGAAGACATTTACTTTAAGAAATTTGTTTATTTATGCTTACTG 1200
Db 1141 TTAATGTTGTTTATTTTGAAGACATTTACTTTAAGAAATTTGTTTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGTGAAGATTTCTTGAAGATTTGAGGACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGTGAAGATTTCTTGAAGATTTGAGGACTACAGATTTTCAAACT 1260
QY 1261 GAACTGAGAGAAATTTGTATTAACCATCTGCTGTTCTTTAGTGAATACAATAAACTCT 1320
Db 1261 GAACTGAGAGAAATTTGTATTAACCATCTGCTGTTCTTTAGTGAATACAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 6
ABL95561
ID ABL95561 standard; cDNA; 1333 BP.
XX ABL95561;
AC ABL95561;
XX 19-JUL-2002 (first entry)
XX Human angiogenesis related cDNA PRO181 SEQ ID NO: 1.
DE Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW cardiac; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW antiarteriosclerotic; gene; ss.
XX Homo sapiens.
XX WO200208284-A2.
XX 31-JAN-2002.
XX 09-JUL-2001; 2001WO-US021735.
XX 20-JUL-2000; 2000US-0219556P.
XX 25-JUL-2000; 2000US-0220624P.
XX 25-JUL-2000; 2000US-0220664P.
XX 28-JUL-2000; 2000WO-US020710.
XX 02-AUG-2000; 2000US-0222695P.
XX 17-AUG-2000; 2000US-00643657.
XX 23-AUG-2000; 2000WO-US023522.
XX 24-AUG-2000; 2000WO-US023328.
XX 07-SEP-2000; 2000US-0230978P.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 24-OCT-2000; 2000US-0242922P.
XX 08-NOV-2000; 2000US-00709238.
XX 08-NOV-2000; 2000WO-US030952.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 22-JAN-2001; 2001US-00767609.
XX 28-FEB-2001; 2001US-00796498.
XX 28-FEB-2001; 2001WO-US006520.
XX 01-MAR-2001; 2001WO-US006666.
XX 09-MAR-2001; 2001US-00802706.
XX 14-MAR-2001; 2001US-00808689.
XX 22-MAR-2001; 2001US-00816744.
XX 05-APR-2001; 2001US-00828366.
XX 10-MAY-2001; 2001US-00854208.
XX 10-MAY-2001; 2001US-00854280.
XX 25-MAY-2001; 2001US-00866028.

```
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 30-MAY-2001; 2001US-00870574.
PR 30-MAY-2001; 2001WO-US017443.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
XX
PA (GETH ) GENENTECH INC.
PA (BAKE ) BAKER K P.
PA (FERR ) FERRARA N.
PA (GERB ) GERBER H.
PA (GERR ) GERRITSEN M E.
PA (GODD ) GODDARD A.
PA (GODO ) GODOFSKI P J.
PA (GURN ) GURNEY A L.
PA (HILL ) HILLAN K J.
PA (MARS ) MARSTERS S A.
PA (PANJ ) PAN J.
PA (PAON ) PAONI N F.
PA (STEP ) STEPHAN J F.
PA (WATA ) WATANABE C K.
PA (WILL ) WILLIAMS P M.
PA (WOOD ) WOOD W I.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-171999/22.
DR P-PSDB; ABB95423.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX
XX Claim 1; Fig 1; 567bp; English.
XX
PS The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial stenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The present sequence is a coding sequence of the invention
XX
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
XX
Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGGCTCGATGGGCTTACGTTTCGGCGCTTCGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGGCTCGATGGGCTTACGTTTCGGCGCTTCGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCCGCTCATCTTCTCGCCATTGGGCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCCGCTCATCTTCTCGCCATTGGGCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACCACTGTAATACCCCTGAATCCCTTGACTCCCAAGTA 180
DB 121 TGATTACAAGAAATCCTATAGACCACTGTAATACCCCTGAATCCCTTGACTCCCAAGTA 180
QY 181 CCTCATCAGCTTCTTCTGTCATGTTCTTCTGTCAGAGTATAGTACAGAGTACCTGGG 240
DB 181 CCTCATCAGCTTCTTCTGTCATGTTCTTCTGTCAGAGTATAGTACAGAGTACCTGGG 240
QY 241 TCTCAATATGCCCTCTTGGGATATCATATTTGGAGGTATATGAGTACAGTATGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGGATATCATATTTGGAGGTATATGAGTACAGTATGATGAG 300
QY 301 TGGCCCCAGGACTCTATGACCCCTACACCATCATGAATGAATGATATTTAGCATATTTGCA 360
DB 301 TGGCCCCAGGACTCTATGACCCCTACACCATCATGAATGAATGATATTTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTAGCAATTTTTTACCTATATGG 420
DB 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTAGCAATTTTTTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCAAGT 480
QY 481 GCATGCAAAAAGCCACCAAAATGAAGGATTCATCCAGCAAGATCCTGTCCAAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAAAATGAAGGATTCATCCAGCAAGATCCTGTCCAAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAATGTTCCCAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAATGTTCCCAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTTATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
DB 601 TTTTGTCTGTGGAAGACTGTTTTTATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
QY 661 TACGTATAAATTAATATAAATGATTAACCTCTGCTGTTTGAAGCTTTGAACTTGCACTTC 720
DB 661 TACGTATAAATTAATATAAATGATTAACCTCTGCTGTTTGAAGCTTTGAACTTGCACTTC 720
QY 721 TTAAGGAACGACCAATTAATCTCTGAATGATGATTAATTAATTAATGATGATGATG 780
DB 721 TTAAGGAACGACCAATTAATCTCTGAATGATGATTAATTAATTAATGATGATGATG 780
QY 781 GAAGCTTTGTTTATAGAACTTCTAGGCTCAATTTGGTTCATTTGAACAGATATCTAA 840
DB 781 GAAGCTTTGTTTATAGAACTTCTAGGCTCAATTTGGTTCATTTGAACAGATATCTAA 840
QY 841 TTATAAATTAAGCTTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGA 900
DB 841 TTATAAATTAAGCTTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGA 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATATAC 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATATAC 960
QY 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAT 1020
DB 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTTAATCTTAAAGCATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTTAATCTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATATCTGTTGAAGAATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAATAATATATGCTGAATATCTGTTGAAGAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTTTATTTTAAAGCAATTTAAGCAATTTAAGCAATTTGTTTATGTTTACTG 1200
DB 1141 TTAATGTTTATTTTAAAGCAATTTAAGCAATTTAAGCAATTTGTTTATGTTTACTG 1200
QY 1201 TTCTAATCTGTTGTTAAAGGATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGTTGTTAAAGGATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACT 1260
QY 1261 GAATGAGGAAATTTGTATACCATCTGCTGTTTCTTTAGTGAATATACATAAACTCT 1320
DB 1261 GAATGAGGAAATTTGTATACCATCTGCTGTTTCTTTAGTGAATATACATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
RESULT 7
```

ACA66900
ID ACA66900 standard; cDNA; 1333 BP.
XX AC
XX ACA66900;
XX AC
XX 23-JUN-2003 (first entry)
XX DT
XX DE cDNA encoding human PRO polypeptide #60.
XX XX
XX Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic;
KW gene; ss.
XX KW
XX OS Homo sapiens.
XX XX
XX US2003036635-A1.
XX PN
XX 20-FEB-2003.
XX PD
XX 28-AUG-2002; 2002US-00230163.
XX PF
XX 25-JUL-2000; 2000US-0220638P.
XX PR
XX 01-JUN-2001; 2001WO-US017800.
XX PR
XX 29-JUN-2001; 2001WO-US021066.
XX PR
XX 09-APR-2002; 2002US-00119480.
XX XX
XX (GETH) GENENTECH INC.
XX PA
XX Baker KP, Desnoyers L, Gerlitsen ME, Goddard A, Godowski PJ;
XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX PI P-PSDB; AB080798.
XX DR WPI: 2003-342045/32.
XX DR P-PSDB; AB080798.
XX XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
XX PT useful for the manufacture of a medicament for diagnosing or treating
XX PT tumor.
XX PT
XX XX
XX Claim 2; Fig 119; 314pp; English.
XX XX
XX The present invention relates to the isolation of novel human PRO
XX CC polypeptides, and the polynucleotide sequences encoding them. The PRO
XX CC polypeptides are secreted and transmembrane proteins. The PRO
XX CC polypeptides and polynucleotides are useful for preparing a medicament
XX CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
XX CC useful in diagnostic assays for PRO, by detecting its expression in
XX CC specific cells, tissues or serum, and for affinity purification of PRO
XX CC from recombinant cell culture or natural sources. ACA66841-ACA66962
XX CC represent cDNA sequences encoding the human PRO polypeptides of the
XX CC invention. Note: The sequence data for this patent was obtained in
XX CC electronic format directly from the USPTO web site at
XX CC seqdata.uspto.gov/psipsDIDEntry.html
XX XX
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
XX SQ
Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGGTTCACGTTGCGGCTTCTGCTACATGCGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGCGGTTCACGTTGCGGCTTCTGCTACATGCGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTCCCATTTGGCACATTATAGCATTTTATGAGCTGAGAC 120
DB 61 CACTGCGCGCTCATCTTCTCCCATTTGGCACATTATAGCATTTTATGAGCTGAGAC 120
QY 121 TGATTACAGATCCCTATAGACAGATGTAATACCTGAACTCCCTGTACTCCACAGTA 180
DB 121 TGATTACAGATCCCTATAGACAGATGTAATACCTGAACTCCCTGTACTCCACAGTA 180
QY 181 CPTCATCCACGCTTCTCTGTGTGTCATGTTCTTTGTGACAGAGTGGCTTACATGGG 240
DB 181 CPTCATCCACGCTTCTCTGTGTGTCATGTTCTTTGTGACAGAGTGGCTTACATGGG 240

Db 181 CCTCATCCACGCTTCTCTGTGTGTCATGTTCTTTGTGACAGAGTGGCTTACATGGG 240
QY 241 TCTCATATGCCCTCTTGTGTCATATCATATTTGGAGGTATATGATAGACAGTGTAG 300
DB 241 TCTCATATGCCCTCTTGTGTCATATCATATTTGGAGGTATATGATAGACAGTGTAG 300
QY 301 TGGCCAGGACTCTATGACCTTCAACCATCATGAATGCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCAGGACTCTATGACCTTCAACCATCATGAATGCAGATATTTCTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACAAACACACAGAGAGATTTGGTCCAGTAAGT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACAAACACACAGAGAGATTTGGTCCAGTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATCTATCCAGCAAGATCCTGTCCAAGATAGC 540
DB 481 GCATGCAAAAAGCCCAAAATGAAGGATCTATCCAGCAAGATCCTGTCCAAGATAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATATAATTAATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACATC 720
DB 661 TACGTATATAATTAATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACATC 720
QY 721 TTAAGGAACAGCCATTAATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAACAGCCATTAATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGAAACAGATATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGAAACAGATATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAG 900
QY 901 TGGGAAACTTCTATGAGTTCCTCATCTGTCATGTCGATGATTAATATATGATGATTTAC 960
DB 901 TGGGAAACTTCTATGAGTTCCTCATCTGTCATGTCGATGATTAATATATGATGATTTAC 960
QY 961 AAAAAATAAAAGCGGGAATTTTCCCTCTGCTGAATATTTATCCCTGTATATTTGATGAAT 1020
DB 961 AAAAAATAAAAGCGGGAATTTTCCCTCTGCTGAATATTTATCCCTGTATATTTGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATATCTGCTTTAATTTCTTAAGCAT 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATATCTGCTTTAATTTCTTAAGCAT 1080
QY 1081 AGTAACATGATATAAATAATATATCTGCTGAATTTTCTGTTGAAGATGCAATTTAAAGCTAT 1140
DB 1081 AGTAACATGATATAAATAATATATCTGCTGAATTTTCTGTTGAAGATGCAATTTAAAGCTAT 1140
QY 1141 TTAAATGTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
DB 1141 TTAAATGTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGGTGAAGGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATAAACCCTCTGCTTCTTTAGTGAATCAATTAATAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGATAAACCCTCTGCTTCTTTAGTGAATCAATTAATAAACTCT 1320

Qy 1321 GAAATTAAGACTC 1333
| | | | | | | | | |
Db 1321 GAAATTAAGACTC 1333

RESULT 8
ACD42697
ID ACD42697 standard; cDNA; 1333 BP.
XX
AC ACD42697;
XX
XX
DT 09-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; virucide; gene therapy;
KW cell death; growth induction cascade; blood coagulation cascade;
KW viral infection; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003050239-A1.
XX
PD 13-MAR-2003.
XX
PF 15-OCT-2001; 2001US-00978191.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077633P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 30-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080103P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081836P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.

22-APR-1998; 98US-0082700P.
22-APR-1998; 98US-0082704P.
22-APR-1998; 98US-0082797P.
22-APR-1998; 98US-0082804P.
23-APR-1998; 98US-0082796P.
27-APR-1998; 98US-0083336P.
28-APR-1998; 98US-0083322P.
28-APR-1998; 98US-0083329P.
29-APR-1998; 98US-0083455P.
29-APR-1998; 98US-0083496P.
29-APR-1998; 98US-0083499P.
29-APR-1998; 98US-0083500P.
29-APR-1998; 98US-0083545P.
29-APR-1998; 98US-0083554P.
29-APR-1998; 98US-0083558P.
29-APR-1998; 98US-0083559P.
30-APR-1998; 98US-0083742P.
05-MAY-1998; 98US-0084366P.
06-MAY-1998; 98US-0084414P.
06-MAY-1998; 98US-0084441P.
07-MAY-1998; 98US-0084588P.
07-MAY-1998; 98US-0084600P.
07-MAY-1998; 98US-0084627P.
07-MAY-1998; 98US-0084637P.
07-MAY-1998; 98US-0084639P.
07-MAY-1998; 98US-0084640P.
07-MAY-1998; 98US-0084643P.
13-MAY-1998; 98US-0085323P.
13-MAY-1998; 98US-0085338P.
13-MAY-1998; 98US-0085339P.
15-MAY-1998; 98US-0085573P.
15-MAY-1998; 98US-0085579P.
15-MAY-1998; 98US-0085580P.
15-MAY-1998; 98US-0085582P.
15-MAY-1998; 98US-0085689P.
15-MAY-1998; 98US-0085697P.
15-MAY-1998; 98US-0085700P.
15-MAY-1998; 98US-0085704P.
18-MAY-1998; 98US-0086023P.
22-MAY-1998; 98US-0086392P.
22-MAY-1998; 98US-0086414P.
22-MAY-1998; 98US-0086430P.
22-MAY-1998; 98US-0086486P.
28-MAY-1998; 98US-0087098P.
28-MAY-1998; 98US-0087106P.
28-MAY-1998; 98US-0087208P.
26-JUN-1998; 98US-00105413.
26-JUN-1998; 98US-0090863P.
26-JUN-1998; 98US-0091010P.
01-JUL-1998; 98US-0091359P.
30-JUL-1998; 98US-0094651P.
11-SEP-1998; 98US-0100038P.
07-OCT-1998; 98US-00168978.
07-OCT-1998; 98US-00211141.
02-NOV-1998; 98US-00184216.
06-NOV-1998; 98US-00187368.
20-NOV-1998; 98US-0109304P.
20-NOV-1998; 98US-00204855.
07-DEC-1998; 98US-00202054.
22-DEC-1998; 98US-00218517.
22-DEC-1998; 98US-0113296P.
23-DEC-1998; 98US-0113621P.
05-JAN-1999; 98US-00254465.
05-MAR-1999; 98US-00254465.
08-MAR-1999; 98US-00255028.
10-MAR-1999; 98US-00265686.
10-MAR-1999; 98US-00265190.
12-MAR-1999; 98US-00267213.
12-MAR-1999; 98US-0123957P.
29-MAR-1999; 98US-0126773P.
12-APR-1999; 98US-00284291.
21-APR-1999; 98US-0130232P.
26-APR-1999; 98US-0131022P.


```
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US028565.
PR 12-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00919585.
XX (GETH ) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCGATGCGCTTACGTTCCGGGCTTCTGTACATGCTGCGCTGCTGCT 60
Db 1 GCCACGCGTCGATGCGCTTACGTTCCGGGCTTCTGTACATGCTGCGCTGCTGCT 60
QY 61 CACTGCCGGCTCATCTTCTTCCGCAATTGGCACAATTATAGCAATTTGATGAGCTGAAGAC 120
```

```
Db 61 CACTGCCGGCTCATCTTCTTCCGCAATTGGCACAATTATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAACTCTATAGACCAAGTGTATAACCTCGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAAGAACTCTATAGACCAAGTGTATAACCTCGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTGTCAATGTTCTTTGTGCGAGCAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCAGCTTCTTCTGTGTCAATGTTCTTTGTGCGAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGATGATGAG 300
Db 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGATGATGAG 300
QY 301 TGGCCGAGGACTATGACCCCTACCAATCATGATGCAGATATTTCTAGCATATTTGCA 360
Db 301 TGGCCGAGGACTATGACCCCTACCAATCATGATGCAGATATTTCTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGCTCAAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGCTCAAGAGTAGC 540
QY 541 CTGTGGAACTGATCAGTTACTTTTAAAAAATGAATCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAACTGATCAGTTACTTTTAAAAAATGAATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAGAGCTGTTTCAATGTTATCTCAGATAAAGATTTTAAATGTTTAA 660
Db 601 TTTTCTTGTGGAAGAGCTGTTTCAATGTTATCTCAGATAAAGATTTTAAATGTTTAA 660
QY 661 TAGGTATAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACATTC 720
Db 661 TAGGTATAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACATTC 720
QY 721 TTAGGAACAGCCATAATCTCTGAATGATGATTAATCTGACTGCTCTAGTACATTTG 780
Db 721 TTAGGAACAGCCATAATCTCTGAATGATGATTAATCTGACTGCTCTAGTACATTTG 780
QY 781 GAAGCTTTTGTATAGGAACTTTGTAGGGCTCATTTTGGTGTGACAGGTTTGAACCTGCACATTC 840
Db 781 GAAGCTTTTGTATAGGAACTTTGTAGGGCTCATTTTGGTGTGACAGGTTTGAACCTGCACATTC 840
QY 841 TTATAAATTAGCTGATAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATCTGACTAG 900
Db 841 TTATAAATTAGCTGATAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGGTTTCTCATCTGCTGATGCTGATGATATATATGATGATATTTAC 960
Db 901 TGGGAAACCTTCATGGGTTTCTCATCTGCTGATGCTGATGATATATATGATGATATTTAC 960
QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCCGTTGAATATATATCCCTGATATATGATGAT 1020
Db 961 AAAAATAAAAGCGGGAATTTTCCCTTCCGTTGAATATATATCCCTGATATATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAATAATATATCTTGTCTTAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAATAATATATCTTGTCTTAATTTCTTAAGCATA 1080
QY 1081 AGTAACATGATATAAAATATATCTGAAATTTACTTGTGAAGAATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAAATATATCTGAAATTTACTTGTGAAGAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTATTTATGCTTACTG 1200
Db 1141 TTAATGTTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTATTTATGCTTACTG 1200
```

QY 1201 TTCTAATCTGCTGAAGGATATCTTAAGATTTGAGGACTACAGATTTTCAAAACT 1260
 Db 1201 TTCTAATCTGCTGAAGGATATCTTAAGATTTGAGGACTACAGATTTTCAAAACT 1260
 QY 1261 GAATGAGAGAAAATGTATACCATCCCTGCTGTTCTTTAGTGCAATACAAATAAACTCT 1320
 Db 1261 GAATGAGAGAAAATGTATACCATCCCTGCTGTTCTTTAGTGCAATACAAATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 9

ACD68652
 ID ACD68652 standard; cDNA; 1333 BP.

XX AC ACD68652;

XX DT 17-SEP-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO181 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; cytostatic;
 KW antiarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
 KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
 KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; bone disorder; cartilage disorder; sports injury;
 KW arthritis; wound; gene; ss.

XX OS Homo sapiens.

XX PN US2003045667-A1.

XX PD 06-MAR-2003.

XX PF 12-AUG-2002; 2002US-00218631.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR WPI; 2003-512315/48.

XX DR P-PSDB; ABO33764.

XX PT New genes, and its encoded secreted and transmembrane polypeptides,
 PT useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or
 PT pericyte proliferation, especially for treating lung tumors, arthritis or
 PT wounds in a mammal.

XX PS Claim 2; Fig 119; 314pp; English.

XX The invention describes an isolated nucleic acid molecule comprising a
 CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
 CC 122 PRO (secreted and transmembrane) polypeptides whose sequences are
 CC fully defined in the specification; or (b) any of 122 nucleotide
 CC sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
 CC specification; or the full length coding sequence of any these 122
 CC nucleotide sequences. The PRO polypeptides or polynucleotides are useful
 CC as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
 CC particularly useful for detecting tumours (e.g. lung tumour, colon
 CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
 CC in a mammal, for stimulating the release of TNF-alpha from human blood,
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells, for stimulating proliferation of pericyte cells, or for modulating
 CC normal human dermal fibroblast proliferation. The PRO nucleic acid or

CC polypeptide is also useful for treating tumours or various bone and/or
 CC cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
 CC PRO polypeptides are useful in drug screening, particularly as targets
 CC for therapeutic intervention in these diseases, and in the diagnostic
 CC determination of the presence of these diseases. The PRO polypeptides are
 CC also useful as molecular weight markers, or for chromosome
 CC identification. The PRO genes are useful as hybridisation probes, or for
 CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
 CC also be used in gene therapy, particularly for replacing a defective
 CC gene. This sequence encodes a novel human secreted and transmembrane PRO
 CC polypeptide

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 7; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCCAGCGCTCCGATGGGTTACGTTTCGGCGCTCTCTGTACATGCTGGCGCTGCTGCT 60
 Db 1 GCCCAGCGCTCCGATGGGTTACGTTTCGGCGCTCTCTGTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120
 Db 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCTATAGACAGTGAATACCTGTAATCCCTGTACTCCAGAGTA 180
 Db 121 TGATTACAGAAATCTATAGACAGTGAATACCTGTAATCCCTGTACTCCAGAGTA 180
 QY 181 CCTCATCCAGCTTTCTTCTGTGTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGG 240
 Db 181 CCTCATCCAGCTTTCTTCTGTGTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGG 240
 QY 241 TCTCAATATGCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGATGAG 300
 Db 241 TCTCAATATGCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGATGAG 300
 QY 301 TGGCCGAGGACTCTATGACCCCTAGCAATCATGATGATGATGATGATGATGATGATGAT 360
 Db 301 TGGCCGAGGACTCTATGACCCCTAGCAATCATGATGATGATGATGATGATGATGATGAT 360
 QY 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTCTTCTTCTTCTTCT 420
 Db 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTCTTCTTCTTCTTCT 420
 QY 421 CATGATCATGTTTGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTAAAGT 480
 Db 421 CATGATCATGTTTGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTAAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGATGAGC 540
 Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGATGAGC 540
 QY 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTGTTGGAAGACTGTTTTTCAATGTTTATCTAGTATGATGATGATGATGATGATGAT 660
 Db 601 TTTTGTGTTGGAAGACTGTTTTTCAATGTTTATCTAGTATGATGATGATGATGATGATGAT 660
 QY 661 TACGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACATC 720
 Db 661 TACGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACATC 720
 QY 721 TTAAGGAAACGCCATAATCTCTGAATGATGATGATGATGATGATGATGATGATGATGAT 780
 Db 721 TTAAGGAAACGCCATAATCTCTGAATGATGATGATGATGATGATGATGATGATGATGAT 780
 QY 781 GAAGCTTTGTTTATAGAACTTTAGGGCTCATTTTGGTGTGATGATGATGATGATGATGAT 840
 Db 781 GAAGCTTTGTTTATAGAACTTTAGGGCTCATTTTGGTGTGATGATGATGATGATGATGAT 840

PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-328860/31.
DR P-PSDB; ABU72240.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 128; 453pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC is at least 80 % sequence identity to, or the full-length coding sequence
CC of, any of 118 300-2100 nucleotide sequences, which encodes its
CC corresponding PRO polypeptide selected from 118 100-700 amino acid
CC sequences, all given in the specification. The nucleic acids and
CC polypeptides are useful for treating inflammatory diseases, organ
CC failure, atherosclerosis, cardiac injury, infertility, birth defects,
CC premature aging, AIDS, cancer, or diabetic complications. The nucleic
CC acids are useful as hybridisation probes, in chromosome and gene mapping,
CC and in generating antisense RNA or DNA. The polypeptides are useful as
CC pharmaceuticals, diagnostics, biosensors or bioreactors. Both are useful
CC in tissue typing. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGGTCGGATGGGCTTCACGTTCCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
Db |||||
QY 1 GCCACGGGTCGGATGGGCTTCACGTTCCGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
Db |||||
QY 61 CACTCCCGGCTCATCTTCTCGCATATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120
Db |||||
QY 61 CACTCCCGGCTCATCTTCTCGCATATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120
Db |||||
QY 121 TGATTACAAGAAATCCTATAGACCAAGTGAATACCTGAAATCCCTTGACTCCCAAGATA 180
Db |||||
QY 121 TGATTACAAGAAATCCTATAGACCAAGTGAATACCTGAAATCCCTTGACTCCCAAGATA 180
Db |||||
QY 181 CCTCATACAGCTTCTTCTGCTGCTCATGTTCTTCTGTCAGGACAGAGTGGCTTACACTGG 240
Db |||||
QY 181 CCTCATACAGCTTCTTCTGCTGCTCATGTTCTTCTGTCAGGACAGAGTGGCTTACACTGG 240
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGTATGAG 300
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGTATGAG 300
Db |||||
QY 301 TGGCCCAAGACTCTATGACCCCTACACCAATCATGATGATGATATTTCTAGCATATTTGTC 360
Db |||||
QY 301 TGGCCCAAGACTCTATGACCCCTACACCAATCATGATGATGATATTTCTAGCATATTTGTC 360
Db |||||
QY 361 GAAGGAAGAGTGGTCAAAATAGCTTTTATCTTCTAGCAATTTTTTCTACTACTATATGG 420
Db |||||
QY 361 GAAGGAAGAGTGGTCAAAATAGCTTTTATCTTCTAGCAATTTTTTCTACTACTATATGG 420
Db |||||

QY 421 CATGATCTATGCTTTTGGTGGGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
Db |||||
QY 421 CATGATCTATGCTTTTGGTGGGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
Db |||||
QY 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGATCCTGTCTCAAGAGTAGC 540
Db |||||
QY 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGATCCTGTCTCAAGAGTAGC 540
Db |||||
QY 541 CTGTGGAATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 541 CTGTGGAATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTTAT 660
Db |||||
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTTAT 660
Db |||||
QY 661 TACGTATAAATTAATAAATAATGATTACCTCTGCTGTTTGACAGGTTTGAACCTTGCACAT 720
Db |||||
QY 661 TACGTATAAATTAATAAATAATGATTACCTCTGCTGTTTGACAGGTTTGAACCTTGCACAT 720
Db |||||
QY 721 TTAAGGAACAGCCCAATATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
Db |||||
QY 721 TTAAGGAACAGCCCAATATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
Db |||||
QY 781 GAAGCTTTTGTATAGGAACCTCTAGGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
Db |||||
QY 781 GAAGCTTTTGTATAGGAACCTCTAGGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
Db |||||
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
Db |||||
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
Db |||||
QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 960
Db |||||
QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 960
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTCGCTGGAATATATATCCCTGTATATTTGATGAAT 1020
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTCGCTGGAATATATATCCCTGTATATTTGATGAAT 1020
Db |||||
QY 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAAATAAATAATATATCTTCTTAAATCTTAAGCATA 1080
Db |||||
QY 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAAATAAATAATATATCTTCTTAAATCTTAAGCATA 1080
Db |||||
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTAAT 1140
Db |||||
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTAAT 1140
Db |||||
QY 1141 TTAATGTTTGTATTTTGTAAAGCATTTACTTTAAGAAATTTGGTATTTATGCTTACTG 1200
Db |||||
QY 1141 TTAATGTTTGTATTTTGTAAAGCATTTACTTTAAGAAATTTGGTATTTATGCTTACTG 1200
Db |||||
QY 1201 TTCTAATCTGTGTAAAGGATTTCTTAAGAAATTTGAGGTAATTAAGGTAATTAAGGTAAT 1260
Db |||||
QY 1201 TTCTAATCTGTGTAAAGGATTTCTTAAGAAATTTGAGGTAATTAAGGTAATTAAGGTAAT 1260
Db |||||
QY 1261 GATGAGGAGAAATTTGTATATACCATCTCTGCTGTTCTTTAGTGAATTAAGGTAATTAAGGTAAT 1320
Db |||||
QY 1261 GATGAGGAGAAATTTGTATATACCATCTCTGCTGTTCTTTAGTGAATTAAGGTAATTAAGGTAAT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||

RESULT 11

ACA71896

ID ACA71896 standard; cDNA; 1333 BP.

XX ACA71896;

AC ACA71896;

XX 11-AUG-2003 (first entry)

DT 11-AUG-2003 (first entry)

XX

Human secreted and transmembrane polypeptide PRO181 cDNA.

DE XX
KW Human; ss; gene; thrombolytic agent; interferon; interleukin; cytokine;
KW erythropoietin; colony stimulating factor; cancer; colorectal carcinoma;
KW apoptosis related condition; AIDS; amyotrophic lateral sclerosis;
KW inflammatory disease; asthma; atherosclerosis; neurodegenerative disease;
KW gastrointestinal disorder; Alzheimer's disease; Parkinson's disease;
KW hypertension; myocardial ischaemia; kidney disease; carcinogenesis;
KW glomerulonephritis; lung disease; pulmonary hypertension; preeclampsia;
KW bronchial asthma; gastric ulcer; renal failure; cardiovascular disease;
KW inflammatory bowel disease; reproductive disorder; premature labour.

OS Homo sapiens.
XX US2002177553-A1.
XX 28-NOV-2002.
XX 15-OCT-2001; 2001US-00978192.
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066366P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-0004022P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 26-JUN-1998; 98US-00105413.
XX 07-OCT-1998; 98US-00168978.
XX 07-OCT-1998; 98US-00168978.
XX 02-NOV-1998; 98US-00184216.
XX 06-NOV-1998; 98US-00187368.
XX 20-NOV-1998; 98US-0024855.
XX 07-DEC-1998; 98US-00202054.
XX 22-DEC-1998; 98US-00218517.
XX 05-JAN-1999; 99US-0000106.
XX 05-JAN-1999; 99US-00254465.
XX 08-MAR-1999; 99US-00505028.
XX 10-MAR-1999; 99US-00285686.
XX 10-MAR-1999; 99US-00505190.
XX 12-MAR-1999; 99US-00267213.
XX 12-APR-1999; 99US-00284291.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99US-00310733.
XX 02-JUN-1999; 99US-0012252.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380142.
XX 30-NOV-1999; 99US-00283113.
XX 02-DEC-1999; 99US-0028551.
XX 02-DEC-1999; 99US-0028565.
XX 16-DEC-1999; 99US-00300095.
XX 30-DEC-1999; 99US-0031243.
XX 30-DEC-1999; 99US-0031274.
XX 05-JAN-2000; 2000US-0000219.
XX 06-JAN-2000; 2000US-0000277.

06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrera N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Klijavir IJ, Kuo SS, Napier WA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart JA, Tumas D, Williams FM, Wood WI;
XX WPI; 2003-328499/31.
XX P-PSDB; ABUS4920.
XX New isolated PRO polypeptides e.g. PRO213, PRO274 and PRO300, for use as
XX pharmaceuticals, diagnostics, biosensors and bioreactors, for identifying
XX modulators of receptor-ligand interactions.
XX Claim 2; SEQ ID NO 321; 55pp; English.
XX The invention relates to an isolated secreted and transmembrane
XX polypeptide, designated as PRO polypeptide. The PRO polypeptide is useful
XX in PRO polypeptide detection methods. The PRO polypeptide is useful for
XX linking a bioactive molecule to a cell. The PRO polypeptide or an
XX antibody against it is useful for modulating a biological activity of a
XX cell. The PRO polypeptide is useful in industrial applications including
XX pharmaceuticals, diagnostics, biosensors and bioreactors. The PRO
XX polypeptide is also useful as a thrombolytic agent, interferon,
XX interleukin, erythropoietin, colony stimulating factor and other
XX cytokines. The PRO polypeptide is useful for treating disease such as
XX cancer e.g. colorectal carcinoma; apoptosis related conditions e.g. AIDS,
XX amyotrophic lateral sclerosis; inflammatory disease e.g. asthma,
XX atherosclerosis; neurodegenerative disease e.g. Alzheimer's disease,
XX Parkinson's disease; cardiovascular disease e.g. hypertension and
XX myocardial ischaemia; kidney disease e.g. renal failure and
XX glomerulonephritis; lung disease e.g. pulmonary hypertension, bronchial
XX asthma; gastrointestinal disorders e.g. gastric ulcer and inflammatory
XX bowel disease; reproductive disorders e.g. premature labour and
XX preeclampsia; carcinogenesis. The present sequence represents a cDNA
XX encoding a PRO polypeptide of the invention. Note: The sequence data for

CC this patent did not form part of the printed specification but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?docid=20020177553

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306; Mismatches 0; Indels 0; Gaps 0;
Matches 1333; Conservative 0;

QY 1 GCCACGGCTCGATGGCGTTCCACGTTTCGGGCTCTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGGCTCGATGGCGTTCCACGTTTCGGGCTCTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTCCGGGCTCATCTTCTTCCGCAATTTGGCAGATTTAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTCCGGGCTCATCTTCTTCCGCAATTTGGCAGATTTAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACAGTGAATACCCCTGAATCCCTTGTACTCCACAGATTA 180
DB 121 TGATTACAGAAATCCTATAGACAGTGAATACCCCTGAATCCCTTGTACTCCACAGATTA 180
QY 181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
QY 301 TGGCCACGAGCTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCACGAGCTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATAGG 420
DB 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATAGG 420
QY 421 CATGATCTATGTTTGGTAGCTCTTAGAACACACACAGAGAAATTTGTCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTAGCTCTTAGAACACACACAGAGAAATTTGTCAGTTAAGT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATCTTATCAGCAAGATCTCTGTCGAAGTAGC 540
DB 481 GCATGCAAAAGCCACCAATGAAGGATCTTATCAGCAAGATCTCTGTCGAAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTATCTAGATAAGATTTTAAATGTTAT 660
DB 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTATCTAGATAAGATTTTAAATGTTAT 660
QY 661 TAGCTATAAATTAATAAATGAATTAACCTCTGCTGTTTGCACAGGTTTGAACCTTGC 720
DB 661 TAGCTATAAATTAATAAATGAATTAACCTCTGCTGTTTGCACAGGTTTGAACCTTGC 720
QY 721 TTAAGGAACAGCATTAATCTCTGAATGATGATTAATTAATGACTGCTGCTAGTCAAT 780
DB 721 TTAAGGAACAGCATTAATCTCTGAATGATGATTAATTAATGACTGCTGCTAGTCAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTTGTTCATTTGAACAGATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTTGTTCATTTGAACAGATCTAA 840
QY 941 TTATAAATTAGCTGTAGATATCAGGCTCTCTCATGAAGTGAATAATGATATCTGACTAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGCTCTCTCATGAAGTGAATAATGATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATATATATGATGATACATTTAC 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATATATATGATGATACATTTAC 960

QY 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
DB 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAATAAATACTTGTGCTTTAATTTCTTAAGCATA 1080
DB 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAATAAATACTTGTGCTTTAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTATTTTGAAGACATTTATTAAGAAATTTGTTATTTATGCTTACTG 1200
DB 1141 TTAATGCTGTTTATTTTGAAGACATTTATTAAGAAATTTGTTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTTAAAGTATTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGCTGTTAAAGTATTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGTTAATACCATCTGCTGCTTCTTGTAGTGAATACATAAATCTCT 1320
DB 1261 GAATGAGAGAAATTTGTTAATACCATCTGCTGCTTCTTGTAGTGAATACATAAATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
RESULT 12
ABX92536
ID ABX92536 standard; cDNA; 1333 BP.
XX AC ABX92536;
XX DT 08-MAY-2003 (first entry)
XX DE cDNA encoding human PRO181 polypeptide.
XX KW Human; PRO polypeptide; secreted and transmembrane protein; immune disorder; diabetes; hyper-insulinaemia; hypo-insulinaemia; cardiac insufficiency; nervous system disorder; kidney disorder; bone disorder; cartilage disorder; arthritis; tumour; wound healing; genetic disorder; cytosolic; antidiabetic; anti-inflammatory; antithrombotic; anti-tumour; vulnery; antianaemic; dermatological; cardiant; gene; ss.
XX OS Homo sapiens.
XX PN US2002169284-A1.
XX PD 14-NOV-2002.
XX PF 16-OCT-2001; 2001US-00978697.
XX PR 26-MAY-1981; 81US-00267213.
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-0040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.

```
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00818920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 03-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 29-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021066.
PR 30-JUL-2001; 2001WO-US021735.
XX PA (GETH ) GENENTECH INC.

XX 98US-0079656P.
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton D;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI: 2003-288163/28.
DR P-PSDB; AB061118.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating cancer, kidney diseases, bone,
PT cartilage disorders and immune deficiencies.
XX
PS Claim 2; Fig 128; 459pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for
CC identifying agonists or antagonists. The bioactive molecule may be a
CC toxin, radiolabel or antibody, and causes apoptosis or death of the cell.
CC The PRO polypeptides are useful for treating immune disorders, diabetes
CC or hyper- or hypo-insulinaemia, cardiac insufficiency, nervous system
CC disorders, kidney disorders, bone and cartilage disorders or arthritis,
CC tumours, and wound healing. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and gene
CC mapping, in the generation of antisense RNA and DNA, in the preparation
CC of PRO polypeptides, for generating transgenic animals or knockout
CC animals, for the genetic analysis of individuals with genetic disorders,
CC and in gene therapy. The present sequence encodes a human PRO polypeptide
CC of the invention. Note: The sequence data for this patent was obtained in
CC electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsideEntry.html
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGGTCCGATGGGCTTCACGCTCGCGGCTTCTGTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGGGTCCGATGGGCTTCACGCTTCGGGCTTCTGTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGGGCTCATCTTCTTCGCCATTGGGCACATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGGGCTCATCTTCTTCGCCATTGGGCACATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGATCCCTATAGACAGCTGTAATACCTGTAATCCCTGTAATCCCTGTAATCC 180
Db 121 TGATTACAGATCCCTATAGACAGCTGTAATACCTGTAATCCCTGTAATCCCTGTAATCC 180

QY 181 CCTCATCCACGGCTTCTTCTGTGTATGTTCTTTGTGCGAGCAGAGTGCTTACACTGG 240
Db 181 CCTCATCCACGGCTTCTTCTGTGTATGTTCTTTGTGCGAGCAGAGTGCTTACACTGG 240

QY 241 TCTCAATATGCCCTTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
Db 241 TCTCAATATGCCCTTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300

QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATGAGTATTTAGTATTTGCA 360
Db 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATGAGTATTTAGTATTTGCA 360

QY 361 GAAGGAAGGATGGTCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGGATGGTCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
```



```
Db 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTCCTCCAGCAAGATCCCTGTCCAAAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTCCTCCAGCAAGATCCCTGTCCAAAGTAGC 540
Qy 541 CTGTGGAAATCTGATCAGTACTTTAAAATAAGTCCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAAATCTGATCAGTACTTTAAAATAAGTCCCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTCTTGTGGAAGAGCTGTTTCAATATGTTTACTCAGATAAAGATTTTAAATGCTAT 660
Db 601 TTTTGTCTTGTGGAAGAGCTGTTTCAATATGTTTACTCAGATAAAGATTTTAAATGCTAT 660
Qy 661 TACGTATAAATTAATAAATAAGTATTACCTCTGGTGTGACAGGTTTGAACCTTCCACATC 720
Db 661 TACGTATAAATTAATAAATAAGTATTACCTCTGGTGTGACAGGTTTGAACCTTCCACATC 720
Qy 721 TTAAGGACACGCCAATATCCCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
Db 721 TTAAGGACACGCCAATATCCCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
Qy 781 GAAGCTTTTGTATAGAACTTTAGGGCTCAATTTGGTTTTCATTTGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGAACTTTAGGGCTCAATTTGGTTTTCATTTGAAACAGATATCTAA 840
Qy 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 900
Qy 901 TGGGAAATCTTCATGGTTCCTCTCTGATGATGATGATGATGATGATGATGATGATGATG 960
Db 901 TGGGAAATCTTCATGGTTCCTCTCTGATGATGATGATGATGATGATGATGATGATGATG 960
Qy 961 AAAAAATAGGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATATGTCATGAAT 1020
Db 961 AAAAAATAGGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATATGTCATGAAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATATATATCTGCTTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATATATATCTGCTTTAAATTTCTTAAGCATA 1080
Qy 1081 AGTAAACATGATATAAATAATATATCTGCTGATGATGATGATGATGATGATGATGATGAT 1140
Db 1081 AGTAAACATGATATAAATAATATATCTGCTGATGATGATGATGATGATGATGATGATGAT 1140
Qy 1141 TTAATATGTTTATTTTGTAAAGACATTTACTTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTTGTAAAGACATTTACTTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Qy 1201 TTCTAAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAAATTTGATTAACCTCTGCTGTTCTTTAGTGCATTAACAATAAACTCT 1320
Db 1261 GAATGAGAGAAAATTTGATTAACCTCTGCTGTTCTTTAGTGCATTAACAATAAACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
```

RESULT 13

ACA66277

ID ACA66277 standard; cdna; 1333 BP.

XX

AC ACA66277;

XX

DT 24-JUN-2003 (first entry)

XX

DE Human cDNA encoding secreted/transmembrane protein PRO181.

XX

Human; ss; gene; secreted protein; transmembrane protein; PRO; malignancy; cancer; ovarian cancer; colorectal cancer; sarcoma; leukaemia; lymphoma; inflammatory disease; necrosis; atherosclerosis; infertility; premature aging; psoriasis; inflammatory disease; renal disease; arthritis; immune-mediated alopecia; stroke; encephalitis; hepatitis; multiple sclerosis; gene therapy.

Homo sapiens.

US2003004102-A1.

02-JAN-2003.

15-OCT-2001; 2001US-00978189.

17-OCT-1997; 97US-0062250P.

03-NOV-1997; 97US-0064249P.

13-NOV-1997; 97US-0065311P.

21-NOV-1997; 97US-0066364P.

10-MAR-1998; 98US-0077450P.

11-MAR-1998; 98US-0077632P.

11-MAR-1998; 98US-0077641P.

11-MAR-1998; 98US-0077791P.

12-MAR-1998; 98US-0078004P.

13-MAR-1998; 98US-00040220.

17-MAR-1998; 98US-0078886P.

20-MAR-1998; 98US-0078910P.

20-MAR-1998; 98US-0078936P.

20-MAR-1998; 98US-0078939P.

25-MAR-1998; 98US-0079294P.

26-MAR-1998; 98US-0079656P.

27-MAR-1998; 98US-0079663P.

27-MAR-1998; 98US-0079664P.

27-MAR-1998; 98US-0079689P.

27-MAR-1998; 98US-0079728P.

27-MAR-1998; 98US-0079786P.

30-MAR-1998; 98US-0079920P.

30-MAR-1998; 98US-0079923P.

26-JUN-1998; 98US-00105413.

07-OCT-1998; 98US-00168978.

07-OCT-1998; 98WO-US021141.

02-NOV-1998; 98US-00184216.

06-NOV-1998; 98US-00187368.

20-NOV-1998; 98WO-US024855.

07-DEC-1998; 98US-00202054.

22-DEC-1998; 98US-00218517.

05-JAN-1999; 99WO-US000106.

05-MAR-1999; 99US-00254465.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99US-00265686.

10-MAR-1999; 99WO-US005190.

12-MAR-1999; 99US-00267213.

12-APR-1999; 99US-00284291.

14-MAY-1999; 99US-00311832.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

25-AUG-1999; 99US-00380137.

25-AUG-1999; 99US-00380138.

25-AUG-1999; 99US-00380142.

30-NOV-1999; 99WO-US028313.

02-DEC-1999; 99WO-US028551.

16-DEC-1999; 99WO-US028565.

30-DEC-1999; 99WO-US031243.

30-DEC-1999; 99WO-US031274.

05-JAN-2000; 2000WO-US000219.

06-JAN-2000; 2000WO-US000277.

11-FEB-2000; 2000WO-US000376.

18-FEB-2000; 2000WO-US003565.

24-FEB-2000; 2000WO-US004341.

01-MAR-2000; 2000WO-US005004.

01-MAR-2000; 2000WO-US005601.

PR 10-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Ashtenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hallan KJ;
PI Kljavin IG, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
XX WPI: 2003-341189/32.
DR P-PSDB; ABU80397.
XX
XX
PT New genes and secreted and transmembrane polypeptides (e.g. PRO337 or
PT PRO1559), useful for treating or diagnosing e.g. cancers,
PT atherosclerosis, infertility, stroke, encephalitis, hepatitis or multiple
PT sclerosis in mammals.
XX
PS Claim 2; Fig 128; 460pp; English.

XX
XX The invention relates to a new isolated nucleic acid molecule comprises a
CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
CC 94 PRO polypeptides whose sequences are fully defined in the
CC specification; or (b) any of 94 nucleotide sequences fully defined in the
CC specification; or the full length coding sequence of any these 94
CC nucleotide sequences. Also included are an isolated PRO polypeptide
CC scoring at least 80% positives when compared to any of the PRO
CC polypeptide sequences cited above (or an isolated PRO polypeptide having
CC at least 80% amino acid sequence identity to: (a) an amino acid sequence
CC encoded by the nucleotide deposited with ATCC numbers listed in the
CC specification; (b) the PRO polypeptide, lacking its associated signal
CC peptide; or (c) an extracellular domain of the PRO polypeptide, with or
CC lacking its associated signal peptide), a vector comprising the nucleic
CC acid molecule, a host cell comprising the vector (and producing a PRO
CC polypeptide), a chimeric molecule comprising the PRO polypeptide fused
CC to a heterologous amino acid sequence and an anti-PRO antibody. The PRO
CC polypeptides or polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. These are particularly useful for
CC detecting or treating e.g. malignancies or cancers (e.g. ovarian cancer,
CC colorectal cancer, sarcoma, leukaemia or lymphoma), inflammatory disease,
CC necrosis, atherosclerosis, infertility, premature aging, psoriasis,
CC inflammatory disease, renal disease, arthritis, immune-mediated alopecia,

CC stroke, encephalitis, hepatitis, or multiple sclerosis in mammals. The
CC PRO polypeptides are useful in drug screening, particularly as targets
CC for therapeutic intervention in these diseases, and in the diagnostic
CC determination of the presence of these diseases. The PRO polypeptides are
CC also useful as molecular weight markers, or for chromosome
CC identification. The PRO genes are useful as hybridisation probes, or for
CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence encodes a PRO polypeptide
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGTCCGATGGCGTTACGTTTCGGCGCCCTTCTGTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGTCCGATGGCGTTACGTTTCGGCGCCCTTCTGTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCCGCTCATCTTCTTGGCCATTTGGCACAATNAGCATTGATGAGTGAAGAC 120
DB 61 CACTGCCCGCTCATCTTCTTGGCCATTTGGCACAATNAGCATTGATGAGTGAAGAC 120
QY 121 TGATTACAAGATCCTATAGACCAGTGTAACTACCTGAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAAGATCCTATAGACCAGTGTAACTACCTGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCACGCTTCTTCTGTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
DB 181 CCTCATCCACGCTTCTTCTGTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACCACTGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACCACTGATGAG 300
QY 301 TGGCCCGAGCTCTATGACCCCTACAACTCATGAATCAGATATTTCTAGCATATTTGTC 360
DB 301 TGGCCCGAGCTCTATGACCCCTACAACTCATGAATCAGATATTTCTAGCATATTTGTC 360
QY 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTACTTATATGG 420
DB 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTACTTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTAACT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTAACT 480
QY 481 GCATGCAAAAAGCCACCACCAATGAAGGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
DB 481 GCATGCAAAAAGCCACCACCAATGAAGGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTTACCTTTAAAAAATGACCTTCTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTTACCTTTAAAAAATGACCTTCTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTGTTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATATAAATGATATCCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
DB 661 TACGTATAAATTAATATAAATGATATCCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACAGCCATAAATCCTCTGAATGATGATTAATTAATCTAGTCTGTCTAGTCAATG 780
DB 721 TTAAGGAACAGCCATAAATCCTCTGAATGATGATTAATTAATCTAGTCTGTCTAGTCAATG 780
QY 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCATTTGGTTCATTGTTTCAATGAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCATTTGGTTCATTGTTTCAATGAACAGTATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTCTGATGAGTGAAGTGAATGTATATCTGACTAG 900

Db 841 TTAATAATTAGCTGATAGATATACAGGTGCTCTGATGAAGTGAAGATGATATCTGACATAG 900
Qy 901 TGGGAACTTCATGGGTTTCCCTCATCTGTCATGTCGATGATGATATATGATATGATATGAT 960
Db 901 TGGGAACTTCATGGGTTTCCCTCATCTGTCATGTCGATGATGATATATGATATGATATGAT 960
Qy 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGATATATGATGAT 1020
Db 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGATATATGATGAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATTTCTTAAGCATA 1080
Qy 1081 AGTAACATGATATATAAATAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATATAAATAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
Qy 1141 TTAATATGTTTTTATTTTGAAGATTAATTTTAAAGATTAATTTTAAAGATTAATTTTAAAGCTATT 1200
Db 1141 TTAATATGTTTTTATTTTGAAGATTAATTTTAAAGATTAATTTTAAAGATTAATTTTAAAGCTATT 1200
Qy 1201 TTCTAATCTGGTGGTAAAGTATTTCTTAAGATTTTGCAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGGTAAAGTATTTCTTAAGATTTTGCAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGATATAACCATCTGCTGTTCTTTAGTGAATTAACATTAACATTAACATCT 1320
Db 1261 GAATGAGAGAAATTTGATATAACCATCTGCTGTTCTTTAGTGAATTAACATTAACATTAACATCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 14
ACAG68556
ID ACAG68556 standard; cDNA; 1333 BP.
XX AC AGAG68556;
XX 25-JUN-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
XX antiangiogenic; hypotensive; vulnery; antiarteriosclerotic;
XX gene therapy; cardiovascular disorder; endothelial disorder;
XX angiogenic disorder; cardiac hypertrophy; trauma; cancer;
XX age-related macular degeneration; atherosclerosis; hypertension;
XX arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
XX thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
XX liver carcinoma; wound healing; chromosome mapping; gene mapping; gene;
XX ss.
XX Homo sapiens.
XX OS
XX US2003088063-AL.
XX PN
XX 08-MAY-2003.
XX PD
XX 12-AUG-2002; 2002US-00219003.
XX PF
XX 25-JUL-2000; 2000US-0220664P.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-APR-2002; 2002US-00119480.
XX PA (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-393229/37.
DR P-PSDB; ABU82107.
XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX Claim 2; Fig 119; 314pp; English.
XX The invention describes one hundred and eighty seven nucleic acids
CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
CC treating or diagnosing a cardiovascular, endothelial or angiogenic
CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
CC related macular degeneration, atherosclerosis, hypertension, arterial
CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
CC have applications in molecular biology, including use as hybridisation
CC probes, and in chromosome and gene mapping. This sequence encodes a novel
CC human secreted and transmembrane PRO polypeptide
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCACGCGTCCGATGGCGTTACGCTTCGCGGCCCTTCTGTACATGCTGGCGCTGCTGT 60
Db 1 GCCACGCGTCCGATGGCGTTACGCTTCGCGGCCCTTCTGTACATGCTGGCGCTGCTGT 60
Qy 61 CACTGCCGCGCTCATCTTCTTCGCCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTTCGCCAATTTGGCACAATTTGATGAGCTGAAGAC 120
Qy 121 TGATTACAGAAATCCCTATAGACAGCTGAATACCTGAAATCCCTTGTACTCCCCAGATGA 180
Db 121 TGATTACAGAAATCCCTATAGACAGCTGAATACCTGAAATCCCTTGTACTCCCCAGATGA 180
Qy 181 CCTCATCCACGCTTTCTTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACATGG 240
Db 181 CCTCATCCACGCTTTCTTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACATGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATAATCATATTTGGAGGTATATGATGAGCCAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATAATCATATTTGGAGGTATATGATGAGCCAGTATGAG 300
Qy 301 TGGCCCGAGCTCTATGACCCCTTACCAACCATCATGATGAGATATTTAGCATATTTGTCA 360
Db 301 TGGCCCGAGCTCTATGACCCCTTACCAACCATCATGATGAGATATTTAGCATATTTGTCA 360
Qy 361 GAAGGAAGATGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGATGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAAATTTGCTCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAAATTTGCTCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCGAAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCGAAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTGTTGGAAGAGCTGTTTTCATATGTTATCTAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTGTTGGAAGAGCTGTTTTCATATGTTATCTAGATAAAGATTTTAAATGGTAT 660


```
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US024855.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028562.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL,
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kijavits IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
XX WPI; 2003-521814/49.
DR P-PSDB; ADA24861.
XX
XX New isolated PRO polypeptides for example extracellular, secreted and
PT membrane bound proteins, useful for modulating the biological activities
PT of cells and for treating, for example diabetes, cancer, rheumatoid
PT arthritis, and hearing loss.
XX
XX Claim 2; Fig 128; 461pp; English.
XX
XX The invention describes an isolated secreted and transmembrane (PRO)
CC polypeptide (I). PRO337 polypeptide is useful for detecting PRO4993
CC polypeptide in a sample, and vice versa. PRO725, PRO700 and PRO739 are
CC useful for detecting PRO1559 polypeptide in a sample, and PRO1559 is
CC useful for detecting PRO725, PRO700 and PRO739 in a sample. PRO4993 is
CC useful for linking a bioactive molecule to a cell expressing a PRO337
CC polypeptide, and PRO337 is useful for linking a bioactive molecule to a
CC cell expressing a PRO4993 polypeptide. PRO1559 is useful for linking a
CC bioactive molecule to a cell expressing a PRO735, PRO700 and PRO739
CC

Query Match 100.0%; Score 1333; DB 8; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306; Mismatches 0; Gaps 0;
Matches 1333; Conservative 0; Indels 0;

QY 1 GCCCAGCGTCCGATGGGTTTCAGGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAGCGTCCGATGGGTTTCAGGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCCGCGTCACTTCTTCTGTCATGTTTCTTGTGCAGCAGAGTGGCTTACACTGGG 120
Db 61 CACTGCCGCGTCACTTCTTCTGTCATGTTTCTTGTGCAGCAGAGTGGCTTACACTGGG 120

QY 121 TGATTACAGGAATCCTATAGACCAGTGAATACCTCGAATCCCTTGCTACTCCAGAGTA 180
Db 121 TGATTACAGGAATCCTATAGACCAGTGAATACCTCGAATCCCTTGCTACTCCAGAGTA 180

QY 181 CCTCATCCAGCTTTCTTCTGTCATGTTTCTTGTGCAGCAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCAGCTTTCTTCTGTCATGTTTCTTGTGCAGCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCCCTTGGCATATCATATTTGGAGGTATATGATAGACAGTATGAG 300
Db 241 TCTCAATATGCCCCCTTGGCATATCATATTTGGAGGTATATGATAGACAGTATGAG 300

QY 301 TGGCCCCAGGACTCTATGACCCCTACAAACCATCATGAATCAGATATTCATGATATGTCA 360
Db 301 TGGCCCCAGGACTCTATGACCCCTACAAACCATCATGAATCAGATATTCATGATATGTCA 360

QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACHACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACHACACAGAGAATTTGGTCCAGTTAAGT 480
```

Db 421 CATGATCTATGTTTGGTGGCTCTTAGAACACACACAGAAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATCTATCCAGCAAGATCTGTCCAAAGATAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATCTATCCAGCAAGATCTGTCCAAAGATAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTAAATAAGTACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTAAATAAGTACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
Db 601 TTTTGTCTTGGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
QY 661 TAGCTATAAATTAATAAATAAGTAACTCTGTGGTGTGACAGTTTGAACCTTGCACTTC 720
Db 661 TAGCTATAAATTAATAAATAAGTAACTCTGTGGTGTGACAGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCATTAATTAATCTGCTCTAGTACATTG 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGCATTAATTAATCTGCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGGAATCTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAATCTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGATGAAGTGAATGATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGATGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGTTCCTCATCTGTCATGTCGATGATTAATATATGGAATACATTAC 960
Db 901 TGGGAACCTTCATGGTTCCTCATCTGTCATGTCGATGATTAATATATGGAATACATTAC 960
QY 961 AAAAATAAAAGCGGAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATGTCATGAAT 1020
Db 961 AAAAATAAAAGCGGAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATGTCATGAAT 1020
QY 1021 GAGAGATTCCTCATATTTCCATCAGAGTAATAATATATCTGCTTAAATCTTAAAGCATA 1080
Db 1021 GAGAGATTCCTCATATTTCCATCAGAGTAATAATATATCTGCTTAAATCTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATCTGCTGATGTAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATCTGCTGATGTAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTTTATTTTGAAGACATTTACTTATTAAGAAATTTGTTTATATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTTGAAGACATTTACTTATTAAGAAATTTGTTTATATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGTAAAGGATTTCTTAAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGTAAAGGATTTCTTAAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATCAGAGAAAATGTTATACCACTCCCTGCTGCTCTTCTTAGTGCATACAAATCACTCT 1320
Db 1261 GAATCAGAGAAAATGTTATACCACTCCCTGCTGCTCTTCTTAGTGCATACAAATCACTCT 1320
QY 1321 GAATTTAAGACTC 1333
Db 1321 GAATTTAAGACTC 1333

RESULT 17

ACD29878
ID ACD29878 standard; cdna; 1333 BP.

XX
AC ACD29878;

XX
DT 08-SEP-2003 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO181 cdna.

KW Human; secreted and transmembrane protein; PRO; cell death; neuropathy;
peripheral neuropathy; diabetic peripheral neuropathy;
KX AIDS-associated neuropathy; Charcot-Marie-Tooth disease;
KW Refsum's disease; Abetalipoproteinemia; Tangier disease;
KW Krabbe's disease; Metachromatic leukodystrophy; Fabry's disease;
KW Dejerine-Sottas syndrome; chromosome mapping; gene mapping; gene therapy;
gene; ss.

XX Homo sapiens.

OS US2003050240-A1.

XX 13-MAR-2003.

XX 16-OCT-2001; 2001US-00978403.

XX 17-OCT-1997; 97US-0062250P.

PR 03-NOV-1997; 97US-0064249P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066364P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077641P.

PR 11-MAR-1998; 98US-0077649P.

PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078910P.

PR 20-MAR-1998; 98US-0078936P.

PR 20-MAR-1998; 98US-0078939P.

PR 25-MAR-1998; 98US-0079294P.

PR 26-MAR-1998; 98US-0079656P.

PR 27-MAR-1998; 98US-0079663P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079728P.

PR 27-MAR-1998; 98US-0079786P.

PR 30-MAR-1998; 98US-0079920P.

PR 30-MAR-1998; 98US-0079923P.

PR 31-MAR-1998; 98US-0080105P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080165P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080328P.

PR 01-APR-1998; 98US-0080333P.

PR 01-APR-1998; 98US-0080334P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081071P.

PR 09-APR-1998; 98US-0081195P.

PR 09-APR-1998; 98US-0081203P.

PR 15-APR-1998; 98US-0081817P.

PR 15-APR-1998; 98US-0081819P.

PR 15-APR-1998; 98US-0081838P.

PR 15-APR-1998; 98US-0081952P.

PR 15-APR-1998; 98US-0081955P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082700P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 22-APR-1998; 98US-0082804P.

PR 23-APR-1998; 98US-0082966P.

PR 27-APR-1998; 98US-0083336P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083392P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083500P.

PR 29-APR-1998; 98US-0083545P.


```
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083555P.
PR 29-APR-1998; 98US-0083556P.
PR 30-APR-1998; 98US-0083557P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 98WO-US028313.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US034956.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier WA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WL;
XX
XX WPI; 2003-503575/47.
DR P-PSDB; ABO19689.
DR
XX
XX Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
XX Claim 2; Fig 128; 459pp; English.
XX
XX The invention describes an isolated, secreted and transmembrane
CC polypeptide, termed PRO polypeptide (I). (I) is useful for detecting
CC PRO4993, PRO337, PRO1559, PRO725, PRO700 or PRO739 polypeptide, and for
CC linking a bioactive molecule to a cell expressing the above polypeptides.
CC The bioactive molecule is a toxin, radiolabel or an antibody and causes
CC cell death. (I) is useful as therapeutic agent, in medical and industrial
CC applications e.g. for treating neuropathy, especially peripheral
CC neuropathy, diabetic peripheral neuropathy, AIDS-associated neuropathy,
CC Charcot-Marie-Tooth disease, Refsum's disease, Abetalipoproteinaemia,
CC
Query Match 100.0%; Score 1333; DB 8; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGTCCGATGGCGGTTCACTGTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAGCGTCCGATGGCGGTTCACTGTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCGCCATTGTCGCACATTATAGCAATTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCGCCATTGTCGCACATTATAGCAATTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAATCTCTATAGACAGTGAATACCTTGAAATCCCTTGATCCCTTGATCCAGATG 180
Db 121 TGATTACAGAATCTCTATAGACAGTGAATACCTTGAAATCCCTTGATCCCTTGATCCAGATG 180
QY 181 CCTCATCCAGCGCTTCTTCTGTCGTCATGTTCTTTGTGTCAGAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCAGCGCTTCTTCTGTCGTCATGTTCTTTGTGTCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATCAGTAGACAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATCAGTAGACAGTATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGAT 360
Db 301 TGGCCAGGACTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGAT 360
```

Db 301 TGGCCAGGACTATGACCCCTACAAACCATGCAATGAGATATCTAGCATATTTGTCA 360
Qy 361 GAAGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTACTACCTATATGG 420
Db 361 GAAGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTACTACCTATATGG 420
Qy 421 CATGATCTATCTTTTGTGAGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATCTTTTGTGAGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCAGAGTAGC 540
Qy 541 CTGTGGATCTGATCAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGATCTGATCAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTCTTGTGGAAGACTGTTTTTCAATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTCTTGTGGAAGACTGTTTTTCAATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
Qy 661 TACGATATAAATTAATAAATGAATTAATCTCTGTTGTTGACAGTTTGAACCTGCACTTC 720
Db 661 TACGATATAAATTAATAAATGAATTAATCTCTGTTGTTGACAGTTTGAACCTGCACTTC 720
Qy 721 TTAAGGAACAGCATAAATCCTCTGAATGATGATTAATTAATCTGCTGCTAGTACATTTG 780
Db 721 TTAAGGAACAGCATAAATCCTCTGAATGATGATTAATTAATCTGCTGCTAGTACATTTG 780
Qy 781 GAAGCTTTTGTATPAGGAACCTGTPAGGGCTCATTTTGGTTTCAATGGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATPAGGAACCTGTPAGGGCTCATTTTGGTTTCAATGGAACAGATATCTAA 840
Qy 841 TTATAAATAGCTGTAGATATCAGGTCTCTGATGAAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTCTCTGATGAAGTGAATGATATATCTGACTAG 900
Qy 901 TGGGAACCTTCATGGTTTCCCTCATCTCATGTCGATGATTAATATGGAATACATTTAC 960
Db 901 TGGGAACCTTCATGGTTTCCCTCATCTCATGTCGATGATTAATATGGAATACATTTAC 960
Qy 961 AAAAATAAAGCGGGAATTTTCCCTTCGTTGAATATATCCCTGTATATTTGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGTTGAATATATCCCTGTATATTTGATGAAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGCAT 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGCAT 1080
Qy 1081 AGTAACATGATATAAATAATATCTGCTGATTTGTAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAATAATATCTGCTGATTTGTAAGATGCAATTTAAAGCTATT 1140
Qy 1141 TTAATGTTTTTTATTTTGAAGCATTTACTTTAATTAAGAAATGGTTTATTTGCTTACTG 1200
Db 1141 TTAATGTTTTTTATTTTGAAGCATTTACTTTAATTAAGAAATGGTTTATTTGCTTACTG 1200
Qy 1201 TTCTAATCTGGTGAAGATTTCTTAAGAAATTTGCAAGTACTACAGATTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGATTTCTTAAGAAATTTGCAAGTACTACAGATTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGTAACCATCTGCTGCTCTTCTTTAGTGCATACATAAATCTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACCATCTGCTGCTCTTCTTTAGTGCATACATAAATCTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 18
ADA12521

ID ADAL2521 standard; cDNA; 1333 BP.
XX
AC ADA12521;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane polypeptide PRO181.
XX
KW ss: gene; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS; cancer;
KW diabetic complication; tissue typing; human.
XX
OS Homo sapiens.
XX
PN US2003055216-A1.
XX
PD 20-MAR-2003.
XX
PF 17-OCT-2001; 2001US-00978824.
XX
PR 21-MAY-1996; 96US-0018049P.
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077751P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-0004022P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.

PR	29-APR-1998;	98US-0083495P.	PR	26-JUL-1999;	99US-0145698P.
PR	29-APR-1998;	98US-0083496P.	PR	28-JUL-1999;	99US-0146222P.
PR	29-APR-1998;	98US-0083499P.	PR	25-AUG-1999;	99US-00380137.
PR	29-APR-1998;	98US-0083500P.	PR	25-AUG-1999;	99US-00380138.
PR	29-APR-1998;	98US-0083545P.	PR	25-AUG-1999;	99US-00380142.
PR	29-APR-1998;	98US-0083554P.	PR	23-OCT-1999;	99US-0162506P.
PR	29-APR-1998;	98US-0083558P.	PR	30-NOV-1999;	99WO-US028313.
PR	29-APR-1998;	98US-0083559P.	PR	02-DEC-1999;	99WO-US028551.
PR	30-APR-1998;	98US-0083742P.	PR	02-DEC-1999;	99WO-US028565.
PR	05-MAY-1998;	98US-0084366P.	PR	16-DEC-1999;	99WO-US030095.
PR	06-MAY-1998;	98US-0084414P.	PR	30-DEC-1999;	99WO-US031243.
PR	07-MAY-1998;	98US-0084598P.	PR	03-DEC-1999;	99WO-US031274.
PR	07-MAY-1998;	98US-0084600P.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-MAY-1998;	98US-0084627P.	PR	06-JAN-2000;	2000WO-US000277.
PR	07-MAY-1998;	98US-0084637P.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-MAY-1998;	98US-0084639P.	PR	11-FEB-2000;	2000WO-US003565.
PR	07-MAY-1998;	98US-0084640P.	PR	18-FEB-2000;	2000WO-US004341.
PR	07-MAY-1998;	98US-0084643P.	PR	24-FEB-2000;	2000WO-US005004.
PR	13-MAY-1998;	98US-0085323P.	PR	02-MAR-2000;	2000WO-US005841.
PR	13-MAY-1998;	98US-0085338P.	PR	10-MAR-2000;	2000WO-US006319.
PR	13-MAY-1998;	98US-0085339P.	PR	21-MAR-2000;	2000WO-US007532.
PR	15-MAY-1998;	98US-0085573P.	PR	21-MAR-2000;	2000WO-US008439.
PR	15-MAY-1998;	98US-0085579P.	PR	17-MAY-2000;	2000WO-US013705.
PR	15-MAY-1998;	98US-0085580P.	PR	22-MAY-2000;	2000WO-US014042.
PR	15-MAY-1998;	98US-0085582P.	PR	30-MAY-2000;	2000WO-US014941.
PR	15-MAY-1998;	98US-0085689P.	PR	02-JUN-2000;	2000WO-US015264.
PR	15-MAY-1998;	98US-0085697P.	PR	28-JUL-2000;	2000WO-US020710.
PR	15-MAY-1998;	98US-0085700P.	PR	24-AUG-2000;	2000WO-US023328.
PR	15-MAY-1998;	98US-0085704P.	PR	08-NOV-2000;	2000US-00709238.
PR	18-MAY-1998;	98US-0086023P.	PR	27-NOV-2000;	2000US-00723749.
PR	22-MAY-1998;	98US-0086392P.	PR	01-DEC-2000;	2000WO-US032678.
PR	22-MAY-1998;	98US-0086414P.	PR	20-DEC-2000;	2000US-00747259.
PR	22-MAY-1998;	98US-0086430P.	PR	28-FEB-2001;	2001WO-US006520.
PR	28-MAY-1998;	98US-0086486P.	PR	22-MAR-2001;	2001US-00816744.
PR	28-MAY-1998;	98US-0087098P.	PR	22-MAR-2001;	2001US-00816920.
PR	28-MAY-1998;	98US-0087106P.	PR	10-MAY-2001;	2001US-00854208.
PR	26-JUN-1998;	98US-00105413.	PR	21-MAY-2001;	2001US-00854280.
PR	26-JUN-1998;	98US-0090863P.	PR	01-JUN-2001;	2001US-00872092.
PR	30-JUL-1998;	98US-0091359P.	PR	01-JUN-2001;	2001US-00872035.
PR	11-SEP-1998;	98US-0100038P.	PR	01-JUN-2001;	2001WO-US017800.
PR	07-OCT-1998;	98US-0168978.	PR	05-JUN-2001;	2001US-00874503.
PR	07-OCT-1998;	98WO-US021141.	PR	14-JUN-2001;	2001US-00882636.
PR	02-NOV-1998;	98US-00184216.	PR	19-JUN-2001;	2001US-00886342.
PR	06-NOV-1998;	98US-00187368.	PR	20-JUN-2001;	2001WO-US019692.
PR	20-NOV-1998;	98US-0109304P.	PR	29-JUN-2001;	2001WO-US021066.
PR	20-NOV-1998;	98WO-US024855.	PR	03-JUL-2001;	2001WO-US021735.
PR	07-DEC-1998;	98US-00202054.	PR	30-JUL-2001;	2001US-00918585.
PR	22-DEC-1998;	98US-00218517.	XX		
PR	22-DEC-1998;	98US-0113296P.	XX		
PR	23-DEC-1998;	98US-0113621P.	PI	Ashkenazi AJ, Baker KP, Borstein D, Desnoyers L, Eaton DU; Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME; (GETH) GENENTECH INC.	
PR	05-JAN-1999;	99WO-US000106.			
PR	05-MAR-1999;	99US-00254465.			
PR	08-MAR-1999;	99WO-US005028.			
PR	10-MAR-1999;				

```
Db 181 CCTCATCCACGGTTCTTCTGTGTGATGTTTCTTTGTGACGAGAGTGGCTTACACTGGG 240
Qy 241 TCTCAATATGCCCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAG 300
Db 241 TCTCAATATGCCCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAG 300
Qy 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATGACAGATATCTAGCATATTTGTCA 360
Db 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATGACAGATATTTCTAGCATATTTGTCA 360
Qy 361 GAAGGAAGGATGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCCTGTCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCCTGTCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
Qy 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TAGCTATAAATTAATAAATGAATGATTAACCTCTGCTGTGTTGACAGTTTGAACCTTC 720
Db 661 TAGCTATAAATTAATAAATGAATGATTAACCTCTGCTGTGTTGACAGTTTGAACCTTC 720
Qy 721 TTAAGGAACGCCATAATCTCTCAATGATGATTAATTAATGATGATTAATGATGATTAATG 780
Db 721 TTAAGGAACGCCATAATCTCTCAATGATGATTAATTAATGATGATTAATGATGATTAATG 780
Qy 781 GAAGCTTTTGTATAGAACTTCTAGGGCTCAATTTGGTTCATGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGAACTTCTAGGGCTCAATTTGGTTCATGAAACAGATATCTAA 840
Qy 841 TTATAAATAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900
Db 841 TTATAAATAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900
Qy 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATGATGATGATGAT 960
Db 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATGATGATGATGAT 960
Qy 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTGGAATATATATCCCTGATATATGATGATGAT 1020
Db 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTGGAATATATATCCCTGATATATGATGATGAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATGATGATGATGATGATGATGATGATG 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATGATGATGATGATGATGATGATGATG 1080
Qy 1081 AGTAAACATGATATAAATAATATGTCGAATTTACTTTGTAAGATGATGATGATGATGATGAT 1140
Db 1081 AGTAAACATGATATAAATAATATGTCGAATTTACTTTGTAAGATGATGATGATGATGATGAT 1140
Qy 1141 TTAATATGTTTATTTTGTAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
Db 1141 TTAATATGTTTATTTTGTAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
Qy 1201 TTCTAACTGCTGGTAAAGGATTTCTTAAGATTTTGCAGGACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAACTGCTGGTAAAGGATTTCTTAAGATTTTGCAGGACTACAGATTTTCAAAACT 1260
Qy 1261 GAATGAGAGAAAATGATTAACCATCTCTGCTGTTCTTTAGTGAATACATAAATAAATCTCT 1320
Db 1261 GAATGAGAGAAAATGATTAACCATCTCTGCTGTTCTTTAGTGAATACATAAATAAATCTCT 1320
```

Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 19

ABT44568
ID ABT44568 standard; cDNA; 1333 BP.

XX

XX

XX

DT 06-NOV-2003 (first entry)

XX

XX Human PRO181 cDNA.

XX

XX

KW PRO; proliferation; gene; pericyte cell; TNF alpha; chondrocyte; blood;

KW tumour necrosis factor; proliferation; differentiation; gene therapy;

KW dermal fibroblast; ss.

XX

OS Homo sapiens.

XX

PN US2003027988-A1.

XX

XX

PD 06-FEB-2003.

XX

XX 26-AUG-2002; 2002US-00227884.

XX

XX 01-JUN-2001; 2001WO-US017800.

PR

PR 29-JUN-2001; 2001WO-US021066.

PR

PR 09-APR-2002; 2002US-00119480.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX

DR WPI; 2003-503301/47.

XX

P-PSDB; ABJ72415.

XX

PT New PRO protein encoding nucleic acid, useful for preparing PRO

PT polypeptides and anti-PRO antibodies for detecting the presence of a

PT tumor in a mammal.

XX

PS Claim 2; Fig 119; 324pp; English.

XX

CC The invention relates to a novel isolated PRO protein encoding nucleic

CC acid. The nucleic acid of the invention may be useful for preparing PRO

CC polypeptides and anti-PRO antibodies for detecting the presence of a

CC tumour in a mammal. Furthermore, the molecules of the invention may be

CC useful for stimulating proliferation or gene expression in pericyte

CC cells, the release of tumour necrosis factor (TNF)-alpha from human

CC blood, the proliferation or differentiation of chondrocyte cells and for

CC inhibiting the proliferation of normal human dermal fibroblast cells.

CC Finally, the molecules may be utilised during gene therapy. The current

CC sequence is that of the human PRO cDNA of the invention

XX

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

XX

Query Match

Best Local Similarity 100.0%; Score 1333; DB 8; Length 1333;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX

Qy 1 GCCCACGCGTCCGATGCGGTTACGTTGCGGCTTCTGCTACATGCTGGCGTCTGCT 60

Db 1 GCCCACGCGTCCGATGCGGTTACGTTGCGGCTTCTGCTACATGCTGGCGTCTGCT 60

XX

Qy 61 CACTGCGCGCTCATCTTCTTCGCCATTTGCCATTATAGCATTTGATGAGCTGAAGAC 120

Db 61 CACTGCGCGCTCATCTTCTTCGCCATTTGCCATTATAGCATTTGATGAGCTGAAGAC 120

XX

Qy 121 TGATTACAAAGATCCTATAGACCAAGTGTATACCTCCCTTGTCTCTCCAGAGTA 180

Db 121 TGATTACAAAGATCCTATAGACCAAGTGTATACCTCCCTTGTCTCTCCAGAGTA 180

[illegible]

Db	1081	AGTAAACATGATATATAAAATATATGCTCAATTAATCTGTGAAGATGCATTTAAAGCTATT	1144
Qy	1141	TTAAATGCTGTTTTATTTGTAAGACATTACTTATTAAGAAATGGTTATTTATGCTTACTG	1200
Db	1141	TTAAATGCTGTTTTATTTGTAAGACATTACTTATTAAGAAATGGTTATTTATGCTTACTG	1200
Qy	1201	TTCTAAATCTGGTGTGAAGATGATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT	1260
Db	1201	TTCTAAATCTGGTGTGAAGATGATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT	1260
Qy	1261	GAATGAGAGAAAATTTGTATACCACTCTGCTGTTCTTTAGTGTCAATACATAAACTCT	1320
Db	1261	GAATGAGAGAAAATTTGTATACCACTCTGCTGTTCTTTAGTGTCAATACATAAACTCT	1320
Qy	1321	GAATTTAAGACTC 1333	
Db	1321	GAATTTAAGACTC 1333	
RESULT 21			
ACD29293			
ID	ACD29293 standard; cDNA; 1333 BP.		
XX	ACD29293;		
AC	27-AUG-2003 (first entry)		
DT	Novel human secreted and transmembrane polypeptide cDNA #81.		
XX	Human; secreted and transmembrane protein; PRO; viral infection;		
KW	tumour growth; retinal disorder; injury; sight loss;		
KW	retinitis pigmentosa; age-related macular degeneration;		
KW	sport-related joint problem; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; wound healing; obesity; diabetes; insulinemia;		
KW	kidney disorder; mesangial cell function; Berger disease; nephropathy;		
KW	celiac disease; dermatitis; Crohn disease; neuropathy;		
KW	cardiac insufficiency disorder; peripheral neuropathy;		
KW	diabetic peripheral neuropathy; autonomic neuropathy;		
KW	reduced motility of the gastrointestinal tract;		
KW	atony of the urinary bladder; post polio syndrome; Krabbe's disease;		
KW	Charcot-Marie-Tooth disease; Fabry's disease; Tangier disease;		
KW	Refsum's disease; gene; ss.		
XX	Homo sapiens.		
OS	US2003049633-A1.		
PN	13-MAR-2003.		
XX	16-OCT-2001; 2001US-00978585.		
PF	17-OCT-1997; 97US-0062250P.		
XX	13-NOV-1997; 97US-0064249P.		
PR	21-NOV-1997; 97US-0065311P.		
PR	10-MAR-1998; 98US-0066364P.		
PR	11-MAR-1998; 98US-0077450P.		
PR	11-MAR-1998; 98US-0077632P.		
PR	11-MAR-1998; 98US-0077641P.		
PR	12-MAR-1998; 98US-0077649P.		
PR	12-MAR-1998; 98US-0077791P.		
PR	13-MAR-1998; 98US-008004P.		
PR	20-MAR-1998; 98US-00804220.		
PR	20-MAR-1998; 98US-0078910P.		
PR	20-MAR-1998; 98US-0078936P.		
PR	20-MAR-1998; 98US-0078939P.		
PR	25-MAR-1998; 98US-0079294P.		
PR	26-MAR-1998; 98US-0079656P.		
PR	27-MAR-1998; 98US-0079663P.		
PR	27-MAR-1998; 98US-0079664P.		
PR	27-MAR-1998; 98US-0079689P.		
PR	27-MAR-1998; 98US-0079728P.		

PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 27-APR-1998; 98US-0082796P.
PR 28-APR-1998; 98US-0083336P.
PR 29-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084411P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0030863P.
PR 26-JUN-1998; 98US-0031010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 01-DEC-2000; 2000US-00723749.
PR 20-DEC-2000; 2000WO-US032678.
PR 28-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001WO-US034956.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.

Query Match 100.0%; Score 1333; DB 8; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATCGGCTTCACGTTCCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
 Db |||||
 QY 1 GCCACGCGTCCGATCGGCTTCACGTTCCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
 Db |||||

QY 61 CACTGCCGGCTCATCTTCTGCGCATTTGGCACATTATAGCAATTGATGAGCTGAAGAC 120
 Db |||||
 QY 61 CACTGCCGGCTCATCTTCTGCGCATTTGGCACATTATAGCAATTGATGAGCTGAAGAC 120
 Db |||||

QY 121 TGNATACAGAAATCCATATAGACCAAGTGTAAATACCTGGAATCCCTTGTACTCCAGAGTA 180
 Db |||||
 QY 121 TGNATACAGAAATCCATATAGACCAAGTGTAAATACCTGGAATCCCTTGTACTCCAGAGTA 180
 Db |||||

QY 181 CTTCAATCCAGCTTCTTCTGCTGTCATGTTCTTGTGTCAGCAGAGTGGCTTACATGGG 240
 Db |||||
 QY 181 CTTCAATCCAGCTTCTTCTGCTGTCATGTTCTTGTGTCAGCAGAGTGGCTTACATGGG 240
 Db |||||

QY 241 TCTCAATATGCCCCCTTTGGGCATATCATATTTGGAGGTATATAGTAGCCAGTGTATGAG 300
 Db |||||
 QY 241 TCTCAATATGCCCCCTTTGGGCATATCATATTTGGAGGTATATAGTAGCCAGTGTATGAG 300
 Db |||||

QY 301 TGGCCCCAGACTCTATGACCCCTACACCATCATGATGAGATGATGATGATGATGATGATGAT 360
 Db |||||
 QY 301 TGGCCCCAGACTCTATGACCCCTACACCATCATGATGAGATGATGATGATGATGATGATGAT 360
 Db |||||

QY 361 GAAGGAAGGATGGTGCMAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCATTTG 420
 Db |||||
 QY 361 GAAGGAAGGATGGTGCMAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCATTTG 420
 Db |||||

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
 Db |||||
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
 Db |||||

QY 481 GCATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCTGTCGAAGAGTAGC 540
 Db |||||
 QY 481 GCATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCTGTCGAAGAGTAGC 540
 Db |||||

QY 541 CTGTGGAATCTGATCAGTACTTTTAAATAATGACCTCTTATTTTAAATGTTTCCACAT 600
 Db |||||
 QY 541 CTGTGGAATCTGATCAGTACTTTTAAATAATGACCTCTTATTTTAAATGTTTCCACAT 600
 Db |||||

QY 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGTTAT 660
 Db |||||
 QY 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGTTAT 660
 Db |||||

QY 661 TACGTATAAATTAATATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTGCACTTC 720
 Db |||||
 QY 661 TACGTATAAATTAATATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTGCACTTC 720
 Db |||||

QY 721 TTAAGGAACACCCATAAATCTCTGAATGATGATTAATTAATCTGCTGCTAGTACATTTG 780
 Db |||||
 QY 721 TTAAGGAACACCCATAAATCTCTGAATGATGATTAATTAATCTGCTGCTAGTACATTTG 780
 Db |||||

QY 781 GAAGCTTTTGTATAGAACTTTGAGGCTCATTTTGGTTTCATTTGAACAGATATCTAA 840
 Db |||||
 QY 781 GAAGCTTTTGTATAGAACTTTGAGGCTCATTTTGGTTTCATTTGAACAGATATCTAA 840
 Db |||||

QY 841 TTATAAATTAGCTGTAGATATCAGTGTCTCTGATGAGTGAAGTGAAGTGTATATCTGACTAG 900
 Db |||||
 QY 841 TTATAAATTAGCTGTAGATATCAGTGTCTCTGATGAGTGAAGTGAAGTGTATATCTGACTAG 900
 Db |||||

QY 901 TGGGAACCTCATGGTTTCTCATCTCTCATGTCGATGATATATATATGATATGATATGATATGAT 960
 Db |||||
 QY 901 TGGGAACCTCATGGTTTCTCATCTCTCATGTCGATGATATATATATGATATGATATGATATGAT 960
 Db |||||

QY 961 AAAAAATAAAGCGGAAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCATGAAT 1020
 Db |||||

Db 961 AAAAAATAAAGCGGAAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATCTGCTTTAATTTCTTAAGCATA 1080
 Db |||||
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATCTGCTTTAATTTCTTAAGCATA 1080
 Db |||||

QY 1081 AGTAAACATGATATATAAATAATATATCTGCTTTAATTTCTGTAAGAAATGCAATTTAAAGCTATT 1140
 Db |||||
 QY 1081 AGTAAACATGATATAAATAATATATCTGCTTTAATTTCTGTAAGAAATGCAATTTAAAGCTATT 1140
 Db |||||

QY 1141 TTAATATGTTTTTATTTTGTAGACATTTATCTGTAAGAAATGCAATTTAAAGCTATT 1200
 Db |||||
 QY 1141 TTAATATGTTTTTATTTTGTAGACATTTATCTGTAAGAAATGCAATTTAAAGCTATT 1200
 Db |||||

QY 1201 TTCTAATCTGGTGTAAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
 Db |||||
 QY 1201 TTCTAATCTGGTGTAAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
 Db |||||

QY 1261 GAATGAGAGAAATTTGTATACCAATCTGCTCTCTTCTTTAGTGCATACATAAATAACTCT 1320
 Db |||||
 QY 1261 GAATGAGAGAAATTTGTATACCAATCTGCTCTCTTCTTTAGTGCATACATAAATAACTCT 1320
 Db |||||

QY 1321 GAAATTAAGACTC 1333
 Db |||||
 QY 1321 GAAATTAAGACTC 1333
 Db |||||

RESULT 22

ABT43941

ID ABT43941 standard; cDNA; 1333 BP.

AC ABT43941;

XX 16-OCT-2003 (first entry)

XX Human membrane bound receptor/protein PRO181 cDNA sequence.
 XX Human; PRO; membrane bound protein; membrane bound receptor;
 XX cell proliferation; cell migration; cell differentiation;
 XX mitogenic factor; survival factor; cytotoxic factor;
 XX differentiation factor; neuroepithelial; hormone; cell receptor;
 XX receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; gene; ss.

OS Homo sapiens.

XX US2003065147-A1.

XX 03-APR-2003.

XX 29-AUG-2002; 2002US-00232224.

XX 28-JUL-1999; 99US-0146222P.

XX 24-FEB-2000; 2000WO-US005004.

XX 02-MAR-2000; 2000WO-US005841.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-522018/49.

XX P-PSDB; ABJ72117.

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,

XX useful for the manufacture of a medicament for diagnosing or treating

XX tumor.

XX Claim 2; Fig 119; 315pp; English.

XX PS

XX

This invention relates to one hundred and twenty two novel nucleic acids encoding human PRO membrane bound proteins or receptors. Extracellular proteins play important roles in the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells (for example proliferation, migration or differentiation) is typically governed by information received from other cells and the immediate environment. The information is often transmitted by secreted polypeptides (for example mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides and hormones) which are received and interpreted by diverse cell receptors or membrane bound proteins. These membrane bound proteins and receptors may be of use as pharmaceutical and diagnostic agents, such as in the blocking of receptor-ligand interactions. The current invention provides the amino acid sequences of novel human membrane bound receptors and proteins, along with the cDNA sequences encoding them. The novel proteins of the invention may have cytostatic activities through the stimulation of chondrocytes. The nucleic acids of the invention may be useful for the manufacture of a medicament for diagnosing or treating a tumour in a mammal. In addition, they may be useful for measuring or detecting the expression of a tumour associated gene. The present sequence is the cDNA sequence encoding a human PRO protein of the invention

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match	100.0%;	Score 1333;	DB 8;	Length 1333;
Best Local Similarity	100.0%;	Pred. No. 9.6e-306;		
Matches 1333; Conservative	0;	Mismatches	0;	Indels

1	QY	1	GCCACGCGTCCGATGCGGTTACGGTTCCGGCGCCTTCTGCTACATGCTGGCGCTGCTGCT	60
1	DB	1	GCCACGCGTCCGATGCGGTTACGGTTCCGGCGCCTTCTGCTACATGCTGGCGCTGCTGCT	60
61	QY	61	CAC TGCCGCGCTCATCTTCTTGGCCATTGGCAATTATAGCAATTTGATGAGCTGAAGAC	120
61	DB	61	CAC TGCCGCGCTCATCTTCTTGGCCATTGGCAATTATAGCAATTTGATGAGCTGAAGAC	120
121	QY	121	TGATTACAAGAACTCTATAGACCAAGTGAATACCCCTGAATCCCTTGTACTCCACAGAGTA	180
121	DB	121	TGATTACAAGAACTCTATAGACCAAGTGAATACCCCTGAATCCCTTGTACTCCACAGAGTA	180
181	QY	181	CCATCATCCAGCTTCTCTGTGTGTCATGTTCTTGTGTGCGACAGAGTGGCTTACCTGGG	240
181	DB	181	CCATCATCCAGCTTCTCTGTGTGTCATGTTCTTGTGTGCGACAGAGTGGCTTACCTGGG	240
241	QY	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGATGAG	300
241	DB	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGATGAG	300
301	QY	301	TGSCCCAGGACTCTATGACCCCTCAACCATCATGAATGCGAGATTTCTAGCATATTTGCA	360
301	DB	301	TGSCCCAGGACTCTATGACCCCTCAACCATCATGAATGCGAGATTTCTAGCATATTTGCA	360
361	QY	361	GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG	420
361	DB	361	GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG	420
421	QY	421	CATGATCTATGTTTTGGTGAGCTTTTGAACAACAACAAGAAATTTGGTCCAGTTAAGT	480
421	DB	421	CATGATCTATGTTTTGGTGAGCTTTTGAACAACAACAAGAAATTTGGTCCAGTTAAGT	480
481	QY	481	GCATGCAAAAGACCAACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGAGTAGC	540
481	DB	481	GCATGCAAAAGACCAACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGAGTAGC	540
541	QY	541	CTGTGGAATCTGATCTAGTTACTTTTAAAAATGACTCCTTATTTTTTAAATGTTTTCCACAT	600
541	DB	541	CTGTGGAATCTGATCTAGTTACTTTTAAAAATGACTCCTTATTTTTTAAATGTTTTCCACAT	600
601	QY	601	TTTTTGCTTGTGGAAGACTGTTTTTCAATGCTATATCTCAGATAAAGATTTTAAATGCTAT	660
601	DB	601	TTTTTGCTTGTGGAAGACTGTTTTTCAATGCTATATCTCAGATAAAGATTTTAAATGCTAT	660
661	QY	661	TACGTATAAATTAAATAAAAAATGATTACCTCTGGTGTGTGACAGGTTTGAACCTTGCAC TTC	720

RESULT 23

ADB83609

ID ADB83609 standard; cDNA: 1333 bp.

AC ADB83609;

XX

DT 04-DEC-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO181 cDNA.

1. **Introduction**
 2. **Background**
 3. **Methodology**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Index**
 10. **Table of Contents**
 11. **Figure 1**
 12. **Figure 2**
 13. **Figure 3**
 14. **Figure 4**
 15. **Figure 5**
 16. **Figure 6**
 17. **Figure 7**
 18. **Figure 8**
 19. **Figure 9**
 20. **Figure 10**
 21. **Figure 11**
 22. **Figure 12**
 23. **Figure 13**
 24. **Figure 14**
 25. **Figure 15**
 26. **Figure 16**
 27. **Figure 17**
 28. **Figure 18**
 29. **Figure 19**
 30. **Figure 20**
 31. **Figure 21**
 32. **Figure 22**
 33. **Figure 23**
 34. **Figure 24**
 35. **Figure 25**
 36. **Figure 26**
 37. **Figure 27**
 38. **Figure 28**
 39. **Figure 29**
 40. **Figure 30**
 41. **Figure 31**
 42. **Figure 32**
 43. **Figure 33**
 44. **Figure 34**
 45. **Figure 35**
 46. **Figure 36**
 47. **Figure 37**
 48. **Figure 38**
 49. **Figure 39**
 50. **Figure 40**
 51. **Figure 41**
 52. **Figure 42**
 53. **Figure 43**
 54. **Figure 44**
 55. **Figure 45**
 56. **Figure 46**
 57. **Figure 47**
 58. **Figure 48**
 59. **Figure 49**
 60. **Figure 50**
 61. **Figure 51**
 62. **Figure 52**
 63. **Figure 53**
 64. **Figure 54**
 65. **Figure 55**
 66. **Figure 56**
 67. **Figure 57**
 68. **Figure 58**
 69. **Figure 59**
 70. **Figure 60**
 71. **Figure 61**
 72. **Figure 62**
 73. **Figure 63**
 74. **Figure 64**
 75. **Figure 65**
 76. **Figure 66**
 77. **Figure 67**
 78. **Figure 68**
 79. **Figure 69**
 80. **Figure 70**
 81. **Figure 71**
 82. **Figure 72**
 83. **Figure 73**
 84. **Figure 74**
 85. **Figure 75**
 86. **Figure 76**
 87. **Figure 77**
 88. **Figure 78**
 89. **Figure 79**
 90. **Figure 80**
 91. **Figure 81**
 92. **Figure 82**
 93. **Figure 83**
 94. **Figure 84**
 95. **Figure 85**
 96. **Figure 86**
 97. **Figure 87**
 98. **Figure 88**
 99. **Figure 89**
 100. **Figure 90**
 101. **Figure 91**
 102. **Figure 92**
 103. **Figure 93**
 104. **Figure 94**
 105. **Figure 95**
 106. **Figure 96**
 107. **Figure 97**
 108. **Figure 98**
 109. **Figure 99**
 110. **Figure 100**
 111. **Figure 101**
 112. **Figure 102**
 113. **Figure 103**
 114. **Figure 104**
 115. **Figure 105**
 116. **Figure 106**
 117. **Figure 107**
 118. **Figure 108**
 119. **Figure 109**
 120. **Figure 110**
 121. **Figure 111**
 122. **Figure 112**
 123. **Figure 113**
 124. **Figure 114**
 125. **Figure 115**
 126. **Figure 116**
 127. **Figure 117**
 128. **Figure 118**
 129. **Figure 119**
 130. **Figure 120**
 131. **Figure 121**
 132. **Figure 122**
 133. **Figure 123**
 134. **Figure 124**
 135. **Figure 125**
 136. **Figure 126**
 137. **Figure 127**
 138. **Figure 128**
 139. **Figure 129**
 140. **Figure 130**
 141. **Figure 131**
 142. **Figure 132**
 143. **Figure 133**
 144. **Figure 134**
 145. **Figure 135**
 146. **Figure 136**
 147. **Figure 137**
 148. **Figure 138**
 149. **Figure 139**
 150. **Figure 140**
 151. **Figure 141**
 152. **Figure 142**
 153. **Figure 143**
 154. **Figure 144**
 155. **Figure 145**
 156. **Figure 146**
 157. **Figure 147**
 158. **Figure 148**
 159. **Figure 149**
 160. **Figure 150**
 161. **Figure 151**
 162. **Figure 152**
 163. **Figure 153**
 164. **Figure 154**
 165. **Figure 155**
 166. **Figure 156**
 167. **Figure 157**
 168. **Figure 158**
 169. **Figure 159**
 170. **Figure 160**
 171. **Figure 161**
 172. **Figure 162**
 173. **Figure 163**
 174. **Figure 164**
 175. **Figure 165**
 176. **Figure 166**
 177. **Figure 167**
 178. **Figure 168**
 179. **Figure 169**
 180. **Figure 170**
 181. **Figure 171**
 182. **Figure 172**
 183. **Figure 173**
 184. **Figure 174**
 185. **Figure 175**
 186. **Figure 176**
 187. **Figure 177**
 188. **Figure 178**
 189. **Figure 179**
 190. **Figure 180**
 191. **Figure 181**
 192. **Figure 182**
 193. **Figure 183**
 194. **Figure 184**
 195. **Figure 185**
 196. **Figure 186**
 197. **Figure 187**
 198. **Figure 188**
 199. **Figure 189**
 200. **Figure 190**
 201. **Figure 191**
 202. **Figure 192**
 203. **Figure 193**
 204. **Figure 194**
 205. **Figure 195**
 206. **Figure 196**
 207. **Figure 197**
 208. **Figure 198**
 209. **Figure 199**
 210. **Figure 200**
 211. **Figure 201**
 212. **Figure 202**
 213. **Figure 203**
 214. **Figure 204**
 215. **Figure 205**
 216. **Figure 206**
 217. **Figure 207**
 218

KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

KW vulnerary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; pericyte cell proliferation;
KW pericyte cell differentiation; pericyte cell proliferation;

KW pericyte cell differentiation; chondrocyte cell proliferation;
chondrocyte cell differentiation

KW chondrocyte cell differentiation; tumour necrosis factor alpha release (TNF)-alpha release; normal fibroblast cell growth; tumour necrosis factor alpha release

KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KTW dermal fibroblast cell differentiation inhibitor

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour
KW colon tumour; breast tumour; prostate tumour; rectal tumour

KW
colon tumour; breast tumour; prostate tumour; rectal tumour;
liver tumour; tissue typing: chromosomal mapping: gene mapping

KW liver cancer;
KW gene therapy.

XX
XX
XX

OS Homo sapiens.

XX
XX
XX

PN US2003073814-

XX PF 12-AUG-2002; 2002US-00218849.
 XX PR 01-JUN-2001; 2001WO-US017800.
 XX PR 29-JUN-2001; 2001WO-US021066.
 XX PR 09-APR-2002; 2002US-00119480.
 XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Deanoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Matanabe CK, Wood WI;
 XX WPI; 2003-644806/61.
 XX DR P-PSDB; ADB83610.
 XX PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX Claim 2; Fig 119; 315pp; English.
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3443, PRO4444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1154, or PRO7425 polypeptide are useful for
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 8; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACCGGTCGATGCGGTTCAGGTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACCGGTCGATGCGGTTCAGGTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCGCGCTCATCTTCTTGGCCATTGGCCATTGGCCATTGGCCATTGGCCATTGGCCATT 120
 DB 61 CACTGCGCGCTCATCTTCTTGGCCATTGGCCATTGGCCATTGGCCATTGGCCATTGGCCATT 120
 QY 121 TGATTACAAGAACTCTATAGACGAGTGAATACCCGAAATCCCTTGTACTCCAGAGTA 180

DB 121 TGATTACAAGAACTCTATAGACGAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
 QY 181 CCTCATCCACGCTTCTTCTGTGTGTCATGTTCTTGTGTGTCAGCAGAGTGGCTTACACTGG 240
 DB 181 CCTCATCCACGCTTCTTCTGTGTGTCATGTTCTTGTGTGTCAGCAGAGTGGCTTACACTGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
 QY 301 TGGCCACGAGCTCTATGACCTTACAACTCATGAATCAGATATTTCTACTACCTATATGG 420
 DB 301 TGGCCACGAGCTCTATGACCTTACAACTCATGAATCAGATATTTCTACTACCTATATGG 420
 QY 361 GAAGAAAGATGGTGCATAATTTAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 480
 DB 361 GAAGAAAGATGGTGCATAATTTAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 480
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAAATGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAAATGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACAAATGAAGGATTTCTATCCAGCAAGATCCCTGCTCAAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACAAATGAAGGATTTCTATCCAGCAAGATCCCTGCTCAAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAATGTTTCCCAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAATGTTTCCCAT 600
 QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTATCTACTCAGATAAGATTTTAAATGGTAT 660
 DB 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTATCTACTCAGATAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATAAATAAATGATTAACCTCTGCTGTTGACAGTTTGAATTCGACTTC 720
 DB 661 TACGTATAAATTAATAAATAAATGATTAACCTCTGCTGTTGACAGTTTGAATTCGACTTC 720
 QY 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTG 780
 DB 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTG 780
 QY 781 GAAGCTTTGTTTATAGAACTCTGAGGCTCAATTTGTTTCAATGAAACAGTATCTAA 840
 DB 781 GAAGCTTTGTTTATAGAACTCTGAGGCTCAATTTGTTTCAATGAAACAGTATCTAA 840
 QY 841 TTATAAATTAGCTGATGATATCAGGCTCTCTGATGAAGTGAATAATGATATCTGACTAG 900
 DB 841 TTATAAATTAGCTGATGATATCAGGCTCTCTGATGAAGTGAATAATGATATCTGACTAG 900
 QY 901 TGGGAACCTTCATGGGTTTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 960
 DB 901 TGGGAACCTTCATGGGTTTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 960
 QY 961 AAAAATAAAGCGGGAATTTTCCCTTCTGCTGAATAATTAATCCCTGATATTCGATCAAT 1020
 DB 961 AAAAATAAAGCGGGAATTTTCCCTTCTGCTGAATAATTAATCCCTGATATTCGATCAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTATAAATAATTAATTAATTTAAATCTTAAGCAT 1080
 DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTATAAATAATTAATTAATTTAAATCTTAAGCAT 1080
 QY 1081 AGTAAACATGATATAAATAATTAATGCTGAATTAATCTGTAAGAAATGCAATTTAAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAATAATTAATGCTGAATTAATCTGTAAGAAATGCAATTTAAAGCTATT 1140
 QY 1141 TTAATATGTTTTTATTTGTAAGACATTAATTAATTAAGAAATGCTTATTAATCTTACTG 1200
 DB 1141 TTAATATGTTTTTATTTGTAAGACATTAATTAATTAAGAAATGCTTATTAATCTTACTG 1200
 QY 1201 TTCTAATCTGGTGAAGGTATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAAACT 1260
 DB 1201 TTCTAATCTGGTGAAGGTATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAAACT 1260

Db 181 ||||| CCTCATCCACGCTTTCTTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCAATATTTGGAGGTATATGAGTAGACAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCAATATTTGGAGGTATATGAGTAGACAGTATGAG 300
QY 301 TGGCCAGAGCTCTATGAGCCCTTACAAACATCATGAAATGAGATATCTAGCATATTTGTCA 360
Db 301 TGGCCAGAGCTCTATGAGCCCTTACAAACATCATGAAATGAGATATCTAGCATATTTGTCA 360
QY 361 GAAGGAAGGATGCTGCAATATGAGCTTTTATCTCTAGCATTTTCTACTCATATGAG 420
Db 361 GAAGGAAGGATGCTGCAATATGAGCTTTTATCTCTAGCATTTTCTACTCATATGAG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAAGATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAAGATTTGGTCCAGTTAAGT 480
QY 481 GCATGAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTGCCAAGATGAG 540
Db 481 GCATGAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTGCCAAGATGAG 540
QY 541 CTGTGAATCTCATCAGTTTACATTTAAATAACGACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGAATCTCATCAGTTTACATTTAAATAACGACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTGTGAAAGAGCTGTTTTCATATGTTTATCTACATGAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTGTGTGAAAGAGCTGTTTTCATATGTTTATCTACATGAAAGATTTTAAATGGTAT 660
QY 661 TACGATATAATTAATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGATATAATTAATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCATAATCTCTGAATGATGCAATTAATTAATGACTGTCTAGTACATG 780
Db 721 TTAAGGAACAGCATAATCTCTGAATGATGCAATTAATTAATGACTGTCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTGGTTTCATGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTGGTTTCATGAAACAGTATCTAA 840
QY 841 TTAATAATTTAGCTGTAGATATCAGGCTCTTCTGATGAAGTGAATGATATCTGACTAG 900
Db 841 TTAATAATTTAGCTGTAGATATCAGGCTCTTCTGATGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAACTTCATGGGTTTCCCTCATCTGTCATGATGATATATATGATGATATTTAC 960
Db 901 TGGGAACTTCATGGGTTTCCCTCATCTGTCATGATGATATATATGATGATATTTAC 960
QY 961 AAAAATAAAGGGGAATTTTCCCTTCCCTTGAATATATATCCCTGATATGATGATAT 1020
Db 961 AAAAATAAAGGGGAATTTTCCCTTCCCTTGAATATATATCCCTGATATGATGATAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAATTTCTTAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAATTTCTTAAGCAT 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGATTAATCTTGTGAAGAAATGCAATTTAAAGTAT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGATTAATCTTGTGAAGAAATGCAATTTAAAGTAT 1140
QY 1141 TTAATATGTTTATTTATGTAAGACATTAATTTAAGAAATGTTGTTATTTGCTTACG 1200
Db 1141 TTAATATGTTTATTTATGTAAGACATTAATTTAAGAAATGTTGTTATTTGCTTACG 1200
QY 1201 TTTAATCTGGTGAAGATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAACT 1260
Db 1201 TTTAATCTGGTGAAGATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTCTATAACCATCTGCTGTTCTTTAGTGCATATCAATAAACTCT 1320

Db 1261 GAATGAGAGAAATTTCTATAACCATCTGCTGTTCTTTAGTGCATATCAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 26
ADB78338
ID ADB78338 standard; cDNA; 1333 BP.
XX
AC ADB78338;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss; cytosstatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW Gene therapy.
XX
OS Homo sapiens.
XX
PN US2003092889-A1.
XX
PD 15-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219478.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI: 2003-765495/72.
DR P-PSDB; ADB78339.
XX
PT New isolated PRO polypeptide useful for tissue typing, gene therapy, as
PT molecular weight markers in protein electrophoresis, and for treating
PT arthritis and tumors.
XX
PS Claim 2; Fig 119; 308pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1336,
CC PRO1343, PRO1376, PRO1387, PRO1403, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO1154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc.,

are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sports injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Query Match 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Best Local Similarity 100.0%; Score 1333; DB 8; Length 1333;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCGTTTCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGGCGTTTCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGTCATCTCTTCCGCAATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGTCATCTCTTCCGCAATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGAATTACAAGAACTCTATAGACAGTGAATAACCTGAACTCCCTTGTACTCCAGAGTA 180
 DB 121 TGAATTACAAGAACTCTATAGACAGTGAATAACCTGAACTCCCTTGTACTCCAGAGTA 180
 QY 181 CCTCATCCAGCTTTCTTCTGTGTCAGCTTTCTTTGTCGACAGAGTGGCTTACACTGG 240
 DB 181 CCTCATCCAGCTTTCTTCTGTGTCAGCTTTCTTTGTCGACAGAGTGGCTTACACTGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACAGCTGATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACAGCTGATGAG 300
 QY 301 TGGCCAGGACTATGACCCCTTACACCATCATGAATGAGATATTCAGCATATTTGCA 360
 DB 301 TGGCCAGGACTATGACCCCTTACACCATCATGAATGAGATATTCAGCATATTTGCA 360
 QY 361 GAAGGAAGATGGTGCACAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
 DB 361 GAAGGAAGATGGTGCACAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
 QY 421 CATGATCTATGTTTTGGTGAGCTCTTAGAACACACAGAGAAATTCGTCAGTTAAGT 480
 DB 421 CATGATCTATGTTTTGGTGAGCTCTTAGAACACACAGAGAAATTCGTCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTATCTTTAAATAAATGACTCCCTATTTTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTATCTTTAAATAAATGACTCCCTATTTTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTGTGGAAGAGCTTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTCTGTGGAAGAGCTTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
 DB 661 TACGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
 QY 721 TTAAGGAACAGCCATAAATCTCTGAAATGATGATTAATTAATGACTGCTCTAGTACATG 780
 DB 721 TTAAGGAACAGCCATAAATCTCTGAAATGATGATTAATTAATGACTGCTCTAGTACATG 780

QY 781 GAAGCTTTTGTATATAGAACTTTGTAGGGCTCATTTTGGTTTCAATGAAACAGATATCTAA 840
 DB 781 GAAGCTTTTGTATATAGAACTTTGTAGGGCTCATTTTGGTTTCAATGAAACAGATATCTAA 840
 QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
 DB 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
 QY 901 TGGGAAACTTCATGGGTTTCTCATCTGTCTGATGCGATGATTAATATGAGATACATTTAC 960
 DB 901 TGGGAAACTTCATGGGTTTCTCATCTGTCTGATGCGATGATTAATATGAGATACATTTAC 960
 QY 961 AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATGTCATGAAT 1020
 DB 961 AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATGTCATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATATCTTAAATCTTAAAGCATA 1080
 DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATATCTTAAATCTTAAAGCATA 1080
 QY 1081 AGTAAAATGATATAAAAAATATATGCTGAATTAATGCTGAAGAAATGCAATTAAGCTATT 1140
 DB 1081 AGTAAAATGATATAAAAAATATATGCTGAATTAATGCTGAAGAAATGCAATTAAGCTATT 1140
 QY 1141 TTAATCTGTTTTTATTTGTAAGACATTAATTAAGAAATGCTTATATGCTTACTG 1200
 DB 1141 TTAATCTGTTTTTATTTGTAAGACATTAATTAAGAAATGCTTATATGCTTACTG 1200
 QY 1201 TTCTAAATCTGCTGCTAAAGGTATTCTTAAAGAAATTCAGAGTACTACAGATTTTCAAAACT 1260
 DB 1201 TTCTAAATCTGCTGCTAAAGGTATTCTTAAAGAAATTCAGAGTACTACAGATTTTCAAAACT 1260
 QY 1261 GAATGAGAGAAAATTTGATTAACCATTCCTGCTGCTTCTTCTAGTGCATTAACAATAAACTCT 1320
 DB 1261 GAATGAGAGAAAATTTGATTAACCATTCCTGCTGCTTCTTCTAGTGCATTAACAATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333
 RESULT 27
 ADB84986
 ID ADB84986 standard; cDNA; 1333 BP.
 XX AC ADB84986;
 XX XX
 DT 04-DEC-2003 (first entry)
 XX Human PRO polynucleotide #60.
 DE Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
 KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
 KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
 KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
 XX arthritis; sports injury; cytostatic; antiarthritic.
 OS Homo sapiens.
 XX XX
 PN US2003073817-A1.
 XX 17-APR-2003.
 XX 26-AUG-2002; 2002US-00227883.
 XX 01-AUG-2000; 2000US-0222425P.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA
 XX

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI PPI Gramaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-730024/69.
 DR DR P-PSDB: ADB84987.
 DR

PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT e.g. in gene therapy, disease diagnosis, chromosome identification and
PT tissue typing.

PS Claim 2; Fig 119; 314pp; English.

The invention relates to human PRO polypeptides (secreted and transmembrane polypeptides) and the PRO polynucleotides encoding them. The PRO polypeptides and polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. They are particularly useful for detecting tumours (e.g. lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour) in a mammal, for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant technology, in generating transgenic animals or knock-out animals which may be used in the development and screening of therapeutically useful reagents, in gene therapy, in chromosome identification, as chromosome markers and in generating probes. The PRO polypeptides, or anti-PRO antibodies, are useful for preparing a medicament for treating a condition which is responsive to the PRO polypeptides or anti-PRO antibodies, such as pericyte-associated tumours and bone and/or cartilage disorders (e.g. arthritis, sports injuries), involving inducing the redifferentiation of chondrocytes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and in tissue typing. This sequence represents a human PRO polynucleotide of the invention.

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match	100.0%;	Score 1333;	DB 9;	Length 1333;
Best Local Similarity	100.0%;	Pred. No. 9.6e-306;		
Matches 1333;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	GCCACGCGTCCGATGAGCTTCAGTTTCGGCGGCCCTCTGCTACATGCTGGCGTGCCTGCT	60	
Db	1	GCCACGCGTCCGATGAGCTTCAGTTTCGGCGGCCCTCTGCTACATGCTGGCGTGCCTGCT	60	
QY	61	CAC TGGCGCGCTCATCTCTTTCGGCATTTGGCACATTATAGCATTTGATGAGCTCAAGAC	120	
Db	61	CAC TGGCGCGCTCATCTCTTTCGGCATTTGGCACATTATAGCATTTGATGAGCTCAAGAC	120	
QY	121	TGATTACAGAAATCCATATAGACGAGTGAATACCTGAATCCCTTGTTACTCCGAGAGTA	180	
Db	121	TGATTACAGAAATCCATATAGACGAGTGAATACCTGAATCCCTTGTTACTCCGAGAGTA	180	
QY	181	CCTCATCCAGCTTTCTCTTCTGTGTCATGTTTCTTTTGTGCACAGAGTGGCTTACACTGGG	240	
Db	181	CCTCATCCAGCTTTCTCTTCTGTGTCATGTTTCTTTTGTGCACAGAGTGGCTTACACTGGG	240	
QY	241	TCTCAATATGCCCTCTTTGGCATATCATATTTTGGAGTATATGAGTAGACCAAGTGATGAG	300	
Db	241	TCTCAATATGCCCTCTTTGGCATATCATATTTTGGAGTATATGAGTAGACCAAGTGATGAG	300	
QY	301	TGGCCCAAGGACTCTATGACCCTCAACCATCATGAATGCAGATATTTAGCATATTGTCA	360	
Db	301	TGGCCCAAGGACTCTATGACCCTCAACCATCATGAATGCAGATATTTAGCATATTGTCA	360	
QY	361	GAAGGAAGGATGGTGCAAAATTAGCTTTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG	420	
Db	361	GAAGGAAGGATGGTGCAAAATTAGCTTTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG	420	
QY	421	CATGATCTATGTTTTTGGTGAGCTCTTAGAACCAACACACAGAAAGAAATTTGGTCCAGTTAAGT	480	

Db	421	CATGATCTATGTTTTGGTGGAGCTCTTTAGAGAACAAACACACAGAGAAATTTGGTCCGAGTTAAAGT	480
Qy	481	GCATGCAAAAAGCCACCAAAATGAAGGGAATCTATCCAGCAAGATCCTGTCCAAAGAGTAGC	540
Db	481	GCATGCAAAAAGCCACCAAAATGAAGGGAATCTATCCAGCAAGATCCTGTCCAAAGAGTAGC	540
Qy	541	CTGTGGAACTGATCAGTTACTTTTAAAAAATGATCCTCTATTTTTTTAAATGTTTCCACAT	600
Db	541	CTGTGGAATCTGATCAGTTACTTTTAAAAAATGATCCTCTATTTTTTTAAATGTTTCCACAT	600
Qy	601	TTTTTGTCTGTGGAAAAGACTGTTTTTTCATATGTTATATCTCAGATAAAGATTTTTAAATGGTAT	660
Db	601	TTTTTGTCTGTGGAAAAGACTGTTTTTTCATATGTTATATCTCAGATAAAGATTTTTAAATGGTAT	660
Qy	661	TACGTATAAATTAATATAAATGATTAACCTCTGGGTGTGACAGGTTTGAACCTTGCACTTC	720
Db	661	TACGTATAAATTAATATAAATGATTAACCTCTGGGTGTGACAGGTTTGAACCTTGCACTTC	720
Qy	721	TTAAGGAAACAGCCATAATCCTCTGAATGATGATTAATTAATCACTGACTGCTCTAGTACATTC	780
Db	721	TTAAGGAAACAGCCATAATCCTCTGAATGATGATTAATTAATCACTGACTGCTCTAGTACATTC	780
Qy	781	GAAGCTTTTGTATATAGGAACTTTGTAGGGCTCATTTTGGTTCATTGAAAACAGTATCTAA	840
Db	781	GAAGCTTTTGTATATAGGAACTTTGTAGGGCTCATTTTGGTTCATTGAAAACAGTATCTAA	840
Qy	841	TTATAAATTAGCTGTAGATACAGTCAAGTCTCTCATGAAGTGAAGAACTGATATCTGACTAG	900
Db	841	TTATAAATTAGCTGTAGATACAGTCAAGTCTCTCATGAAGTGAAGAACTGATATCTGACTAG	900
Qy	901	TGGGAAACTTCATGGGTTTCCTCATCTGTGCATGTTCGATGATATATATGATGATACATTTAC	960
Db	901	TGGGAAACTTCATGGGTTTCCTCATCTGTGCATGTTCGATGATATATATGATGATACATTTAC	960
Qy	961	AAAAATAAAAGCGGGAATTTTCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT	1020
Db	961	AAAAATAAAAGCGGGAATTTTCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT	1020
Qy	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAATAATATACTTGCTTTTAAATTTCTTAAAGCATA	1080
Db	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAATAATATACTTGCTTTTAAATTTCTTAAAGCATA	1080
Qy	1081	AGTAAACATGATATAAAAAATATAGCTGGAATTAATCTTGTGAAGAAATGCAATTTAAAGCTATT	1140
Db	1081	AGTAAACATGATATAAAAAATATAGCTGGAATTAATCTTGTGAAGAAATGCAATTTAAAGCTATT	1140
Qy	1141	TTAAATCTGTTTTTATTTTGTGAAGACATTTACTTTTAAAGAAATTTGGTTATTATGCTTACTG	1200
Db	1141	TTAAATCTGTTTTTATTTTGTGAAGACATTTACTTTTAAAGAAATTTGGTTATTATGCTTACTG	1200
Qy	1201	TTCTTAATCTCGTGGTAAAGGTATTTCTTAAGAAATTTGCGAGGTACTACAGATTTTCAAACCT	1260
Db	1201	TTCTTAATCTCGTGGTAAAGGTATTTCTTAAGAAATTTGCGAGGTACTACAGATTTTCAAACCT	1260
Qy	1261	GAATGAGAGAAAAATTTGATTAACCATCTCGTGTTCCTTTTAGTGCAAATACAAATAAACTCT	1320
Db	1261	GAATGAGAGAAAAATTTGATTAACCATCTCGTGTTCCTTTTAGTGCAAATACAAATAAACTCT	1320
Qy	1321	GAATTTAAGACTC	1333
Db	1321	GAATTTAAGACTC	1333

RESULT 28

ADB78092
ID ADB78092 standard: cDNA: 1333 BP.

XX ADB78092:

XX
DT 04-DEC-2003 (first entry)

XX
Neuro[human account of end]

DE Novel human secreted and transmembrane protein PRO181 cDNA.

XXV

KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnery; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour;
 KW tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.

OS Homo sapiens.

PN US2003092886-A1.

15-MAY-2003

PF 09-AUG-2002: 2002US-00216165 XX

25-III-2000-2000US-0220607B
XX
PR

PR 01-JUN-2001; 2001WO-US017800.
PR 20 JUN 2001; 2001WO-US021800.
PR 20 JUN 2001; 2001WO-US021800.

PR 09-APR-2002; 2002US-00119480.

PA (GETH) GENENTECH INC.

PI Baker KP, Desnoyers L

XX

DR P-PSDB; ADB78093.

PT Novel isolated PRO p

PT arthritis, tumor.

PS Claim 2; Fig 119; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (1). PRO382, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO331, PRO357, PRO375, PRO1155, PRO1205 or PRO1410 polypeptide

are useful for stimulating the re-

PRO247, PRO337, PRO356, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1130, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1403, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO8940, PRO6079, PRO8936 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

QY 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTACTCATGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTACTCATGATAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAAATAAGATTACCTCTGCTGTGTTGACAGGTTTGAACCTTGCACCTTC 720
Db 661 TAGCTATAAATTAATAAATAAGATTACCTCTGCTGTGTTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTCTCTCTAGTACATTTG 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTCTCTCTAGTACATTTG 780
QY 781 GAAGCTTTTGTATAGGAAGCTTGTAGGCTCTCATTTTGGTTTCATTTCAAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAAGCTTGTAGGCTCTCATTTTGGTTTCATTTCAAAACAGATATCTAA 840
QY 841 TTATAAATAGCTAGATATCAGTCTCTCTGATGAAGTGAATGATAATCTATATCTGACTAG 900
Db 841 TTATAAATAGCTAGATATCAGTCTCTCTGATGAAGTGAATGATAATCTATATCTGACTAG 900
QY 901 TGGGAACCTCATGGGTTTCCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960
Db 901 TGGGAACCTCATGGGTTTCCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATAATACTGTTTAACTTTAAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATAATACTGTTTAACTTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTATTTGTAAGACATTAATTAAGAAATGCTTATTAATGCTTACTG 1200
Db 1141 TTAATGCTGTTTATTTGTAAGACATTAATTAAGAAATGCTTATTAATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTTGTAAGATTTCTTAAAGATTTTGCAGGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGCTGTTGTAAGATTTCTTAAAGATTTTGCAGGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTCTTTAGTGCATTAACATAAAACTCT 1320
Db 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTCTTTAGTGCATTAACATAAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 31
ADB84740
ID ADB84740 standard; cDNA; 1333 BP.
XX ADB84740;
AC ADB84740;
XX
DT 04-DEC-2003 (first entry)
XX Human PRO polynucleotide #60.
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX Homo sapiens.
XX
PN US2003092890-A1.

XX 15-MAY-2003.
XX 14-AUG-2002; 2002US-00219536.
XX 28-JUL-1999; 99US-0146222P.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-777259/73.
DR P-PSDB; ADB84741.
XX New isolated PRO polypeptides, useful for tissue typing, gene therapy, as
PT molecular weight markers in protein electrophoresis, and for treating
PT arthritis and tumors.
XX
PS Claim 2; Fig 119; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumour, rectal tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACAGCGTCCGATGGCGTTTCAGCTTCGCGGCTTCTGTACATGCTGGGCTGCTGCT 60
Db 1 GCCACAGCGTCCGATGGCGTTTCAGCTTCGCGGCTTCTGTACATGCTGGGCTGCTGCT 60
QY 61 CACTGCCCGGCTCATCTTCTTCGCGCATTTGGCAGATTAATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCCGGCTCATCTTCTTCGCGCATTTGGCAGATTAATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCATAGACCACTGTAATACCTGTAATCCCTTGTACTCCCAAGATA 180
Db 121 TGATTACAGAAATCCATAGACCACTGTAATACCTGTAATCCCTTGTACTCCCAAGATA 180
QY 181 CCTCATCCAGCGCTTTCTTCTGTGTCATCTTTCTTTGTGTCAGCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCAGCGCTTTCTTCTGTGTCATCTTTCTTTGTGTCAGCAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCAATCATATTTGGAGGTATATGATGATGACGAGTGATGAG 300
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCAATCATATTTGGAGGTATATGATGATGACGAGTGATGAG 300
Db |||||
QY 301 TGGCCCCAGGACTCTATGACCCCTCAACACCATCATGAATGCGAGATTTCTAGCATATTTGCA 360
Db |||||
QY 301 TGGCCCCAGGACTCTATGACCCCTCAACACCATCATGAATGCGAGATTTCTAGCATATTTGCA 360
Db |||||
QY 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTAGCAATTTTCTAGCAATTTTCTAGCAATTTG 420
Db |||||
QY 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTAGCAATTTTCTAGCAATTTTCTAGCAATTTG 420
Db |||||
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACAGAGAAATTTGGTCCAGTTAAGT 480
Db |||||
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACAGAGAAATTTGGTCCAGTTAAGT 480
Db |||||
QY 481 GCATGCAAAAGCCCAACCAATGAAGGATTTCTATCCAGCAAGATTCCTGTCCAGAGTAGC 540
Db |||||
QY 481 GCATGCAAAAGCCCAACCAATGAAGGATTTCTATCCAGCAAGATTCCTGTCCAGAGTAGC 540
Db |||||
QY 541 CTGTGGAACTGATCAGTACTTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 541 CTGTGGAACTGATCAGTACTTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Db |||||
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Db |||||
QY 661 TACGTATAAATTAATAAATGATACCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
Db |||||
QY 661 TACGTATAAATTAATAAATGATACCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
Db |||||
QY 721 TTAAGGAACGCCATATCTCTCAAGATGATGATTAATTAATGACTCTCTAGTACATTC 780
Db |||||
QY 721 TTAAGGAACGCCATATCTCTCAAGATGATGATTAATTAATGACTCTCTAGTACATTC 780
Db |||||
QY 781 GAAGCTTTTGTATAGGAACCTTGAAGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
Db |||||
QY 781 GAAGCTTTTGTATAGGAACCTTGAAGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
Db |||||
QY 841 TTATAAATAGCTGTAGATATCAGTGTCTGTGATGAGAGTGAATGATATATGATGATGATG 900
Db |||||
QY 841 TTATAAATAGCTGTAGATATCAGTGTCTGTGATGAGAGTGAATGATATATGATGATGATG 900
Db |||||
QY 901 TGGGAACCTTCACTGGTTTCTCATCTGTCATGTCGATGATGATATATGATGATGATGATG 960
Db |||||
QY 901 TGGGAACCTTCACTGGTTTCTCATCTGTCATGTCGATGATGATATATGATGATGATGATG 960
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTTGGTGTGAATATATATCCCTGTATATTTGCATGAAT 1020
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTTGGTGTGAATATATATCCCTGTATATTTGCATGAAT 1020
Db |||||
QY 1021 GAGGATTTCCATATTTCCATCAGATGATTAATATATCTGCTTTTAAATTTCTTAAGCATA 1080
Db |||||
QY 1021 GAGGATTTCCATATTTCCATCAGATGATTAATATATCTGCTTTTAAATTTCTTAAGCATA 1080
Db |||||
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTGTTGAAGATGATGATTAAGCTATT 1140
Db |||||
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTGTTGAAGATGATGATTAAGCTATT 1140
Db |||||
QY 1141 TTAATATGTTTATTTTATTTGTAAGACATTAATTAAGAAATTTGGTATTATGCTTACTG 1200
Db |||||
QY 1141 TTAATATGTTTATTTTATTTGTAAGACATTAATTAAGAAATTTGGTATTATGCTTACTG 1200
Db |||||
QY 1201 TTCTAATCTGTGTGTAAGGATTTTAAAGATTTGAGGATTTGAGGATTTTCAAACT 1260
Db |||||
QY 1201 TTCTAATCTGTGTGTAAGGATTTTAAAGATTTGAGGATTTGAGGATTTTCAAACT 1260
Db |||||
QY 1261 GAATGAGAGAAATTTGATATACCATCTCTGCTGTTTCTTTAGTGCATTAATTAATCTCT 1320
Db |||||
QY 1261 GAATGAGAGAAATTTGATATACCATCTCTGCTGTTTCTTTAGTGCATTAATTAATCTCT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333

Db |||||
1321 GAAATTAAGACTC 1333

RESULT 32

ADB83855

ID ADB83855 standard; cDNA; 1333 BP.

XX ADB83855;

XX DT 04-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO181 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
XX vulnary; antarthritic; pericyte cell proliferation;
XX pericyte cell differentiation; chondrocyte cell proliferation;
XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX (TNF)-alpha release; dermal fibroblast cell proliferation;
XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX colon tumour; breast tumour; prostate tumour; rectal tumour;
XX liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.

XX Homo sapiens.

XX US2003069397-A1.

XX 10-APR-2003.

XX 09-AUG-2002; 2002US-00216159.

XX 25-JUL-2000; 2000US-0220607P.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

(GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-657584/62.

P-PSDB; ADB83856.

XX New isolated polypeptides designated PRO polypeptides including

XX polypeptides useful for stimulating the proliferation or differentiation

XX of specific cell types, and for diagnosing cancer.

XX Claim 2; Fig 119; 314pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides

QY 76T GAAGCTTTTGGTTATAGGAACCTGGTAGGGCTCATTTTGGTTTCATTGGAAACAGTATCTAA 840

PA (GET
vv

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI; 2003-777258/73.
P-PSDB; ADB73011.

Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
molecular weight markers, for treating arthritis, tumor.

Claim 2; Fig 119; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO3229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO531, PRO1093, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1279, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1249, PRO1340, PRO1338, PRO1343, PRO1363, PRO1387, PRO1409, PRO1474, PRO1471, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

1	GCCACGGCTCGATGGCGCTT	CAGGTTGCGGCGCTTCTGCTAC	TGCTGGCGCTGCTGCT	60
1	GCCACGGCTCGATGGCGCTT	CAGGTTGCGGCGCTTCTGCTAC	TGCTGGCGCTGCTGCT	60
61	CAC TGCGGCGCTCATCTTCTT	CGCCATTGGCACA	TATATAGATTGATGAGCTGAAGAC	120
61	CAC TGCGGCGCTCATCTTCTT	CGCCATTGGCACA	TATATAGATTGATGAGCTGAAGAC	120
121	TGATTACAGAATCCCTATAGAC	CAAGTGTTAATACCC	TGAATCCCTTGTACTCCAGAGTA	180
121	TGATTACAGAATCCCTATAGAC	CAAGTGTTAATACCC	TGAATCCCTTGTACTCCAGAGTA	180
181	CCTCATCCACGGCTTCTTCTGT	GTCATGTTCTTTGTCAGACAGAGT	GCGCTTACACTGGG	240
181	CCTCATCCACGGCTTCTTCTGT	GTCATGTTCTTTGTCAGACAGAGT	GCGCTTACACTGGG	240
241	TCTCAATATGCCCGCTCTTGGC	ATATCATATTTGGAGGTTATAGAGT	AGACCAAGTATGAG	300
241	TCTCAATATGCCCGCTCTTGGC	ATATCATATTTGGAGGTTATAGAGT	AGACCAAGTATGAG	300

RESULT 34
ADB76543
ID ADB76543 standard; cDNA; 1333 BP.
XX AC ADB76543;
XX DT 04-DEC-2003 (first entry)
XX DE Human PRO polynucleotide sequence #81.
XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW cell death; neuropathy; neuropathy related disease;
KW Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW chromosome mapping; gene mapping; genetic disorder; septic shock;
KW antibacterial; immunosuppressive; neuroprotective; gene; ss.
XX OS Homo sapiens.
XX PN US2003083248-A1.
XX PD 01-MAY-2003.
XX PF 16-OCT-2001; 2001US-00978757.
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 21-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087088P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000356.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014942.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001WO-US009552.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 30-JUL-2001; 2001US-00918585.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AV, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen MB;
 PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tumas D, Williams PM, Wood WI;
 XX WPI; 2003-755118/71.
 DR P-PSDB; ADB76544.
 XX
 PT New PRO polypeptides useful for treating peripheral neuropathy,
 PT neuropathies associated with systemic disease such as post-polio syndrome
 PT or AIDS-associated syndrome.
 XX
 PS Claim 2; Fig 128; 425pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for linking
 CC bioactive molecules to cells expressing PRO polypeptides, for modulating
 CC biological activities of cells expressing PRO polypeptides, and for
 CC identifying agonists or antagonists. The bioactive molecule maybe a
 CC toxin, radiolabel or antibody, and cause cell death. The PRO polypeptides
 CC are useful for treating neuropathy and neuropathy related diseases such
 CC as Charcot-Marie-Tooth disorder, Refsum's disease, and Krabbe's disease.
 CC The polynucleotide sequences encoding PRO polypeptides are useful as
 CC hybridisation probes, in chromosome and gene mapping, in the generation
 CC
 Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCCAGCGGCCGATGGCGTTCCAGTTCCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
 DB 1 GCCCAGCGGCCGATGGCGTTCCAGTTCCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
 QY 61 CACTGGCGCGCTCATCTCTTCCTGGCAATTTGGCAATPATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGGCGCGCTCATCTCTTCCTGGCAATTTGGCAATPATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCCTATAGACAGCTGTAATACCTGAATCCCTTGCTACTCCAGAGTA 180
 DB 121 TGATTACAGAAATCCCTATAGACAGCTGTAATACCTGAATCCCTTGCTACTCCAGAGTA 180

QY 181 CCTCATCCACGCTTCTCTGTCGTCATGTTTCTTTGTGACGAGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCACGCTTCTCTGTCGTCATGTTTCTTTGTGACGAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
 DB 241 TCTCAATATGCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
 QY 301 TGGCCCGAGGACTCTATGACCCCTACCAACCATCATGAAATGCAGATATTTCTAGCATATTTGTC 360
 DB 301 TGGCCCGAGGACTCTATGACCCCTACCAACCATCATGAAATGCAGATATTTCTAGCATATTTGTC 360
 QY 361 GAAGGAAGATGCTGCAAAATAGCTTTTATCTTCTAGCATATTTTATCTACCTATATGG 420
 DB 361 GAAGGAAGATGCTGCAAAATAGCTTTTATCTTCTAGCATATTTTATCTACCTATATGG 420
 QY 421 CATGATCTATGTTTGTGAGCTCTTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGTGAGCTCTTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
 QY 601 TTTTGTCTTGGAAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTGTCTTGGAAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TAGCTATAAATTAATAAATGAATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTTC 720
 DB 661 TAGCTATAAATTAATAAATGAATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTTC 720
 QY 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
 DB 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
 QY 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCATTTGGTGTGATTTGTTTCAATGAAACAGTATCTAA 840
 DB 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCATTTGGTGTGATTTGTTTCAATGAAACAGTATCTAA 840
 QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAGTGAATGATATATCTGACTAG 900
 DB 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAGTGAATGATATATCTGACTAG 900
 QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATATGATGATATTTAC 960
 DB 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATATGATGATATTTAC 960
 QY 961 AAAAATAAAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTAATTTGATGAAT 1020
 DB 961 AAAAATAAAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTAATTTGATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATCTGCTTTAAATCTTAAGCATA 1080
 DB 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATCTGCTTTAAATCTTAAGCATA 1080
 QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTTGTAAGATGCAATTTAAAGCTAT 1140
 DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTTGTAAGATGCAATTTAAAGCTAT 1140
 QY 1141 TTAATATGCTTTTATTTGTAAGACATTAATTTAAGAAATTTGGTATTTATGCTTACTG 1200
 DB 1141 TTAATATGCTTTTATTTGTAAGACATTAATTTAAGAAATTTGGTATTTATGCTTACTG 1200
 QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 DB 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAAATTTGATATAACCATCTCTGCTTCTTTAGTGAATACAAATAAAACTCT 1320

```
Db      1261 GAATGAGAGAAAATTGTATACCATCTCTGCTGTTCTTCTTTAGTGCATACCAATAAACTCT 1320
QY      1321 GAAATTAGACTC 1333
Db      1321 GAAATTAGACTC 1333

RESULT 35
ID      ADC43969 standard; cDNA; 1333 BP.
AC      ADC43969;
XX
XX
XX      18-DEC-2003 (first entry)
DE      Human cDNA encoding secreted/transmembrane protein, PRO181.
XX      Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW      cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW      vulnery; auditory; tumour growth; retinal disorder;
KW      sports-related joint problem; articular cartilage defects;
KW      osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
XX      Homo sapiens.
XX
XX      US2003054986-A1.
XX
XX      20-MAR-2003.
XX
XX      16-OCT-2001; 2001US-00981915.
XX
XX      17-OCT-1997; 97US-0062250P.
XX      03-NOV-1997; 97US-0064249P.
XX      13-NOV-1997; 97US-0065311P.
XX      21-NOV-1997; 97US-0066364P.
XX      10-MAR-1998; 98US-0077450P.
XX      11-MAR-1998; 98US-0077632P.
XX      11-MAR-1998; 98US-0077641P.
XX      11-MAR-1998; 98US-0077649P.
XX      12-MAR-1998; 98US-0077791P.
XX      13-MAR-1998; 98US-0078004P.
XX      17-MAR-1998; 98US-0080402P.
XX      20-MAR-1998; 98US-0078886P.
XX      20-MAR-1998; 98US-0078910P.
XX      20-MAR-1998; 98US-0078936P.
XX      20-MAR-1998; 98US-0078939P.
XX      25-MAR-1998; 98US-0079294P.
XX      26-MAR-1998; 98US-0079656P.
XX      27-MAR-1998; 98US-0079663P.
XX      27-MAR-1998; 98US-0079664P.
XX      27-MAR-1998; 98US-0079689P.
XX      27-MAR-1998; 98US-0079728P.
XX      27-MAR-1998; 98US-0079786P.
XX      30-MAR-1998; 98US-0079920P.
XX      30-MAR-1998; 98US-0079923P.
XX      31-MAR-1998; 98US-0080105P.
XX      31-MAR-1998; 98US-0080107P.
XX      31-MAR-1998; 98US-0080165P.
XX      31-MAR-1998; 98US-0080194P.
XX      01-APR-1998; 98US-0080327P.
XX      01-APR-1998; 98US-0080328P.
XX      01-APR-1998; 98US-0080333P.
XX      01-APR-1998; 98US-0080334P.
XX      08-APR-1998; 98US-0081049P.
XX      08-APR-1998; 98US-0081070P.
XX      08-APR-1998; 98US-0081071P.
XX      09-APR-1998; 98US-0081195P.
XX      09-APR-1998; 98US-0081203P.
XX      09-APR-1998; 98US-0081229P.
XX      15-APR-1998; 98US-0081817P.
XX      15-APR-1998; 98US-0081819P.
XX      15-APR-1998; 98US-0081838P.
XX      15-APR-1998; 98US-0081952P.
XX      15-APR-1998; 98US-0081955P.
XX      21-APR-1998; 98US-0082568P.
XX      21-APR-1998; 98US-0082569P.
XX      22-APR-1998; 98US-0082700P.
XX      22-APR-1998; 98US-0082704P.
XX      22-APR-1998; 98US-0082797P.
XX      22-APR-1998; 98US-0082804P.
XX      23-APR-1998; 98US-0082796P.
XX      27-APR-1998; 98US-0083336P.
XX      28-APR-1998; 98US-0083322P.
XX      29-APR-1998; 98US-0083392P.
XX      29-APR-1998; 98US-0083495P.
XX      29-APR-1998; 98US-0083496P.
XX      29-APR-1998; 98US-0083499P.
XX      29-APR-1998; 98US-0083500P.
XX      29-APR-1998; 98US-0083545P.
XX      29-APR-1998; 98US-0083554P.
XX      29-APR-1998; 98US-0083558P.
XX      29-APR-1998; 98US-0083559P.
XX      30-APR-1998; 98US-0083742P.
XX      05-MAY-1998; 98US-0084366P.
XX      06-MAY-1998; 98US-0084414P.
XX      06-MAY-1998; 98US-0084598P.
XX      07-MAY-1998; 98US-0084600P.
XX      07-MAY-1998; 98US-0084627P.
XX      07-MAY-1998; 98US-0084637P.
XX      07-MAY-1998; 98US-0084639P.
XX      07-MAY-1998; 98US-0084640P.
XX      07-MAY-1998; 98US-0084643P.
XX      13-MAY-1998; 98US-0085323P.
XX      13-MAY-1998; 98US-0085338P.
XX      15-MAY-1998; 98US-0085573P.
XX      15-MAY-1998; 98US-0085579P.
XX      15-MAY-1998; 98US-0085580P.
XX      15-MAY-1998; 98US-0085582P.
XX      15-MAY-1998; 98US-0085689P.
XX      15-MAY-1998; 98US-0085697P.
XX      15-MAY-1998; 98US-0085700P.
XX      15-MAY-1998; 98US-0085704P.
XX      18-MAY-1998; 98US-0086023P.
XX      22-MAY-1998; 98US-0086392P.
XX      22-MAY-1998; 98US-0086414P.
XX      22-MAY-1998; 98US-0086430P.
XX      22-MAY-1998; 98US-0086434P.
XX      28-MAY-1998; 98US-0086486P.
XX      28-MAY-1998; 98US-0087106P.
XX      28-MAY-1998; 98US-0087098P.
XX      28-MAY-1998; 98US-0087208P.
XX      26-JUN-1998; 98US-00105413.
XX      26-JUN-1998; 98US-0090863P.
XX      26-JUN-1998; 98US-0091010P.
XX      01-JUL-1998; 98US-0091359P.
XX      30-JUL-1998; 98US-0094651P.
XX      11-SEP-1998; 98US-0100038P.
XX      07-OCT-1998; 98US-00168978.
XX      07-OCT-1998; 98WO-US021141.
XX      02-NOV-1998; 98US-00184216.
XX      06-NOV-1998; 98US-00187368P.
XX      20-NOV-1998; 98US-0109304P.
XX      20-NOV-1998; 98WO-US024855.
XX      07-DEC-1998; 98US-00202054.
XX      22-DEC-1998; 98US-00218517.
XX      22-DEC-1998; 98US-0113296P.
XX      23-DEC-1998; 98US-0113621P.
XX      05-JAN-1999; 99WO-US000106.
XX      05-MAR-1999; 99US-00254465.
XX      08-MAR-1999; 99WO-US005028.
XX      10-MAR-1999; 99US-00265686.
XX      10-MAR-1999; 99WO-US005190.
XX      12-MAR-1999; 99US-00267213.
XX      12-MAR-1999; 99US-0123957P.
```

PR	29-MAR-1999;	99US-0126773P.	QY	61	CACTGCCGCTCATCTTCTTCCCATTTGGCACAATTAAGCATTTGATGAGCTGAAGAC	120
PR	12-APR-1999;	99US-00284291.	Db	61	CACTGCCGCTCATCTTCTTCCCATTTGGCACAATTAAGCATTTGATGAGCTGAAGAC	120
PR	21-APR-1999;	99US-0130232P.	QY	121	TGATTACAAGAAATCCCTATAGACAGTGTAATACCCCTGAATCCCTTGTACTCCACAGTA	180
PR	26-APR-1999;	99US-0131022P.	Db	121	TGATTACAAGAAATCCCTATAGACAGTGTAATACCCCTGAATCCCTTGTACTCCACAGTA	180
PR	28-APR-1999;	99US-0131445P.	QY	181	CCTCATCCAGCTTCTTCTTGTCTCATGTTCTTTGTGAGAGAGTGGCTTACACTGG	240
PR	14-MAY-1999;	99US-00311832.	Db	181	CCTCATCCAGCTTCTTCTTGTCTCATGTTCTTTGTGAGAGAGTGGCTTACACTGG	240
PR	14-MAY-1999;	99US-0134287P.	QY	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG	300
PR	14-MAY-1999;	99WO-US010733.	Db	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG	300
PR	02-JUN-1999;	99WO-US012252.	QY	301	TGCCCCCAGGACTCTATGACCTTACACCATCATGAATGAGATATTTCTAGCATATTTGTCA	360
PR	16-JUN-1999;	99US-0139557P.	Db	301	TGCCCCCAGGACTCTATGACCTTACACCATCATGAATGAGATATTTCTAGCATATTTGTCA	360
PR	23-JUN-1999;	99US-0141037P.	QY	361	GAGGAAGGATGGTGCAAAATTTAGCTTTTATCTTCTAGCATATTTTCTACTATATGG	420
PR	07-JUL-1999;	99US-0142680P.	Db	361	GAGGAAGGATGGTGCAAAATTTAGCTTTTATCTTCTAGCATATTTTCTACTATATGG	420
PR	26-JUL-1999;	99US-0145698P.	QY	421	CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT	480
PR	28-JUL-1999;	99US-0146222P.	Db	421	CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT	480
PR	25-AUG-1999;	99US-00380137.	QY	481	GCATGCAAAAAGCCACCAATTTAGAGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGC	540
PR	25-AUG-1999;	99US-00380142.	Db	481	GCATGCAAAAAGCCACCAATTTAGAGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGC	540
PR	29-OCT-1999;	99US-0162506P.	QY	541	CTGTGGAATCTGATCAGTTACTTTTAAATAAGATGATCTCTTATTTTAAATGTTTCCACAT	600
PR	30-DEC-1999;	99WO-US031243.	Db	541	CTGTGGAATCTGATCAGTTACTTTTAAATAAGATGATCTCTTATTTTAAATGTTTCCACAT	600
PR	02-DEC-1999;	99WO-US030095.	QY	601	TTTTTGTCTGGAAGACGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGTTTAAATGTTT	660
PR	30-DEC-1999;	99WO-US031274.	Db	601	TTTTTGTCTGGAAGACGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGTTTAAATGTTT	660
PR	05-JAN-2000;	2000WO-US000219.	QY	661	TAGGTATAAATTAATAAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCATTC	720
PR	06-JAN-2000;	2000WO-US000277.	Db	661	TAGGTATAAATTAATAAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCATTC	720
PR	11-FEB-2000;	2000WO-US003565.	QY	721	TTAGGAACAGCCATAATCTCTGATGATGATGATTAATTTACTGACTGTCTTAGTACATTTG	780
PR	18-FEB-2000;	2000WO-US004341.	Db	721	TTAGGAACAGCCATAATCTCTGATGATGATGATTAATTTACTGACTGTCTTAGTACATTTG	780
PR	24-FEB-2000;	2000WO-US005004.	QY	781	GAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTTGTTGAAACAGATATCTAA	840
PR	02-MAR-2000;	2000WO-US005841.	Db	781	GAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTTGTTGAAACAGATATCTAA	840
PR	10-MAR-2000;	2000WO-US006319.	QY	841	TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT	900
PR	21-MAR-2000;	2000WO-US007532.	Db	841	TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT	900
PR	30-MAR-2000;	2000WO-US008439.	QY	901	TGGGAACTTCTATGGGTTTCTCATCTGTCATGTCGATGATGATGATGATGATGATGATGAT	960
PR	17-MAY-2000;	2000WO-US013705.	Db	901	TGGGAACTTCTATGGGTTTCTCATCTGTCATGTCGATGATGATGATGATGATGATGATGAT	960
PR	22-MAY-2000;	2000WO-US014042.	QY	961	AAAAATAAAAAGCGGAAATTTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTT	1020
PR	30-MAY-2000;	2000WO-US014941.	Db	961	AAAAATAAAAAGCGGAAATTTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTT	1020
PR	02-JUN-2000;	2000WO-US015264.	QY	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATAAATAAATAAATAAATAAATAAATAA	1080
PR	28-JUL-2000;	2000WO-US020710.	Db	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATAAATAAATAAATAAATAAATAAATAA	1080
PR	24-AUG-2000;	2000WO-US023328.	QY	1081	AGTAAACATGATATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA	1140
PR	08-NOV-2000;	2000US-00792338.	Db	1081	AGTAAACATGATATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA	1140
PR	21-NOV-2000;	2000US-00723749.	QY	1141	TTAAATGTCTTTTATTTTGTGAAGACATTTACTTTTAAAGAAATTTGGTATTATGCTTAC	1200
PR	01-DEC-2000;	2000WO-US032678.	Db			
PR	20-DEC-2000;	2000US-00747259.	QY			
PR	20-DEC-2000;	2000WO-US034956.	Db			
PR	28-FEB-2001;	2001WO-US006520.	QY			
PR	22-MAR-2001;	2001US-00816744.	Db			
PR	22-MAR-2001;	2001US-00816920.	QY			
PR	22-MAR-2001;	2001WO-US009552.	Db			
PR	10-MAY-2001;	2001US-00854208.	QY			
PR	25-MAY-2001;	2001US-00854280.	Db			
PR	01-JUN-2001;	2001WO-US017092.	QY			
PR	01-JUN-2001;	2001US-00872035.	Db			
PR	08-JUN-2001;	2001US-00874503.	QY			
PR	14-JUN-2001;	2001US-00882636.	Db			
PR	19-JUN-2001;	2001US-00886342.	QY			
PR	20-JUN-2001;	2001WO-US019692.	Db			
PR	29-JUN-2001;	2001WO-US021066.	QY			
PR	09-JUL-2001;	2001WO-US021735.	Db			
PR	30-JUL-2001;	2001US-00918585.	QY			
XX						
PA						
XX						

(GETH) GENENTECH INC.

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGTCCGATCGGTTCCAGTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAGCGTCCGATCGGTTCCAGTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

```
Db 1141 TTAATGCTTTTATTGTAAGACATTCTTATTAAAGAAATGGTTATTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGGTAATCTTAAGAATTTGCAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGGTAATCTTAAAGAATTTGCAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATCAGAGAAAATGTATTAACATCTCTCTCTTTAGTGCATTAACAATAAACTCT 1320
Db 1261 GAATCAGAGAAAATGTATTAACATCTCTCTCTTTAGTGCATTAACAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 36
ADC61729
ID ADC61729 standard; cDNA; 1333 BP.
XX
AC ADC61729;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003049684-A1.
XX
PD 13-MAR-2003.
XX
PF 24-OCT-2001; 2001US-00017081.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 21-NOV-1997; 97US-0065311P.
PR 11-MAR-1998; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077643P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0079920P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0080863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-010038P.
PR 07-OCT-1998; 98US-00168978.
PR 02-NOV-1998; 98US-00184214.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
```


PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99US-00265686.
PR 12-MAR-1999; 99WO-US0005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 12-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 28-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 24-FEB-2000; 2000WO-US004341.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US006319.
PR 30-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 28-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 10-MAY-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 28-JUN-2001; 2001WO-US019692.
PR 28-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX
PI

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGCGTTCAGGTTCCGGGCTTCTGCTACATGCTCGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGCGTTCAGGTTCCGGGCTTCTGCTACATGCTCGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTGCGCATTTGGCACAFTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTGCGCATTTGGCACAFTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGAATTACAGAAATCCCTATAGACCAAGTGTAAATACCCCTGAATCCCTTGTACTCCACAGTA 180
DB 121 TGAATTACAGAAATCCCTATAGACCAAGTGTAAATACCCCTGAATCCCTTGTACTCCACAGTA 180
QY 181 CCTCATCCACGCTTCTTCTGCTGTATGTTCTTCTTGCGCAGAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTCTTCTGCTGTATGTTCTTCTTGCGCAGAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATATCTAGCATATTTGTCA 360
DB 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATATCTAGCATATTTGTCA 360
QY 361 GAAGGAAGGATGGTCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACCTATATGG 420
DB 361 GAAGGAAGGATGGTCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAGATTTGCTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAGATTTGCTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTGTCGCAAGTAGC 540
DB 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTGTCGCAAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTTTTAAAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTTTTAAAAATGTTTCCACAT 600
QY 601 TTTTGGCTTGGAAAGACTGTTTTCATATGTTATCTAGATTAAGATTTTAAATGTTAT 660
DB 601 TTTTGGCTTGGAAAGACTGTTTTCATATGTTATCTAGATTAAGATTTTAAATGTTAT 660
QY 661 TAGGTATAAATTAATAAATGATTTACCTCTGGTGTTCACAGGTTTGAATTTGCACTTTC 720
DB 661 TAGGTATAAATTAATAAATGATTTACCTCTGGTGTTCACAGGTTTGAATTTGCACTTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGATGATGATTAATTTACTGACTGCTCTAGTACATTTG 780
DB 721 TTAAGGAACAGCCATAATCTCTGATGATGATTAATTTACTGACTGCTCTAGTACATTTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTTCATTGAAACAGATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTTCATTGAAACAGATCTAA 840
QY 841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATATATCTGACTAG 900
DB 841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATGATGATCAATTTAC 960
DB 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATGATGATCAATTTAC 960
QY 961 AAAAATAAAAGCGGGAATTTCCCTCGCTTGAATATATCCCTGTATATTTGCAAT 1020
DB 961 AAAAATAAAAGCGGGAATTTCCCTCGCTTGAATATATCCCTGTATATTTGCAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGATAAATAATATCTTGTCTTAATTTCTTAAGCATA 1080

```
Db      1021 GAGAGATTCCCATATTTCCATCAGAGTAATAAATATATCTTGCTTTAAITCTTAAGCATA 1080
QY      1081 AGTAAACATGATATAAAATATATGCTGAATTAATCTTGGAAGAAATGCATTTAAAGCTATT 1140
Db      1081 AGTAAACATGATATAAAATATATGCTGAATTAATCTTGGAAGAAATGCATTTAAAGCTATT 1140
QY      1141 TTAATATGTTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db      1141 TTAATATGTTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
QY      1201 TTCTAATCTGGTGGTAAAGGTTATCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
Db      1201 TTCTAATCTGGTGGTAAAGGTTATCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
QY      1261 GAATCAGAGAAATTTGTAATACCATCTGCTGCTTTCTTTAGTGCATACATAAAACTCT 1320
Db      1261 GAATCAGAGAAATTTGTAATACCATCTGCTGCTTTCTTTAGTGCATACATAAAACTCT 1320
QY      1321 GAAATTAAGACTC 1333
Db      1321 GAAATTAAGACTC 1333

RESULT 37
ID      ADC63693
XX      ADC63693 standard; cDNA; 1333 BP.
AC      ADC63693;
XX
DT      18-DEC-2003 (first entry)
DE      Human cDNA encoding secreted/transmembrane protein, PRO181.
KW      Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW      cytosolic; ophthalmological; antirheumatic; osteopathic; antirheumatic;
KW      vulnery; auditory; tumour growth; retinal disorder;
KW      sports-related joint problem; articular cartilage defects;
KW      osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
OS      Homo sapiens.
XX
FN      US2003054405-A1.
XX
PD      20-MAR-2003.
XX
PF      24-OCT-2001; 2001US-00998933.
XX
PR      17-OCT-1997; 97US-0062250P.
PR      03-NOV-1997; 97US-0064249P.
PR      13-NOV-1997; 97US-0065311P.
PR      21-NOV-1997; 97US-0066364P.
PR      10-MAR-1998; 98US-0077450P.
PR      11-MAR-1998; 98US-0077632P.
PR      11-MAR-1998; 98US-0077641P.
PR      11-MAR-1998; 98US-0077649P.
PR      12-MAR-1998; 98US-0077791P.
PR      13-MAR-1998; 98US-0078004P.
PR      17-MAR-1998; 98US-00040220.
PR      20-MAR-1998; 98US-0078886P.
PR      20-MAR-1998; 98US-0078910P.
PR      20-MAR-1998; 98US-0078936P.
PR      20-MAR-1998; 98US-0078939P.
PR      25-MAR-1998; 98US-0079294P.
PR      26-MAR-1998; 98US-0079656P.
PR      27-MAR-1998; 98US-0079663P.
PR      27-MAR-1998; 98US-0079664P.
PR      27-MAR-1998; 98US-0079689P.
PR      27-MAR-1998; 98US-0079728P.
PR      27-MAR-1998; 98US-0079786P.
PR      30-MAR-1998; 98US-0079920P.
PR      30-MAR-1998; 98US-0079923P.
PR      31-MAR-1998; 98US-0080105P.
PR      31-MAR-1998; 98US-0080107P.
PR      31-MAR-1998; 98US-0080165P.
PR      31-MAR-1998; 98US-0080194P.
PR      01-APR-1998; 98US-0080327P.
PR      01-APR-1998; 98US-0080328P.
PR      01-APR-1998; 98US-0080333P.
PR      01-APR-1998; 98US-0080334P.
PR      08-APR-1998; 98US-0081049P.
PR      08-APR-1998; 98US-0081070P.
PR      08-APR-1998; 98US-0081071P.
PR      09-APR-1998; 98US-0081195P.
PR      09-APR-1998; 98US-0081203P.
PR      15-APR-1998; 98US-0081229P.
PR      15-APR-1998; 98US-0081817P.
PR      15-APR-1998; 98US-0081819P.
PR      15-APR-1998; 98US-0081838P.
PR      15-APR-1998; 98US-0081952P.
PR      21-APR-1998; 98US-0081955P.
PR      21-APR-1998; 98US-0082568P.
PR      22-APR-1998; 98US-0082569P.
PR      22-APR-1998; 98US-0082700P.
PR      22-APR-1998; 98US-0082704P.
PR      22-APR-1998; 98US-0082797P.
PR      23-APR-1998; 98US-0082804P.
PR      27-APR-1998; 98US-0082796P.
PR      27-APR-1998; 98US-0083336P.
PR      28-APR-1998; 98US-0083322P.
PR      29-APR-1998; 98US-0083392P.
PR      29-APR-1998; 98US-0083495P.
PR      29-APR-1998; 98US-0083496P.
PR      29-APR-1998; 98US-0083499P.
PR      29-APR-1998; 98US-0083500P.
PR      29-APR-1998; 98US-0083545P.
PR      29-APR-1998; 98US-0083554P.
PR      29-APR-1998; 98US-0083558P.
PR      30-APR-1998; 98US-0083559P.
PR      05-MAY-1998; 98US-0083742P.
PR      05-MAY-1998; 98US-0084366P.
PR      06-MAY-1998; 98US-0084414P.
PR      06-MAY-1998; 98US-0084441P.
PR      07-MAY-1998; 98US-0084598P.
PR      07-MAY-1998; 98US-0084600P.
PR      07-MAY-1998; 98US-0084627P.
PR      07-MAY-1998; 98US-0084637P.
PR      07-MAY-1998; 98US-0084639P.
PR      07-MAY-1998; 98US-0084640P.
PR      07-MAY-1998; 98US-0084643P.
PR      13-MAY-1998; 98US-0085323P.
PR      13-MAY-1998; 98US-0085338P.
PR      15-MAY-1998; 98US-0085339P.
PR      15-MAY-1998; 98US-0085573P.
PR      15-MAY-1998; 98US-0085579P.
PR      15-MAY-1998; 98US-0085580P.
PR      15-MAY-1998; 98US-0085582P.
PR      15-MAY-1998; 98US-0085689P.
PR      15-MAY-1998; 98US-0085697P.
PR      15-MAY-1998; 98US-0085700P.
PR      15-MAY-1998; 98US-0085704P.
PR      18-MAY-1998; 98US-0086023P.
PR      22-MAY-1998; 98US-0086392P.
PR      22-MAY-1998; 98US-0086414P.
PR      22-MAY-1998; 98US-0086430P.
PR      22-MAY-1998; 98US-0086486P.
PR      28-MAY-1998; 98US-0087098P.
PR      28-MAY-1998; 98US-0087106P.
PR      28-MAY-1998; 98US-0087208P.
PR      26-JUN-1998; 98US-00105413.
PR      26-JUN-1998; 98US-0090863P.
PR      01-JUL-1998; 98US-0091010P.
PR      30-JUL-1998; 98US-0091359P.
PR      11-SEP-1998; 98US-0094651P.
PR      07-OCT-1998; 98US-0100038P.
PR      98US-00168978.
```

```
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187366.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-JAN-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001WO-US017092.
PR 25-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-008866342.

PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH ) GENENTECH INC.
XX

Query Match      100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGGTTCACTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGGTTCACTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTGCCANTTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTGCCANTTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGAATTACAAGAAATCCTATAGACAGTGAATACCTCGAATCCCTTGTACTCCCGAGTGA 180
DB 121 TGAATTACAAGAAATCCTATAGACAGTGAATACCTCGAATCCCTTGTACTCCCGAGTGA 180
QY 181 CCTCATCCACGCTTCTTCTGTGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGG 240
DB 181 CCTCATCCACGCTTCTTCTGTGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCCCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGAATGAG 300
DB 241 TCTCAATATGCCCCCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGAATGAG 300
QY 301 TGGCCCCAGGACTCTATGACCCCTACCAACCATCATGATGAGATATCTAGCATATTTGCA 360
DB 301 TGGCCCCAGGACTCTATGACCCCTACCAACCATCATGATGAGATATCTAGCATATTTGCA 360
QY 361 GAAAGGAAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
DB 361 GAAAGGAAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACAAACACACAGAGAATTTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACAAACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAAGAGGATTTCTATCCAGCAAGATCCTGTCCAAAGAGTAGC 540
DB 481 GCATGCAAAAAGCCCAAAAGAGGATTTCTATCCAGCAAGATCCTGTCCAAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTTCTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTTCTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
QY 601 TTTTGTGTTGGAAAGACCTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTGTTGGAAAGACCTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATGATTACCTCTGGTGTGTCACAGGTTTGCACTTTC 720
DB 661 TACGTATAAATTAATAAATGATTACCTCTGGTGTGTCACAGGTTTGCACTTTC 720
QY 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATCTGACTGTCTAGTACATG 780
DB 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATCTGACTGTCTAGTACATG 780
QY 781 GAAGCTTTGTTTATAGGAACCTTAGGGCTCATTTTGGTTCATTTGAAACAGATATCAA 840
DB 781 GAAGCTTTGTTTATAGGAACCTTAGGGCTCATTTTGGTTCATTTGAAACAGATATCAA 840
QY 841 TTATATAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTAAATATATCTGACTAG 900
DB 841 TTATATAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTAAATATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGGTTTCTCTCATGTGTCGATGATTAATATATATGGAATACATTTAC 960
```

```
Db 901 TCGGAACTTCATGGTTTCCTCATCTGTCATGTCGATGATATATATGATCAATTTAC 960
QY 961 AAAATAAAAGCGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTCATGAT 1020
Db 961 AAAATAAAAGCGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTCATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTCTTAACTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTCTTAACTTCTTAAGCATA 1080
QY 1081 AGTAACATGATATAAAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTTTTTATTTGTAAGACATTAATCTTATTAAGAAATGTTTATGCTTACTG 1200
Db 1141 TTAATATGTTTTTATTTGTAAGACATTAATCTTATTAAGAAATGTTTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGGTAAGGATTTCTTAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGGTAAGGATTTCTTAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGTAACCACTCTGCTCTTCTTTAGTGCATACATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACCACTCTGCTCTTCTTTAGTGCATACATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 38
ADC66793
ID ADC66793 standard; cDNA; 1333 BP.
XX AC ADC66793;
XX AC
XX DT 18-DEC-2003 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX KW vulnary; virucide; neuroprotective; cytostatic; gene therapy;
XX KW tumour cell proliferation inhibitor;
XX KW secreted and transmembrane protein; PRO; viral infection; wound healing;
XX KW tissue growth; muscle generation; muscle regeneration;
XX KW amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
XX KW diabetic peripheral neuropathy; chromosome identification; antagonist;
XX KW tissue typing; immunohistochemical staining; gene; ss.
XX OS Homo sapiens.
XX PN US2003060406-A1.
XX PD 27-MAR-2003.
XX PF 30-JUL-2001; 2001US-00918585.
XX PR 17-OCT-1997; 97US-0062250B.
XX PR 03-NOV-1997; 97US-0064249P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 21-NOV-1997; 97US-0066364P.
XX PR 10-MAR-1998; 98US-0077450P.
XX PR 11-MAR-1998; 98US-0077632P.
XX PR 11-MAR-1998; 98US-0077641P.
XX PR 11-MAR-1998; 98US-0077649P.
XX PR 12-MAR-1998; 98US-0077791P.
XX PR 13-MAR-1998; 98US-0078004P.
XX PR 17-MAR-1998; 98US-0004022D.
XX PR 20-MAR-1998; 98US-0078866P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 20-MAR-1998; 98US-0078936P.
XX PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99US-0000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99US-0005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99US-0005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-00310733.
PR 02-JUN-1999; 99US-0012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99US-0028313.
PR 02-DEC-1999; 99US-0028551.
PR 02-DEC-1999; 99US-0028565.
PR 16-DEC-1999; 99US-0030095.
PR 30-DEC-1999; 99US-0031243.
PR 30-DEC-1999; 99US-0031274.
PR 05-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000277.
PR 06-JAN-2000; 2000US-0000376.
PR 11-FEB-2000; 2000US-0003565.
PR 18-FEB-2000; 2000US-0004341.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 10-MAR-2000; 2000US-0006319.
PR 21-MAR-2000; 2000US-0007532.
PR 30-MAR-2000; 2000US-0008439.
PR 17-MAY-2000; 2000US-0013705.
PR 22-MAY-2000; 2000US-0014042.
PR 30-MAY-2000; 2000US-0014941.
PR 02-JUN-2000; 2000US-0015264.
PR 28-JUL-2000; 2000US-0020710.
PR 24-AUG-2000; 2000US-0023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000US-0032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000US-00349556.
PR 28-FEB-2001; 2001US-0006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001US-0009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-0017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-0017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-0019692.
PR 29-JUN-2001; 2001US-0021066.
PR 09-JUL-2001; 2001US-0021735.
```

XX (GETH) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;
 XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NP, Roy MA, Shelton DL;
 PI Stewart TA, Tumas D, Williams PM, Wood WI,
 XX WPI; 2003-596568/56.
 DR P-PSDB; ADC66794.

XX Novel secreted and transmembrane polypeptides and polynucleotides
 PT encoding them, useful for treating wound healing, tissue growth and
 PT muscle generation and regeneration, amiotrophic lateral sclerosis or
 PT neuropathy.

XX Claim 2; SEQ ID NO 321; 472pp; English.

XX The invention describes an isolated secreted and transmembrane PRO
 CC polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615
 CC is useful in biotechnological and medical research, as well as in various
 CC industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
 CC PRO708, PRO320, PRO351, PRO352, PRO381, PRO615, PRO618, PRO772, PRO853,
 CC PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
 CC therapeutically in vivo for lessening the effects of viral infection.
 CC PRO200 is useful for the treatment of wound healing, tissue growth and
 CC muscle generation and regeneration. PRO337 is useful for treating
 CC amiotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or
 CC diabetic peripheral neuropathy. A polynucleotide (II) encoding (I) is
 CC useful for generating transgenic animals or knockout animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents, as probes for generating a pool of sequences for identifying
 CC related PRO coding sequences, and to construct hybridisation probes for
 CC mapping the gene which encodes the PRO and for the genetic analysis of
 CC individuals with genetic disorders, for recombinantly expressing (I) and
 CC for chromosome identification. (I) is useful as molecular marker for
 CC protein electrophoresis purposes, and as therapeutic agents. (I) is also
 CC useful for screening compounds to identify those that mimic the PRO
 CC polypeptide (agonists) or prevent the effect of the PRO polypeptide
 CC (antagonists). (I) and (II) are useful for tissue typing. PRO antibodies
 CC are useful for immunohistochemical staining and/or assay of sample
 CC fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. This sequence encodes a human secreted and transmembrane PRO
 CC protein.

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGCGGTTCAAGTTCGCGGCTTCTGCTACATGCTGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGCGGTTCAAGTTCGCGGCTTCTGCTACATGCTGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAAGATCCTATAGACAGCTGAATACCTCAATCCCTCTTACTCCACAGATTA 180
 DB 121 TGATTACAAGATCCTATAGACAGCTGAATACCTCAATCCCTCTTACTCCACAGATTA 180

QY 181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTGTGTCAGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTGTGTCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGACCATGATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGACCATGATGAG 300

QY 301 TGGCCCGAGACTCTATGACCCCTACAAACATCATGAATGAGATATCTTAGCATATTTGTC 360
 DB 301 TGGCCCGAGACTCTATGACCCCTACAAACATCATGAATGAGATATCTTAGCATATTTGTC 360

QY 361 GAAGGAAGGATGGTGCMAATTAGCTTTTATCTCTCTAGCATTTTCTTACTACTATATGG 420
 DB 361 GAAGGAAGGATGGTGCMAATTAGCTTTTATCTCTCTAGCATTTTCTTACTACTATATGG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAT 480
 DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAT 480

QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGTCTCTGCGAAGATGAG 540
 DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGTCTCTGCGAAGATGAG 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGAAAGACCTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTGTCTGTGAAAGACCTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGCTATAAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTGCACTTC 720
 DB 661 TAGCTATAAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTGCACTTC 720

QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGCAATTAATTAATTAATTAATTAATTAAT 780
 DB 721 TTAAGGAACAGCCATAATCCTCTGAATGATGCAATTAATTAATTAATTAATTAATTAAT 780

QY 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCATTTGGTTCATTTGAAACAGATATCTAA 840
 DB 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCATTTGGTTCATTTGAAACAGATATCTAA 840

QY 841 TTATAAATTAATGCTGATGATCAGGTCCTCTGATGAAGTGAATATGATATCTGACTAG 900
 DB 841 TTATAAATTAATGCTGATGATCAGGTCCTCTGATGAAGTGAATATGATATCTGACTAG 900

QY 901 TGGAAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATGATATGATATGATAT 960
 DB 901 TGGAAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATGATATGATATGATAT 960

QY 961 AAAATAAAGGCGGAATTTTCCCTTCCCTTGAATATATCCCTGATATGATGATGAT 1020
 DB 961 AAAATAAAGGCGGAATTTTCCCTTCCCTTGAATATATCCCTGATATGATGATGAT 1020

QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATACTTGTCTTAAATTTCTTAAGCATA 1080
 DB 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATACTTGTCTTAAATTTCTTAAGCATA 1080

QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATGCTGAAGATGCAATTTAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATGCTGAAGATGCAATTTAAGCTATT 1140

QY 1141 TTAATATGCTTTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
 DB 1141 TTAATATGCTTTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200

QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAAGATTTTGCAGTACTACAGATTTTCAAAACT 1260
 DB 1201 TTCTAATCTGGTGAAGGATTTCTTAAAGATTTTGCAGTACTACAGATTTTCAAAACT 1260

QY 1261 GAATGAGAGAAATTTGTAFAAACCATCTGCTGTTCTTTAGTGAATATGAAATTAATCTCT 1320
 DB 1261 GAATGAGAGAAATTTGTAFAAACCATCTGCTGTTCTTTAGTGAATATGAAATTAATCTCT 1320

QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333

RESULT 39
ADC68917
ID ADC68917 standard; cDNA; 1333 BP.
XX AC
XX ADC68917;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
XX
PN US2003064407-A1.
XX
XX 03-APR-2003.
XX
XX 24-OCT-2001; 2001US-00999834.
XX
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 01-APR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083498P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091010P.
PR 30-JUL-1998; 98US-0091359P.
PR 11-SEP-1998; 98US-0094651P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-00184216.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-00204855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-00218517.
PR 23-DEC-1998; 98US-0013621P.
PR 05-JAN-1999; 99US-00000106.
PR 05-JAN-1999; 99US-00254465.
PR 08-MAR-1999; 99US-0005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-00123957P.
PR 29-MAR-1999; 99US-00126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-00130232P.
PR 26-APR-1999; 99US-00130232P.
PR 28-APR-1999; 99US-00131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.

PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-007093238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
PA
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGTCCGATGGCGTTCACGTTCCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
DB 1 GCCCAGCGTCCGATGGCGTTCACGTTCCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTGGCCATTGGSCAATPATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTGGCCATTGGSCAATPATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGATCCCTATAGACAGAGTGTATACCTGAATCCCGTTGTACTCCAGAT 180
DB 121 TGATTACAAGATCCCTATAGACAGAGTGTATACCTGAATCCCGTTGTACTCCAGAT 180

QY 181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCAGAGAGTGGCTTACATGG 240
DB CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCAGAGAGTGGCTTACATGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATATATTTGGAGGTATATAGTAGCAGATGATGAG 300
DB TCTCAATATGCCCTCTTGGCATATATATTTGGAGGTATATAGTAGCAGATGATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATCAGATATTTAGCATATTTGCA 360
DB TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATCAGATATTTAGCATATTTGCA 360
QY 361 GAAGGAAGAGTGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTACTACTATATGG 420
DB GAAGGAAGAGTGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAAATTCGTCAGTTAAGT 480
DB CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAAATTCGTCAGTTAAGT 480
QY 481 GCATGCAAAAAGGCCAACCAATGAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
DB GCATGCAAAAAGGCCAACCAATGAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
DB CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAAGACTGTTTTCATATGTTTATCTACTCAGATAAAGATTTTAAATGGTAT 660
DB TTTTCTTGTGGAAAGACTGTTTTCATATGTTTATCTACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATATAATTAATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
DB TACGTATATAATTAATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGATGATTAATTAATTAATTAATTAATTAATTAATTAAT 780
DB TTAAGGAACAGCCATAATCTCTGATGATTAATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTAGGCTCATTTGGTTTCATTTGAACAGATATCTAA 840
DB GAAGCTTTTGTATAGGAACCTTAGGCTCATTTGGTTTCATTTGAACAGATATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTCTTCTGATGAGTGAATGAATGATATCTGACTAG 900
DB TTATAAATTAGCTGTAGATATCAGGTCTTCTGATGAGTGAATGAATGATATCTGACTAG 900
QY 901 TGGGAAACTTCATGGGTTCCCTCATCTGTCATGTCATGATTAATATATGATACATTTAC 960
DB TGGGAAACTTCATGGGTTCCCTCATCTGTCATGTCATGATTAATATATGATACATTTAC 960
QY 961 AAAAAATAAAGGGGAATTTCCCTCGCTTGAATATATATCCCTGTATATTTGCAATGAAT 1020
DB AAAAAATAAAGGGGAATTTCCCTCGCTTGAATATATATCCCTGTATATTTGCAATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTCTGCTTTAATTTCTTAAGCAT 1080
DB GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTCTGCTTTAATTTCTTAAGCAT 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTTGGAAGATGCAATTTAAGCAAT 1140
DB AGTAAACATGATATAAATAATATGCTGAATTTACTTTGGAAGATGCAATTTAAGCAAT 1140
QY 1141 TTAATATGTTTATTTGTAAGACATTTACTTATTAAGAAATGGTATATATGCTTACTG 1200
DB TTAATATGTTTATTTGTAAGACATTTACTTATTAAGAAATGGTATATATGCTTACTG 1200
QY 1201 TTTCTAATCTGGTGAAGATTTCTTAAGATTTTCCAGGTACTACAGATTTTCAAACT 1260
DB TTTCTAATCTGGTGAAGATTTCTTAAGATTTTCCAGGTACTACAGATTTTCAAACT 1260


```
QY 1261 GAATGAGAGAAATTGTATACCACTCTGCTGTTCCCTTTACTGCAATACATAAACTCT 1320
Db |||||||
QY 1261 GAATGAGAGAAATTGTATACCACTCTGCTGTTCCCTTTACTGCAATACATAAACTCT 1320
Db |||||||
QY 1321 GAAATTAGACTC 1333
Db |||||||
QY 1321 GAAATTAGACTC 1333
Db |||||||

RESULT 40
ADC62977
ID ADC62977 standard; cDNA; 1333 BP.
AC ADC62977;
XX
XX
XX 18-DEC-2003 (first entry)
XX Human cDNA encoding secreted/transmembrane protein, PRO181.
XX
XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
XX Homo sapiens.
XX
XX US2003068648-A1.
XX
XX 10-APR-2003.
XX
XX 25-OCT-2001; 2001US-00013921.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081223P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081223P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081851P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 23-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US01073.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
```

PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Baton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI: 2003-695924/66.
DR P-PSDB; ADC62978.
XX
XX New isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 2; SEQ ID NO 321; 467pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX 1 GCCACGGCTCCGATGGCGTTCACGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGGCTCCGATGGCGTTCACGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCAATATTAGCATTTGATGAGCTGAAGAC 120
DB |||||
DB 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCAATATTAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAATCCTATAGACCACTGTAATACCTCGAATCCCTTGTTACTCCCAAGAT 180
DB |||||
DB 121 TGATTACAGAATCCTATAGACCACTGTAATACCTCGAATCCCTTGTTACTCCCAAGAT 180
QY 181 CCTCATCCACGGCTTTCTTCTGTGTCATGTTCTTTGTGCGACAGAGTGGCTTACATGGG 240
DB |||||
DB 181 CCTCATCCACGGCTTTCTTCTGTGTCATGTTCTTTGTGCGACAGAGTGGCTTACATGGG 240
QY 241 TCTGATATGCCCCCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
DB |||||
DB 241 TCTCAATATGCCCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
QY 301 TGGCCCGAGGACTCTATGATGACCCCTACCAACCATCATGATGAGATATTTCTAGCATATTGTCA 360
DB |||||
DB 301 TGGCCCGAGGACTCTATGATGACCCCTACCAACCATCATGATGAGATATTTCTAGCATATTGTCA 360
QY 361 GAAGGAAGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTACTACTATATGG 420
DB |||||
DB 361 GAAGGAAGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACAGAGAAATTTGGTCCAGTTAAGT 480
DB |||||
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACAGAGAAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAATGAGGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
DB |||||
DB 481 GCATGCAAAAAGCCACCAATGAGGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTA CTTTAAAAAAGACTCCCTTATTTTAAATGTTTCCACAT 600
DB |||||
DB 541 CTGTGGAATCTGATCAGTTA CTTTAAAAAAGACTCCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTGTGAAAGACTGTTTTCATATGTTATCTCAGATAAGATTTTAAATGGTAT 660
DB |||||
DB 601 TTTTCTGTGTGAAAGACTGTTTTCATATGTTATCTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720
DB |||||
DB 661 TACGTATAAATTAATAAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATCTGAGCTGCTTAGTACATG 780
DB |||||
DB 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATCTGAGCTGCTTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTGAAACAGATCTAA 840
DB |||||
DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTGAAACAGATCTAA 840
QY 841 TTTATAATTTAGCTGTAGATATCAGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
DB |||||
DB 841 TTTATAATTTAGCTGTAGATATCAGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAACTTCAATGGGTTTCTCTCATCTGTCATGTCGATGATATATATGGAATTTAC 960
DB |||||
DB 901 TGGGAACTTCAATGGGTTTCTCTCATCTGTCATGTCGATGATATATATGGAATTTAC 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGATGAT 1020
DB |||||
DB 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGATGAT 1020
QY 1021 GAGAGATTTCCCAATATTTCCATCAGAGTAATAAATAATATATCTTGTAAATTTTAAAGCATA 1080
DB |||||
DB 1021 GAGAGATTTCCCAATATTTCCATCAGAGTAATAAATAATATATCTTGTAAATTTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTGTGAAGATGCAATTTTAAAGCTATT 1140
DB |||||
DB 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTGTGAAGATGCAATTTTAAAGCTATT 1140

```
QY 1141 TTTAAATGCTTTTATTGTTAAAGACATTAAGGATTTGTTATTATGCTTACTG 1200
Db 1141 TTTAAATGCTTTTATTGTTAAAGACATTAAGGATTTGTTATTATGCTTACTG 1200
QY 1201 TTCTAAATCTGGTGTGAAGGTTATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAAATCTGGTGTGAAGGTTATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTTCTTTTATGTCGAATACAAATAAACTCT 1320
Db 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTTCTTTTATGTCGAATACAAATAAACTCT 1320
QY 1321 GAATTAAGACTC 1333
Db 1321 GAATTAAGACTC 1333

RESULT 41
ADC68042
ID ADC68042 standard; cDNA; 1333 BP.
XX AC
XX AC
XX 18-DEC-2003 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
XX KW cystostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
XX KW vulvular; auditory; tumour growth; retinal disorder;
XX KW sports-related joint problem; articular cartilage defects;
XX KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX OS Homo sapiens.
XX PN US2003069178-A1.
XX PD 10-APR-2003.
XX PF 16-OCT-2001; 2001US-00978423.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 13-NOV-1997; 97US-0064249P.
XX PR 21-NOV-1997; 97US-0065311P.
XX PR 10-MAR-1998; 98US-0066364P.
XX PR 11-MAR-1998; 98US-0077450P.
XX PR 11-MAR-1998; 98US-0077632P.
XX PR 11-MAR-1998; 98US-0077641P.
XX PR 12-MAR-1998; 98US-0077649P.
XX PR 13-MAR-1998; 98US-0077791P.
XX PR 20-MAR-1998; 98US-0078004P.
XX PR 20-MAR-1998; 98US-0078886P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 20-MAR-1998; 98US-0078936P.
XX PR 20-MAR-1998; 98US-0078939P.
XX PR 25-MAR-1998; 98US-0079294P.
XX PR 26-MAR-1998; 98US-0079565P.
XX PR 27-MAR-1998; 98US-0079663P.
XX PR 27-MAR-1998; 98US-0079664P.
XX PR 27-MAR-1998; 98US-0079689P.
XX PR 27-MAR-1998; 98US-0079726P.
XX PR 27-MAR-1998; 98US-0079786P.
XX PR 30-MAR-1998; 98US-0079920P.
XX PR 30-MAR-1998; 98US-0079923P.
XX PR 31-MAR-1998; 98US-0080105P.
XX PR 31-MAR-1998; 98US-0080194P.
XX PR 01-APR-1998; 98US-0080327P.
XX PR 01-APR-1998; 98US-0080328P.
XX PR 01-APR-1998; 98US-0080333P.
XX PR 01-APR-1998; 98US-0080334P.
XX PR 08-APR-1998; 98US-0081049P.
XX PR 08-APR-1998; 98US-0081070P.
XX PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082966P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
```

PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003376.
PR 18-FEB-2000; 2000WO-US003565.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001WO-US0918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI: 2003-657582/62.
DR P-FSDB; ADC68043.
XX
PT Novel secreted and transmembrane polypeptides, designated PRO
PT polypeptides, and polynucleotides encoding them useful for treating
PT kidney diseases, bone, cartilage and retinal disorders.
XX
PS Claim 2; SEQ ID NO 321; 469pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCACGCGCCGATGGCGGTTACGTTGCGGGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCACGCGCCGATGGCGGTTACGTTGCGGGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTGGCCATTGGCCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTGGCCATTGGCCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAACTCTATAGACCAAGTGTAAATACCCCTGTAATCCCTGTAATCCCTGTA 180
DB 121 TGATTACAAGAACTCTATAGACCAAGTGTAAATACCCCTGTAATCCCTGTAATCCCTGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACCAAGTGAAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACCAAGTGAAG 300
QY 301 TGGCCCAAGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTCAGCATATTGTCA 360
DB 301 TGGCCCAAGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTCAGCATATTGTCA 360
QY 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACCAACACACAGAAAGATTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACCAACACACAGAAAGATTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCACCACCAATGAAGGATCTTCTCCAGCAAGATCCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAGCACCACCAATGAAGGATCTTCTCCAGCAAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTACTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTGGAAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTGTGTGGAAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATGATTAACCTCTGCTGTGTTGACAGGTTTGAACCTGCACCTC 720
DB 661 TACGTATAAATTAATAAATGATTAACCTCTGCTGTGTTGACAGGTTTGAACCTGCACCTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATCTGATCTGCTAGTACATTG 780
DB 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATCTGATCTGCTAGTACATTG 780
QY 781 GAAGCTTTGTTTATAGGAACCTGTAGGCTCATTTTGGTTTCAFTGAACAGATATCTAA 840
DB 781 GAAGCTTTGTTTATAGGAACCTGTAGGCTCATTTTGGTTTCAFTGAACAGATATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGTGTCTCTGATGAAGTGAATGATAATCTGACTAG 900
DB 841 TTATAAATAGCTGTAGATATCAGTGTCTCTGATGAAGTGAATGATAATCTGACTAG 900
QY 901 TGGGAAACTTCATGGGTTTCTCATCTGTCTGATCGATGATTATATATGATACATTAC 960
DB 901 TGGGAAACTTCATGGGTTTCTCATCTGTCTGATCGATGATTATATATGATACATTAC 960
QY 961 AAAAATAAAGCGGGAAATTTTCCCTGCTGCTGTAATATATCCCTGTATATTTGATGAAT 1020
DB 961 AAAAATAAAGCGGGAAATTTTCCCTGCTGCTGTAATATATCCCTGTATATTTGATGAAT 1020

```
QY 1021 GAGAGATTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATTCCTTAAGCATA 1080
Db 1021 GAGAGATTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATTCCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTTGTTTTTATTTTGAAGACATTTACTTATTAAGAAATGCTTATTAATGCTTACTG 1200
Db 1141 TTAATGTTGTTTTTATTTTGAAGACATTTACTTATTAAGAAATGCTTATTAATGCTTACTG 1200
QY 1201 TTCTAATCTGTTGGTAAAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGTTGGTAAAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAATTTGATAACCATCTGCTGCTTCTTTAGTGAATCAATTAATAAACTCT 1320
Db 1261 GAATGAGAGAAAATTTGATAACCATCTGCTGCTTCTTTAGTGAATCAATTAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 42
AD41362
ID AD41362 standard; cdna; 1333 BP.
XX
AC AD41362;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cystostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
FN US2003072745-A1.
XX
PD 17-APR-2003.
XX
PF 25-OCT-2001; 2001US-00013929.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077633P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 25-MAR-1998; 98US-0078939P.
PR 26-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 30-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 31-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 15-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 21-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 23-APR-1998; 98US-0082804P.
PR 27-APR-1998; 98US-0082796P.
PR 28-APR-1998; 98US-0083336P.
PR 29-APR-1998; 98US-0083342P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091010P.
PR 30-JUL-1998; 98US-0091359P.
PR 11-SEP-1998; 98US-0094651P.
PR 07-OCT-1998; 98US-0100038P.
PR 20-NOV-1998; 98US-0109304P.
```

20-NOV-1998; 98WO-US024855.
22-DEC-1998; 98US-0113296P.
23-DEC-1998; 98US-0113621P.
05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US005028.
10-MAR-1999; 99WO-US005190.
12-MAR-1999; 99US-0123957P.
29-MAR-1999; 99US-0126773P.
21-APR-1999; 99US-0130232P.
26-APR-1999; 99US-0131022P.
28-APR-1999; 99US-0131445P.
14-MAY-1999; 99US-0134287P.
14-MAY-1999; 99WO-US010733.
02-JUN-1999; 99WO-US012252.
16-JUN-1999; 99US-0139557P.
23-JUN-1999; 99US-0141037P.
07-JUL-1999; 99US-0142680P.
26-JUL-1999; 99US-0145698P.
28-JUL-1999; 99US-0146222P.
29-OCT-1999; 99US-0162506P.
30-NOV-1999; 99WO-US028313.
02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US003565.
18-FEB-2000; 2000WO-US004341.
24-FEB-2000; 2000WO-US005004.
02-MAR-2000; 2000WO-US005841.
10-MAR-2000; 2000WO-US006319.
21-MAR-2000; 2000WO-US007532.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
24-AUG-2000; 2000WO-US023328.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001WO-US006520.
22-MAR-2001; 2001WO-US009552.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001WO-US017800.
20-JUN-2001; 2001WO-US019692.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-743806/70.
DR P-PSDB; ADC41363.
XX
XX Novel isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
XX Claim 2; SEQ ID NO 321; 466pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given

CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. NO. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCGATGGCGTTCAGTTCGGCGGCTTCTGCTACATGCTGGCGTGTGCT 60
DB 1 GCCACGCGTCGATGGCGTTCAGTTCGGCGGCTTCTGCTACATGCTGGCGTGTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTCGCCATTTCGCCATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTCGCCATTTCGCCATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAACTCTATAGACAGAGTGAATACCTGAAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAAGAACTCTATAGACAGAGTGAATACCTGAAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTTCGTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTCTTCGTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGA 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGA 300
QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATTTCTAGCATATTTGCA 360
DB 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATTTCTAGCATATTTGCA 360
QY 361 GAAGGAAGGTGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAAGGTGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAAGTCTTTAGAACAAACACAGAGAAGTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAAGTCTTTAGAACAAACACAGAGAAGTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTTCCAGCAAGATCCTGTCCAAGATGAGC 540
DB 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTTCCAGCAAGATCCTGTCCAAGATGAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTGCGAAGAGCTGTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTGTGCGAAGAGCTGTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
DB 661 TACGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGCAATTAATTAATGCTGCTAGTACATG 780
DB 721 TTAAGGAACAGCCATAATCCTCTGAATGATGCAATTAATTAATGCTGCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCAITTTGGTTTCAITTTGAAAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCAITTTGGTTTCAITTTGAAAACAGTATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATACAGTGTCTCTGATGAAGTGAATAATGATATCTGACTAG 900
DB 841 TTATAAATTAGCTGTAGATATACAGTGTCTCTGATGAAGTGAATAATGATATCTGACTAG 900

```
QY 901 TGGGAACTTCATGGGTTTCCCATCTGTCATCTGCATGATGATATATATGATACATTTAC 960
Db 901 TGGGAACTTCATGGGTTTCCCATCTGTCATCTGCATGATGATATATATGATACATTTAC 960
QY 961 AAAAAATAAAAGCGGAAATTTTCCCTTCGCTTGAATATTATCCCTGTATATTGTCATGAAT 1020
Db 961 AAAAAATAAAAGCGGAAATTTTCCCTTCGCTTGAATATTATCCCTGTATATTGTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCCAGAGTAATAAATATCTGCTTTAAATCTTTAAGCATTA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCCAGAGTAATAAATATCTGCTTTAAATCTTTAAGCATTA 1080
QY 1081 AGTAACATCATATAAAATATATGCTGTAATTAATCTTGTGAAGATGCAATTAAGCTATT 1140
Db 1081 AGTAACATCATATAAAATATATGCTGTAATTAATCTTGTGAAGATGCAATTAAGCTATT 1140
QY 1141 TTAATATGTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTATATGCTTACTG 1200
Db 1141 TTAATATGTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTATATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGATTTCTTAAGAAATTTGCAAGATTTGCAAGATTTTCAAACCT 1260
Db 1201 TTCTAATCTGCTGTAAGATTTCTTAAGAAATTTGCAAGATTTTCAAACCT 1260
QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTCTTTAGTGCATACATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTCTTTAGTGCATACATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 43
ADC67417
ID ADC67417 standard; cdna; 1333 BP.
XX
AC ADC67417;
XX
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cdna encoding secreted/transmembrane protein, PRO181.
XX
KW vulnerary; virucide; neuroprotective; cytostatic; gene therapy;
KW tumour cell proliferation inhibitor;
KW secreted and transmembrane protein; PRO; viral infection; wound healing;
KW tissue growth; muscle generation; muscle regeneration;
KW amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
KW diabetic peripheral neuropathy; chromosome identification; antagonist;
KW tissue typing; immunohistochemical staining; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003073131-A1.
XX
PD 17-APR-2003.
XX
XX
PF 25-OCT-2001; 2001US-00016177.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 12-MAR-1998; 98US-0077649P.
PR 13-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078888P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 01-APR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 23-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
```


Qy	781	GAAGCTTTTGGTTATAGAACTTGTAGGGCTCATTTTGGTTTCATTCGAAACAGATCTAA	840	98US-0077791P
Db	781	GAAGCTTTTGGTTATAGAACTTGTAGGGCTCATTTTGGTTTCATTCGAAACAGATCTAA	840	98US-0078004P
Qy	841	TTATAAAATTAGCTGTAGATATCAGGTCTCTCTGATGAAGTGAAAGTGATATCTGACTAG	900	98US-0078886P
Db	841	TTATAAATTAGCTGTAGATATCAGGTCTCTCTGATGAAGTGAAAGTGATATCTGACTAG	900	98US-0078910P
Qy	901	TGGGAAACTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATATGATATTC	960	98US-0078936P
Db	901	TGGGAAACTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATATGATATTC	960	98US-0079244P
Qy	961	AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATATATATATATATATATAT	1020	98US-0079565P
Db	961	AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATATATATATATATATATAT	1020	98US-0079633P
Qy	1021	GAGAGATTCCCATATTTCCATCAGAGTAATAATATATATATATATATATATATATATAT	1080	98US-0079664P
Db	1021	GAGAGATTCCCATATTTCCATCAGAGTAATAATATATATATATATATATATATATATAT	1080	98US-0079728P
Qy	1081	AGTAAACATGATATAAAAAATATATGCTGAAATTAATCTGCTGAAGATGCATTTAAAGCTATT	1140	98US-0079786P
Db	1081	AGTAAACATGATATAAAAAATATATGCTGAAATTAATCTGCTGAAGATGCATTTAAAGCTATT	1140	98US-0079920P
Qy	1141	TTAATAGTGTTTTTATTTGTAAGACATTAATCTTAAAGAAATTTGGTTATTATGCTTACTG	1200	98US-0079923P
Db	1141	TTAATAGTGTTTTTATTTGTAAGACATTAATCTTAAAGAAATTTGGTTATTATGCTTACTG	1200	98US-0080105P
Qy	1201	TTCTAAATCTGGTGAAGGTATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAAACT	1260	98US-0080107P
Db	1201	TTCTAAATCTGGTGAAGGTATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAAACT	1260	98US-0080117P
Qy	1261	GAATGAGAGAAAATTTGATATAACCATCTGCTGTTTCCCTTTAGTGCATACAAATAAACTCT	1320	98US-0081813P
Db	1261	GAATGAGAGAAAATTTGATATAACCATCTGCTGTTTCCCTTTAGTGCATACAAATAAACTCT	1320	98US-0081952P
Qy	1321	GAATTAAGACTC 1333		98US-0081955P
Db	1321	GAATTAAGACTC 1333		98US-0082568P
RESULT 44				98US-0082569P
ID	ADC62353	standard; cdna; 1333 BP.		98US-0082704P
XX	XX			98US-0082797P
AC	AC			98US-0082804P
XX	XX			98US-0082796P
DI	18-DEC-2003	(first entry)		98US-0083322P
XX	XX			98US-0083322P
XX	XX			98US-0083495P
KW	KW			98US-0083496P
KW	KW			98US-0083499P
KW	KW			98US-0083500P
KW	KW			98US-0083545P
KW	KW			98US-0083554P
OS	OS			98US-0084414P
XX	XX			98US-0084414P
XX	XX			98US-0084598P
XX	XX			98US-0084600P
PN	PN			98US-0084627P
XX	XX			98US-0084637P
PD	PD			98US-0084639P
XX	XX			98US-0084640P
PF	PF			98US-0084643P
XX	XX			98US-0085233P
XX	XX			98US-0085338P
XX	XX			98US-0085339P
XX	XX			98US-0085373P
XX	XX			98US-0085579P
XX	XX			98US-0085579P
XX	XX			98US-0085580P
XX	XX			98US-0085582P
XX	XX			98US-0085689P
XX	XX			98US-0085697P
XX	XX			98US-0085700P

```
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-00211141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 29-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 04-FEB-2000; 2000US-0180165P.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH ) GENENTECH INC.
XX
XX

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0;

Qy 1 GCCCAGCGTCCGATGGCGTTCACGTTGCGGGCTTCGTCTACATGCTGGCGTCTGCT 60
Db 1 GCCCAGCGTCCGATGGCGTTCACGTTGCGGGCTTCGTCTACATGCTGGCGTCTGCT 60
Qy 61 CACTGCGCGCTCATCTTCTTCCGCAATTGGCACTTATAGCACTTATAGCACTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCCGCAATTGGCACTTATAGCACTTATAGCACTGAAGAC 120
Qy 121 TGATTACAAGAACTCTATAGACAGTGTAACTCCTCAATCCCTTCTTCTACTCCAGAGTA 180
Db 121 TGATTACAAGAACTCTATAGACAGTGTAACTCCTCAATCCCTTCTTCTACTCCAGAGTA 180
Qy 181 CCTCATCCAGCTTCTTCTTCTGTCATGTTTCTTGTGACAGAGTGGCTTACCTGGG 240
Db 181 CCTCATCCAGCTTCTTCTTCTGTCATGTTTCTTGTGACAGAGTGGCTTACCTGGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTAG 300
Qy 301 TGGCCAGGACTCTATGACCCCTACAACCATCATGAATGCAGATATTTCTAGCATATTGCA 360
Db 301 TGGCCAGGACTCTATGACCCCTACAACCATCATGAATGCAGATATTTCTAGCATATTGCA 360
Qy 361 GAAGGAAGATGGTGCATAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
Db 361 GAAGGAAGATGGTGCATAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTGTGCTGCTTTAGAACACACACAGAAATGCTCCAGTAAGT 480
Db 421 CATGATCTATGTTTGTGCTGCTTTAGAACACACACAGAAATGCTCCAGTAAGT 480
Qy 481 GCATCAAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
Db 481 GCATCAAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCACTTCTTAAATAAATGACTCTCTATTTTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCACTTCTTAAATAAATGACTCTCTATTTTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTCTGTGGAAGACTGTTTTTATATGTTTACTCAGATAAAGATTTTTAAATGTTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTTATATGTTTACTCAGATAAAGATTTTTAAATGTTAT 660
```



```
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 07-DEC-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 23-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00285686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.

PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US031095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
PR XX
PR PA (GETH ) GENENTECH INC.
PR XX

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGTCGGATGGCGTTCCAGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGTCGGATGGCGTTCCAGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTCGCCATTGGGCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTCGCCATTGGGCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACCCAGTGTAATACCTCGAATCCCTTGACTCCCGAGTA 180
DB 121 TGATTACAAGAAATCCTATAGACCCAGTGTAATACCTCGAATCCCTTGACTCCCGAGTA 180
QY 181 CCTCATCCACGCTTCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCACGCTTCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGGG 240
```

Qy	241	TCTCAATATGCCCTCTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTATGAG	300
Db	241	TCTCAATATGCCCTCTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTATGAG	300
Qy	301	TGGCCCAAGGACTCTATGACCCCTCAACCATCATGAATGCAGATATCTAGCATATGTCA	360
Db	301	TGGCCCAAGGACTCTATGACCCCTCAACCATCATGAATGCAGATATCTAGCATATGTCA	360
Qy	361	GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTAGCATTTTCTACTCTATATGCG	420
Db	361	GAAGGAAGGATGGTGCAAAATAGCTTTTATCTCTAGCATTTTCTACTCTATATGCG	420
Qy	421	CATGATCTATGTTTGGTGAGCTCTTAGAAACAACACACAGAAGAATGGTCAGTTAAGT	480
Db	421	CATGATCTATGTTTGGTGAGCTCTTAGAAACAACACACAGAAGAATGGTCAGTTAAGT	480
Qy	481	GCATCAAAAAGCCACCAAAATGAAGGATCTATCCAGCAAGATCCCTGTCCAAAGTAGC	540
Db	481	GCATCAAAAAGCCACCAAAATGAAGGATCTATCCAGCAAGATCCCTGTCCAAAGTAGC	540
Qy	541	CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTTATTTTAAAAATGTTTCCACAT	600
Db	541	CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTTATTTTAAAAATGTTTCCACAT	600
Qy	601	TTTTGCTCTGTGGAAGACGTGTTTCTATGTTATCTCAGATAAAGATTTTAAATGGTAT	660
Db	601	TTTTGCTCTGTGGAAGACGTGTTTCTATGTTATCTCAGATAAAGATTTTAAATGGTAT	660
Qy	661	TAGCTATAAATTAATATAAATGATTAACCTCTGGTGTTGACAGGTTTGAATTCGACTTC	720
Db	661	TAGCTATAAATTAATATAAATGATTAACCTCTGGTGTTGACAGGTTTGAATTCGACTTC	720
Qy	721	TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATCTGACTGTCTCTAGTACATTG	780
Db	721	TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATCTGACTGTCTCTAGTACATTG	780
Qy	781	GAAGCTTTTCTTTATAGGAACCTGTAGGGCTCATTTTGGTTTCATGAAACAGATATCTAA	840
Db	781	GAAGCTTTTCTTTATAGGAACCTGTAGGGCTCATTTTGGTTTCATGAAACAGATATCTAA	840
Qy	841	TTATAAATAGCTGTAGATATCAGGTGTTCTGATGAAGTCAAAATGATATCTCGACTAG	900
Db	841	TTATAAATAGCTGTAGATATCAGGTGTTCTGATGAAGTCAAAATGATATCTCGACTAG	900
Qy	901	TGGGAACCTTCATGGGTTTCTCATCTCTCATGTCGATGATTATATATGGATACATTTAC	960
Db	901	TGGGAACCTTCATGGGTTTCTCATCTCTCATGTCGATGATTATATATGGATACATTTAC	960
Qy	961	AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTGATATTTGATGAT	1020
Db	961	AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTGATATTTGATGAT	1020
Qy	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAATCTTAAAGCAT	1080
Db	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAATCTTAAAGCAT	1080
Qy	1081	AGTAACATGATATAAATAATATGCTGAATTTACTTGTGAAGAAATGCAATTTAAAGCTATT	1140
Db	1081	AGTAACATGATATAAATAATATGCTGAATTTACTTGTGAAGAAATGCAATTTAAAGCTATT	1140
Qy	1141	TTAAATGTGTTTTTATTTGTAGACATATCTTATTAAGAAATGGTTATATGCTTACTG	1200
Db	1141	TTAAATGTGTTTTTATTTGTAGACATATCTTATTAAGAAATGGTTATATGCTTACTG	1200
Qy	1201	TTCTAATCTGGTGGTAAGGATTTCTTAAGAAATTCGAGTACTACAGATTTTCAAAACT	1260
Db	1201	TTCTAATCTGGTGGTAAGGATTTCTTAAGAAATTCGAGTACTACAGATTTTCAAAACT	1260
Qy	1261	GAATGAGACAAAATCTATAAACCATCTGCTGTTCTTTAGTGCATATCAATAAACTCT	1320
Db	1261	GAATGAGACAAAATCTATAAACCATCTGCTGTTCTTTAGTGCATATCAATAAACTCT	1320
Qy	1321	GAATTTAAGACTC	1333

|||||

Db 1321 GAAATTAAGACTC 1333

RESULT 47

ADC21838

ID ADC21838 standard; cDNA; 1333 BP.

XX AC ADC21838;

XX 18-DEC-2003 (first entry)

XX Human PRO polynucleotide #60.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;

KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;

KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;

KW arthritis; sports injury; cytostatic; antiarthritic.

XX

OS Homo sapiens.

XX US2003096969-A1.

XX 22-MAY-2003.

XX 29-AUG-2002; 2002US-00232225.

XX 02-JUN-2000; 2000WO-US015264.

PR 05-JUN-2000; 2000US-0209832P.

PR 20-JUN-2000; 2000US-0212901P.

PR 22-JUN-2000; 2000US-0213807P.

PR 20-JUL-2000; 2000US-0219556P.

PR 25-JUL-2000; 2000US-0220585P.

PR 25-JUL-2000; 2000US-0220605P.

PR 25-JUL-2000; 2000US-0220607P.

PR 25-JUL-2000; 2000US-0220624P.

PR 25-JUL-2000; 2000US-0220638P.

PR 25-JUL-2000; 2000US-0220664P.

PR 25-JUL-2000; 2000US-0220666P.

PR 26-JUL-2000; 2000US-0220893P.

PR 01-AUG-2000; 2000US-0222425P.

PR 22-AUG-2000; 2000US-0227133P.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 10-NOV-2000; 2000WO-US030873.

PR 28-NOV-2000; 2000US-0253646P.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001WO-US017800.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.

XX

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AU, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-765526/72.

DR P-PSDB; ADC21839.

XX Novel isolated PRO polypeptide useful for tissue typing, as molecular

PT weight markers in protein electrophoresis, for treating arthritis, tumor

XX Claim 2; Fig 119; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the PRO polynucleotides encoding them.

CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,

CC diagnostics, biosensors or bioreactors. They are particularly useful for

CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides and/or cartilage
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGGTTTCAGTTCGCGGCTTCTGCTACATGTCGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGGTTTCAGTTCGCGGCTTCTGCTACATGTCGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTGCGCATTTGGCAGATATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTGCGCATTTGGCAGATATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAACTCTATAGACAGCTGTAATAACCTGAACTCCCTTGTACTCCCAAGATA 180
DB 121 TGATTACAGAACTCTATAGACAGCTGTAATAACCTGAACTCCCTTGTACTCCCAAGATA 180
QY 181 CTTCTATCCACGCTTTCTTCTGTGTCACTTTCTTTGTGAGCAGAGTGGCTTACACTGG 240
DB 181 CTTCTATCCACGCTTTCTTCTGTGTCACTTTCTTTGTGAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTTCTTGGCATATCATATTTGGAGGTATATGATGACAGTATGATGAG 300
DB 241 TCTCAATATGCCCTTCTTGGCATATCATATTTGGAGGTATATGATGACAGTATGATGAG 300
QY 301 TGGCCGAGGACTCTATGACCTTACACCATCATGATGATGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCGAGGACTCTATGACCTTACACCATCATGATGATGATATTTCTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATATTTTCTAGCATATTTG 420
DB 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATATTTTCTAGCATATTTG 420
QY 421 CATGATCTATTTTGGTGGCTCTTAGACACACACAGAAATTTGGTCCAGTTAAAGT 480
DB 421 CATGATCTATTTTGGTGGCTCTTAGACACACACAGAAATTTGGTCCAGTTAAAGT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCACAGAGTAGC 540
DB 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCACAGAGTAGC 540
QY 541 CTGTGGAACTGATCAGTTACTTTTAAATAAGTCCCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAACTGATCAGTTACTTTTAAATAAGTCCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
DB 601 TTTTGTCTTGGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
QY 661 TACGTAAATAATAATAAATGATATCTCTGCTGTTGACAGGTTTGAACCTTGCACCTTC 720
DB 661 TACGTAAATAATAATAAATGATATCTCTGCTGTTGACAGGTTTGAACCTTGCACCTTC 720

DB 661 TACGTAAATAATAATAAATGATATCTCTGCTGTTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAAATGATGATTAATTAATTAATTAATTAATTAATTA 780
DB 721 TTAAGGAACAGCCATAATCTCTGAAATGATGATTAATTAATTAATTAATTAATTAATTA 780
QY 781 GAAGCTTTTGTGTTTATAGGAACCTTGTAGGCTCATTTTGGTTTCAATTTGAACAGTATCTAA 840
DB 781 GAAGCTTTTGTGTTTATAGGAACCTTGTAGGCTCATTTTGGTTTCAATTTGAACAGTATCTAA 840
QY 841 TTAATAATTAAGCTGTAGATATCAGGCTGCTTCGATGAAGTGAAGTGAAGTGAAGTGAAG 900
DB 841 TTAATAATTAAGCTGTAGATATCAGGCTGCTTCGATGAAGTGAAGTGAAGTGAAGTGAAG 900
QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAAT 960
DB 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAAT 960
QY 961 AAAAAATAAAGCGGGAATTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCC 1020
DB 961 AAAAAATAAAGCGGGAATTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCC 1020
QY 1021 GAGGATTTCCCATATTTCCCATCAGAGTAAATAATATATCTTCTTAATTTCTTAAGCATATA 1080
DB 1021 GAGGATTTCCCATATTTCCCATCAGAGTAAATAATATATCTTCTTAATTTCTTAAGCATATA 1080
QY 1081 AGTAAACATCATATAAAAAATATATCTTCTGGAAGTAAATGATTAATTAATTAATTAATTAAT 1140
DB 1081 AGTAAACATCATATAAAAAATATATCTTCTGGAAGTAAATGATTAATTAATTAATTAATTAAT 1140
QY 1141 TTAATGTTTGTATTTTGTGAAGCATTTCTTATTAAGAAATGTTGTTTATTAATTAATTAATTAAT 1200
DB 1141 TTAATGTTTGTATTTTGTGAAGCATTTCTTATTAAGAAATGTTGTTTATTAATTAATTAATTAAT 1200
QY 1201 TTTCTAATCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 1260
DB 1201 TTTCTAATCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 1260
QY 1261 GAATGAGAGAAAATTTGTATAACCATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
DB 1261 GAATGAGAGAAAATTTGTATAACCATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
RESULT 48
ADC49869
ID ADC49869 standard; cDNA; 1333 BP.
XX
AC ADC49869;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW chondrocyte cell differentiation; chondrocyte cell proliferation;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX
OS Homo sapiens.
XX
PN US2003088064-A1.
XX
PD 08-MAY-2003.
XX

14-AUG-2002; 2002US-00219075.
 25-JUL-2000; 2000US-0220605P.
 01-JUN-2001; 2001MO-US017800.
 29-JUN-2001; 2001MO-US021066.
 09-APR-2002; 2002US-00119480.
 (GETH) GENENTECH INC.
 Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
 Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;
 P-PSDB; ADC49870.
 WPI; 2003-801154/75.
 New secreted and transmembrane PRO polypeptide useful for preparing a
 medicament for treating a condition that is responsive to the PRO
 polypeptide or anti-PRO antibody, e.g. cancer.
 Claim 2; SEQ ID NO 119; 314pp; English.
 The invention describes an isolated PRO (secreted and transmembrane)
 polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 useful for stimulating the proliferation of or gene expression in
 pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 for stimulating the proliferation or differentiation of chondrocyte
 cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 are useful for stimulating the release of tumour necrosis factor (TNF)-
 alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 PRO347, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 PRO1478, PRO1134, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 PRO1025, PRO1181, PRO1126, PRO1186, PRO1193, PRO1274, PRO1412,
 PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
 PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1760, PRO1567,
 PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3444, PRO4322,
 PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 stimulating the proliferation of normal human dermal fibroblasts cells.
 PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 inhibiting the proliferation of normal human dermal fibroblast cells.
 Polypeptides such as PRO6004, PRO4981, PRO1174, PRO5778, PRO4332, etc.,
 are useful for detecting the presence of tumour in a mammal which
 involves comparing the level of expression of the above PRO polypeptides
 in a test sample of cells taken from the mammal, and a control sample of
 normal cells of the same cell type, where a higher level of expression of
 the PRO polypeptides in the test sample as compared to the control sample
 is indicative of the presence of tumour in the mammal. The tumour is lung
 tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 liver tumour. (i) is useful as molecular weight markers, for tissue
 typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
 useful for chromosome and gene mapping or gene therapy. (ii) is useful
 for generating transgenic animals or knock-out animals which are useful
 screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 sport injuries). This sequence encodes a human secreted and transmembrane
 PRO polypeptide.

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GCCCACGGCTCCGATGGCGTTACGTTTCGGCGCTTCGTGACATGCTGGCGCTGCTGCT 60
 1 GCCCACGGCTCCGATGGCGTTACGTTTCGGCGCTTCGTGACATGCTGGCGCTGCTGCT 60
 61 CACTGCGCGCTGCTGCTTCCTTCGGCATTTGGCATTATAGCATTTGATGAGCTGAGAC 120
 61 CACTGCGCGCTGCTGCTTCCTTCGGCATTTGGCATTATAGCATTTGATGAGCTGAGAC 120
 121 TGATTACAGATCCTATAGACAGGTGTAATACCCCTGATCCCTTGTACTCCACAGTA 180

Db QY 121 TGATTACAGATCCTATAGACAGGTGTAATACCCCTGATCCCTTGTACTCCACAGTA 180
 QY 181 CCTCATCCAGCTTTCTTCTGTGTCTGTCATGTTTCTTTGTGACAGAGTGGCTTACACGGG 240
 Db 181 CCTCATCCAGCTTTCTTCTGTGTCTGTCATGTTTCTTTGTGACAGAGTGGCTTACACGGG 240
 QY 241 TCTCAATATGCCCCCTCTTTGGCATATCATATTTGGAGGTATATGATAGACAGCTGATGAG 300
 Db 241 TCTCAATATGCCCCCTCTTTGGCATATCATATTTGGAGGTATATGATAGACAGCTGATGAG 300
 QY 301 TGGCCCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTTAGCATATTTCTCA 360
 Db 301 TGGCCCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTTAGCATATTTCTCA 360
 QY 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACCTATATAGG 420
 Db 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACCTATATAGG 420
 QY 421 CATGATCTATGTTTGTGGAGCTCTTAGAACAAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 Db 421 CATGATCTATGTTTGTGGAGCTCTTAGAACAAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 Db 481 GCATGCAAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 QY 600 CTGTGGATCTGATCAGTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGATCTGATCAGTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTGTGTGGAAGAGCTTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 Db 601 TTTTCTGTGTGGAAGAGCTTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 720 TACGTATATAATATAATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGACCTTC 720
 Db 661 TACGTATATAATATAATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGACCTTC 720
 QY 780 TTAAGGAACGCAATAAATCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 780
 Db 721 TTAAGGAACGCAATAAATCTGATGATGATGATGATGATGATGATGATGATGATGATG 780
 QY 840 TTAAGGAACGCAATAAATCTGATGATGATGATGATGATGATGATGATGATGATGATG 840
 Db 781 GAAGCTTTTGTATTAGGAACCTTTAGGGCTCATTTTGGTTCATGAAACAGTATCTAA 840
 QY 841 TTAATAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900
 Db 841 TTAATAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900
 QY 960 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATGATGATGATGATGATGATG 960
 Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATGATGATGATGATGATGATG 960
 QY 1020 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATGTCATGAT 1020
 Db 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATGTCATGAT 1020
 QY 1080 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATGCTGAAATTTCTTGAAGCAT 1080
 Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATGCTGAAATTTCTTGAAGCAT 1080
 QY 1140 AGTAAACATGATATAAATAATATATGCTGAAATTTCTTGAAGCATGCAATTTAAAGCTAT 1140
 Db 1081 AGTAAACATGATATAAATAATATATGCTGAAATTTCTTGAAGCATGCAATTTAAAGCTAT 1140
 QY 1200 TTAATATGCTTTTATTTGTAAGCAATTAATCTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
 Db 1141 TTAATATGCTTTTATTTTGAAGCAATTAATCTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
 QY 1260 TTTCAATCTGGTGAAGGATTTCTTAAAGATTTGCGGCTACTACAGATTTTCAAAACT 1260
 Db 1201 TTTCAATCTGGTGAAGGATTTCTTAAAGATTTGCGGCTACTACAGATTTTCAAAACT 1260

QY 1261 GAATGAGAGAAAATTGTATACCATCTCGCTGTTCTTCTTGTAGTGCATACATATAAACTCT 1320
 DB 1261 GAATGAGAGAAAATTGTATACCATCTCGCTGTTCTTCTTGTAGTGCATACATATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333

RESULT 49
 ADC49068
 ID ADC49068 standard; cDNA; 1333 BP.
 AC ADC49068;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.
 XX
 KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulvar; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 KW Homo sapiens.
 XX
 PN US2003088070-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 28-AUG-2002; 2002US-00230260.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR P-PSDB; ADC49069.
 DR
 DR WPI; 2003-801155/75.
 XX
 XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 PS Claim 2; SEQ ID NO 119; 315pp; English.
 XX
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO3441, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,

CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (III) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGGTTTCACTTCGCGCCCTTCTGTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGGGTTTCACTTCGCGCCCTTCTGTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGCTCATCTTTTGGCCATTGGCACAATTATAGCAATTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGCTCATCTTTTGGCCATTGGCACAATTATAGCAATTGATGAGCTGAAGAC 120
 QY 121 TGATTAAGAATCCTATAGACCAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTAAT 180
 DB 121 TGATTAAGAATCCTATAGACCAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTAAT 180
 QY 181 CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGTCAGCAGAGTGGCTTACATGGG 240
 DB 181 CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGTCAGCAGAGTGGCTTACATGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCCATATCATATTTGGAGGTATATGAGTAGACAGTATGATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGCCATATCATATTTGGAGGTATATGAGTAGACAGTATGATGAG 300
 QY 301 TGGCCAGGACTCTATGACCCCTACCAACCAATCAATGATGAGATATTTCTAGCATATTTGTC 360
 DB 301 TGGCCAGGACTCTATGACCCCTACCAACCAATCAATGATGAGATATTTCTAGCATATTTGTC 360
 QY 361 GAAGGAAGGATGGTGCATATTTAGCTTTTATCTTCTAGCATTTTCTTACTATATATGAG 420
 DB 361 GAAGGAAGGATGGTGCATATTTAGCTTTTATCTTCTAGCATTTTCTTACTATATATGAG 420
 QY 421 CATGATCTATGTTTGGTGGAGCTTTAGAACACACACAGAGAATTTGCTCCAGTTAACT 480
 DB 421 CATGATCTATGTTTGGTGGAGCTTTAGAACACACACAGAGAATTTGCTCCAGTTAACT 480
 QY 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
 DB 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTTACCTTTTAAAAAATGACTCTTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTTACCTTTTAAAAAATGACTCTTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTGTTGGAAAGACTCTTTTCAATGTTATGTTATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
 DB 601 TTTTGTGTTGGAAAGACTCTTTTCAATGTTATGTTATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
 QY 661 TAGGTATAATTAATATAAATGATTTACCTCTGGTGTTCACAGGTTTGAACCTTGCACCTTC 720
 DB 661 TAGGTATAATTAATATAAATGATTTACCTCTGGTGTTCACAGGTTTGAACCTTGCACCTTC 720

Db CCTCATCCAGCTTCTCTGTCGTCATGTTCTTTGTGCAGAGTGGCTTACATGGG 240
Qy TCTCAATATGCCCTCTTGGCATATCATATTTGAGGTATATGATGACAGTGTAG 300
Db TCTCAATATGCCCTCTTGGCATATCATATTTGAGGTATATGATGACAGTGTAG 300
Qy TGGCCAGAGTCTATGACCTTACACCATCATGATGATGATATTTCTAGCATATTTGCA 360
Db TGGCCAGAGTCTATGACCTTACACCATCATGATGATGATATTTCTAGCATATTTGCA 360
Qy GAAGAAGATGTTGTCAGATTTTATTTTCTTCTAGCATATTTTCTTCTAGCATATTTG 420
Db GAAGAAGATGTTGTCAGATTTTATTTTCTTCTAGCATATTTTCTTCTAGCATATTTG 420
Qy CATGATCATCTTTTGTGAGCTCTTGAACAAACACACAGAGAAATTTGGTCCAGTTAAGT 480
Db CATGATCATCTTTTGTGAGCTCTTGAACAAACACACAGAGAAATTTGGTCCAGTTAAGT 480
Qy GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCACAGTAGC 540
Db GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCACAGTAGC 540
Qy CTGTGGAATCTGATCAGTACTTTAAATAATGATCCTTATTTTAAATGTTTCCCAT 600
Db CTGTGGAATCTGATCAGTACTTTAAATAATGATCCTTATTTTAAATGTTTCCCAT 600
Qy TTTTGTCTGTGGAAGACTGTTTCAATGTTTATCTACTCAGATTAAGATTTTAAATGTTAT 660
Db TTTTGTCTGTGGAAGACTGTTTCAATGTTTATCTACTCAGATTAAGATTTTAAATGTTAT 660
Qy TACGTATAAATTAATAAATGATTAACCTCTGTGTTGACAGTCTTGAACCTTGCACTTC 720
Db TACGTATAAATTAATAAATGATTAACCTCTGTGTTGACAGTCTTGAACCTTGCACTTC 720
Qy TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATCTGATGCTGCTTGAATGTTG 780
Db TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATCTGATGCTGCTTGAATGTTG 780
Qy GAAGCTTTGTTTATAGGAATCTGTAGGCTCAATTTGGTTTCAATGGAACAGTATCTAA 840
Db GAAGCTTTGTTTATAGGAATCTGTAGGCTCAATTTGGTTTCAATGGAACAGTATCTAA 840
Qy TTATAAATTAAGTCTGATATATCAGTCTGCTGCTGATGAATGAATGATATCTGACTAG 900
Db TTATAAATTAAGTCTGATATATCAGTCTGCTGCTGATGAATGAATGATATCTGACTAG 900
Qy TGGGAATCTCATGGTTTCTCATCTGCTGATGATGATGATGATGATGATGATGATGATGAT 960
Db TGGGAATCTCATGGTTTCTCATCTGCTGATGATGATGATGATGATGATGATGATGATGAT 960
Qy AAAAATAAAGCGGGAATTTTCCCTTCCCTGCTGATGATGATGATGATGATGATGATGAT 1020
Db AAAAATAAAGCGGGAATTTTCCCTTCCCTGCTGATGATGATGATGATGATGATGATGAT 1020
Qy GAGAGATTTCCATATTTTCCATGAGATTAATAATATATATATATATATATATATATATAT 1080
Db GAGAGATTTCCATATTTTCCATGAGATTAATAATATATATATATATATATATATATATAT 1080
Qy AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGATGATGATGATGATGAT 1140
Db AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGATGATGATGATGATGAT 1140
Qy TTAATGTTGTTTATTTGTAAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1200
Db TTAATGTTGTTTATTTGTAAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1200
Qy TTCTAATCTGTTGTTAAGGATTTCTTAAAGATTTTGAAGATTTTGAAGATTTTGAAGAT 1260
Db TTCTAATCTGTTGTTAAGGATTTCTTAAAGATTTTGAAGATTTTGAAGATTTTGAAGAT 1260
Qy GAATGAGAGAAATGTTATTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db GAATGAGAGAAATGTTATTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT

Db 1261 GAATGAGAGAAATGTTATTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 51
ADC47446
ID ADC47446 standard; cDNA; 1333 BP.
XX AC ADC47446;
XX DT 18-DEC-2003 (first entry)
XX DT Novel human secreted and transmembrane protein PRO181 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
XX vulerary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX Homo sapiens.
OS
XX US2003088072-A1.
PN
XX 08-MAY-2003.
PF
XX 29-AUG-2002; 2002US-00232233.
XX
XX 25-JUL-2000; 2000US-0220605P.
PR
XX 01-JUN-2001; 2001WO-US017800.
PR
XX 29-JUN-2001; 2001WO-US021066.
PR
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;
XX WPI; 2003-801157/75.
XX P-PSDB; ADC47447.
XX
XX New PRO polypeptide for use as molecular weight markers for protein
XX electrophoresis purposes and for detecting the presence of tumor in a
XX mammal.
XX
XX Claim 2; Fig 119; 314pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1413, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
XX PRO1897, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO

CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GCCACGGCTCGATGGGCTTCACGCTTCGGGCTTCCTGCTACATGCTGGGCTGCTGCT	60
DB	1	GCCACGGCTCGATGGGCTTCACGCTTCGGGCTTCCTGCTACATGCTGGGCTGCTGCT	60
QY	61	CACCTCCGCGCTCATCTTCCTCCGCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC	120
DB	61	CACCTCCGCGCTCATCTTCCTCCGCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC	120
QY	121	TCATTACAGATCCTATAGACGCTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTAAT	180
DB	121	TCATTACAGATCCTATAGACGCTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTAAT	180
QY	181	CCTCATCCACGCTTCCTTCCTGCTGTCATGTTCTTTGTCGAGCAGAGTGCTTACACTGGG	240
DB	181	CCTCATCCACGCTTCCTTCCTGCTGTCATGTTCTTTGTCGAGCAGAGTGCTTACACTGGG	240
QY	241	TCTCAATATGCTTCCTTCCTGCTGTCATGTTCTTTGTCGAGCAGAGTGCTTACACTGGG	300
DB	241	TCTCAATATGCTTCCTTCCTGCTGTCATGTTCTTTGTCGAGCAGAGTGCTTACACTGGG	300
QY	301	TGGCCGAGGACTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGATGAT	360
DB	301	TGGCCGAGGACTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGATGAT	360
QY	361	GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCAATTTTATCTTCTAGCAATTTT	420
DB	361	GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCAATTTTATCTTCTAGCAATTTT	420
QY	421	CATGATCTATGTTTGGTGAGCTCTTAGAACACACACACACACACACACACACACACACAC	480
DB	421	CATGATCTATGTTTGGTGAGCTCTTAGAACACACACACACACACACACACACACACACAC	480
QY	481	GCATGCAAAAGACCAACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCGAAGTAGC	540
DB	481	GCATGCAAAAGACCAACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCGAAGTAGC	540
QY	541	CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTTTAAATAATGATCTCTTTTAA	600
DB	541	CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTTTAAATAATGATCTCTTTTAA	600
QY	601	TTTTTGTCTGGGAAGACCTGTTTTCATGTTATGTTATCTCAGATAAAGATTTTAAATGGTAT	660
DB	601	TTTTTGTCTGGGAAGACCTGTTTTCATGTTATGTTATGTTATCTCAGATAAAGATTTTAAAT	660
QY	661	TACGTATAAATTAATAAATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT	720
DB	661	TACGTATAAATTAATAAATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT	720
QY	721	TTAAGGAACAGCAATATCTCTGAATGATGATGATGATGATGATGATGATGATGATGATGAT	780
DB	721	TTAAGGAACAGCAATATCTCTGAATGATGATGATGATGATGATGATGATGATGATGATGAT	780

Db	721	TTAAGGAACAGCAATATCTCTGAATGATGATGATGATGATGATGATGATGATGATGATGAT	780
QY	781	GAAGCTTTTGTATATAGGAATCTTGTAGGCTCATTTTGGTTTCAATTTGAAACAGTATCTAA	840
Db	781	GAAGCTTTTGTATATAGGAATCTTGTAGGCTCATTTTGGTTTCAATTTGAAACAGTATCTAA	840
QY	841	TTATAAATTAGCTGTAGATATCAGGTCTCTCTGATGAAGTGAAATGATATATCTGACTAG	900
Db	841	TTATAAATTAGCTGTAGATATCAGGTCTCTCTGATGAAGTGAAATGATATATCTGACTAG	900
QY	901	TGGAAATCTCATGGGTTTCTCATCTGTCATGTCGATGTCGATGTCGATGTCGATGTCGAT	960
Db	901	TGGAAATCTCATGGGTTTCTCATCTGTCATGTCGATGTCGATGTCGATGTCGATGTCGAT	960
QY	961	AAAAATAAAAGCGGAATTTTCCCTTCGCTGGAATATATCCCTGCTATATTTGATGATGAT	1020
Db	961	AAAAATAAAAGCGGAATTTTCCCTTCGCTGGAATATATCCCTGCTATATTTGATGATGAT	1020
QY	1021	GAGAGATTTCCCATATTTTCCCATCAGAGTAATAATAATAATAATAATAATAATAATAATA	1080
Db	1021	GAGAGATTTCCCATATTTTCCCATCAGAGTAATAATAATAATAATAATAATAATAATAATA	1080
QY	1081	AGTAAACATGATATAAAAAATATATGCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTAT	1140
Db	1081	AGTAAACATGATATAAAAAATATATGCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTAT	1140
QY	1141	TTAAATGTTTATTTTATTTGTAAGACATTTACATTTTAAAGAAATGCTTATATGCTTACTG	1200
Db	1141	TTAAATGTTTATTTTATTTGTAAGACATTTACATTTTAAAGAAATGCTTATATGCTTACTG	1200
QY	1201	TTCTAATCTGCTGTTAAAGGTAATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT	1260
Db	1201	TTCTAATCTGCTGTTAAAGGTAATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT	1260
QY	1261	GAATGAGAGAAATTTGTAACCATCTCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	1320
Db	1261	GAATGAGAGAAATTTGTAACCATCTCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	1320
QY	1321	GAAATTAAGACTC 1333	
Db	1321	GAAATTAAGACTC 1333	
RESULT 52			
ADC47191			
ID	ADC47191	standard; cDNA; 1333 BP.	
XX	ADC47191;		
AC	ADC47191;		
XX			
DT	18-DEC-2003	(first entry)	
XX			
DE	Novel human secreted and transmembrane protein PRO181 cDNA.		
XX			
KW	Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;		
KW	vulnary; antiarthritic; pericyte cell proliferation;		
KW	pericyte cell differentiation; chondrocyte cell proliferation;		
KW	chondrocyte cell differentiation; tumour necrosis factor alpha release;		
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;		
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;		
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;		
XX	gene therapy.		
OS	Homo sapiens.		
XX			
PN	US2003105288-A1.		
XX			
PD	05-JUN-2003.		
XX			
PF	13-AUG-2002; 2002US-00219070.		
XX			
PR	25-JUL-2000; 2000US-0220666P.		
PR	01-JUN-2001; 2001WO-US017800.		

PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski RJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 PI WPI; 2003-801246/75.
 DR P-FSDB; ADC47192.
 XX
 XX New isolated nucleic acid encoding a secreted and transmembrane
 PT polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,
 PT as a hybridization probe, and in gene therapy.
 XX
 XX Claim 2; Fig 119; 308pp; English.
 XX
 CC - The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4406,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 SQ
 Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGCGTCCGATGGGTTTCACGTTCCGCGCCCTTCGTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGGGTTTCACGTTCCGCGCCCTTCGTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGTCACTCTTCGCGCATTTGGCACAATTAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGTCACTCTTCGCGCATTTGGCACAATTAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAAGAAATCCTATAGACCACTGTAATACCTGAAATCCCTTGTACTCCACAGATA 180
 DB 121 TGATTACAAGAAATCCTATAGACCACTGTAATACCTGAAATCCCTTGTACTCCACAGATA 180
 QY 181 CCTCATCCACGCTTCTCTCTGTGTCATGTTTCTTTGTGCGACGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCACGCTTCTCTCTGTGTCATGTTTCTTTGTGCGACGAGTGGCTTACACTGGG 240

QY 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 53
 ID ADC78066
 ID ADC78066 standard; cDNA; 1333 BP.
 AC ADC78066;
 XX
 XX 01-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnery; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003096972-A1.
 XX
 PD 22-MAY-2003.
 XX
 XX 29-AUG-2002; 2002US-00232234.
 XX
 PF 01-JUN-2003; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 XX WPI; 2003-765529/72.
 DR P-PSDB; ADC78067.
 XX
 PT Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
 PT molecular weight markers, for treating arthritis and tumor.
 XX
 XX Claim 2; Fig 119; 308pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO382, PRO1160, PRO187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1283, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides

CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e+306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCGTTCACGTTGCGGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
 Db 1 GCCACGCGTCCGATGGCGTTCACGTTGCGGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGCTCATCTTCTTGGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
 Db 61 CACTGCCGCGCTCATCTTCTTGGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAAGAAATCCTATAGACCAGTGAATACCCCTGAATCCCTTGTACTCCACAGATA 180
 Db 121 TGATTACAAGAAATCCTATAGACCAGTGAATACCCCTGAATCCCTTGTACTCCACAGATA 180
 QY 181 CCTCATCCACGCTTCTTCTGTGTCATGTTTCTTGTGACGAGAGTGCTTACACTGGG 240
 Db 181 CCTCATCCACGCTTCTTCTGTGTCATGTTTCTTGTGACGAGAGTGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTGGAGGTATATGAGTACAGCATGATGAG 300
 Db 241 TCTCAATATGCCCTCTTGGCATATCATATTGGAGGTATATGAGTACAGCATGATGAG 300
 QY 301 TGCCCCAGGACTCTATGACCCCTTACAAACCATCATGAATCAGATATTTAGCATATTTGCA 360
 Db 301 TGCCCCAGGACTCTATGACCCCTTACAAACCATCATGAATCAGATATTTAGCATATTTGCA 360
 QY 361 GAGGAAGAGATGCTCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 Db 361 GAGGAAGAGATGCTCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAATTCGTCAGTTAAGT 480
 Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAATTCGTCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATTAAGAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
 Db 481 GCATGCAAAAAGCCACCAATTAAGAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
 QY 541 CTGTGGATCTGATCAGTACTTTTAAAAAAGACCTCCCTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGATCTGATCAGTACTTTTAAAAAAGACCTCCCTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTTGTGGAAGAGCTGTTTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
 Db 601 TTTTCTTGTGGAAGAGCTGTTTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATTAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTTGACATTC 720
 Db 661 TACGTATTAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTTGACATTC 720
 QY 721 TTAAGGAACAGCCATAATCCCTCTGAATGATCAATTAATTAATTAATTAATTAATTAAT 780
 Db 721 TTAAGGAACAGCCATAATCCCTCTGAATGATCAATTAATTAATTAATTAATTAATTAAT 780
 QY 781 GAAGCTTTTGTATTATAGGAAGCTTTGTAGGGCTCAITTTTGGTTCATTGTAACAGATATCTAA 840

Db	781	GAAGCTTTTGTATAGCACTTGTAGGGCTCAATTTGGTTTCATTGAAACAGTACTTAA	840
Qy	841	TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAATGTATATCTGACTAG	900
Db	841	TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAATGTATATCTGACTAG	900
Qy	901	TGGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTTATATATGATACATTAC	960
Db	901	TGGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTTATATATGATACATTAC	960
Qy	961	AAAAATAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGATATATGATCAAT	1020
Db	961	AAAAATAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGATATATGATCAAT	1020
Qy	1021	GAGAGATTTCCTCATATTTCCATCAGAGTAATAATATATCTTGCCTTTAAATCTTAAGCAT	1080
Db	1021	GAGAGATTTCCTCATATTTCCATCAGAGTAATAATATATCTTGCCTTTAAATCTTAAGCAT	1080
Qy	1081	AGTAAACATGATAPAAAAATATATGCTGAATTAATCTGTGAAGATGCAATTAAGCTATT	1140
Db	1081	AGTAAACATGATAPAAAAATATATGCTGAATTAATCTGTGAAGATGCAATTAAGCTATT	1140
Qy	1141	TTAAATGCTTTTATTTTGAAGACATTAATTAAGAAATGCTTTATATATGCTTACTG	1200
Db	1141	TTAAATGCTTTTATTTTGAAGACATTAATTAAGAAATGCTTTATATATGCTTACTG	1200
Qy	1201	TTCTAAATCTGGTGTAAAGGATTTCTTAAAGAAATTTGCAGTACTACAGATTTTCAAACT	1260
Db	1201	TTCTAAATCTGGTGTAAAGGATTTCTTAAAGAAATTTGCAGTACTACAGATTTTCAAACT	1260
Qy	1261	GAATGAGAGAAAATGTATATACCATTCCTGCTGCTTCTTGTAGTGAATACATTAACCTCT	1320
Db	1261	GAATGAGAGAAAATGTATATACCATTCCTGCTGCTTCTTGTAGTGAATACATTAACCTCT	1320
Qy	1321	GAATTAAGACTC 1333	
Db	1321	GAATTAAGACTC 1333	
RESULT 54			
ID	ADD06301	standard; cDNA; 1333 BP.	
XX	AC	ADD06301;	
DT	01-JAN-2004	(first entry)	
DE	Novel human secreted and transmembrane protein PRO181 cDNA.		
KW	human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;		
KW	vulnary; antiarthritic; pericyte cell proliferation;		
KW	pericyte cell differentiation; chondrocyte cell proliferation;		
KW	chondrocyte cell differentiation; tumour necrosis factor alpha release;		
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;		
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;		
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;		
OS	gene therapy.		
XX	Homo sapiens.		
PN	US2003073816-A1.		
XX	17-APR-2003.		
XX	26-AUG-2002; 2002US-00227873.		
XX	01-JUN-2001; 2001WO-US017800.		
PR	29-JUN-2001; 2001WO-US021066.		
PR	09-APR-2002; 2002US-00119480.		
XX	(GETH) GENENTECH INC.		
PA			

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI, P-PSDB; ADD06302.

WPI; 2003-644807/61.

New PRO polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

Claim 2; SEQ ID NO 119; 314pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO214, PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1130, PRO1347, PRO1305, PRO1273, PRO1279, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO329, PRO788, PRO1194, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of expression of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match	100.0%;	Score 1333;	DB 9;	Length 1333;
Best Local Similarity	100.0%;	Pred. No. 9.6e-306;		
Matches 1333;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy	1	GCCACGGCTCCGATGGCGTTTCACTTCGGGCTTCTGCTACATGCTGGCGCTGCTGCT	60
Db	1	GCCACGGCTCCGATGGCGTTTCACTTCGGGCTTCTGCTACATGCTGGCGCTGCTGCT	60
Qy	61	CACTGCGGCTCATCTTCTTCGCCATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC	120
Db	61	CACTGCGGCTCATCTTCTTCGCCATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC	120
Qy	121	TGATTACAGAATCCTATAGACAGTGAATACCTTGATCCCTTGTTACTCCAGAGTA	180
Db	121	TGATTACAGAATCCTATAGACAGTGAATACCTTGATCCCTTGTTACTCCAGAGTA	180
Qy	181	CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGTCAGAGTGGCTTACACTGG	240
Db	181	CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGTCAGAGTGGCTTACACTGG	240
Qy	241	TCTCAATATGCCCTTCTTGGCATATCATATTTGGAGTATATGAGTACAGTATGATGAG	300

Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACACAGTGATGAG 300
Qy 301 TGGCCCGAGGACTTATGACCCCTACCAACCATCATGAATGACAGATATCTAGCATATTTGCA 360
Db 301 TGGCCCGAGGACTTATGACCCCTACCAACCATCATGAATGACAGATATCTAGCATATTTGCA 360
Qy 361 GAAGGAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATATTTTACTACCTATATGG 420
Db 361 GAAGGAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATATTTTACTACCTATATGG 420
Qy 421 CATGATCTATCTTTTGGTGGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATCTTTTGGTGGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTTCCAGCAAGATCCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTTCCAGCAAGATCCTGTCCAGAGTAGC 540
Qy 541 CTGTGGATCTGATCAGTTACTTTAAATAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGATCTGATCAGTTACTTTAAATAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTCTTGTGGAAGACTGTTTTCAATGTATTAATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTTGTGGAAGACTGTTTTCAATGTATTAATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATATATAAATGATTAATCTCTGTTGTTGACAGGTTTGAATTCGACTTC 720
Db 661 TACGTATAAATATATAAATGATTAATCTCTGTTGTTGACAGGTTTGAATTCGACTTC 720
Qy 721 TTAAGGAACACCCATAATCTCTGATGATGATTAATCTGATGATTAATCTGATGATTAATG 780
Db 721 TTAAGGAACACCCATAATCTCTGATGATGATTAATCTGATGATTAATCTGATGATTAATG 780
Qy 781 GAAGCTTTTGTATAGGAATCTGTTAGGCTCAITTTGGTTTCAITTTGTTTCAITTTGTTTCA 840
Db 781 GAAGCTTTTGTATAGGAATCTGTTAGGCTCAITTTGGTTTCAITTTGTTTCAITTTGTTTCA 840
Qy 841 TTATAAATAGCTGTAGATATCAGTGCTTCTGATGAATGAATGAATGAATGAATGAATGAAT 900
Db 841 TTATAAATAGCTGTAGATATCAGTGCTTCTGATGAATGAATGAATGAATGAATGAATGAAT 900
Qy 901 TGGGAACCTTCATGGTTTCTCTCACTGATGATGATTAATGATGATTAATGATGATTAATG 960
Db 901 TGGGAACCTTCATGGTTTCTCTCACTGATGATGATTAATGATGATTAATGATGATTAATG 960
Qy 961 AAAATAAAGCGGGAATTTCCCTTCCTGTAATATATCCCTGTTATATGCAATGAAT 1020
Db 961 AAAATAAAGCGGGAATTTCCCTTCCTGTAATATATCCCTGTTATATGCAATGAAT 1020
Qy 1021 GAGGATTTCCATATTTCCATCAGATTAATAATATATCTGCTTTAATTTCTTAAGCATTA 1080
Db 1021 GAGGATTTCCATATTTCCATCAGATTAATAATATATCTGCTTTAATTTCTTAAGCATTA 1080
Qy 1081 AGTAACATGATATAAATAATATGCTGAATTTGTAAGAAATGCAATTTAAAGCTAAT 1140
Db 1081 AGTAACATGATATAAATAATATGCTGAATTTGTAAGAAATGCAATTTAAAGCTAAT 1140
Qy 1141 TTAAGTGTGTTTTTATTTGTAAGACATTAATTTAAGAAATGTTGTTATTTGCTTACTG 1200
Db 1141 TTAAGTGTGTTTTTATTTGTAAGACATTAATTTAAGAAATGTTGTTATTTGCTTACTG 1200
Qy 1201 TTCTAATCTGGTGGTAAGGATTTCTTAAGAAATTTGAGGATTTGAGGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGGTAAGGATTTCTTAAGAAATTTGAGGATTTGAGGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGATAACCATCTCTCTCTTCTTTAGTGCATATACATAAATACTCT 1320
Db 1261 GAATGAGAGAAATTTGATAACCATCTCTCTCTTCTTTAGTGCATATACATAAATACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 55
ADD10290
ID ADD10290 standard; cDNA; 1333 BP.
XX AC ADD10290;
XX DT 01-JAN-2004 (first entry)
XX DE Human secreted/transmembrane PRO polypeptide cDNA #1.
XX ss: gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
XX OS Homo sapiens.
XX PN US2003105011-A1.
XX PD 05-JUN-2003.
XX PF 16-AUG-2002; 2002US-00223084.
XX PR 15-SEP-2000; 2000US-0232887P.
XX PR 20-JUN-2001; 2001WO-US019692.
XX PR 09-JUL-2001; 2001WO-US021735.
XX PR 20-FEB-2002; 2002US-00081056.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
XX WPI; 2003-810831/76.
XX P-FSDB; ADD10291.
XX New isolated nucleic acid encoding a secreted and transmembrane
polypeptide for treating a cardiovascular, endothelial, or angiogenic
disorder in a mammal, such as cancer or age-related macular degeneration.
XX Claim 2; SEQ ID NO 1; 493pp; English.

XX The invention relates to an isolated nucleic acid encoding a secreted and
transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
by the nucleic acid, or an agonist or antagonist, is used to treat a
cardiovascular, endothelial, or angiogenic disorder in a mammal,
preferably a human. The human may have suffered a myocardial infarction
or has cardiac hypertrophy, trauma, a cancer, or age-related macular
degeneration. The cardiac hypertrophy is characterised by the presence of
an elevated level of PGF-2 alpha. A PRO polypeptide, given in the
specification, or an agonist is used to inhibit or stimulate endothelial
cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
polypeptide, given in the specification, or an agonist is used to
stimulate or inhibit smooth muscle cell growth, or to induce endothelial
cell tube formation. The present sequence represents a cDNA encoding a
PRO polypeptide of the invention.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCACGCGTCCGATGGCGTTTCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTCT 60
Db 1 GCCACGCGTCCGATGGCGTTTCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTCT 60

QY 61 CACTGCGGCTCATCTCTTCCTGCGCATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGGCGCTCATCTCTTCCTGCGCATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGAATTAAGAATCTATATAGACAGTGTAAATACCCCTGAATCCCTTGTAATCCCAAGAGTA 180
DB 121 TGAATTAAGAATCTATATAGACAGTGTAAATACCCCTGAATCCCTTGTAATCCCAAGAGTA 180
QY 181 CTTATATCCACGCTTCTCTCTGCTGATGCTTTCTTTGTGCGAGAGAGTGCTTACACTGGG 240
DB 181 CTTATATCCACGCTTCTCTCTGCTGATGCTTTCTTTGTGCGAGAGAGTGCTTACACTGGG 240
QY 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACACCAAGTATGAG 300
DB 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACACCAAGTATGAG 300
QY 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGAATGAGATATCTAGCATATTTGTCA 360
DB 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGAATGAGATATCTAGCATATTTGTCA 360
QY 361 GAAGGAAGGATGTCGAATAGCTTTTATCTTCTAGCATATTTTATCTATATGG 420
DB 361 GAAGGAAGGATGTCGAATAGCTTTTATCTTCTAGCATATTTTATCTATATGG 420
QY 421 CATGATCTATGTTTGGTGGCTCTTAGACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGGCTCTTAGACACACACAGAGAAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTGTCACAGAGTAGC 540
DB 481 GCATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTGTCACAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTTTAAAGATGATCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTACTTTTAAAGATGATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGGCTTTGGAAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTGGCTTTGGAAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTTAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
DB 661 TACGTTAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCATATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAACAGCATATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTCTTTATAGAACTTTGAGGCTCAATTTTGGTTCATTTGAACAGTATCTAA 840
DB 781 GAAGCTTTTCTTTATAGAACTTTGAGGCTCAATTTTGGTTCATTTGAACAGTATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTCCTCTGATGAAGTGAATATATATCTGACTAG 900
DB 841 TTATAAATAGCTGTAGATATCAGGTCCTCTGATGAAGTGAATATATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCTGATGATGATGATGATGATGATGATGATGATGATGAT 960
DB 901 TGGGAACCTTCATGGGTTTCTCTGATGATGATGATGATGATGATGATGATGATGATGAT 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCTCTGATATATGATCAAT 1020
DB 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCTCTGATATATGATCAAT 1020
QY 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAATATATCTGCTTTAAATCTTAAAGATA 1080
DB 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAATATATCTGCTTTAAATCTTAAAGATA 1080
QY 1081 AGTAAACATGATATAAATAATATCTGCTGATATCTGCTGATGATGATGATGATGATGAT 1140
DB 1081 AGTAAACATGATATAAATAATATCTGCTGATATCTGCTGATGATGATGATGATGATGAT 1140

QY 1141 TTAATGTTGTTTATTTTAAAGACATTAATTAAGAAATTTGTTATTTGCTTACTG 1200
DB 1141 TTAATGTTGTTTATTTTAAAGACATTAATTAAGAAATTTGTTATTTGCTTACTG 1200
QY 1201 TTTAATCTGTTGTTAAAGGTTATTTTAAAGATTTTGCAGGTACTACAGATTTTCAAACT 1260
DB 1201 TTTAATCTGTTGTTAAAGGTTATTTTAAAGATTTTGCAGGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGTTATTAACCATCTGCTGCTTCTTTAGTGCATTAATTAACACTCT 1320
DB 1261 GAATGAGAGAAATTTGTTATTAACCATCTGCTGCTTCTTTAGTGCATTAATTAACACTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
RESULT 56
ADC77820
ID ADC77820 standard; cDNA; 1333 BP.
XX
AC ADC77820;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW Gene therapy.
XX
OS Homo sapiens.
XX
PN US2003088066-A1.
XX
PD 08-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219466.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-657980/62.
DR P-PSDB; ADC77821.
DR
XX
PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful in gene therapy, or for preparing a medicament for treating a
PT condition that is responsive to the PRO polypeptide or anti-PRO antibody,
PT e.g. cancer.
XX
PS Claim 2; Fig 119; 314pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,

CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1379, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO225, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCGATGGCGCTTCACTGTCGGCGCTTCTGCTACATGCTGGCGCGCTGCTGCT 60
Db 1 GCCACGCGTCGATGGCGCTTCACTGTCGGCGCTTCTGCTACATGCTGGCGCGCTGCTGCT 60

QY 61 CACTGCCGCGTCATCTTCTCGCCATTTGGCACATTAAGCATTTGATGAGCTGAGAC 120
Db 61 CACTGCCGCGTCATCTTCTCGCCATTTGGCACATTAAGCATTTGATGAGCTGAGAC 120

QY 121 TGATTACAAAGATCCCTATAGACAGCTGTAATACCCCTGTAATCCCTTGATCCCGAGATA 180
Db 121 TGATTACAAAGATCCCTATAGACAGCTGTAATACCCCTGTAATCCCTTGATCCCGAGATA 180

QY 181 CTTCTACAGCGCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240
Db 181 CTTCTACAGCGCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300

QY 301 TGCCCCAGGACTCTATGACCCCTACAAACCATATGAAATGAGATATTTCTAGCATATTTGTC 360
Db 301 TGCCCCAGGACTCTATGACCCCTACAAACCATATGAAATGAGATATTTCTAGCATATTTGTC 360

QY 361 GAAGGAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTTACTTATG 420
Db 361 GAAGGAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTTACTTATG 420

QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAAATTTGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCACAAATGAGGATTTCTATCCAGCAAGATCTCTGTCGAAGATGAG 540
Db 481 GCATGCAAAAGCCACAAATGAGGATTTCTATCCAGCAAGATCTCTGTCGAAGATGAG 540

QY 541 CTGTGGAATCTGATCAGTACTTAAATAATGATCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTAAATAATGATCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTTGGGAAGAGACTGTTTTTATATGTTTATCTACATGAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTTGGGAAGAGACTGTTTTTATATGTTTATCTACATGAAGATTTTAAATGGTAT 660

QY 661 TACGTATAAAATTAATAATAAAATGATTACCTCTGCTGTTGACAGGTTTGAACCTTC 720
Db 661 TACGTATAAAATTAATAATAAAATGATTACCTCTGCTGTTGACAGGTTTGAACCTTC 720

QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTA 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTA 780

QY 781 GAACCTTTTGTATAGGAACCTTGTAGGCTCAATTTGGTTTCATTTGAAACAGATATCTAA 840
Db 781 GAACCTTTTGTATAGGAACCTTGTAGGCTCAATTTGGTTTCATTTGAAACAGATATCTAA 840

QY 841 TTATAAAATAGCTAGATATCAGGTGCTCTGTAAGAGTGAAGTGAAGTGAAGTGAAGTGA 900
Db 841 TTATAAAATAGCTAGATATCAGGTGCTCTGTAAGAGTGAAGTGAAGTGAAGTGAAGTGA 900

QY 901 TGGGAAATCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTA 960
Db 901 TGGGAAATCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTA 960

QY 961 AAAAATAAAAGCGGGAATTTCCCTTCCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
Db 961 AAAAATAAAAGCGGGAATTTCCCTTCCGCTTGAATATATCCCTGTATATTTGATGAAT 1020

QY 1021 GAGAGATTTCCATATTTTCCATCAGAGTAAATAATATATCTGCTTTAAATTTTAAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTTCCATCAGAGTAAATAATATATCTGCTTTAAATTTTAAAGCATA 1080

QY 1081 AGTAAACATGATATAAAATAATATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
Db 1081 AGTAAACATGATATAAAATAATATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140

QY 1141 TTAATGCTGCTTTTATTTTGAAGCATTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
Db 1141 TTAATGCTGCTTTTATTTTGAAGCATTTATTAAGAAATTTGGTATTTATGCTTACTG 1200

QY 1201 TTTTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGGATTTGAGGATTTGAGGATTTGAGG 1260
Db 1201 TTTTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGGATTTGAGGATTTGAGGATTTGAGG 1260

QY 1261 GAATCAGAGAAAATTTGATTAACCATCTGCTGCTTCTTTAGTGAATTAATTAATTAATTA 1320
Db 1261 GAATCAGAGAAAATTTGATTAACCATCTGCTGCTTCTTTAGTGAATTAATTAATTAATTA 1320

QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 57
ADD11250
ID ADD11250 standard; cdNA; 1333 BP.
XX
AC ADD11250;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane PRO polypeptide cdNA #1.
XX
KW ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
XX
OS Homo sapiens.
XX
PN US2003105013-A1.

XX DT 15-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO181 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic;

XX KW vulnary; antiarthritic; pericyte cell proliferation;

XX KW pericyte cell differentiation; chondrocyte cell proliferation;

XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

XX KW (TNF)-alpha release; dermal fibroblast cell proliferation;

XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;

XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;

XX KW gene therapy.

XX OS Homo sapiens.

XX PN US2003105291-A1.

XX PD 05-JUN-2003.

XX PF 26-AUG-2002; 2002US-00227877.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR WPI; 2003-829361/77.

XX DR P-PSDB; ADD50784.

XX PT New isolated nucleic acid encoding a secreted and transmembrane

XX PT polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,

XX PT as a hybridization probe, and in gene therapy.

XX PS Claim 2; Fig 119; 308pp; English.

XX CC The invention describes an isolated PRO (secreted and transmembrane)

XX CC polypeptide (I). PRO982, PRO1187 or PRO1329 polypeptide are

XX CC useful for stimulating the proliferation of or gene expression in

XX CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful

XX CC for stimulating the proliferation or differentiation of chondrocyte

XX CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide

XX CC are useful for stimulating the release of tumour necrosis factor (TNF)-

XX CC alpha from human blood. PRO982, PRO357, PRO1083, PRO840, PRO1040,

XX CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1071, PRO1411, PRO1309,

XX CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1192, PRO1244, PRO1412,

XX CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1273, PRO1279, PRO1340, PRO1338,

XX CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,

XX CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,

XX CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,

XX CC PRO940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for

XX CC stimulating the proliferation of normal human dermal fibroblasts cells.

XX CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,

XX CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO

XX CC polypeptides such as PRO6004, PRO4981, PRO1174, PRO5778, PRO4332, etc.,

XX CC are useful for detecting the presence of tumour in a mammal which

XX CC involves comparing the level of expression of the above PRO polypeptides

XX CC in a test sample of cells taken from the mammal, and a control sample of

XX CC normal cells of the same cell type, where a higher level of expression of

XX CC the PRO polypeptides in the test sample as compared to the control sample

XX CC is indicative of the presence of tumour in the mammal. The tumour is lung

XX CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or

XX CC liver tumour. (i) is useful as molecular weight markers, for tissue

XX CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is

XX CC useful for chromosome and gene mapping or gene therapy. (ii) is useful

XX CC for generating transgenic animals or knock-out animals which are useful

XX CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide

XX CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,

CC sport injuries). This sequence encodes a human secreted and transmembrane

CC PRO polypeptide.

XX

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306; Indels 0; Gaps 0;

Matches 1333; Conservative 0; Mismatches 0;

QY 1 GCCACGCGTCGGATGGCGCTTACGCTTCGCGCGCTTCTCTACATGCTCGCGCTGCTGCT 60

DB 1 GCCACGCGTCGGATGGCGCTTACGCTTCGCGCGCTTCTCTACATGCTCGCGCTGCTGCT 60

QY 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120

DB 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAAGAATCCCTATAGACCCAGTGAATCCCTGTAATCCCTTGTAATCCCTGTAATCCCTGTA 180

DB 121 TGATTACAAGAATCCCTATAGACCCAGTGAATCCCTGTAATCCCTTGTAATCCCTGTAATCCCTGTA 180

QY 181 CCTCATGCCGCTTCTTCTGTCATGTTTCTTGTGCAGCAGAGTGGCTTACACTGGG 240

DB 181 CCTCATGCCGCTTCTTCTGTCATGTTTCTTGTGCAGCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCCCTTGGCATAATTTGGAGGTATATGAGTACCAAGTATGATGAG 300

DB 241 TCTCAATATGCCCCCTTGGCATAATTTGGAGGTATATGAGTACCAAGTATGATGAG 300

QY 301 TGGCCCCAGGACTCTATGACCCCTACCAACCATCATGAATGAGATATTTAGCATATTTGTCTCA 360

DB 301 TGGCCCCAGGACTCTATGACCCCTACCAACCATCATGAATGAGATATTTAGCATATTTGTCTCA 360

QY 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGAG 420

DB 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGAG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480

DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGAGTAGC 540

DB 481 GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTTATTTTAAAAATGTTTCCACAT 600

DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTTATTTTAAAAATGTTTCCACAT 600

QY 601 TTTTGGCTTCTGGAAGACGCTTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

DB 601 TTTTGGCTTCTGGAAGACGCTTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGTATAAATTAATAAATGATTAATCACTCTGTTGTTGACAGGTTTGAACCTTGCATTC 720

DB 661 TAGTATAAATTAATAAATGATTAATCACTCTGTTGTTGACAGGTTTGAACCTTGCATTC 720

QY 721 TTAAGGAACAGCATAATCTCTGATGATTAATTAATTTACTGACTGCTCTAGTACATTC 780

DB 721 TTAAGGAACAGCATAATCTCTGATGATTAATTAATTTACTGACTGCTCTAGTACATTC 780

QY 781 GAAGCTTTTGTATTATAGGAATCTTGTAGGCTCATTTTGGTTCATTGAAACAGTATCTAA 840

DB 781 GAAGCTTTTGTATTATAGGAATCTTGTAGGCTCATTTTGGTTCATTGAAACAGTATCTAA 840

QY 841 TTATAAATPAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900

DB 841 TTATAAATPAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900

QY 901 TGGGAACCTTCATGGGTTTCTTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960

DB 901 TGGGAACCTTCATGGGTTTCTTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960


```
Db 421 CATGATCATGTTTGGTGAGCTCTTAGACACACACAGAGAATGGTCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTTGTGAAAAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGTTAT 660
Db 601 TTTTCTGTTGTGAAAAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGTTAT 660
QY 661 TACGATATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGATATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
Db 721 TTAAGGAACAGCCATAATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCAATTTTGGTTTCAATTTGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCAATTTTGGTTTCAATTTGAAACAGATATCTAA 840
QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAG 900
Db 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAG 900
QY 901 TGGGAAACCTTCATGCTGTTTCCCTCATCTGTCATGTCATGATTAATTAATTAATTAATTAAT 960
Db 901 TGGGAAACCTTCATGCTGTTTCCCTCATCTGTCATGTCATGATTAATTAATTAATTAATTAAT 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATATTTSCATGAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATATTTSCATGAAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATATATCTGTTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATATATCTGTTTAAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATTTGTAAGAAATGCAATTTAAAGTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATTTGTAAGAAATGCAATTTAAAGTATT 1140
QY 1141 TTAATGCTGTTTTTATTTGTAAGACATTAATTTAAGAAATTTGGTTTATTTATGCTTACTG 1200
Db 1141 TTAATGCTGTTTTTATTTGTAAGACATTAATTTAAGAAATTTGGTTTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTCTATAACCATCTGCTGTTTCTTTAGTGCAATATAAATAAATCTCT 1320
Db 1261 GAATGAGAGAAATTTCTATAACCATCTGCTGTTTCTTTAGTGCAATATAAATAAATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
```

RESULT 60

ADD37043

ID ADD37043 standard; cDNA; 1333 BP.

XX AC

XX ADD37043;

XX DT 15-JAN-2004 (first entry)

XX DE Human secreted/transmembrane PRO polypeptide cDNA #1.

```
XX ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
XX Homo sapiens.
XX US2003105012-A1.
XX 05-JUN-2003.
XX 16-AUG-2002; 2002US-00223088.
XX 15-SEP-2000; 2000US-0232887P.
XX 20-JUN-2001; 2001WO-US019692.
XX 09-JUL-2001; 2001WO-US021735.
XX 20-FEB-2002; 2002US-00081056.
XX (GETH ) GENENTECH INC.
XX Baker KP, Ferrara N, Gerber H, Gerecht H, Goddard A,
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
XX WPI; 2003-829354/77.
XX P-PSDB; ADD37044.
XX New isolated nucleic acids encoding a secreted and transmembrane
PT polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT disorder in a mammal, such as cancer or age-related macular degeneration.
XX Claim 2; SEQ ID NO 1; 492pp; English.
XX The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGP-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.
XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACCGGTCGATGGGCTTCACTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCT 60
Db 1 GCCACCGGTCGATGGGCTTCACTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCT 60
QY 61 CACTGCCGCTCATCTTCTTCCCATTTGGCCATTATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCTCATCTTCTTCCCATTTGGCCATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACACAGTAAATACCTGATCCCTTGTACTCCCAAGATA 180
Db 121 TGATTACAAGAAATCCTATAGACACAGTAAATACCTGATCCCTTGTACTCCCAAGATA 180
QY 181 CCTCATCAACGCTTCTTCTGTCATGTTCTTTGTGTCAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCAACGCTTCTTCTGTCATGTTCTTTGTGTCAGAGTGGCTTACACTGGG 240
```

Db 181 CCTCATCCACGCTTCTCTGTCATGTTCTTTGTGACAGAGTGGCTTACACTGGG 240
Qy 241 TCTCAATATGCCCCCTCTTGGGATATCATATTTGGAGGTATATGATGATAGACAGTGATGAG 300
Db 241 TCTCAATATGCCCCCTCTTGGGATATCATATTTGGAGGTATATGATGATAGACAGTGATGAG 300
Qy 301 TGGCCCCAGGACTCTATGAGCCCTACAAACATCATCAATGTCAGATATTTCTAGCATATTTCTCA 360
Db 301 TGGCCCCAGGACTCTATGAGCCCTACAAACATCAATGTCAGATATTTCTAGCATATTTCTCA 360
Qy 361 GAAGAGAGGTGTCGCAAAATAGCTTTTATTCCTTAGCAATTTTCTTACTACCTATATGG 420
Db 361 GAAGAGAGGTGTCGCAAAATAGCTTTTATTCCTTAGCAATTTTCTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTTTGGTAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTTTGGTAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTTCCACAT 600
Qy 601 TTTTGTCTTGGAAAGACTGTTTTTCAATGTTTATCTACTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTTGGAAAGACTGTTTTTCAATGTTTATCTACTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATATAATATAAATAAATGATTAACCTCTGCTGTTGACAGGTTTGAACCTGCACCTC 720
Db 661 TACGTATATAATATAAATAAATGATTAACCTCTGCTGTTGACAGGTTTGAACCTGCACCTC 720
Qy 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATCTGACTGTCTCTAGTACATTTG 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATCTGACTGTCTCTAGTACATTTG 780
Qy 781 GAAGCTTTTGTATAGAACTTTGAGGCTCATTTTGGTTTCAATGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGAACTTTGAGGCTCATTTTGGTTTCAATGAAACAGATATCTAA 840
Qy 841 TTATAAATAGCTCTAGATATCAGTGCTTCTGATGAAGTCAAAATGATATATCTGACTAG 900
Db 841 TTATAAATAGCTCTAGATATCAGTGCTTCTGATGAAGTCAAAATGATATATCTGACTAG 900
Qy 901 TGGGAACTTCATGGGTTTCCATCTGTCATGTCGATGATTAATATATGATATGATATAC 960
Db 901 TGGGAACTTCATGGGTTTCCATCTGTCATGTCGATGATTAATATATGATATGATATAC 960
Qy 961 AAAAATAAAGCGGGAATTTCCCTTGGCTTGAATATATCCCTGTATATGTCATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTCCCTTGGCTTGAATATATCCCTGTATATGTCATGAAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATCTGCTTAAATCTTAAAGATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATCTGCTTAAATCTTAAAGATA 1080
Qy 1081 AGTAAACATGATATAAATAATATGCTGAATATCTGTGAAGATGATATTAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATATCTGTGAAGATGATATTAAGCTATT 1140
Qy 1141 TTAATGTTTTTATTTTGAAGACATTTTACATTTTGAAGATTTGGTATTTATGCTTACTG 1200
Db 1141 TTAATGTTTTTATTTTGAAGACATTTTACATTTTGAAGATTTGGTATTTATGCTTACTG 1200
Qy 1201 TTCTAATCTGCTGTAAGGATTTCTTAAAGATTTGAGGTAATCTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGATTTCTTAAAGATTTGAGGTAATCTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAAATGATATAACCATCTGCTGCTTTTGTGCAATACATAAACTCT 1320
Db 1261 GAATGAGAGAAAATGATATAACCATCTGCTGCTTTTGTGCAATACATAAACTCT 1320

Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 61

ADD50510
ID ADD50510 standard; cDNA; 1333 BP.

XX ADD50510;

XX AC AC

XX DT 15-JAN-2004 (first entry)

XX Human PRO polynucleotide #60.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX OS

XX US2003096971-A1.

XX PN

XX 22-MAY-2003.

XX 29-AUG-2002; 2002US-00232229.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;

XX Grimaldi JC, Garney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-765528/72.

XX P-PSDB; ADD50511.

XX Novel isolated PRO polypeptide useful for tissue typing, as molecular

XX weight markers in protein electrophoresis, for treating arthritis, tumor.

XX Claim 2; Fig 119; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a PRO
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGCTCCGATGGCGCTTCACGTTCCGCGCTTCTCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGCTCCGATGGCGCTTCACGTTCCGCGCTTCTCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCCGCGCTCATCTTCTTGCCCATTTGGCACATATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTGCCCATTTGGCACATATAGCAATTTGATGAGCTGAAGAC 120

QY 121 TGAATACAGAACTCTATAGACAGAGTGAATACCCCTGAATCCCTTGTAATCCAGAGTA 180
DB 121 TGAATACAGAACTCTATAGACAGAGTGAATACCCCTGAATCCCTTGTAATCCAGAGTA 180

QY 181 CTTCAATCAAGCTTTCTTCTGCTGCTATGTTCTTTGTCAGAGAGTGGCTTACACTGG 240
DB 181 CTTCAATCAAGCTTTCTTCTGCTGCTATGTTCTTTGTCAGAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300

QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGATGAGTATCTAGCATATTTGTCA 360
DB 301 TGGCCAGGACTCTATGACCCCTACACCATCATGATGAGTATCTAGCATATTTGTCA 360

QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACCTATATGG 420
DB 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACCTATATGG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACAACAGAGAATTTGTCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACAACAGAGAATTTGTCAGTTAAGT 480

QY 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTGTCCTCAAGAGTAGC 540
DB 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTGTCCTCAAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTTACTTTAAATAAAGTCTCTTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTTACTTTAAATAAAGTCTCTTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGCTTGTGGAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGCTTGTGGAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGCTATAAATTAATATAAATGATTAACCTCTGCTGTTGACAGGTTTGAACCTTGCACTTC 720
DB 661 TAGCTATAAATTAATATAAATGATTAACCTCTGCTGTTGACAGGTTTGAACCTTGCACTTC 720

QY 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATGACGTCTGCTAGTACATGG 780
DB 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATGACGTCTGCTAGTACATGG 780

QY 781 GAAGCTTTTGTATAGGAATTTGAGGCTCATTTTGGTTTCTCATTTGAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAATTTGAGGCTCATTTTGGTTTCTCATTTGAACAGTATCTAA 840

QY 841 TTATAAATTAAGCTGTAGATATCAGGTTCTCTGATGAAGTGAATAATCTGACTAG 900
DB 841 TTATAAATTAAGCTGTAGATATCAGGTTCTCTGATGAAGTGAATAATCTGACTAG 900

QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCAGATGATTAATATGATGATCAATTC 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCAGATGATTAATATGATGATCAATTC 960

QY 961 AAAAATAAAGCGGAAATTTTCCCTCGCTTGAATATATCCCTGTATATTCATGAT 1020
DB 961 AAAAATAAAGCGGAAATTTTCCCTCGCTTGAATATATTCCTGTATATTCATGAT 1020

RESULT 62

ADD50264

ID ADD50264 standard; cDNA; 1333 BP.

XX AC ADD50264;

XX XX AC

DT 15-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #60.

XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX OS Homo sapiens.

XX XX US2003096970-A1.

XX XX 22-MAY-2003.

XX XX 29-AUG-2002; 2002US-00232227.

XX XX 26-JUL-2000; 2000US-0220893P.

XX XX 01-JUN-2001; 2001WO-US017800.

XX XX 29-JUN-2001; 2001WO-US021066.

XX XX 09-APR-2002; 2002US-00119480.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX XX WPI; 2003-765527/72.

XX XX P-PSDB; ADD50265.

XX PT Novel isolated PRO polypeptides useful as molecular weight markers in
protein electrophoresis, and useful for tissue typing, for treating
arthritis, tumor.

XX XX Claim 2; Fig 119; 308pp; English.

XX CC The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioeffectors. They are particularly useful for
XX CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour).

CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
 CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, for stimulating the proliferation or differentiation of
 CC chondrocyte cells, for stimulating the proliferation of or gene
 CC expression in pericyte cells or for stimulating the proliferation of
 CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
 CC technology, in generating transgenic animals or knock-out animals which
 CC may be used in the development and screening of therapeutically useful
 CC reagents, in gene therapy, in chromosome identification, as chromosome
 CC markers and in generating probes. The PRO polypeptides, or anti-PRO
 CC antibodies, are useful for preparing a medicament for treating a
 CC condition which is responsive to the PRO polypeptides or anti-PRO
 CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
 CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
 CC differentiation of chondrocytes. The PRO polypeptides are useful as
 CC molecular markers for protein electrophoresis, and in tissue typing. This
 CC sequence represents a human PRO polynucleotide of the invention.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCGTTACGCTTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGGCGTTACGCTTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGCTCATCTTCTTCGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGCTCATCTTCTTCGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCTTATAGACCACTGTAATACCTGTAATCCCTTGCTACCCAGATA 180
 DB 121 TGATTACAGAAATCTTATAGACCACTGTAATACCTGTAATCCCTTGCTACCCAGATA 180
 QY 181 CCTCATCCACGCTTCTTCTGCTGTCATCTTCTTGTGTCAGACAGAGTGGCTTACACTGG 240
 DB 181 CCTCATCCACGCTTCTTCTGCTGTCATCTTCTTGTGTCAGAGTGGCTTACACTGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTATGAG 300
 QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAAATCAGATATTTAGCATATTTGCA 360
 DB 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAAATCAGATATTTAGCATATTTGCA 360
 QY 361 GAAGGAAGATGGTGCATATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 DB 361 GAAGGAAGATGGTGCATATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACAACACACAGAAAGATTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACAACACACAGAAAGATTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAGCCACCAAAAGAGGATTTCTATCCACAGATCCCTGTCAGAGTAGC 540
 DB 481 GCATGCAAAAGCCACCAAAAGAGGATTTCTATCCACAGATCCCTGTCAGAGTAGC 540
 QY 541 CTGTGGAACTCATGATCAGTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAACTCATGATCAGTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGGCTTGGGAAGACTGTTTTCATATGTTTATCTACAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTGGCTTGGGAAGACTGTTTTCATATGTTTATCTACAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATATAAATGATTACTCTGGTGTGACAGGTTTGAACTTGCACCTC 720
 DB 661 TACGTATAAATTAATATAAATGATTACTCTGGTGTGACAGGTTTGAACTTGCACCTC 720

QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCATTAATTAATCTGACTGCTCTAGTACATTG 780
 DB 721 TTAAGGAACAGCCATAATCTCTGAATGATGCATTAATTAATCTGACTGCTCTAGTACATTG 780
 QY 781 GAAGCTTTTGTATAGGAACCTTCTAGGGCTCATTTTGGTTTCAATTTGAAACAGATATCTAA 840
 DB 781 GAAGCTTTTGTATAGGAACCTTCTAGGGCTCATTTTGGTTTCAATTTGAAACAGATATCTAA 840
 QY 841 TTATAAATTAGCTCTAGATATCAGTGCTTCTGAATGAAGTGAAGTGTATATCTGACTAG 900
 DB 841 TTATAAATTAGCTCTAGATATCAGTGCTTCTGAATGAAGTGAAGTGTATATCTGACTAG 900
 QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
 DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
 QY 961 AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
 DB 961 AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTTCTTAAATCTTAAAGCTATT 1140
 DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTTCTTAAATCTTAAAGCTATT 1140
 QY 1081 AGTAAACATGATATAAATAATATATCTGCTGCTTGAATATATCCCTGTATATTTGATGAAT 1140
 DB 1081 AGTAAACATGATATAAATAATATATCTGCTGCTTGAATATATCCCTGTATATTTGATGAAT 1140
 QY 1141 TTAATGCTTTTATTTTGAAGCAATTAATTAAGAAATTTGTTTATTAATGCTTACTG 1200
 DB 1141 TTAATGCTTTTATTTTGAAGCAATTAATTAAGAAATTTGTTTATTAATGCTTACTG 1200
 QY 1201 TTCTAATCTGGTGTAAAGGTAATTTCTTAAGAAATTTGAGGTAATTTCAAGATTTTCAAAACT 1260
 DB 1201 TTCTAATCTGGTGTAAAGGTAATTTCTTAAGAAATTTGAGGTAATTTCAAGATTTTCAAAACT 1260
 QY 1261 GAATGAGAGAAATTTGATATACCATCTGCTGCTTCTTGTAGTGAATATACATTAATCTCT 1320
 DB 1261 GAATGAGAGAAATTTGATATACCATCTGCTGCTTCTTGTAGTGAATATACATTAATCTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333
 XX ADD51275 standard; cDNA; 1333 BP.
 AC ADD51275;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.
 KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003105289-A1.
 XX
 XX 05-JUN-2003.
 PD
 XX 13-AUG-2002; 2002US-00219472.

XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-829359/77.
 DR P-PSDB; ADD51276.
 DR
 XX New isolated nucleic acids and their encoded secreted and transmembrane
 PT polypeptides (PRO), useful e.g. for stimulating cell proliferation or
 PT differentiation and for diagnosis of cancer.
 XX
 PS Claim 2; Fig 119; 308pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO329, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO321, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO247, PRO337, PRO526, PRO1126, PRO1186, PRO1071, PRO1411, PRO1309,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1244, PRO1274, PRO1412,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1338,
 CC PRO1286, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGCGTCCGATGCGGTTACGTTGCGGGCTTCGTACATGTCGGCGTGTGCT 60
 DB 1 GCCACGCGTCCGATGCGGTTACGTTGCGGGCTTCGTACATGTCGGCGTGTGCT 60
 QY 61 CACTGCCGCGCTCATCTTCTTCGCAATTTGGCAATATATGCAATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGCTCATCTTCTTCGCAATTTGGCAATATATGCAATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAUCCCTATAGACCAAGTGTATACCTGAATCCCTTGTACTCCAGAGTA 180
 DB 121 TGATTACAGAAUCCCTATAGACCAAGTGTATACCTGAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCACGCTTCTCTCTCTGTCATGTTTCTTTGTGTCAGCAGAGTGCTTACACTGGG 240
 DB 181 CCTCATCCACGCTTCTCTCTCTGTCATGTTTCTTTGTGTCAGCAGAGTGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGGTGATGAG 300
 DB 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGGTGATGAG 300
 QY 301 TGGCCCGAGGACTATAGACCCCTAACCATCATGAATGTCAGATATTTAGCATATTTGTCA 360
 DB 301 TGGCCCGAGGACTATAGACCCCTAACCATCATGAATGTCAGATATTTAGCATATTTGTCA 360
 QY 361 GAGGAGGAGTGTGCAAAATAGCTTTTATCTCTAGCAATTTTCTTACTACCTATATG 420
 DB 361 GAGGAGGAGTGTGCAAAATAGCTTTTATCTCTAGCAATTTTCTTACTACCTATATG 420
 QY 421 CATGATCATCTTTTGTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCATCTTTTGTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 QY 481 GCATCAAAAAAGCCACCAAAATGAGGGATTTCTATCCAGCAAGATCCTCTCCAGAGTAGC 540
 DB 481 GCATCAAAAAAGCCACCAAAATGAGGGATTTCTATCCAGCAAGATCCTCTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTTCTTTAAAAAATGACTCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTTCTTTAAAAAATGACTCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTTGTGGAAGAGCTGTTTTCATATGTTTATACTCAGATAAGATTTTAAATGGTAT 660
 DB 601 TTTTCTTGTGGAAGAGCTGTTTTCATATGTTTATACTCAGATAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATATAAATGATTAAGTCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
 DB 661 TACGTATAAATTAATATAAATGATTAAGTCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
 QY 721 TTAAGCAACAGCATAAATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATG 780
 DB 721 TTAAGCAACAGCATAAATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATG 780
 QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTGGTTCATTTGAAACAGTATCTAA 840
 DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTGGTTCATTTGAAACAGTATCTAA 840
 QY 841 TTATAAATTAGCTGATAGATACAGGCTCTCTGATGAGTGAATGATATATCTGACTAG 900
 DB 841 TTATAAATTAGCTGATAGATACAGGCTCTCTGATGAGTGAATGATATATCTGACTAG 900
 QY 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGATGATATATATGATGATACATTTAC 960
 DB 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGATGATATATATGATGATACATTTAC 960
 QY 961 AAAATAAAGGGGAAATTTCCCTCGCTTGAATATATATCCCTGATATATGTCATGAAT 1020
 DB 961 AAAATAAAGGGGAAATTTCCCTCGCTTGAATATATATCCCTGATATATGTCATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATACTTCTGCTTTAAATCTTTAAGCATA 1080
 DB 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATACTTCTGCTTTAAATCTTTAAGCATA 1080
 QY 1081 AGTAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGAAATGCAATTTAAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGAAATGCAATTTAAAGCTATT 1140
 QY 1141 TTAATATGTTTATTTTGTAGACATTTACTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
 DB 1141 TTAATATGTTTATTTTGTAGACATTTACTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
 QY 1201 TTCTAATCTGGTGAAGGATTTCTTTAAGAAATTTTCAGTACTACAGATTTTCAAAACT 1260
 DB 1201 TTCTAATCTGGTGAAGGATTTCTTTAAGAAATTTTCAGTACTACAGATTTTCAAAACT 1260
 QY 1261 GAATGAGAGAAATTTGATAAACCCTGCTGTTCTTTAGTGAATAACAATAAAACTCT 1320


```
12-APR-1999; 99US-00284291.
21-APR-1999; 99US-0130232P.
26-APR-1999; 99US-0131022P.
28-APR-1999; 99US-0131445P.
14-MAY-1999; 99US-00311832.
14-MAY-1999; 99US-0134287P.
14-MAY-1999; 99WO-US010733.
02-JUN-1999; 99WO-US012252.
16-JUN-1999; 99US-0139557P.
23-JUN-1999; 99US-0141037P.
07-JUL-1999; 99US-0142680P.
26-JUL-1999; 99US-0145698P.
28-JUL-1999; 99US-0146222P.
25-AUG-1999; 99US-00380137.
25-AUG-1999; 99US-00380138.
26-AUG-1999; 99US-00380142.
29-OCT-1999; 99US-0162506P.
30-NOV-1999; 99WO-US028313.
02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US0000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US0003565.
18-FEB-2000; 2000WO-US0004341.
24-FEB-2000; 2000WO-US0005004.
02-MAR-2000; 2000WO-US0005841.
10-MAR-2000; 2000WO-US0006319.
21-MAR-2000; 2000WO-US0007532.
30-MAR-2000; 2000WO-US0008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000US-00709238.
27-NOV-2000; 2000US-00723749.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001WO-US0006520.
22-MAR-2001; 2001US-00816744.
22-MAR-2001; 2001US-00816920.
22-MAR-2001; 2001WO-US009552.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00886342.
19-JUN-2001; 2001US-00886346.
20-JUN-2001; 2001WO-US019692.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
30-JUL-2001; 2001US-00918585.
XX (GETH ) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCTCCGATGGCGCTTACGTTTCGGGCTTCTGCTACATGCTGCGCGCTGCTGCT 60
Db 1 GCCACGCTCCGATGGCGCTTACGTTTCGGGCTTCTGCTACATGCTGCGCGCTGCTGCT 60
61 CACTGCGGCGCTCATCTTCTTCCCATTTTGGGCACTATATAGCATTTGATGAGCTGAAGAC 120
61 CACTGCGGCGCTCATCTTCTTCCCATTTTGGGCACTATATAGCATTTGATGAGCTGAAGAC 120
121 TGATTACAAGAACTCTATAGACCAAGTGTAAATCCCTGAAATCCCTCTTGTACTCCAGTA 180
121 TGATTACAAGAACTCTATAGACCAAGTGTAAATCCCTGAAATCCCTCTTGTACTCCAGTA 180
181 CCTCATCCAGCGCTTCTTCTGTCATGTTCTTTTGTGAGGAGTGTGAGTGTGAGTGTGAG 240
181 CCTCATCCAGCGCTTCTTCTGTCATGTTCTTTTGTGAGGAGTGTGAGTGTGAGTGTGAG 240
241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGTGAG 300
241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGTGAG 300
301 TGGCCCGAGGACTCTATGACCCCTACAAACCATCATGAATGAGATATTTCTAGCATATTTG 360
301 TGGCCCGAGGACTCTATGACCCCTACAAACCATCATGAATGAGATATTTCTAGCATATTTG 360
361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTAGCATATTTG 420
361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTAGCATATTTG 420
421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACACAGAGAAATTTGCTCAAGT 480
421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACACAGAGAAATTTGCTCAAGT 480
481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCGAAGAGTAGC 540
481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCGAAGAGTAGC 540
541 CTGTGGAACTCATGATGAGTCTTAAATAATGACCTCTTATTTTAAATGTTTCAAT 600
541 CTGTGGAACTCATGATGAGTCTTAAATAATGACCTCTTATTTTAAATGTTTCAAT 600
601 TTTTGGCTGTGGAAGACGCTTTTCATATGTTTATCTAGTAAGATTTTAAATGTTT 660
601 TTTTGGCTGTGGAAGACGCTTTTCATATGTTTATCTAGTAAGATTTTAAATGTTT 660
661 TAGCTATAAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAACCTTGC 720
661 TAGCTATAAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAACCTTGC 720
721 TTAAGGAACAGGACATAAATCTCTGAATGATGATTAATTTACTGACTGTCTAGT 780
721 TTAAGGAACAGGACATAAATCTCTGAATGATGATTAATTTACTGACTGTCTAGT 780
781 GAAGCTTTTGTATTAGGAACTTTGAGGCTCATTTTGGTTTCAATTTGAACAGTATCT 840
781 GAAGCTTTTGTATTAGGAACTTTGAGGCTCATTTTGGTTTCAATTTGAACAGTATCT 840
841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGT 900
841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGT 900
901 TGGGAACTTCAATGGGTTTCCCTCATCTGTCATGTCATGTCATGTCATGTCATGTC 960
901 TGGGAACTTCAATGGGTTTCCCTCATCTGTCATGTCATGTCATGTCATGTCATGTC 960
961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGATATTTGCA 1020
961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGATATTTGCA 1020
1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTTCTGTTAAATTTCTTA 1080
1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTTCTGTTAAATTTCTTA 1080
1081 AGTAAACATGATATAAATAATACTGTCATGTCATGTCATGTCATGTCATGTCATG 1140
1081 AGTAAACATGATATAAATAATACTGTCATGTCATGTCATGTCATGTCATGTCATG 1140
1141 TTAATATGTTTATTTTGAAGACATTTACTTATTAAGAAATTTGTTATTTGCTT 1200
```

Db 1141 TTAATATCTGTTTATTTATTTGTAAGACATTAATTAAGAAATCGTTATATGCTTACTG 1200
 QY 1201 TTCTAATCTGCTGTAAGATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAAC 1260
 Db 1201 TTCTAATCTGCTGTAAGATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAAC 1260
 QY 1261 GAATGAGAGAAAATTTGTAACCATCTGCTGTTCTTTAGTGCATACAAATAAACTCT 1320
 Db 1261 GAATGAGAGAAAATTTGTAACCATCTGCTGTTCTTTAGTGCATACAAATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 65

ADE35409

ID ADE35409 standard; cDNA; 1333 BP.

XX AC ADE35409;

XX DT 29-JAN-2004 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein, PRO181.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
 KW cytotatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
 KW vulnary; auditory; tumour growth; retinal disorder;
 KW sports-related joint problem; articular cartilage defects;
 KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX OS Homo sapiens.

XX PN US2003203434-A1.

XX PD 30-OCT-2003.

XX PF 18-OCT-2001; 2001US-00145088.

XX PR 15-MAY-1998; 98US-0085689P.

XX PR 08-MAR-1999; 99NO-US005028.

XX PR 28-APR-1999; 99US-0131445P.

XX PR 25-AUG-1999; 99US-00380138.

XX PR 18-FEB-2000; 2000WO-US004341.

XX PR 30-JUL-2001; 2001US-00918585.

XX PA (GETH) GENENTECH INC.

XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;

XX PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

XX PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;

XX PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;

XX PI Stewart TA, Tumas D, Williams PM, Wood WI;

XX DR WPI: 2003-875641/81.

XX DR P-PSDB; ADE35410.

XX XX

XX PT New genes, and its encoded secreted and transmembrane polypeptides,

XX PT useful for treating e.g. lung or breast tumors, osteoarthritis,

XX PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,

XX PT hypoinsulinemia or wounds.

XX XX

XX PS Claim 2; SEQ ID NO 321; 462pp; English.

XX XX

XX CC The invention relates to an isolated PRO polypeptide (secreted or

XX CC transmembrane protein) having at least 80% amino acid sequence identity

XX CC to an amino acid sequence chosen from 94 fully defined sequences as given

XX CC in the specification (including PRO lacking its associated signal

XX CC peptide, a PRO extracellular domain with or without its associated signal

XX CC peptide). Also included are nucleic acids encoding the PRO proteins

XX CC mentioned above, a vector comprising a PRO nucleic acid, a host cell

XX CC comprising the vector and producing PRO, a chimaeric molecule comprising

XX CC

CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
 CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
 CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
 CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
 CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
 CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
 CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
 CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
 CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
 CC causes death of the cell. PRO337 polypeptide is useful for linking a
 CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
 CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
 CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
 CC useful for linking a bioactive molecule to a cell expressing PRO725,
 CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
 CC polypeptide is useful for modulating at least one biological activity of
 CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
 CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
 CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
 CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
 CC modulating the biological activity of the cell expressing PRO1559
 CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
 CC PRO739 polypeptide is useful for modulating the biological activity of
 CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
 CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
 CC sports-related joint problems, articular cartilage defects,
 CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
 CC mammals. The present sequence encodes a PRO protein.

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306; Indels 0; Gaps 0;

Matches 1333; Conservative C; Mismatches 0;

QY 1 GCCACGCGTCCGATGGCGTTTCACGTTCCGCGGCTTCTCTACATGCTGGCGTCTGCT 60
 Db 1 GCCACGCGTCCGATGGCGTTTCACGTTCCGCGGCTTCTCTACATGCTGGCGTCTGCT 60
 QY 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120
 Db 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTAACAAGAAATCTATAGACCAAGTAAATACCTGATCCCTGATCCCTGATCCCAAGATA 180
 Db 121 TGATTAACAAGAAATCTATAGACCAAGTAAATACCTGATCCCTGATCCCTGATCCCAAGATA 180
 QY 181 CCTCATCCAGCTTCTTCTTCTGTGTCAATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
 Db 181 CCTCATCCAGCTTCTTCTTCTGTGTCAATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
 QY 241 TCTGATATGCCCCCTTGGCATATCATATTTGGAGGTATATGAGTAGCAGCAGTAGAG 300
 Db 241 TCTGATATGCCCCCTTGGCATATCATATTTGGAGGTATATGAGTAGCAGCAGTAGAG 300
 QY 301 TGGCCGAGGACTCTATGACCCCTACAACTCATGAATCAGATATTTCTAGCATATTGTCA 360
 Db 301 TGGCCGAGGACTCTATGACCCCTACAACTCATGAATCAGATATTTCTAGCATATTGTCA 360
 QY 361 GAAGGAAGAGTGGTGCATAATTTAGCTTTTATCTTCTAGCAATTTTACTACCTATATGG 420
 Db 361 GAAGGAAGAGTGGTGCATAATTTAGCTTTTATCTTCTAGCAATTTTACTACCTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGACAACAACACAGAGAATTTGGTCCAGTTAAGT 480
 Db 421 CATGATCTATGTTTGGTGAGCTCTTAGACAACAACACAGAGAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAAAAGAGGGATTTCTATCCAGCAAGATCCTCTCCAGAGTAGC 540
 Db 481 GCATGCAAAAAGCCACCAAAAGAGGGATTTCTATCCAGCAAGATCCTCTCCAGAGTAGC 540
 QY 541 CTGTGGAACTGATCAGTACTTTTAAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600

Db 541 CTGTGGAATCTGATCAGTTACTTTAAATAATGACTCCTTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAAGAGCTGTTTTCATATGTTATCTACATAGATTAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAAGAGCTGTTTTCATATGTTATCTACATAGATTAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATATAAATAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
Db 661 TACGTATAAATTAATATAAATAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACAGCCATTAATCTCTGAATGATGCAATTAATTAATCTGACTGTCTGATGACATTC 780
Db 721 TTAAGGAACAGCCATTAATCTCTGAATGATGCAATTAATTAATCTGACTGTCTGATGACATTC 780
QY 781 GAAGCTTTTGTATATAGGAATCTGTAGGCTCATTTTGGTTCATTTGAACAGATTAATA 840
Db 781 GAAGCTTTTGTATATAGGAATCTGTAGGCTCATTTTGGTTCATTTGAACAGATTAATA 840
QY 841 TTATAAATTAAGCTGTATATATAGGCTCTCTCATGATGAAGTGAAGTGAAGTGAAGTGAAGT 900
Db 841 TTATAAATTAAGCTGTATATATAGGCTCTCTCATGATGAAGTGAAGTGAAGTGAAGTGAAGT 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATGATTAATATGATGATCAATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATGATTAATATGATGATCAATTTAC 960
QY 961 AAAAAATAAAGCGGAATTTTCCCTTCGCTTCAATTAATATCCCTGATATATGATGATCAATTTAC 1020
Db 961 AAAAAATAAAGCGGAATTTTCCCTTCGCTTCAATTAATATCCCTGATATATGATGATCAATTTAC 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAATTTCTTAAGCATTA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAATTTCTTAAGCATTA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGATTAATCTGCTGATGATGATGATGATGATGATGAT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGATTAATCTGCTGATGATGATGATGATGATGATGAT 1140
QY 1141 TTAATATGTTTATTTATTTGTAAGACATTAATTAAGAAATTTGGTATTAATGCTTAACTG 1200
Db 1141 TTAATATGTTTATTTATTTGTAAGACATTAATTAAGAAATTTGGTATTAATGCTTAACTG 1200
QY 1201 TTTAATCTGCTGTTAAAGTATTTTAAGAAATTTGCGAGTACTACAGATTTTCAAAACT 1260
Db 1201 TTTAATCTGCTGTTAAAGTATTTTAAGAAATTTGCGAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTTCTTTAGTCAATTAATTAATTAATTAATTAAT 1320
Db 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTTCTTTAGTCAATTAATTAATTAATTAATTAAT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 66

ADE16523

ID ADE16523 standard; cdna; 1333 BP.

XX AC ADE16523;

XX AC ADE16523;

DT 29-JAN-2004 (first entry)

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

XX DE

PN US2003203435-A1.
XX 30-OCT-2003.
XX 18-OCT-2001; 2001US-00145092.
XX 30-APR-1998; 98US-0083742P.
PR 08-MAR-1999; 99WO-US005028.
PR 23-JUN-1999; 99US-0140307P.
PR 25-AUG-1999; 99US-0038013B.
PR 18-FEB-2000; 2000WO-US004341.
XX 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Filvaroff E, Fong S, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-875642/81.
DR P-PSDB; ADE16524.
XX New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for treating e.g. lung or breast tumors, osteoarthritis,
PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
PT hypoinsulinemia or wounds.
XX Claim 2; SEQ ID NO 321; 452pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ

Query Match

Best Local Similarity 100.0%; Score 1333; DB 9; Length 1333;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGTCCGATGGGCTTCACGTTCCGGCCCTCTCTACATGCTGGCGCTGCT 60
Db |||||
QY 1 GCCACGGTCCGATGGGCTTCACGTTCCGGCCCTCTCTACATGCTGGCGCTGCT 60
Db |||||
QY 61 CACTCGCGGCTCATCTTCTTCGCCATTTGGCACATTATAGCAATTTGATGAGCTGAAGAC 120
Db |||||
QY 61 CACTCGCGGCTCATCTTCTTCGCCATTTGGCACATTATAGCAATTTGATGAGCTGAAGAC 120
Db |||||
QY 121 TGATTACAGAAATCCTATAGACAGTGAATACCTGTAATCCCTTTGACTCCCGAGTGA 180
Db |||||
QY 121 TGATTACAGAAATCCTATAGACAGTGAATACCTGTAATCCCTTTGACTCCCGAGTGA 180
Db |||||
QY 181 COTCATCCACGCTTCTCTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACACTGG 240
Db |||||
QY 181 COTCATCCACGCTTCTCTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACACTGG 240
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACAGTGAATGCA 300
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACAGTGAATGCA 300
Db |||||
QY 301 TGGCCACAGACTCTATGACCTTACACCATCATGATGAGTGCAGATATTTGCTATTTGCA 360
Db |||||
QY 301 TGGCCACAGACTCTATGACCTTACACCATCATGATGAGTGCAGATATTTGCTATTTGCA 360
Db |||||
QY 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db |||||
QY 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db |||||
QY 421 CATGATCATGTTTGGTGGCTCTTGAACAACAACAACAACAACAACAACAACAACAACA 480
Db |||||
QY 421 CATGATCATGTTTGGTGGCTCTTGAACAACAACAACAACAACAACAACAACAACAACA 480
Db |||||
QY 481 GCATCAAAAGCCACCAAAATCAAGGATCTTATCCAGCAGATCTCTCCAGAGTAGC 540
Db |||||
QY 481 GCATCAAAAGCCACCAAAATCAAGGATCTTATCCAGCAGATCTCTCCAGAGTAGC 540
Db |||||
QY 541 CTGTGGAACTCTGATCAGTACTTTAAAAATGACTCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 541 CTGTGGAACTCTGATCAGTACTTTAAAAATGACTCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db |||||
QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db |||||
QY 661 TACGTATAAATTAATATAAATGATGATCTCTGGGTTGACAGGTTTGAACCTGCACTTC 720
Db |||||
QY 661 TACGTATAAATTAATATAAATGATGATCTCTGGGTTGACAGGTTTGAACCTGCACTTC 720
Db |||||
QY 721 TTAAGGAACGCCATAATCCTCTGAATGATGATTAATCTGACTGCTCTAGTACATTG 780
Db |||||
QY 721 TTAAGGAACGCCATAATCCTCTGAATGATGATTAATCTGACTGCTCTAGTACATTG 780
Db |||||
QY 781 GAAGCTTTTGTATAGAACTCTGAGGCTCATTTTGGTTTCATGTAAGAACAGTATCTAA 840
Db |||||
QY 781 GAAGCTTTTGTATAGAACTCTGAGGCTCATTTTGGTTTCATGTAAGAACAGTATCTAA 840
Db |||||
QY 841 TTATAAATTAGCTGTAGATATCAGTCTCTCTGATGAGTGAATGATGATATCTGACTAG 900
Db |||||
QY 841 TTATAAATTAGCTGTAGATATCAGTCTCTCTGATGAGTGAATGATGATATCTGACTAG 900
Db |||||
QY 901 TGGGAAACTTCATGGGTTTCTCTATCTGCTATGTCGATGATATATATGAGTACATTTAC 960
Db |||||
QY 901 TGGGAAACTTCATGGGTTTCTCTATCTGCTATGTCGATGATATATATGAGTACATTTAC 960
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATGATGAAT 1020
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATGATGAAT 1020
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTCTTAAATTTCTTAAGCATA 1080
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTCTTAAATTTCTTAAGCATA 1080
Db |||||

QY 1081 AGTAAACATGATATATAAATAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1081 AGTAAACATGATATATAAATAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1141 TTAATATGTTTATTTTATTTGTAAGACATTAATTAAGAAATTTGCTTATTTATGCTTACTG 1200
Db |||||
QY 1141 TTAATATGTTTATTTTATTTGTAAGACATTAATTAAGAAATTTGCTTATTTATGCTTACTG 1200
Db |||||
QY 1201 TTCTAATCTGGTGGTAAAGGTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAACT 1260
Db |||||
QY 1201 TTCTAATCTGGTGGTAAAGGTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAACT 1260
Db |||||
QY 1261 GAATCAGAGAAATTTGTAATACCATCTCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
Db |||||
QY 1261 GAATCAGAGAAATTTGTAATACCATCTCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
RESULT 67
ADD73138
ID ADD73138 standard; cDNA; 1333 BP.
XX
AC ADD73138;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO181.
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnery; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
FN US2003203436-A1.
XX
PD 30-OCT-2003.
XX
PF 18-OCT-2001; 2001US-00145129.
XX
XX 22-MAY-1998; 98US-0086414P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-APR-1999; 99US-00284291.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NP, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI,
XX WPI; 2003-875643/81.
DR P-PSDB; ADD73139.
XX
PT New PRO genes and encoded secreted and transmembrane polypeptides, useful
PT for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid
PT arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or
PT wounds.
XX Claim 2; SEQ ID NO 321; 453bp; English.
PS The invention relates to an isolated PRO polypeptide (secreted or
XX

CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.

XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0;
QY 1 GCCACGCGTCCGATGGCGTTTCAGTTTCGGCGCTTCTGCTACATGCTGGCGTGTGCT 60
DB 1 GCCACGCGTCCGATGGCGTTTCAGTTTCGGCGCTTCTGCTACATGCTGGCGTGTGCT 60
QY 61 CACTGCGCGCTCATCTCTTCGGCCATTTGGCCATTTAGCATTTTATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTCTTCGGCCATTTGGCCATTTAGCATTTTATGAGCTGAAGAC 120
QY 121 TGATTACAAGAACTCTATAGACCACTGTAATACCTCAATCCCTCTGCTACTCCAGAGTA 180
DB 121 TGATTACAAGAACTCTATAGACCACTGTAATACCTCAATCCCTCTGCTACTCCAGAGTA 180
QY 181 CTTTCATCCAGCTTTCTCTGTGTCATGTTTCTTTTGTGCGAGAGTGGCTTACCTGGG 240
DB 181 CTTTCATCCAGCTTTCTCTGTGTCATGTTTCTTTTGTGCGAGAGTGGCTTACCTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATGATAGACCAAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATGATAGACCAAGTATGAG 300
QY 301 TGGCCCGAGGACTCTATGACCCCTCAACCATCATGAATCGAGATATTTAGCATATTTGCA 360
DB 301 TGGCCCGAGGACTCTATGACCCCTCAACCATCATGAATCGAGATATTTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTGCATAATAGCTTTTATCTTCTAGCATATTTTCTACCTATATGG 420
DB 361 GAAGGAAGGATGGTGCATAATAGCTTTTATCTTCTAGCATATTTTCTACCTATATGG 420
QY 421 CATCATCTATGTTTTTGGTGGAGCTCTTACAAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
DB 421 CATCATCTATGTTTTTGGTGGAGCTCTTACAAACACACACAGAGAAATTTGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTTACATTTTAAAAAATGACTCTTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTTACATTTTAAAAAATGACTCTTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACATGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 560
DB 601 TTTTGTCTGTGGAAGACATGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 560
QY 661 TAGCTATAAATAATAATAAATGATTTACCTCTGGTCTGCACAGGTTTGAACCTGCACTTC 720
DB 661 TAGCTATAAATAATAATAAATGATTTACCTCTGGTCTGCACAGGTTTGAACCTGCACTTC 720
QY 721 TTAAGGAACAGCCATTAATCTCTGAATGATGATTAATTTACTGACTGTCTAGTACATTG 780
DB 721 TTAAGGAACAGCCATTAATCTCTGAATGATGATTAATTTACTGACTGTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTTTCATTTGAAACAGATATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTTTCATTTGAAACAGATATCTAA 840
QY 841 TTATAAATTTAGCTGTAGATATCAGGTTGCTTCTGATCAAGTGAATAATGTTATCTGACTAG 900
DB 841 TTATAAATTTAGCTGTAGATATCAGGTTGCTTCTGATCAAGTGAATAATGTTATCTGACTAG 900
QY 901 TGGAAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATACATTAC 960
DB 901 TGGAAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATACATTAC 960
QY 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATTTATCCCTGTATATTCCTGATGAAT 1020
DB 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATTTATCCCTGTATATTCCTGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAATAATATCTTGTCTTAATTTCTTAAGCATA 1080
DB 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAATAATATCTTGTCTTAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAAAAATATATGCTGAATTAATCTTGTGAAGAAATGCAATTAAGCTATT 1140
DB 1081 AGTAAACATGATATAAAAAATATATGCTGAATTAATCTTGTGAAGAAATGCAATTAAGCTATT 1140
QY 1141 TTAATGTGTTTTTATTTGTAAGACATTAATCTTATTAAGAAATGTTTATTTATCTTACTG 1200
DB 1141 TTAATGTGTTTTTATTTGTAAGACATTAATCTTATTAAGAAATGTTTATTTATCTTACTG 1200
QY 1201 TTCTAATCTGGTGTAAAGCTATTCTTAAGAAATTTGCAGTACTACAGATTTTCAAAACT 1260
DB 1201 TTCTAATCTGGTGTAAAGCTATTCTTAAGAAATTTGCAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGTAACCATCTCTGCTGTCTTCTTTAGTGCATATACATAAATCTCT 1320
DB 1261 GAATGAGAGAAATTTGTAACCATCTCTGCTGTCTTCTTTAGTGCATATACATAAATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 68

ADD72496

ID ADD72496 standard; cDNA; 1333 BP.

XX ADD72496;

AC ADD72496;

DT 29-JAN-2004 (first entry)

XX Human cDNA encoding secreted/transmembrane protein, PRO181.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;

Db 421 CATGATCTATGTTTGGTGAGCTTCTTGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGACCACAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGATAGC 540
Db 481 GCATGCAAAAGACCACAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGATAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTTATCTACAGATAAGATTTTAAATGTTAT 660
Db 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTTATCTACAGATAAGATTTTAAATGTTAT 660
QY 661 TAGCTATAATTAATAAATGATTAACCTCTCGGTGTGACAGTTTGAACCTTGCATTC 720
Db 661 TAGCTATAATTAATAAATGATTAACCTCTCGGTGTGACAGTTTGAACCTTGCATTC 720
QY 721 TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATCTGACTGTCTAGTACATG 780
Db 721 TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATCTGACTGTCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTTGTTCATTCGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTTGTTCATTCGAAACAGTATCTAA 840
QY 841 TTAATAATTAAGCTGTAGATATCAGGTCTCTCTGATGAAGTGAATAATGATATCTAGTAG 900
Db 841 TTAATAATTAAGCTGTAGATATCAGGTCTCTCTGATGAAGTGAATAATGATATCTAGTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGATGATACATTTAC 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATATTCATGAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATATTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGATTAATTAATTAATCTGTTTAAATCTTAAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGATTAATTAATTAATCTGTTTAAATCTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTCTGGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTCTGGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATAATGTTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTTATTTATGCTTACTG 1200
Db 1141 TTAATAATGTTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTTATTTATGCTTACTG 1200
QY 1201 TTCTAAATCTGGTGAAGTATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACT 1260
Db 1201 TTCTAAATCTGGTGAAGTATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTTCCCTTTAGTGAATACAAATAAATCTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTTCCCTTTAGTGAATACAAATAAATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 69

ADE17147

ID ADE17147 standard; cDNA; 1333 BP.

XX AC

XX AC ADE17147;

XX AC

DT 29-JAN-2004 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein, PRO181.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO; cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery; auditory; tumour growth; retinal disorder; sports-related joint problem; articular cartilage defects; osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX OS Homo sapiens.
XX PN US2003203433-A1.
XX PD 30-OCT-2003.
XX PF 18-OCT-2001; 2001US-00145016.
XX PR 06-MAY-1998; 98US-0084414P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-APR-1999; 99US-00284291.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX PA Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DL; Ferrera N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME; Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ; Kijavlin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL; Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-875660/81.
XX DR P-FSDB; ADE17148.

XX New genes, and its encoded secreted and transmembrane polypeptides, useful for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or wounds.

PS Claim 2; SEQ ID NO 321; 459pp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule causes death of the cell. PRO337 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO725, PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337 polypeptide is useful for modulating at least one biological activity of the cell expressing PRO337 polypeptide, where the cell is killed. PRO337 polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-PRO739 polypeptide is useful for modulating the biological activity of

CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
 CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
 CC sports-related joint problems, articular cartilage defects,
 CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
 CC mammals. The present sequence encodes a PRO protein.

XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGGCTTCAGTTCGCGGCCCTTCGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGGGCTTCAGTTCGCGGCCCTTCGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGCTCATCTCTTCGCGCATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGCTCATCTCTTCGCGCATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCTATAGACCAAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
 DB 121 TGATTACAGAAATCCTATAGACCAAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
 QY 181 CCTCATCCACGCTTCTCTGCTGCTCATGTTCTTTGTCGAGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCACGCTTCTCTGCTGCTCATGTTCTTTGTCGAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
 QY 301 TGGCCCGAGACTCTATGACCCCTACAAACCATCATGAATGCAGATATTTAGCATATTTGCA 360
 DB 301 TGGCCCGAGACTCTATGACCCCTACAAACCATCATGAATGCAGATATTTAGCATATTTGCA 360
 QY 361 GAAGGAAGATGGTCAAAATAGCTTTTATCTCTGAGCTTTTCTTACTACTATATGG 420
 DB 361 GAAGGAAGATGGTCAAAATAGCTTTTATCTCTGAGCTTTTCTTACTACTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACACACACAGAAATTTGTCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACACACACAGAAATTTGTCAGTTAAGT 480
 QY 481 GCATGCAAAACGACCAATGAAGGATCTATCAGCAAGATCCTGTCCAGAGTAGC 540
 DB 481 GCATGCAAAACGACCAATGAAGGATCTATCAGCAAGATCCTGTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTAAATAAGTCACTCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTAAATAAGTCACTCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGCTTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTGCTTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTTC 720
 DB 661 TACGTATAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTTC 720
 QY 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
 DB 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
 QY 781 GAAGCTTTTGTATATAGGAATCTGATAGGCTCATTTTGGTTTCATTTGAACAGTACTTAA 840
 DB 781 GAAGCTTTTGTATATAGGAATCTGATAGGCTCATTTTGGTTTCATTTGAACAGTACTTAA 840
 QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTATATCTGACTAG 900
 DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTATATCTGACTAG 900
 QY 901 TGGGAAACTTTCATGCTGCTCATCTGATGATGATTAATATATGATGATGATGATGATGAT 960

DB 901 TGGGAAACTTTCATGCTGCTCATCTGCTGATGATTAATATGATGATGATGATGATGAT 960
 QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGATATATGATGATGAT 1020
 DB 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGATATATGATGATGAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATTAATTTAAATTTCTTAAGCATATA 1080
 DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATTAATTTAAATTTCTTAAGCATATA 1080
 QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTTGGAAGATGCAATTTAAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTTGGAAGATGCAATTTAAAGCTATT 1140
 QY 1141 TTAATCTGTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTAATGCTTACTG 1200
 DB 1141 TTAATCTGTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTAATGCTTACTG 1200
 QY 1201 TTCTAAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
 DB 1201 TTCTAAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
 QY 1261 GAATGAGAGAAAATGATTAACCATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
 DB 1261 GAATGAGAGAAAATGATTAACCATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333

RESULT 70

ADC48822
 ID ADC48822 standard; cDNA; 1333 BP.

AC ADC48822;

XX AC

XX 15-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO181 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

KW vulnary; antiarthritic; pericyte cell proliferation;

KW pericyte cell differentiation; chondrocyte cell proliferation;

KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;

KW colon tumour; breast tumour; prostate tumour; rectal tumour;

KW liver tumour; tissue typing; chromosome mapping; gene mapping;

XX gene therapy.

OS Homo sapiens.

XX US2003092888-A1.

XX 15-MAY-2003.

XX 13-AUG-2002; 2002US-00219468.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-031186/03.

DR P-PSDB; ADC48823.

XX Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as

PT molecular weight markers in protein electrophoresis, for treating
PT arthritis, tumor.

Claim 2; SEQ ID NO 119; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO1725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO183, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1373, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGGTTACGTTCCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
DB 1 GCCACGCGTCCGATGCGGTTACGTTCCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
QY 61 CACTGCGCGCTCATCTCTTCCGCTATTCGCATTTAGCATTTAGCATTTAGCATTTAGCAT 120
DB 61 CACTGCGCGCTCATCTCTTCCGCTATTCGCATTTAGCATTTAGCATTTAGCATTTAGCAT 120
QY 121 TGATTACAGAACTCCTATAGACAGTGTATACCTGATCCCTCTGCTACTCCACAGTA 180
DB 121 TGATTACAGAACTCCTATAGACAGTGTATACCTGATCCCTCTGCTACTCCACAGTA 180
QY 181 CCTCATCCAGCTTCTCTTCTGTGTCATGTTCTTTTGTGACAGAGTGGCTTACATGGG 240
DB 181 CCTCATCCAGCTTCTCTTCTGTGTCATGTTCTTTTGTGACAGAGTGGCTTACATGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGTACCGATGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGTACCGATGATGAG 300
QY 301 TGGCCGAGGACTCTATGACCTCAACCAATCATGATATTTCTAGCATATTTCTGCA 360
DB 301 TGGCCGAGGACTCTATGACCTCAACCAATCATGATATTTCTAGCATATTTCTGCA 360
QY 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTCTTCTTCTTCT 420
DB 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTCTTCTTCTTCT 420

RESULT 71
ADE20993
ID ADE20993 standard; cdna; 1333 BP.
XX AC ADE20993;
XX

DB 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTCTTCTTCTTCT 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAACAACAACAACAACAACAACA 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAACAACAACAACAACAACAACA 480
QY 481 GCATCAAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCCTGTCGAAGAGTAGC 540
DB 481 GCATCAAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCCTGTCGAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGACTCTTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGACTCTTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTCTGGAAGACAGCTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTTCTGGAAGACAGCTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAAATGATTAACCTCTGCTGTTTGCACAGGTTTGAACCTTGCACTTC 720
DB 661 TAGCTATAAATTAATAAATGATTAACCTCTGCTGTTTGCACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCATAATCCTCTGAATGATGATTAATTAATCTGACTGTCTAGTACATG 780
DB 721 TTAAGGAACAGCATAATCCTCTGAATGATGATTAATTAATCTGACTGTCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAAGCTTAGGGCTCATTTTGGTTTTCATTTGAAACAGTACTAA 840
DB 781 GAAGCTTTTGTATAGGAAGCTTAGGGCTCATTTTGGTTTTCATTTGAAACAGTACTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATCTGACTAG 900
DB 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATCTGACTAG 900
QY 901 TGGAAACTTCATGCGGTTTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960
DB 901 TGGAAACTTCATGCGGTTTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960
QY 961 AAAAAAAGGCGGAATTTCCCTTCCCTGCTGATTAATCCCTGCTATATGTCATGAAT 1020
DB 961 AAAAAAAGGCGGAATTTCCCTTCCCTGCTGATTAATCCCTGCTATATGTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGTTTAAATCTTTAAGCATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGTTTAAATCTTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGATTAATCTTGAAGATGATTAAGATTAAT 1140
DB 1081 AGTAAACATGATATAAATAATATATGCTGATTAATCTTGAAGATGATTAAGATTAAT 1140
QY 1141 TTAATGTTTGTATTTTATTTGTAAGACATTAATTAAGAAATTTGGTTTATGTTTACTG 1200
DB 1141 TTAATGTTTGTATTTTATTTGTAAGACATTAATTAAGAAATTTGGTTTATGTTTACTG 1200
QY 1201 TTCTAATCTGTTGTTAAAGGATTTCTTAAGAAATTTCCAGGACTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGTTGTTAAAGGATTTCTTAAGAAATTTCCAGGACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTTCTTCTAGTGCATATCAATAAATCTCT 1320
DB 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTTCTTCTAGTGCATATCAATAAATCTCT 1320
QY 1321 GAAATTTAAGACTC 1333
DB 1321 GAAATTTAAGACTC 1333

DT 29-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO181 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX Homo sapiens.
OS US2003100735-A1.
XX 29-MAY-2003.
XX 28-AUG-2002; 2002US-00230433.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI: 2004-008985/01.
XX P-PSDB; A0E20994.
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells, PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1071, PRO1411, PRO1309,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1338,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC

CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGTCCGATGGCGTTCAGTTCGGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGTCCGATGGCGTTCAGTTCGGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTCTTCGCGCATTTGCGCATATATAGCATATGATGAGTCAAGAC 120
DB 61 CACTGCCGCGCTCATCTCTTCGCGCATTTGCGCATATATAGCATATGATGAGTCAAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACCACTAGTAAATACCTCAATCCCTGTAATCCCTGTAATCCCAAGATA 180
DB 121 TGATTACAAGAAATCCTATAGACCACTAGTAAATACCTCAATCCCTGTAATCCCAAGATA 180
QY 181 CCTCATCCAGCTTCTCTGTCATGTTTCTTGTGTCAGAGTGGCTTACCTGGG 240
DB 181 CCTCATCCAGCTTCTCTGTCATGTTTCTTGTGTCAGAGTGGCTTACCTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACACAGTCAATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACACAGTCAATGAG 300
QY 301 TGGCCAGAGCTCTATGACCCCTACCAACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCAGAGCTCTATGACCCCTACCAACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
QY 361 GAAGAGAGTGGTCAAAATAGCTTTTATCTCTAGCATTTTCTACTACCTATATGG 420
DB 361 GAAGAGAGTGGTCAAAATAGCTTTTATCTCTAGCATTTTCTACTACCTATATGG 420
QY 421 CATGATCTATCTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTCGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATTCGTCCAGTTAAGT 480
QY 481 GCATCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
DB 481 GCATCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
QY 541 CTGTGGATCTGATCAGTACCTTTTAAATGACCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGATCTGATCAGTACCTTTTAAATGACCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAGAGCTGTTTTCATATGTTTATCTACTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTTGTGGAAGAGCTGTTTTCATATGTTTATCTACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGATATAAATTAATAAATGATTAATCTCTGTTGACAGGTTTGAACCTTGACCTTC 720
DB 661 TACGATATAAATTAATAAATGATTAATCTCTGTTGACAGGTTTGAACCTTGACCTTC 720
QY 721 TTAAGGAACAGCCATAAATCCCTGATGATGATTAATCTACTGATGATGATGATGATGATG 780
DB 721 TTAAGGAACAGCCATAAATCCCTGATGATGATTAATCTACTGATGATGATGATGATGATG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
QY 841 TTATAAATAGCTGTAGATATACAGTGTCTTCTGATGAAGTGAATGATATATCTGACTAG 900
DB 841 TTATAAATAGCTGTAGATATACAGTGTCTTCTGATGAAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAACTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
DB 901 TGGGAACTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960

QY 961 AAAAAAAGCGGGAATTTTCCCTTCGTTGAATATATATCCCTGTATATTCATGAAT 1020
Db |||||
QY 961 AAAAAAAGCGGGAATTTTCCCTTCGTTGAATATATATCCCTGTATATTCATGAAT 1020
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATCTGCTTTAAATCTTTAAGCATA 1080
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATCTGCTTTAAATCTTTAAGCATA 1080
Db |||||
QY 1081 AGTAACATGATATATAAATATATGCTGAATTTACTTTGTGAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1081 AGTAACATGATATATAAATATATGCTGAATTTACTTTGTGAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1141 TTAATATGTTTTTATTTGTAAGACATTTACTTTATTAAGAAATGTTTATTAAGCTATT 1200
Db |||||
QY 1141 TTAATATGTTTTTATTTGTAAGACATTTACTTTATTAAGAAATGTTTATTAAGCTATT 1200
Db |||||
QY 1201 TTCTAATCTGTTGTAAGAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACT 1260
Db |||||
QY 1201 TTCTAATCTGTTGTAAGAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACT 1260
Db |||||
QY 1261 GAATGAGAGAAATTTGTAACATCTGCTGTTCTTTAGTGCATTAACAATAAACTCT 1320
Db |||||
QY 1261 GAATGAGAGAAATTTGTAACATCTGCTGTTCTTTAGTGCATTAACAATAAACTCT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||

RESULT 72

ADE05837
ID ADE05837 standard; cDNA; 1333 BP.
XX
AC ADE05837;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #60.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100728-A1.
XX
PD 29-MAY-2003.
XX
PF 28-AUG-2002; 2002US-00230024.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;
XX
DR WPI; 2004-008978/01.
XX P-PSDE; ADE05838.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.
XX
PS Claim 2; Fig 119; 308pp; English.
XX
CC The invention relates to human PRO polypeptides (secreted and

transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGGTTTCCAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db |||||
QY 1 GCCACGCGTCCGATGGGTTTCCAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db |||||
QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGGCACATTAATAGCATTTGATGAGCTGAAGAC 120
Db |||||
QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGGCACATTAATAGCATTTGATGAGCTGAAGAC 120
Db |||||
QY 121 TGAATACAGATTCCTATAGACCGAGTGAATACCTGATCCCTGATCCCTGATCCAGATTA 180
Db |||||
QY 121 TGAATACAGATTCCTATAGACCGAGTGAATACCTGATCCCTGATCCCTGATCCAGATTA 180
Db |||||
QY 181 CTTCTATCCACGCTTTCTTCTGCTGATGTTTCTTTGTGCGAGCAGAGTGGCTTACATGGG 240
Db |||||
QY 181 CTTCTATCCACGCTTTCTTCTGCTGATGTTTCTTTGTGCGAGCAGAGTGGCTTACATGGG 240
Db |||||
QY 241 TCTCAATATGCCCCCTTTCGGCATATCATATTTGGAGGTATATGAGTAGCAGATGATGAG 300
Db |||||
QY 241 TCTCAATATGCCCCCTTTCGGCATATCATATTTGGAGGTATATGAGTAGCAGATGATGAG 300
Db |||||
QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATGAGATATTTCTAGCATATTTGTC 360
Db |||||
QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATGAGATATTTCTAGCATATTTGTC 360
Db |||||
QY 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTATCTTCTATGATGG 420
Db |||||
QY 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTATCTTCTATGATGG 420
Db |||||
QY 421 CATGATCTATGTTTTGGTGAGCTTTAGAACACACACACAGAGAAATTTGCTCCAGTAAAT 480
Db |||||
QY 421 CATGATCTATGTTTTGGTGAGCTTTAGAACACACACACAGAGAAATTTGCTCCAGTAAAT 480
Db |||||
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGAGTAGC 540
Db |||||
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGAGTAGC 540
Db |||||
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 601 TTTTGTCTGTGGAAGAGCTGTTTTTCAATGTTATCTACATTAAGATTTTAAATGTTAT 660
Db |||||
QY 601 TTTTGTCTGTGGAAGAGCTGTTTTTCAATGTTATCTACATTAAGATTTTAAATGTTAT 660
Db |||||

```
QY 661 TAGGTAAATTAATATAAAAGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
Db 661 TAGGTAAATTAATATAAAAGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACAGCCATATCCCTCTGAATGATGCAATTAATTACTGACTGCTCCTAGTACATTG 780
Db 721 TTAAGGAACAGCCATATCCCTCTGAATGATGCAATTAATTACTGACTGCTCCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTTGGTTTCAATGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTTGGTTTCAATGAAACAGTATCTAA 840
QY 841 TTAATAATTAAGCTGTAGATACAGTCTCTGATGAAGTGAATGTAATGTAATCTGACTAG 900
Db 841 TTAATAATTAAGCTGTAGATACAGTCTCTGATGAAGTGAATGTAATGTAATCTGACTAG 900
QY 901 TGGGAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATATGATGATACATTAC 960
Db 901 TGGGAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATATGATGATACATTAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTCGCTTGAATTAATTAATCCCTGTAATGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTCGCTTGAATTAATTAATCCCTGTAATGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATACCTGCTTTAAATCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATACCTGCTTTAAATCTTAAGCATA 1080
QY 1081 AGTAACATGATATAAAATATATGCTGGAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAAATATATGCTGGAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAAGTGTGTTTATTTGAAGACATTAATTAATTAAGAAATGTTGTTATTAATGCTTACTG 1200
Db 1141 TTAAGTGTGTTTATTTGAAGACATTAATTAATTAAGAAATGTTGTTATTAATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGGTATTCTTAAAGATTTGCGAGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGTATTCTTAAAGATTTGCGAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCCCTTTAGTGAATACAAATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCCCTTTAGTGAATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
```

RESULT 73

ADD75066

ID ADD75066 standard; cDNA; 1333 BP.

XX ADD75066;

AC ADD75066;

DT 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #60.

DE Human PRO polynucleotide #60.

XX

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; tumour; cancer; lung; colon; breast; prostate; rectum; liver; tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; pericyte cell; dermal fibroblast; bone disorder; cartilage disorder; arthritis; sports injury; cyrostatic; antiarthritic.

XX Homo sapiens.

XX

XX US2003100712-A1.

XX

XX 29-MAY-2003.

XX

XX 09-AUG-2002; 2002US-00216168.

PF

XX

PR 01-JUN-2001; 2001WO-US017800.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX

XX WPI; 2004-008962/01.

DR

XX P-PSDB; ADD75067.

XX

PT New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.

XX

PS Claim 2; Fig 119; 308pp; English.

XX

CC The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent can also be obtained in electronic
CC format directly from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

XX

Query Match 100.0%; Score 1333; DB 10; Length 1333;

Best Local Similarity 100.0%; Pred No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1 GCCACGCTCCGATGGGCTTCAAGTTCGCGGCTTCTGCTACATGCTGCGGCTGCTGCT 60

Db

1 GCCACGCTCCGATGGGCTTCAAGTTCGCGGCTTCTGCTACATGCTGCGGCTGCTGCT 60

QY

61 CACTGCCGCGCTCATCTTCTTCCCATTTGGCACATTAATAGCATTTGATGAGCTGAAGAC 120

Db

61 CACTGCCGCGCTCATCTTCTTCCCATTTGGCACATTAATAGCATTTGATGAGCTGAAGAC 120

QY

121 TGAATACAGAAATCCCTATAGACAGAGTGAATACCTGAAATCCCTTGTACTCCACAGATA 180

Db

121 TGAATACAGAAATCCCTATAGACAGAGTGAATACCTGAAATCCCTTGTACTCCACAGATA 180

QY

181 CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACATGGG 240

Db

181 CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACATGGG 240

QY

241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACCATGATGAG 300

Db

241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACCATGATGAG 300

QY

301 TGGCCCGAGGACTCTATGACCTTACCAACCATCATGAATGACAGATATTTCTAGCATATTGTGCA 360

Db 301 TGGCCAGGACTCTATGACCCCTACACCAATCATGAATGAGATATTTAGCATATGTCAC 360
Qy 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTCTTAGCATTTTCTTACTATATAGG 420
Db 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTCTTAGCATTTTCTTACTATATAGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGAAAAGCCCAAAATGAAGGATCTCTCCAGCAAGATCTCTGTCGAAGTAGC 540
Db 481 GCATGAAAAGCCCAAAATGAAGGATCTCTCCAGCAAGATCTCTGTCGAAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTTTATTTTAAAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTTTATTTTAAAAATGTTTCCACAT 600
Qy 601 TTTTGGCTTGGAAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGGCTTGGAAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAATTAATAATAAATGATTAACCTCTGGTCTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGTATAATTAATAATAAATGATTAACCTCTGGTCTGACAGGTTTGAACCTTGCACTTC 720
Qy 721 TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATCTGACTGCTCTAGTCAATG 780
Db 721 TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATCTGACTGCTCTAGTCAATG 780
Qy 781 GAAGCTTTTGTATAGGAACCTGTTAGGCTCAATTTGGTTTCATTTGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTGTTAGGCTCAATTTGGTTTCATTTGAACAGATATCTAA 840
Qy 841 TTATAAATTAGCTGTAGATATCAGTCTCTCTCATGAAGTGAAGTGAATATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGTCTCTCTCATGAAGTGAAGTGAATATATCTGACTAG 900
Qy 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATATGATACATTTAC 960
Qy 961 AAAAATAAAAGCGGAAATTTCCCTTCGCTTGAATATATCCCTGATATTTCCATCAAT 1020
Db 961 AAAAATAAAAGCGGAAATTTCCCTTCGCTTGAATATATCCCTGATATTTCCATCAAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATCTGCTTTAAATCTTAAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATCTGCTTTAAATCTTAAAGCAT 1080
Qy 1081 AGTAAACATGATATAAAATATATGCTGAAATTTACTGTAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAAATATATGCTGAAATTTACTGTAAGATGCAATTTAAAGCTATT 1140
Qy 1141 TTAATCTGTTTATTTTGAAGCATATCTTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db 1141 TTAATCTGTTTATTTTGAAGCATATCTTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Qy 1201 TTCTAATCTGTTGTAAGGATTTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAACCT 1260
Db 1201 TTCTAATCTGTTGTAAGGATTTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAACCT 1260
Qy 1261 GAATGAGAAAAATGTATATACCATCTGCTGTTTCCCTTAGTGCATATCAATAAATCTCT 1320
Db 1261 GAATGAGAAAAATGTATATACCATCTGCTGTTTCCCTTAGTGCATATCAATAAATCTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

ADD75812
ID ADD75812 standard; cDNA; 1333 BP.
XX AC ADD75812;
XX DT 29-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX KW gene therapy.
XX OS Homo sapiens.
XX PN US2003100717-A1.
XX PD 29-MAY-2003.
XX PF 13-AUG-2002; 2002US-00219465.
XX PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI: 2004-008967/01.
DR P-PSDB; ADD75813.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
PS Claim 2; SEQ ID NO 119; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
CC PRO1887, PRO1928, PRO3441, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue

CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GCCACGCGTCCGATGGGCTTCACTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGGCTTCACTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCCGCTCATCTTCTGCGCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCTCATCTTCTGCGCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAAGATCCCTATAGACAGTGAATACCCCTGAATCCCTTGTAATCCCTTGTAATCCCAAGATA 180
DB 121 TGATTACAAGATCCCTATAGACAGTGAATACCCCTGAATCCCTTGTAATCCCAAGATA 180

QY 181 CCTGATCCAGGCTTCTTCTGCTGTCATGTTCTTTGTGCGAGCAGAGTGCTTACACTGG 240
DB 181 CCTGATCCAGGCTTCTTCTGCTGTCATGTTCTTTGTGCGAGCAGAGTGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTCAATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTCAATGAG 300

QY 301 TGGCCGAGGACTCTATGACCCCTACCAACCATCATGAATGAGATATTTAGCATATTTGCA 360
DB 301 TGGCCGAGGACTCTATGACCCCTACCAACCATCATGAATGAGATATTTAGCATATTTGCA 360

QY 361 GAAGGAAGATGGTGAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
DB 361 GAAGGAAGATGGTGAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420

QY 421 CATGATCATGTTTGTGAGCTCTTAGAACACACACAGAGAATTTGTCAGTTAAGT 480
DB 421 CATGATCATGTTTGTGAGCTCTTAGAACACACACAGAGAATTTGTCAGTTAAGT 480

QY 481 GCATCAAAAGCCCAATGAAGGATTTCTATCCAGCAGATCTCTGCCAAGAGTAGC 540
DB 481 GCATCAAAAGCCCAATGAAGGATTTCTATCCAGCAGATCTCTGCCAAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGCTATAAATTAATAAATGAATTAATCTCTGGTGTGACAGGTTTGAACITGCACTTC 720
DB 661 TAGCTATAAATTAATAAATGAATTAATCTCTGGTGTGACAGGTTTGAACITGCACTTC 720

QY 721 TTAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780

QY 781 GAAGCTTTTGTATAGGAATCTGTAGGCTCATTTTGTGTTTCAATTAAGAACAGTACTAA 840
DB 781 GAAGCTTTTGTATAGGAATCTGTAGGCTCATTTTGTGTTTCAATTAAGAACAGTACTAA 840

QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAG 900
```

```
QY 901 TGGAAACTTCATGGGTTTCTCTCATCTGTCTCATGTCGATGATTATATATGATCATTTAC 960
DB 901 TGGAAACTTCATGGGTTTCTCTCATCTGTCTCATGTCGATGATTATATATGATCATTTAC 960

QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGGCTTGAATATATATCCCTGTATATTCATGAAT 1020
DB 961 AAAAATAAAAGCGGGAATTTTCCCTTCGGCTTGAATATATATCCCTGTATATTCATGAAT 1020

QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAACTTTAAGCATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAACTTTAAGCATA 1080

QY 1081 AGTAAACATGATATAAAATATATATGCTGAATTTCTTGAAGAAATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAAATATATATGCTGAATTTCTTGAAGAAATGCAATTTAAAGCTATT 1140

QY 1141 TTAATGTGTTTTTATTTTGAAGCAATTTTATTAAGAAATTTGTTATATGCTTACTG 1200
DB 1141 TTAATGTGTTTTTATTTTGAAGCAATTTTATTAAGAAATTTGTTATATGCTTACTG 1200

QY 1201 TTCTAATCTGTGTGAAGGATTTCTTAAGAAATTTGAGGTAATGAGGTAATTTTCAAACT 1260
DB 1201 TTCTAATCTGTGTGAAGGATTTCTTAAGAAATTTGAGGTAATGAGGTAATTTTCAAACT 1260

QY 1261 GAATGAGAGAAATTTGATATAACCATCTGCTGTTCTTCTTGTGCAATACAAATAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGATATAACCATCTGCTGTTCTTCTTGTGCAATACAAATAAACTCT 1320

QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
```

RESULT 75
ADD85044

ID ADD85044 standard; cDNA; 1333 BP.

XX AC ADD85044;

XX DT 29-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO181 cDNA.

XX KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

XX KW vulnary; antiarthritic; pericyte cell proliferation;

XX KW pericyte cell differentiation; chondrocyte cell proliferation;

XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

XX KW (TNF)-alpha release; dermal fibroblast cell proliferation;

XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;

XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;

XX KW gene therapy.

XX OS Homo sapiens.

XX XX US2003100722-A1.

XX PD 29-MAY-2003.

XX PF 13-AUG-2002; 2002US-00219476.

XX XX 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Deanoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;

XX XX WPI; 2004-008972/01.

XX DR P-PSDB; ADD85045.

XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX Claim 2; SEQ ID NO 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO326, PRO363, PRO351, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATCGGCTTCAGTTCGCGGCTTCGTACATCGTGGCGTGTGCT 60
DB 1 GCCACGCGTCCGATCGGCTTCAGTTCGCGGCTTCGTACATCGTGGCGTGTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCCACATTATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTAACAAGATTCCTATAGACAGTGTATACCTGGAATCCCTTGTATCTCCAGAGTA 180
DB 121 TGATTAACAAGATTCCTATAGACAGTGTATACCTGGAATCCCTTGTATCTCCAGAGTA 180

QY 181 CCTCATCCGCTTCTTCTGTGTCAGTTCCTTGTGTCAGAGTGGCTTACACCTGGG 240
DB 181 CCTCATCCGCTTCTTCTGTGTCAGTTCCTTGTGTCAGAGTGGCTTACACCTGGG 240

QY 241 TCTCAATATGCCCTCTTGGCAATCATATTTGGAGGTATATAGTAGACAGGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCAATCATATTTGGAGGTATATAGTAGACAGGATGAG 300

QY 301 TGGCCCGAGACTCTATGACCCCTCAACACCATCATGAATGCAGATATCTAGCATATTGTC 360
DB 301 TGGCCCGAGACTCTATGACCCCTCAACACCATCATGAATGCAGATATCTAGCATATTGTC 360

RESULT 76
ADD86870
ID ADD86870 standard; cdna; 1333 BP.
XX

CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGCGGTTTCAGTTCGCGGCGCTTCTGCTACATGTCGCGTCTGCT 60
 DB 1 GCCACGCGTCCGATGCGGTTTCAGTTCGCGGCGCTTCTGCTACATGTCGCGTCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTGGCCATTGGCCATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCGCGCTCATCTTCTTGGCCATTGGCCATTATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAACTCCTATAGACCACTGTAATACCTCCCTGCTTACTCCAGAGTA 180
 DB 121 TGATTACAGAACTCCTATAGACCACTGTAATACCTCCCTGCTTACTCCAGAGTA 180

QY 181 CCTCATCCAGCTTTCTTCTGTGTATGTTTCTTGTGACGAGTGGCTTACATGG 240
 DB 181 CCTCATCCAGCTTTCTTCTGTGTATGTTTCTTGTGACGAGTGGCTTACATGG 240

QY 241 TCTCAATGATGCGCTTCTTGGCATATCATTTTGGAGGTATATGATGACCACTGATGAG 300
 DB 241 TCTCAATGATGCGCTTCTTGGCATATCATTTTGGAGGTATATGATGACCACTGATGAG 300

QY 301 TGGCCGAGCATCTATGACCTTACCAACCATCATGAATCAGATATTTAGCATATTTGTCA 360
 DB 301 TGGCCGAGCATCTATGACCTTACCAACCATCATGAATCAGATATTTAGCATATTTGTCA 360

QY 361 GAAGGAGGATGGTGCATAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGG 420
 DB 361 GAAGGAGGATGGTGCATAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGG 420

QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGCTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGCTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGATAGC 540
 DB 481 GCATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGATAGC 540

QY 541 CTGTGGAATCTCATCAGTTACTTTTAAATAAGTCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTCATCAGTTACTTTTAAATAAGTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTGTTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTAAATGGTAT 660
 DB 601 TTTTGTGTTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTAAATGGTAT 660

QY 661 TACGTATAAATTAATAAATAAGTATTCCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
 DB 661 TACGTATAAATTAATAAATAAGTATTCCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720

QY 721 TTAAGAACAGCCATTAATCTCTGAATGATGATTAATTAATCTGACCTCTAGTACATTG 780
 DB 721 TTAAGAACAGCCATTAATCTCTGAATGATGATTAATTAATCTGACCTCTAGTACATTG 780

QY 781 GAAGCTTTTGTATAGGAACTTTGTAGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
 DB 781 GAAGCTTTTGTATAGGAACTTTGTAGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840

QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATATCTGACTAG 900
 DB 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATATCTGACTAG 900

QY 901 TGGGAAACCTTCATGGGTTTCTCTCATCTGTCATCTCGATGATTATATATGATGATATTC 960

AC ADD86870;
 XX 29-JAN-2004 (first entry)
 XX Novel human secreted and transmembrane protein PRO181 cDNA.

DE human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.

XX Homo sapiens.
 XX US2003100738-A1.
 XX 29-MAY-2003.
 XX 29-AUG-2002; 2002US-00232222.
 XX 15-SEP-2000; 2000US-0232887P.
 XX 01-JUN-2001; 2001WO-US017800.
 XX 29-JUN-2001; 2001WO-US021066.
 XX 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.

FA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 PI WPI: 2004-008988/01.
 XX P-PSDB; ADD86871.

DR New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 XX in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.

XX Claim 2; SEQ ID NO 119; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO1083, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1419, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful

gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

Claim 2; Fig 119; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO531, PRO533, PRO535, PRO537, PRO539, PRO540, PRO541, PRO542, PRO543, PRO544, PRO545, PRO546, PRO547, PRO548, PRO549, PRO550, PRO551, PRO552, PRO553, PRO554, PRO555, PRO556, PRO557, PRO558, PRO559, PRO560, PRO561, PRO562, PRO563, PRO564, PRO565, PRO566, PRO567, PRO568, PRO569, PRO570, PRO571, PRO572, PRO573, PRO574, PRO575, PRO576, PRO577, PRO578, PRO579, PRO580, PRO581, PRO582, PRO583, PRO584, PRO585, PRO586, PRO587, PRO588, PRO589, PRO590, PRO591, PRO592, PRO593, PRO594, PRO595, PRO596, PRO597, PRO598, PRO599, PRO600, PRO601, PRO602, PRO603, PRO604, PRO605, PRO606, PRO607, PRO608, PRO609, PRO610, PRO611, PRO612, PRO613, PRO614, PRO615, PRO616, PRO617, PRO618, PRO619, PRO620, PRO621, PRO622, PRO623, PRO624, PRO625, PRO626, PRO627, PRO628, PRO629, PRO630, PRO631, PRO632, PRO633, PRO634, PRO635, PRO636, PRO637, PRO638, PRO639, PRO640, PRO641, PRO642, PRO643, PRO644, PRO645, PRO646, PRO647, PRO648, PRO649, PRO650, PRO651, PRO652, PRO653, PRO654, PRO655, PRO656, PRO657, PRO658, PRO659, PRO660, PRO661, PRO662, PRO663, PRO664, PRO665, PRO666, PRO667, PRO668, PRO669, PRO670, PRO671, PRO672, PRO673, PRO674, PRO675, PRO676, PRO677, PRO678, PRO679, PRO680, PRO681, PRO682, PRO683, PRO684, PRO685, PRO686, PRO687, PRO688, PRO689, PRO690, PRO691, PRO692, PRO693, PRO694, PRO695, PRO696, PRO697, PRO698, PRO699, PRO700, PRO701, PRO702, PRO703, PRO704, PRO705, PRO706, PRO707, PRO708, PRO709, PRO710, PRO711, PRO712, PRO713, PRO714, PRO715, PRO716, PRO717, PRO718, PRO719, PRO720, PRO721, PRO722, PRO723, PRO724, PRO725, PRO726, PRO727, PRO728, PRO729, PRO730, PRO731, PRO732, PRO733, PRO734, PRO735, PRO736, PRO737, PRO738, PRO739, PRO740, PRO741, PRO742, PRO743, PRO744, PRO745, PRO746, PRO747, PRO748, PRO749, PRO750, PRO751, PRO752, PRO753, PRO754, PRO755, PRO756, PRO757, PRO758, PRO759, PRO760, PRO761, PRO762, PRO763, PRO764, PRO765, PRO766, PRO767, PRO768, PRO769, PRO770, PRO771, PRO772, PRO773, PRO774, PRO775, PRO776, PRO777, PRO778, PRO779, PRO780, PRO781, PRO782, PRO783, PRO784, PRO785, PRO786, PRO787, PRO788, PRO789, PRO790, PRO791, PRO792, PRO793, PRO794, PRO795, PRO796, PRO797, PRO798, PRO799, PRO800, PRO801, PRO802, PRO803, PRO804, PRO805, PRO806, PRO807, PRO808, PRO809, PRO810, PRO811, PRO812, PRO813, PRO814, PRO815, PRO816, PRO817, PRO818, PRO819, PRO820, PRO821, PRO822, PRO823, PRO824, PRO825, PRO826, PRO827, PRO828, PRO829, PRO830, PRO831, PRO832, PRO833, PRO834, PRO835, PRO836, PRO837, PRO838, PRO839, PRO840, PRO841, PRO842, PRO843, PRO844, PRO845, PRO846, PRO847, PRO848, PRO849, PRO850, PRO851, PRO852, PRO853, PRO854, PRO855, PRO856, PRO857, PRO858, PRO859, PRO860, PRO861, PRO862, PRO863, PRO864, PRO865, PRO866, PRO867, PRO868, PRO869, PRO870, PRO871, PRO872, PRO873, PRO874, PRO875, PRO876, PRO877, PRO878, PRO879, PRO880, PRO881, PRO882, PRO883, PRO884, PRO885, PRO886, PRO887, PRO888, PRO889, PRO890, PRO891, PRO892, PRO893, PRO894, PRO895, PRO896, PRO897, PRO898, PRO899, PRO900, PRO901, PRO902, PRO903, PRO904, PRO905, PRO906, PRO907, PRO908, PRO909, PRO910, PRO911, PRO912, PRO913, PRO914, PRO915, PRO916, PRO917, PRO918, PRO919, PRO920, PRO921, PRO922, PRO923, PRO924, PRO925, PRO926, PRO927, PRO928, PRO929, PRO930, PRO931, PRO932, PRO933, PRO934, PRO935, PRO936, PRO937, PRO938, PRO939, PRO940, PRO941, PRO942, PRO943, PRO944, PRO945, PRO946, PRO947, PRO948, PRO949, PRO950, PRO951, PRO952, PRO953, PRO954, PRO955, PRO956, PRO957, PRO958, PRO959, PRO960, PRO961, PRO962, PRO963, PRO964, PRO965, PRO966, PRO967, PRO968, PRO969, PRO970, PRO971, PRO972, PRO973, PRO974, PRO975, PRO976, PRO977, PRO978, PRO979, PRO980, PRO981, PRO982, PRO983, PRO984, PRO985, PRO986, PRO987, PRO988, PRO989, PRO990, PRO991, PRO992, PRO993, PRO994, PRO995, PRO996, PRO997, PRO998, PRO999, PRO1000.

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match	100.0%	Score 1333	DB 10	Length 1333
Best Local Similarity	100.0%	Pred. No. 9.6e-306	Mismatches 0	Gaps 0
Matches 1333	Conservative 0			
QY	1	GGCCACGGTCCGATGGGTTTCCACGTTCCGCGCCCTTCTGCTACATGCTGGCGCTGCTGCT	60	
Db	1	GGCCACGGTCCGATGGGTTTCCACGTTCCGCGCCCTTCTGCTACATGCTGGCGCTGCTGCT	60	
QY	61	CACTGCGCGCTCATCTTCTTCCGCAATTTGGCAGATTTAGCATTTGATGAGTCAAGAC	120	
Db	61	CACTGCGCGCTCATCTTCTTCCGCAATTTGGCAGATTTAGCATTTGATGAGTCAAGAC	120	
QY	121	TGATTAAGAATCTTATAGACGAGTGAATCCCTGAATCCCTTGTATCCCGAGTA	180	
Db	121	TGATTAAGAATCTTATAGACGAGTGAATCCCTGAATCCCTTGTATCCCGAGTA	180	
QY	181	CCTCATCCAGCTTCTTCTGCTGCTATGTTTCTTGTGAGAGTGGCTTACATGGG	240	
Db	181	CCTCATCCAGCTTCTTCTGCTGCTATGTTTCTTGTGAGAGTGGCTTACATGGG	240	
QY	241	TCTCAATATGCCCTCTTGGCAGATTTGGAGTATATGATGAGTCAAGTATGATGAG	300	
Db	241	TCTCAATATGCCCTCTTGGCAGATTTGGAGTATATGATGAGTCAAGTATGATGAG	300	
QY	301	TGGCCAGGAGTCTATGACCCCTACACCATCATGATGAGATATCTAGCATTTGTCTCA	360	
Db	301	TGGCCAGGAGTCTATGACCCCTACACCATCATGATGAGATATCTAGCATTTGTCTCA	360	
QY	361	GAAGGAGGATGGTGCAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTTCT	420	

Db	901	TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATACATTTAC	960
QY	961	AAAAATAAAAAGCGGAAATTTCCCTTCGCTTGAATATATATCCCTGATATTTGATGAAT	1020
Db	961	AAAAATAAAAAGCGGAAATTTCCCTTCGCTTGAATATATATCCCTGATATTTGATGAAT	1020
QY	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAAATAAATATATCTTCTTAAATTTCTTAAGCATA	1080
Db	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAAATAAATATATCTTCTTAAATTTCTTAAGCATA	1080
QY	1081	AGTAAACATGATATAAAATATATATCTGTAATTTACCTTGTGAGAGTCAATTTAAAGTATT	1140
Db	1081	AGTAAACATGATATAAAATATATATCTGTAATTTACCTTGTGAGAGTCAATTTAAAGTATT	1140
QY	1141	TTAAATGCTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTTATATATGCTTACTG	1200
Db	1141	TTAAATGCTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTTATATATGCTTACTG	1200
QY	1201	TTCTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATCAAGATTTTCAAACT	1260
Db	1201	TTCTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATCAAGATTTTCAAACT	1260
QY	1261	GAATGAGAGAAATTTGTAAGCAATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	1320
Db	1261	GAATGAGAGAAATTTGTAAGCAATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	1320
QY	1321	GAATTAAGACTC	1333
Db	1321	GAATTAAGACTC	1333

RESULT 77

ID	ADE20747	standard; cDNA; 1333 BP.
AC	ADE20747;	
DT	29-JAN-2004	(first entry)
XX	Novel human secreted and transmembrane protein PRO181 cDNA.	
XX	Human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;	
XX	vulnary; antiarthritic; pericyte cell proliferation;	
XX	pericyte cell differentiation; chondrocyte cell proliferation;	
XX	chondrocyte cell differentiation; tumour necrosis factor alpha release;	
XX	(TNF)-alpha release; dermal fibroblast cell proliferation;	
XX	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;	
XX	colon tumour; breast tumour; prostate tumour; rectal tumour;	
XX	liver tumour; tissue typing; chromosome mapping; gene mapping;	
XX	gene therapy.	
XX	Homo sapiens.	
XX	US2003100734-A1.	
XX	29-MAY-2003.	
XX	28-AUG-2002; 2002US-00230427.	
XX	01-JUN-2001; 2001WO-US017800.	
XX	29-JUN-2001; 2001WO-US021066.	
XX	09-APR-2002; 2002US-00119480.	
XX	(GETH) GENENTECH INC.	
XX	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;	
XX	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood MT;	
XX	WPI; 2004-008984/01.	
XX	P-PSDB; ADE20748.	
XX	New PRO polypeptide and nucleic acid encoding the polypeptide, useful in	

CC is useful for treating bone and/or cartilage disorders (e.g., arthritis, CC sport injuries). This sequence encodes a human secreted and transmembrane CC PRO polypeptide.

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other; Mismatches 0; Indels 0; Gaps 0;

Query Match 100.0%; Score 1333; DB 10; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGGCTCACTCTTCTGCGCATTTGGCAGATTAATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGGCTCACTCTTCTGCGCATTTGGCAGATTAATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTAACAAGATCCCTATAGACCAGTGAATACCCCTGTAATCCCTTGTACTCCCAAGATTA 180
Db 121 TGATTAACAAGATCCCTATAGACCAGTGAATACCCCTGTAATCCCTTGTACTCCCAAGATTA 180
QY 181 CTTCAATCCAGCTTCTTCTGCTGCTCATGTTCTTTGTGCGAGAGTGGCTTTACACTGG 240
Db 181 CTTCAATCCAGCTTCTTCTGCTGCTCATGTTCTTTGTGCGAGAGTGGCTTTACACTGG 240
QY 241 TCTCAATATGCCCTCTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGATGAG 300
Db 241 TCTCAATATGCCCTCTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGATGAG 300
QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATGAGATATTTAGCATATTTGCA 360
Db 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATGAGATATTTAGCATATTTGCA 360
QY 361 GAAGAAGATGGTGAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGAAGATGGTGAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGATTTGGTCCAGTTAAGT 480
QY 481 GCATCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCCAAAGATGAGC 540
Db 481 GCATCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCCAAAGATGAGC 540
QY 541 CTGTGGAATCTGATGAGTTACTTTTAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATGAGTTACTTTTAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATGATTACCTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGTATAAATTAATAAATGATTACCTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGGCATTAATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATTG 780
Db 721 TTAAGGAACAGGCATTAATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTAGAGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTAGAGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
QY 841 TTATAAATTAAGTGTAGATATCAGGTGCTTCTCATGAAGTGAATATATATCTGACTAG 900
Db 841 TTATAAATTAAGTGTAGATATCAGGTGCTTCTCATGAAGTGAATATATATCTGACTAG 900
QY 901 TGGGAACACTTCAAGGTTTCTTCTCATCTGTCATGTCATGATATATATGATGATATTTAC 960
Db 901 TGGGAACACTTCAAGGTTTCTTCTCATCTGTCATGTCATGATATATATGATGATATTTAC 960

QY 961 AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCATGAAT 1020
Db 961 AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCGAGTAATAAATATATCTGTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCGAGTAATAAATATATCTGTTAAATTTCTTAAGCATA 1080
QY 1081 AGTAACAATGATATAAAAATATATGCTGAATTTACTTGTGAAGAATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACAATGATATAAAAATATATGCTGAATTTACTTGTGAAGAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTTTTTATTTGTAAGACATTTATTAAGAAATGTTGTTATTTGCTTACTG 1200
Db 1141 TTAATGTTTTTATTTGTAAGACATTTATTAAGAAATGTTGTTATTTGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGGTTATTTAAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGTTATTTAAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAAATTTGTAACCATCTGCTGTTCTTTAGTGAATAAATAAACTCT 1320
Db 1261 GAATGAGAGAAAAATTTGTAACCATCTGCTGTTCTTTAGTGAATAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 79

ADE05591

ID ADE05591 standard; cDNA; 1333 BP.

XX ADE05591;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #60.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

tumour; cancer; lung; colon; breast; prostate; rectum; liver;

tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;

pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;

arthritis; sports injury; cytostatic; antiarthritic.

OS Homo sapiens.

XX US2003100727-A1.

XX 29-MAY-2003.

XX 28-AUG-2002; 2002US-00229974.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WL;

XX WPI; 2004-008977/01.

XX P-PSDB; ADE05592.

XX New secreted and transmembrane PRO polypeptide useful for preparing a

XX medicament for treating a condition that is responsive to the PRO

XX polypeptide or anti-PRO antibody, e.g. cancer.

XX Claim 2; Fig 119; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and

transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention.
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 GCCACAGCGTCCGATGGGTTACGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
1 GCCACAGCGTCCGATGGGTTACGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
61 CACTGCCGCGTCACTCTTCTTCCGCAATTTGGCAATTTAGCATTTGATGAGTCAAGAC 120
61 CACTGCCGCGTCACTCTTCTTCCGCAATTTGGCAATTTAGCATTTGATGAGTCAAGAC 120
121 TGATTACAGAACTCTATAGACAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTG 180
121 TGATTACAGAACTCTATAGACAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTG 180
181 CCTCATCCAGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
181 CCTCATCCAGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
241 TCTCAATATGCCCTCTTGGCAATTTAGCATTTGATGAGTCAAGAC 300
241 TCTCAATATGCCCTCTTGGCAATTTAGCATTTGATGAGTCAAGAC 300
301 TGGCCCGAGCTCTATGACCTTACCAATCATGATGATGATGATGATGATGATGATGATGAT 360
301 TGGCCCGAGCTCTATGACCTTACCAATCATGATGATGATGATGATGATGATGATGATGAT 360
361 GAAGGAGGATGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTCTAGCTTATATGG 420
361 GAAGGAGGATGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTCTAGCTTATATGG 420
421 CATGATCTATGTTTGGTGGCTCTTAGAACAACACACAGAGAAATGGTCCAGTTAAGT 480
421 CATGATCTATGTTTGGTGGCTCTTAGAACAACACACAGAGAAATGGTCCAGTTAAGT 480
481 GCATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCTCAAGAGTAGC 540
481 GCATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCTCAAGAGTAGC 540
541 CTGTGGAACTCTGATCAGTACTTTTAAATAAAGTCTTATTTTAAATGTTTCCACAT 600
541 CTGTGGAACTCTGATCAGTACTTTTAAATAAAGTCTTATTTTAAATGTTTCCACAT 600
601 TTTTGTCTGTGGAAGAGCTGTTTCAATGATTTATCTCAGATAAGATTTTAAATGGTAT 660
601 TTTTGTCTGTGGAAGAGCTGTTTCAATGATTTATCTCAGATAAGATTTTAAATGGTAT 660

Qy 661 TACGTATAAATTAATATAAATAAGATTAACCTCTGCTGTTGACAGGTTTGAACCTGCACATTC 720
Db 661 TACGTATAAATTAATATAAATAAGATTAACCTCTGCTGTTGACAGGTTTGAACCTGCACATTC 720
Qy 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
Qy 781 GAAGCTTTTGTATAGGAACCTCTGAGGGCTCATTTTGGTTTCAATGGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTCTGAGGGCTCATTTTGGTTTCAATGGAACAGATATCTAA 840
Qy 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
Qy 901 TGGGAAACCTTCATGGGTTTCTCATCTGCTGATGCTGATGATATATATATGATATGATAT 960
Db 901 TGGGAAACCTTCATGGGTTTCTCATCTGCTGATGCTGATGATATATATATGATATGATAT 960
Qy 961 AAAAATAAAGCGGGAATTTTCCCTTCCGCTTGAATATTTATCCCTGATATTTGATGAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCCGCTTGAATATTTATCCCTGATATTTGATGAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATATCTGCTTAAATCTTAAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATATCTGCTTAAATCTTAAAGCAT 1080
Qy 1081 AGTAAACATGATATAAATAATATATCTGCTGGAATTAATCTGCTGAAGATGATTTAAAGCTAT 1140
Db 1081 AGTAAACATGATATAAATAATATATCTGCTGGAATTAATCTGCTGAAGATGATTTAAAGCTAT 1140
Qy 1141 TTAATGCTGTTTATTTGTAAGACATTTATTAAGAAATGCTTATTAAGAAATGCTTATTAAGCT 1200
Db 1141 TTAATGCTGTTTATTTGTAAGACATTTATTAAGAAATGCTTATTAAGAAATGCTTATTAAGCT 1200
Qy 1201 TTCTAAATCTGCTGTAAGGTTTCTTAAGAAATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260
Db 1201 TTCTAAATCTGCTGTAAGGTTTCTTAAGAAATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260
Qy 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 80
ADD73576
ID ADD73576 standard; cDNA; 1333 BP.
XX AC ADD73576;
XX AC
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #60.
XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX KW arthritis; sports injury; cytostatic; antiarthritic.
XX OS Homo sapiens.
XX PN US2003100711-A1.
XX PD 29-MAY-2003.
XX PF 09-AUG-2002; 2002US-00216167.

RESULT 81

AD48655
ID ADE48655 standard; cDNA; 1333 BP.
XX AC ADE48655;
XX DT 29-JAN-2004 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX OS Homo sapiens.
XX PN US2003104536-A1.
XX PD 05-JUN-2003.
XX PF 19-OCT-2001; 2001US-00166709.
XX PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US024855.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX PA (GETH) GENENTECH INC.
XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI KJavain ID, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood W;

DR WPI; 2004-008994/01.
DR P-PSDB; ADE48655.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO4993 or
PT PRO337, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.

XX Claim 2; SEQ ID NO 321; 450pp; English.

CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting a
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCACGCGTCCGATGCGGTTACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60

Db 1 GCCACGCGTCCGATGCGGTTACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60

Qy 61 CACTGCGCGCTCATCTTCTTCGCGCATTCGCGCATTTAGCATTTGATGAGCTGAAGAC 120

Db 61 CACTGCGCGCTCATCTTCTTCGCGCATTCGCGCATTTAGCATTTGATGAGCTGAAGAC 120

Qy 121 TGATTACAAGAATCCTATAGACAGTGTATACCTGAAATCCCTTGTACTCCAGAGTA 180

Db 121 TGATTACAAGAATCCTATAGACAGTGTATACCTGAAATCCCTTGTACTCCAGAGTA 180

Qy 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTTGTGCGAGCAGAGTGGCTTACACATGGG 240

Db 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTTGTGCGAGCAGAGTGGCTTACACATGGG 240

Qy 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATGATGAGACAGGATGATGAG 300

Db 241 TCTCAATATGCCCTCTTGGCATATCATTTTGGAGGTATATGATGAGACAGGATGATGAG 300

Qy 301 TGGCCCGAGGACTCTATGACCCCTACAGCATTCATGATGCGAGATATTCTTAGCATATTGTCA 360

Db 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATGCAGATATCTAGCATATTGTCA 360
Qy 361 GAAGGAAGGATGGTGCAGAAATAGCTTTTATCTCTAGCATTTTTTTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGGTGCAGAAATAGCTTTTATCTCTAGCATTTTTTTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTCTGTGGAAGACTGTTTCAATGATGTATATCTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTCAATGATGTATATCTCAGATAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATAAATAATGATTAACCTCTGGTGTGACAGCTTTGAACCTTGCATTC 720
Db 661 TACGTATAAATTAATAAATAATGATTAACCTCTGGTGTGACAGCTTTGAACCTTGCATTC 720
Qy 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATGATGATTAATGATGATTAATG 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATGATGATTAATGATGATTAATG 780
Qy 781 GAAGCTTTTGTATAGAACTCTGAGGCTCATTTTGGTTTCAATGGAACAGATCTAA 840
Db 781 GAAGCTTTTGTATAGAACTCTGAGGCTCATTTTGGTTTCAATGGAACAGATCTAA 840
Qy 841 TTATAAATTAAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 900
Db 841 TTATAAATTAAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 900
Qy 901 TGGGAACCTCATGGGTTTCTCATCTGATGATGATGATGATGATGATGATGATGATGATGAT 960
Db 901 TGGGAACCTCATGGGTTTCTCATCTGATGATGATGATGATGATGATGATGATGATGATGAT 960
Qy 961 AAAATAAAGCGGAAATTTTCCCTTCGTTGAATATTTATCCCTGATATATGATGATGAT 1020
Db 961 AAAATAAAGCGGAAATTTTCCCTTCGTTGAATATTTATCCCTGATATATGATGATGAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATATCTGCTTTAATTTCTTAAGCATA 1080
Qy 1081 AGTAACATGATATAAATAATATATCTGATGATGATGATGATGATGATGATGATGATGATGAT 1140
Db 1081 AGTAACATGATATAAATAATATATCTGATGATGATGATGATGATGATGATGATGATGATGAT 1140
Qy 1141 TTAATATGCTTTTATTTGTAAGACATTAATTTAAGAAATGGTATTTATGCTTACTG 1200
Db 1141 TTAATATGCTTTTATTTGTAAGACATTAATTTAAGAAATGGTATTTATGCTTACTG 1200
Qy 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGGATGATGATGATGATGATGATGATGAT 1260
Db 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGGATGATGATGATGATGATGATGATGAT 1260
Qy 1261 GAATGAGGAAATTTGTAATACCCCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
Db 1261 GAATGAGGAAATTTGTAATACCCCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

ADD78416
ID ADD78416 standard; cDNA; 1333 BP.
XX
AC ADD78416;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003100737-A1.
XX
XX 29-MAY-2003.
XX
XX 28-AUG-2002; 2002US-00230438.
XX
XX 15-SEP-2000; 2000US-0232897P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WJ;
XX WPI: 2004-008987/01.
XX P-PSDB; ADD78417.
XX
XX New PRO polypeptide and nucleic acid encoding the polypeptide, useful for
XX gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 2; SEQ ID NO 119; 309pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO1154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO174, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of expression of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or

CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO329, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGCGTCCGATGCGTTCACGTTGCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
 DB 1 GCCACGCGTCCGATGCGTTCACGTTGCGGGCTTCTGCTACATGCTGGCGTGTGCT 60
 QY 61 CACTGCGGCGTCACTCTTCTGCGCATTTGGCAGATTATAGCATTTGATGAGCTGAGAC 120
 DB 61 CACTGCGGCGTCACTCTTCTGCGCATTTGGCAGATTATAGCATTTGATGAGCTGAGAC 120
 QY 121 TGATTACAGAACTCTATAGACAGTCTAAATACCTGAAATCCCTTCTACTCCACAGTA 180
 DB 121 TGATTACAGAACTCTATAGACAGTCTAAATACCTGAAATCCCTTCTACTCCACAGTA 180
 QY 181 CTTCAATCCAGCTTCTCTGTCATGTTTCTTTGTCAGAGAGTGGCTTACACTGG 240
 DB 181 CTTCAATCCAGCTTCTCTGTCATGTTTCTTTGTCAGAGAGTGGCTTACACTGG 240
 QY 241 TCTCAATATGCCCCCTCTGTCATGTTTCTTTGTCAGAGTGGCTTACACTGG 300
 DB 241 TCTCAATATGCCCCCTCTGTCATGTTTCTTTGTCAGAGTGGCTTACACTGG 300
 QY 301 TGGCCAGGACTCTATGACCCCTACAACTCATGAAATGCGATATTTCTAGCATATTTGCA 360
 DB 301 TGGCCAGGACTCTATGACCCCTACAACTCATGAAATGCGATATTTCTAGCATATTTGCA 360
 QY 361 GAAGGAAGGATGGTGCAGAAATTTAGCTTTTATCTTCTAGCATTTTCTACCTATATGG 420
 DB 361 GAAGGAAGGATGGTGCAGAAATTTAGCTTTTATCTTCTAGCATTTTCTACCTATATGG 420
 QY 421 CATGATCTATGTTTGTGAGCTCTTAGAAACACACAGAGAAATGGTCCAGTAAAT 480
 DB 421 CATGATCTATGTTTGTGAGCTCTTAGAAACACACAGAGAAATGGTCCAGTAAAT 480
 QY 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTCTCCAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTCTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTCTGGAAGAGCTGTTTTCATATGTTATATCTCAGATAAGATTTTAAATGGTAT 660
 DB 601 TTTTGTCTGGAAGAGCTGTTTTCATATGTTATATCTCAGATAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAAATTAATATAAAATGATTAAGTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
 DB 661 TACGTATAAAATTAATATAAAATGATTAAGTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
 QY 721 TTAAGGAACAGCAATAAATCTCTGAATGATTAATTAATTAATTAATTAATTAATTAATTA 780
 DB 721 TTAAGGAACAGCAATAAATCTCTGAATGATTAATTAATTAATTAATTAATTAATTAATTA 780
 QY 781 GAAGCTTTGTTTATAGGAACCTTGTAGGCTCATTTTGTGTTTCAATGAAACAGTATCTAA 840
 DB 781 GAAGCTTTGTTTATAGGAACCTTGTAGGCTCATTTTGTGTTTCAATGAAACAGTATCTAA 840
 QY 841 TTATAAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900

DB 841 TTATAAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
 QY 901 TGGGAAACTTTCATGGGTTTCTTCATCTGTCATGTCGATGATATATATGATACATTAC 960
 DB 901 TGGGAAACTTTCATGGGTTTCTTCATCTGTCATGTCGATGATATATATGATACATTAC 960
 QY 961 AAAAAATAAAAGCGGAAATTTCCCTTCGCTTGAATATATATCCCTCTATATTCGATGAAT 1020
 DB 961 AAAAAATAAAAGCGGAAATTTCCCTTCGCTTGAATATATATCCCTCTATATTCGATGAAT 1020
 QY 1021 GAGAGATTTTCCCATATTTTCCATCAGAGTAATAAATATATCTGTTGTTTAAATCTTAAGCAT 1080
 DB 1021 GAGAGATTTTCCCATATTTTCCATCAGAGTAATAAATATATCTGTTGTTTAAATCTTAAGCAT 1080
 QY 1081 AGTAACATGATATAAATAATATATGCTGATATCTGTCGATGATGATGATGATGATGATGAT 1140
 DB 1081 AGTAACATGATATAAATAATATATGCTGATATCTGTCGATGATGATGATGATGATGATGAT 1140
 QY 1141 TTAATATGTTTATTTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTTATTTATGCTTACTG 1200
 DB 1141 TTAATATGTTTATTTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTTATTTATGCTTACTG 1200
 QY 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGTCAGGATCTACAGATTTTCAAACT 1260
 DB 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGTCAGGATCTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTTCTTTAGTGAATACATAAATAAATCTCT 1320
 DB 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTTCTTTAGTGAATACATAAATAAATCTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333
 RESULT 83
 ADE41251
 ID ADE41251 standard; cdna; 1333 BP.
 XX AC ADE41251;
 XX DT
 XX 29-JAN-2004 (first entry)
 XX Human secreted/transmembrane PRO polypeptide cDNA #1.
 DE ss; gene; human; secreted protein; transmembrane protein;
 KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
 KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
 KW age-related macular degeneration; angiogenesis;
 KW endothelial cell apoptosis; smooth muscle cell growth;
 KW endothelial cell tube formation.
 XX Homo sapiens.
 OS US2003100497-A1.
 XX PN
 XX 29-MAY-2003.
 XX PF 16-AUG-2002; 2002US-00223085.
 XX PR 20-JUN-2001; 2001WO-US019692.
 XX PR 09-JUL-2001; 2001WO-US021735.
 XX PR 20-FEB-2002; 2002US-00081056.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Ferrara N, Gerber H, Gerttsen ME, Goddard A;
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
 PI Watanabe CK, Williams PM, Wood WI, Ye W;
 XX WPI; 2004-008957/01.
 DR P-PSDB; ADE41252.
 XX

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO205 or
PT PRO214, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and for treating disorders involving
PT angiogenesis.

XX Claim 2; SEQ ID NO 1; 492pp; English.

XX The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGF-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306; Mismatches 0; Indels 0; Gaps 0;
Matches 1333; Conservative 0;

QY 1 GCCACGGGTCGGATGGCGTTCACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGGGTCGGATGGCGTTCACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCAATATATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCAATATATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAGATCTATAGACGAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTA 180
DB 121 TGATTACAGAGATCTATAGACGAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTA 180
QY 181 CCTCATCCAGCTTCTTCTGCTGCTCATGTTTCTTTGTGCGAGAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTCTTCTGCTGCTCATGTTTCTTTGTGCGAGAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCGCCCTTCTTGGCAATATCATATTTGGAGGTATATGAGTACAGTGAATGAG 300
DB 241 TCTCAATATGCGCCCTTCTTGGCAATATCATATTTGGAGGTATATGAGTACAGTGAATGAG 300
QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATATTTCTAGCATATTTGTCA 360
DB 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATATTTCTAGCATATTTGTCA 360
QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCAT 420
DB 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCAT 420
QY 421 CATGATCTATGTTTGGTGAATTTAGCAATATGAGTGAATTTGAGTGAATTTGAGTGAATTT 480
DB 421 CATGATCTATGTTTGGTGAATTTAGCAATATGAGTGAATTTGAGTGAATTTGAGTGAATTT 480
QY 481 GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCAGAGTAGC 540
DB 481 GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGGGAAGACTGTTTTCATATGTTTATCTAGTAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTTGGGAAGACTGTTTTCATATGTTTATCTAGTAAAGATTTTAAATGGTAT 660

QY 661 TACGTATAAATTAATAAATGAATACCTCTCTGTTGTTGACAGGTTTGAACCTTCACCTTC 720
DB 661 TACGTATAAATTAATAAATGAATACCTCTCTGTTGTTGACAGGTTTGAACCTTCACCTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTCAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAACAGCCATAATCTCTCAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGAACTTCTAGGGCTCATTTTGGTTTTCATTGGAACAGATCTAA 840
DB 781 GAAGCTTTTGTATAGAACTTCTAGGGCTCATTTTGGTTTTCATTGGAACAGATCTAA 840
QY 841 TTATAAATTAAGTCTAGATATCAGTCTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
DB 841 TTATAAATTAAGTCTAGATATCAGTCTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
QY 901 TGGGAACCTTCATCGGTTTCTCATCTCTCATGTCGATGATTAATTAATTAATTAATTAATTA 960
DB 901 TGGGAACCTTCATCGGTTTCTCATCTCTCATGTCGATGATTAATTAATTAATTAATTAATTA 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCCGTTGAATATATATATATATATATATATATATAT 1020
DB 961 AAAAATAAAGCGGGAATTTTCCCTTCCGTTGAATATATATATATATATATATATATATAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATTAATTAATTAATTAATTAATTAAT 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATTAATTAATTAATTAATTAATTA 1080
QY 1081 AGTAAACATGATATAAATAAT 1140
DB 1081 AGTAAACATGATATAAATAAT 1140
QY 1141 TTAATGTTGTTTATTTTGAAGCATTTATTAAGAAATTTGTTTATTAATTAATTAATTAATTA 1200
DB 1141 TTAATGTTGTTTATTTTGAAGCATTTATTAAGAAATTTGTTTATTAATTAATTAATTAATTA 1200
QY 1201 TTCTAATCTGTTGTTAAGGATTTCTTAAGAAATTTGAGGATTAACAGATTTTCAAAACT 1260
DB 1201 TTCTAATCTGTTGTTAAGGATTTCTTAAGAAATTTGAGGATTAACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTTCTTTAGTGAATTAACAATAAACTCT 1320
DB 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTTCTTTAGTGAATTAACAATAAACTCT 1320
QY 1321 GAATTAAGACTC 1333
DB 1321 GAATTAAGACTC 1333

RESULT 84

ADE21239

ID ADE21239 standard; cDNA; 1333 BP.

XX AC ADE21239;

XX DT 29-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO181 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

XX KW vulnary; antiarthritic; pericyte cell proliferation;

XX KW pericyte cell differentiation; chondrocyte cell proliferation;

XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

XX KW (TNF)-alpha release; dermal fibroblast cell proliferation;

XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;

XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;

XX KW gene therapy.

XX OS Homo sapiens.

XX XX

XX PN US2003100736-A1.

XX 29-MAY-2003.
 XX 28-AUG-2002; 2002US-00230435.
 XX 01-JUN-2001; 2001WO-US017800.
 XX 29-JUN-2001; 2001WO-US021066.
 XX 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
 XX Grimaldi JC, Garney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;
 XX WPI; 2004-008986/01.
 XX P-PSDB; ADE21240.
 XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 XX in gene therapy, chromosome identification, tissue typing, or as
 XX hybridization probes in chromosome and gene mapping.
 XX Claim 2; Fig 119; 309pp; English.
 XX The invention describes an isolated PRO (secreted and transmembrane)
 XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 XX useful for stimulating the proliferation of or gene expression in
 XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 XX for stimulating the proliferation or differentiation of chondrocyte
 XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 XX are useful for stimulating the release of tumour necrosis factor (TNF)-
 XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 XX PRO247, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
 XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 XX PRO2940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 XX stimulating the proliferation of normal human dermal fibroblasts cells.
 XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 XX PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 XX polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 XX are useful for detecting the presence of tumour in a mammal which
 XX involves comparing the level of expression of the above PRO polypeptides
 XX in a test sample of cells taken from the mammal, and a control sample of
 XX normal cells of the same cell type, where a higher level of expression of
 XX the PRO polypeptides in the test sample as compared to the control sample
 XX is indicative of the presence of tumour in the mammal. The tumour is lung
 XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 XX liver tumour. (I) is useful as molecular weight markers, for tissue
 XX typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 XX useful for chromosome and gene mapping or gene therapy. (II) is useful
 XX for generating transgenic animals or knock-out animals which are useful
 XX screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 XX is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 XX sport injuries). This sequence encodes a human secreted and transmembrane
 XX PRO polypeptide.
 XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 XX Query Match 100.0%; Score 1333; DB 10; Length 1333;
 XX Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 XX Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 1 GCCACGCGTCGATGCGCTTCACGTCGCGGCTTCCTGCTACATGCTGCGCTGCTGCT 60
 XX Db 1 GCCACGCGTCGATGCGCTTCACGTCGCGGCTTCCTGCTACATGCTGCGCTGCTGCT 60
 XX 61 CACTGCGGCGCTCATCTTCTTGGCCATTTGGCCATATAGCATTTGATGAGCTGAGAC 120
 XX Db 61 CACTGCGGCGCTCATCTTCTTGGCCATTTGGCCATATAGCATTTGATGAGCTGAGAC 120

QY 121 TGATTACAAGATCCCTATAGACCAGTGTATACCCCTGAATCCCTTCTACTCCACAGTA 180
 Db 121 TGATTACAAGATCCCTATAGACCAGTGTATACCCCTGAATCCCTTCTACTCCACAGTA 180
 QY 181 CCTCATCCACGCTTCTTCTGTGTATGTTTCTTGTGACAGAGTGGCTTACACTGGG 240
 Db 181 CCTCATCCACGCTTCTTCTGTGTATGTTTCTTGTGACAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTATGAGTATGAG 300
 Db 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTATGAGTATGAG 300
 QY 301 TGGCCAGGAGTCTATGACCCCTACCAACATCATGATGACAGATATTTCTAGCATATTTCTCA 360
 Db 301 TGGCCAGGAGTCTATGACCCCTACCAACATCATGATGACAGATATTTCTAGCATATTTCTCA 360
 QY 361 GAAGGAAGGATGGTGCMAAATTAGCTTTTATCTTCTAGCATTTTCTTCTACCTATATGG 420
 Db 361 GAAGGAAGGATGGTGCMAAATTAGCTTTTATCTTCTAGCATTTTCTTCTACCTATATGG 420
 QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
 Db 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAAGTAGC 540
 Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTCTGTGGAAGACTCTTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
 Db 601 TTTTGTCTGTGGAAGACTCTTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
 QY 661 TACGTATAAAATTAATAAATGATTAACCTCTGCTGTGTGACAGGTTTGAACCTGCACCTC 720
 Db 661 TACGTATAAAATTAATAAATGATTAACCTCTGCTGTGTGACAGGTTTGAACCTGCACCTC 720
 QY 721 TTAGGAACAGCCATTAATCTCTGAATGATGATTAATTAATGATGCTGCTAGTACATTTG 780
 Db 721 TTAGGAACAGCCATTAATCTCTGAATGATGATTAATTAATGATGCTGCTAGTACATTTG 780
 QY 781 GAAGCTTTGTTTATAGGAATCTTTAGGGCTCATTTTGGTTTCATTTGAAACAGTATCTAA 840
 Db 781 GAAGCTTTGTTTATAGGAATCTTTAGGGCTCATTTTGGTTTCATTTGAAACAGTATCTAA 840
 QY 841 TTATAAATTAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
 Db 841 TTATAAATTAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
 QY 901 TGGGAACCTCATGGGTTTCT 960
 Db 901 TGGGAACCTCATGGGTTTCT 960
 QY 961 AAAATAAAAAAGCGGAATTTTCCCTGCTGGAATATATATCCCTGTTATATTTGATGATGAAT 1020
 Db 961 AAAATAAAAAAGCGGAATTTTCCCTGCTGGAATATATATATATATATATATATATATAT 1020
 QY 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATAATATATCTTGCCTTAATTTCTTAAGCATA 1080
 Db 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATAATATATCTTGCCTTAATTTCTTAAGCATA 1080
 QY 1081 AGTAAACATGATATATAAATATATGCTGAATTTCTTGTGAAGATGCAATTTAAAGCTAAT 1140
 Db 1081 AGTAAACATGATATATAAATATATGCTGAATTTCTTGTGAAGATGCAATTTAAAGCTAAT 1140
 QY 1141 TTAATATGTTTATTTTGAAGCATTACTTTATTAAGAAATTTGGTATTTATGCTTACTTG 1200
 Db 1141 TTAATATGTTTATTTTGAAGCATTACTTTATTAAGAAATTTGGTATTTATGCTTACTTG 1200
 QY 1201 TTCTAATCTGGTGTAAAGGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260

Db 661 TACGTATAAATTAATAAATAATGATTACCTCTGGTGTGACAGGTTTGAACTTGCACCTC 720
Qy 721 TTAAGGAACAGCCATAATCCTCTGAATGATGCAATTAATTAAGTCACTGCTCTAGTACATG 780
Db 721 TTAAGGAACAGCCATAATCCTCTGAATGATGCAATTAATTAAGTCACTGCTCTAGTACATG 780
Qy 781 GAAGCTTTTCTTTATAGGAATCTGTAGGCTCAATTTTGGTTTCATTTGAACAGATCTAA 840
Db 781 GAAGCTTTTCTTTATAGGAATCTGTAGGCTCAATTTTGGTTTCATTTGAACAGATCTAA 840
Qy 841 TTATAAATTAGCTGTAGATATCAGGTCTCTCTGATGAAGTGAATATATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTCTCTCTGATGAAGTGAATATATATCTGACTAG 900
Qy 901 TGGGAATCTTCATGGGTTTCTCTCTGATGATGATGATGATGATGATGATGATGATGAT 960
Db 901 TGGGAATCTTCATGGGTTTCTCTCTGATGATGATGATGATGATGATGATGATGATGAT 960
Qy 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATAATATATATATATATATATATAT 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATAATATATATATATATATATAT 1080
Qy 1081 AGTAAACATGATATAAATAATATATGCTGAATATCTGTGAAGATGATTAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATATCTGTGAAGATGATTAAGCTATT 1140
Qy 1141 TTAATGCTGTTTATTTGTAAGACATTTACATTTATTAAGAAATGCTTTATATGCTTACTG 1200
Db 1141 TTAATGCTGTTTATTTGTAAGACATTTACATTTATTAAGAAATGCTTTATATGCTTACTG 1200
Qy 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGCAGGTAATACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGCAGGTAATACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGATTAACATCTCTGCTGCTGCTTCTTAGTGAATACATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACATCTCTGCTGCTGCTTCTTAGTGAATACATAAACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 86
ADE20501
ID ADE20501 standard; cDNA; 1333 BP.
AC ADE20501;
XX DT
XX 29-JAN-2004 (first entry)
XX DE
XX Novel human secreted and transmembrane protein PRO181 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX OS
XX Homo sapiens.
XX PN US2003100733-A1.
XX 29-MAY-2003.
XX PD
XX

PF 28-AUG-2002; 2002US-00230426.
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX P-PSDB; ADE20502.
XX WPI; 2004-008983/01.
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1084, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1186, PRO1192, PRO1274, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCCACGCGTCCGATGGGTTACGTTTCGGGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCACGCGTCCGATGGGTTACGTTTCGGGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Qy 61 CACTGCGCGCTCATCTTTTCGGCCATTGGCCATTATAGCATTGATAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTTTCGGCCATTGGCCATTATAGCATTGATAGCTGAAGAC 120
Qy 121 TGATTACAGAAATCCTATAGACCGATGTAATACCTGTAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAGAAATCCTATAGACCGATGTAATACCTGTAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATGACGCTTTCTTCTGTGTCATGTTCTTTGTGACGAGAGTGGCTTACACTGGG 240
Db 181 CCTCATGACGCTTTCTTCTGTGTCATGTTCTTTGTGACGAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGAGGTATATGATAGTACAGAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGAGGTATATGATAGTACAGAGTATGAG 300
QY 301 TGGCCAGGACTATAGACCCCTACACCATCATGAATGCAGANATCTAGCATATTTGCA 360
Db 301 TGGCCAGGACTATAGACCCCTACACCATCATGAATGCAGANATCTAGCATATTTGCA 360
QY 361 GAAGGAGGATGCTGCAAAATTTAGCTTTTCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAGGATGCTGCAAAATTTAGCTTTTCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGTAGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGTAGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGTAGC 540
Db 481 GCATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGTAGC 540
QY 541 CTGTGGGATCTGATCAGTTACTTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
Db 541 CTGTGGGATCTGATCAGTTACTTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACAT 600
QY 601 TTTTGTGTTGGAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTGTTGGAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAAATGATTAATCTGCTGTTGTTGAAGTTTGAACCTGCACTTC 720
Db 661 TAGCTATAAATTAATAAATGATTAATCTGCTGTTGTTGAAGTTTGAACCTGCACTTC 720
QY 721 TTAAGGAACGCCATAATCTCTGAATGATCATTAATTAATGATGCTGCTAGTACATTTG 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATCATTAATTAATGATGCTGCTAGTACATTTG 780
QY 781 GAAGCTTTGTTTATAGAACTTTGAGGGCTCAITTTGTTTCAITGAAACAGATATCTAA 840
Db 781 GAAGCTTTGTTTATAGAACTTTGAGGGCTCAITTTGTTTCAITGAAACAGATATCTAA 840
QY 841 TTTAAATTTAGCTGATATACAGTGTCTGATGAGTGAATGATATATCTGACTAG 900
Db 841 TTTAAATTTAGCTGATATACAGTGTCTGATGAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAAACTTTCATGGGTTTCCCTCATCTGCTGATGATATATATGGATATATTTAC 960
Db 901 TGGGAAACTTTCATGGGTTTCCCTCATCTGCTGATGATATATATGGATATATTTAC 960
QY 961 AAAATAAAAGCGGGAATTTTCCCTGCTGTTGAATATATCCCTGTTATATGATGAAT 1020
Db 961 AAAATAAAAGCGGGAATTTTCCCTGCTGTTGAATATATCCCTGTTATATGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGATA 1080
QY 1081 AGTAACATGATATAAAATATATCTGCTGATTTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAAATATATCTGCTGATTTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTTTATTTTGAAGATTTATCTTATTAAGAAATGTTTATATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTTGAAGATTTATCTTATTAAGAAATGTTTATATGCTTACTG 1200
QY 1201 TTTCTAATCTGGTGGTAAAGGTTATCTTAAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTTCTAATCTGGTGGTAAAGGTTATCTTAAAGATTTGCAAGTACTACAGATTTTCAAACT 1260

QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCTTCTTAGTCAATTAATAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCTTCTTAGTCAATTAATAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 87
ADD75566
ID ADD75566 standard; cDNA; 1333 BP.
XX AC ADD75566;
XX AC
XX 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #60.
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX arthritis; sports injury; cytostatic; antiarthritic.
XX Homo sapiens.
XX
XX US2003100064-A1.
XX 29-MAY-2003.
XX 12-AUG-2002; 2002US-00219060.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008955/01.
XX P-PSDB; ADD75567.
XX New nucleic acid, for the manufacture of a medicament for diagnosing or
XX treating tumor or for measuring or detecting expression of an associated
XX gene.
XX Claim 2; Fig 119; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as

CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human p90 polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC at segdata.uspto.gov/sequence.html.

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

```
Query Match      100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. NO. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0;
```

Qy	1	GCCACGGCTCGATGGCGTTCACCTTCGGCGCCCTTCGTACATGCTGGCGCTGCTGCT	60
Db	1	GCCACGGCTCGATGGCGTTCACCTTCGGCGCCCTTCGTACATGCTGGCGCTGCTGCT	60
Qy	61	CACCTGCCGCGCTCATCTCTCTTCGCGCATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC	120
Db	61	CACCTGCCGCGCTCATCTCTCTTCGCGCATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC	120
Qy	121	TGATTTACAAGAATCCTATAGACCAAGTGTAATACCGTGAATCCCTTGTACTCCCAAGATA	180
Db	121	TGATTTACAAGAATCCTATAGACCAAGTGTAATACCGTGAATCCCTTGTACTCCCAAGATA	180
Qy	181	CCTCATCCACGCTTCTCTTCGTGTCATGTTCTTGTGTCGACAGAGTGGCTTACACTGGG	240
Db	181	CCTCATCCACGCTTCTCTTCGTGTCATGTTCTTGTGTCGACAGAGTGGCTTACACTGGG	240
Qy	241	TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTCATGAG	300
Db	241	TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTCATGAG	300
Qy	301	TGGGCCAGGACTCTATAGACCTTAACAACCATGTAAGTGGAGGTATATGAGTAGACCAAGTGA	360
Db	301	TGGGCCAGGACTCTATAGACCTTAACAACCATGTAAGTGGAGGTATATGAGTAGACCAAGTGA	360
Qy	361	GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACTCTATATGG	420
Db	361	GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACTCTATATGG	420
Qy	421	CATGATCTATGTTTTTGGTGAGCTCTTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT	480
Db	421	CATGATCTATGTTTTTGGTGAGCTCTTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT	480
Qy	481	GCATGCAAAAAGCCACCAAAATGAAGGATTTATCCAGCAGAGATCCTGTCCMAAGTAGTC	540
Db	481	GCATGCAAAAAGCCACCAAAATGAAGGATTTATCCAGCAGAGATCCTGTCCMAAGTAGTC	540
Qy	541	CTGTGGAACTCTGATCAGTTACTTTTAAAAATGACTCCTTTATTTTTTAAATGTTTCCACAT	600
Db	541	CTGTGGAACTCTGATCAGTTACTTTTAAAAATGACTCCTTTATTTTTTAAATGTTTCCACAT	600
Qy	601	TTTTGCTTGTGGAAGAAGCTGTTTTTCAATATGTTTATCTCAGATAAAGATTTTAAATGGTAT	660
Db	601	TTTTGCTTGTGGAAGAAGCTGTTTTTCAATATGTTTATCTCAGATAAAGATTTTAAATGGTAT	660
Qy	661	TACGTATAAATTAATATAAATGATTTACTCTGGTGTGACAGGTTTGAATTGACATTC	720
Db	661	TACGTATAAATTAATATAAATGATTTACTCTGGTGTGACAGGTTTGAATTGACATTC	720
Qy	721	TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTTACTGACTGTCTTAGTACATTG	780
Db	721	TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTTACTGACTGTCTTAGTACATTG	780
Qy	781	GAAGCTTTTGTTTATAGGAACCTTGATAGGCTCATTTTGGTTTCATTTGAACAGTATCTAA	840
Db	781	GAAGCTTTTGTTTATAGGAACCTTGATAGGCTCATTTTGGTTTCATTTGAACAGTATCTAA	840
Qy	841	TTATAAAATTAGCTGTAGATATCAGGTGCTTCTGTGATGACAGTGAATATGATATCTCACTAG	900
Db	841	TTATAAAATTAGCTGTAGATATCAGGTGCTTCTGTGATGACAGTGAATATGATATCTCACTAG	900
Qy	901	TGGGAAACCTTCATGGGTTTCTTCATCTGTGATGTGGATGATATATATGGATACATTTTAC	960

RESULT 88
ADD74082

ID ADD74082 standard; cDNA; 1333 BP.

AA ADD74082;

DT 29-JAN-2004 (first entry)

XX DE Human pro polynucleotide #60.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX PN US2003100708-A1

XX PD 29-MAY-2003

XX
PF 09-AUG-2002: 2002US-00216160.XX
PR 01-AUG-2000: 2000US-0222425P.

PR	01-JUN-2001; 2001WO-US017800;
PR	29-JUN-2001; 2001WO-US021066;

PR 09-APR-2002; 2002US-00119480: XX

PA (GETH) GENENTECH INC.
XX

PI Baker KP, Desnoyers L
PI Grimaldi JC, Gurnev A

XX
DR WPT: 2004-008958/01-

DR P-PSDB; ADD74083.
XX

PT
New secreted and treated
medicament for treatment

PT polypeptide or an
yy

PS Claim 2; Fig 119; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCGGATGCGGCTTCACTGTCGGGCTTCTGCTACATGCTGCGCGCTGCTGCT 60
DB 1 GCCACGCGTCGGATGCGGCTTCACTGTCGGGCTTCTGCTACATGCTGCGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTGCGCATATGCGCATATGCGCATATGCGCATATGCGCATATGCGCAT 120
DB 61 CACTGCGCGCTCATCTTCTGCGCATATGCGCATATGCGCATATGCGCATATGCGCATATGCGCAT 120
QY 121 TCATTACAGAGATCCCTATAGACAGGTATATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTA 180
DB 121 TGATTACAGAGATCCCTATAGACAGGTATATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTA 180
QY 181 CTTCAATCCAGCTTTCTTCTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGGG 240
DB 181 CTTCAATCCAGCTTTCTTCTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTTTGGCATATCATATTTGGAGGTATATGAGTACAGTGGATGAG 300
DB 241 TCTCAATATGCCCTTTGGCATATCATATTTGGAGGTATATGAGTACAGTGGATGAG 300
QY 301 TGGCCGAGGACTCTATGACCTTACACCATCATGATGAATGAGATATTTAGCATATTTGTC 360
DB 301 TGGCCGAGGACTCTATGACCTTACACCATCATGATGAATGAGATATTTAGCATATTTGTC 360
QY 361 GAAGGAGAGATGGTGCAATATAGCTTTTATCTTCTAGCATTTTATCTTCTAGCATTTTATCT 420
DB 361 GAAGGAGAGATGGTGCAATATAGCTTTTATCTTCTAGCATTTTATCTTCTAGCATTTTATCT 420
QY 421 CATGATCTATGTTTGGTGGCTCTTAGACACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGGCTCTTAGACACACACACAGAGAAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCAGCAAGATCTCTGTCGAAGATAGC 540
DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCAGCAAGATCTCTGTCGAAGATAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATATAATTAATAAATGATTAACCTCTGCTGTTGACAGGTTTGAACCTTGCACTTC 720
DB 661 TACGTATATAATTAATAAATGATTAACCTCTGCTGTTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGACACGCCATAATCTCTGAATGATGCAATTAATTAATCTGCTGCTAGTACATTTG 780
DB 721 TTAAGGACACGCCATAATCTCTGAATGATGCAATTAATTAATCTGCTGCTAGTACATTTG 780
QY 781 GAAGCTTTGTTTATAGAACTTTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
DB 781 GAAGCTTTGTTTATAGAACTTTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
QY 841 TTATAAATTAAGCTGTAGATATACAGTGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
DB 841 TTATAAATTAAGCTGTAGATATACAGTGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
QY 901 TGGGAAACTTTCATGGGTTTCTCTCATGTCATGTCGATGATTAATATATATATATATATATAT 960
DB 901 TGGGAAACTTTCATGGGTTTCTCTCATGTCATGTCGATGATTAATATATATATATATATATAT 960
QY 961 AAAAATAAAGCGGAAATTTCCCTTCGCTTGAATATATATATATATATATATATATATATATAT 1020
DB 961 AAAAATAAAGCGGAAATTTCCCTTCGCTTGAATATATATATATATATATATATATATATATAT 1020
QY 1021 GAGAGATTTCCCAVATTTCCATCAGAGTAATAAATAATATATATATATATATATATATATAT 1080
DB 1021 GAGAGATTTCCCAVATTTCCATCAGAGTAATAAATAATATATATATATATATATATATATAT 1080
QY 1081 AGTAACATGATATAAATAATATATGCTGAATATCTGTGGAAGATGCAATTTAAAGCTATT 1140
DB 1081 AGTAACATGATATAAATAATATATGCTGAATATCTGTGGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTTGTTTATTTTGAAGACATTAATTAATAAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1200
DB 1141 TTAATGTTGTTTATTTTGAAGACATTAATTAATAAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1200
QY 1201 TTTCAATCTGCTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
DB 1201 TTTCAATCTGCTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320
DB 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 89
ADD74328
ID ADD74328 standard; cDNA; 1333 BP.
XX
AC ADD74328;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #60.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
OS Homo sapiens.
XX
PN US2003100709-A1.

XX	29-MAY-2003.	QY	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTATGAG	300
PD		DB		
XX	09-AUG-2002; 2002US-00216162.	QY	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTATGAG	300
PF		DB		
XX	25-JUL-2000; 2000US-0220585P.	QY	TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATGAGATATTTCTAGCATATTTGTCA	360
XX	01-JUN-2001; 2001WO-US017800.	DB		
PR	29-JUN-2001; 2001WO-US021066.	QY	TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATGAGATATTTCTAGCATATTTGTCA	360
PR	09-APR-2002; 2002US-00119480.	DB		
XX	(GETH) GENENTECH INC.	QY	GAAGGAGGATGGTGCAGATTTAGCTTTTATCTTCTAGCAATTTTCTACCTATATGG	420
XX		DB		
XX	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;	QY	CATGATCTATGTTTGGTGGAGCTCTTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT	480
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;	DB		
XX	WPI; 2004-008959/01.	QY	CATGATCTATGTTTGGTGGAGCTCTTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT	480
DR	P-PSDB; ADD74329.	DB		
XX		QY	GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCACAGAGTAGC	540
XX		DB		
XX	New secreted and transmembrane PRO polypeptide useful for preparing a	QY	GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCACAGAGTAGC	540
PT	medicament for treating a condition that is responsive to the PRO	DB		
PT	polypeptide or anti-PRO antibody, e.g. cancer.	QY	CTGCGAATCTGATCAGTTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT	600
XX		DB		
XX	Claim 2; Fig 119; 309pp; English.	QY	CTGCGAATCTGATCAGTTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT	600
XX		DB		
XX	The invention relates to human PRO polypeptides (secreted and	QY	TTTTGCTTGTGGAAGACTGTTTTTCAATGTTATCTCAGATAAAGATTTTAAATGTTAT	660
CC	transmembrane polypeptides) and the PRO polynucleotides encoding them.	DB		
CC	The PRO polypeptides and polynucleotides are useful as pharmaceuticals,	QY	TTTTGCTTGTGGAAGACTGTTTTTCAATGTTATCTCAGATAAAGATTTTAAATGTTAT	660
CC	diagnostics, biosensors or bioreactors. They are particularly useful for	DB		
CC	detecting tumours (e.g. lung tumour, colon tumour, breast tumour,	QY	TAGTATAAATTAATAAATGAATGATTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT	720
CC	prostate tumour, rectal tumour or liver tumour) in a mammal, for	DB		
CC	stimulating the release of tumour necrosis factor (TNF)-alpha from human	QY	TAGTATAAATTAATAAATGAATGATTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT	720
CC	blood, for stimulating the proliferation or differentiation of	DB		
CC	chondrocyte cells, for stimulating the proliferation of or gene	QY	TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTTACTGATCTGCTCTAGTACATTTG	780
CC	expression in pericyte cells or for stimulating the proliferation of	DB		
CC	normal human dermal fibroblasts. The PRO nucleic acids are useful as	QY	TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTTACTGATCTGCTCTAGTACATTTG	780
CC	hybridisation probes, in chromosome and gene mapping, in generating	DB		
CC	antisense RNA and DNA, in preparing PRO polypeptides by recombinant	QY	GAAGCTTTTGTGTTATAGGAATCTGTAGGGTTCATTTTGGTTCATTTGAACAGATATCTAA	840
CC	technology, in generating transgenic animals or knock-out animals which	DB		
CC	may be used in the development and screening of therapeutically useful	QY	GAAGCTTTTGTGTTATAGGAATCTGTAGGGTTCATTTTGGTTCATTTGAACAGATATCTAA	840
CC	reagents, in gene therapy, in chromosome identification, as chromosome	DB		
CC	markers and in generating probes. The PRO polypeptides, or anti-PRO	QY	TTATAAATAGCTGTAGATATCAGGTCTCTGTGATGAGTGAAATGTTATCTATCTGACTAG	900
CC	antibodies, are useful for preparing a medicament for treating a	DB		
CC	condition which is responsive to the PRO polypeptides or anti-PRO	QY	TTATAAATAGCTGTAGATATCAGGTCTCTGTGATGAGTGAAATGTTATCTATCTGACTAG	900
CC	antibodies, such as pericyte-associated tumours and bone and/or cartilage	DB		
CC	disorders (e.g. arthritis, sports injuries), involving inducing the re-	QY	TGGGAAACTTCATGGGTTTCTCATCTGTCTGATGCGATGATTTATATGATGATACATTTAC	960
CC	differentiation of chondrocytes. The PRO polypeptides are useful as	DB		
CC	molecular markers for protein electrophoresis, and in tissue typing. This	QY	TGGGAAACTTCATGGGTTTCTCATCTGTCTGATGCGATGATTTATATGATGATACATTTAC	960
CC	sequence represents a human PRO polynucleotide of the invention. Note:	DB		
CC	The sequence data for this patent is also available in electronic format	QY	AAAAATAAAGCGGGAAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATTTGATGAT	1020
CC	at seqdata.uspto.gov/sequence.html.	DB		
XX		QY	AAAAATAAAGCGGGAAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATTTGATGAT	1020
XX		DB		
SQ	Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;	QY	GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGTTTAAATCTTAAAGCAT	1080
	Query Match 100.0%; Score 1333; DB 10; Length 1333;	DB		
	Best Local Similarity 100.0%; Pred. No. 9.6e-306;	QY	GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGTTTAAATCTTAAAGCAT	1080
	Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	DB		
QY	1 GCCACGCGTCCGATGGGTTTACCTTGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60	QY	AGTAAACATGATATAAATAATATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	1140
DB	1 GCCACGCGTCCGATGGGTTTACCTTGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60	DB		
QY	61 CACTCCCGGCTCATCTTCTCGCATATTTGGCAGATATAGCATTTGATGAGCTGAAGAC 120	QY	TTAAATGTTTATTTTGAAGACATTTTAAAGAAATTTGGTATTTATTTGCTTACTG	1200
DB	61 CACTCCCGGCTCATCTTCTCGCATATTTGGCAGATATAGCATTTGATGAGCTGAAGAC 120	DB		
QY	121 TGATTAAGAATCTCTATAGACAGTGTATATACCTGTAATCCCTGTGATCTCCAGAGTA 180	QY	TTTCTAACTGCTGGTGAAGGATTTCTTAAAGAAATTTGCAAGTACACAGATTTTCAAACT	1260
DB	121 TGATTAAGAATCTCTATAGACAGTGTATATACCTGTAATCCCTGTGATCTCCAGAGTA 180	DB		
QY	181 CCTCATCCAGCTTCTTCTGTCATGTTTCTTTGTCGACAGAGTGGCTTACACTGGG 240	QY	GAATGAGAGAAAATTTGTATAACCATCTCTGCTGCTGCTTCTTCTTCTTCTTCTTCTTCT	1320
DB	181 CCTCATCCAGCTTCTTCTGTCATGTTTCTTTGTCGACAGAGTGGCTTACACTGGG 240	DB		
XX		QY	GAATGAGAGAAAATTTGTATAACCATCTCTGCTGCTGCTTCTTCTTCTTCTTCTTCTTCT	1320
XX		DB		
XX		QY	GAATTAAGACTC 1333	

Db 1321 GAAATTAGACTC 1333
|||||
RESULT 90
ADD76058
ID ADD76058 standard; cDNA; 1333 BP.
AC ADD76058;
XX 29-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO181 cDNA.
XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX Homo sapiens.
OS US2003100718-A1.
FN 29-MAY-2003.
XX 13-AUG-2002; 2002US-00219467.
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008968/01.
DR P-PSDB; ADD76059.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.
XX Claim 2; SEQ ID NO 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (i). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1083, PRO840, PRO1080,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1071, PRO1411, PRO1309,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4444, PRO4322,
CC PRO9840, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5776, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides

CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGTCCGATGGCGTTTCACGTTTCGGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGTCCGATGGCGTTTCACGTTTCGGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTCGCCATTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTCGCCATTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACCGAGTGAATACCTGAAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAAGAAATCCTATAGACCGAGTGAATACCTGAAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCACGCTTCTTCTGTGTCATGTTCTTGTGTCAGACAGTGGCTTACACTGG 240
DB 181 CCTCATCCACGCTTCTTCTGTGTCATGTTCTTGTGTCAGACAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACAGTGAATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACAGTGAATGAG 300
QY 301 TGGCCGAGGACTATGACCCCTACACCATCATGAAATGACATATTTAGCATATTTGCA 360
DB 301 TGGCCGAGGACTATGACCCCTACACCATCATGAAATGACATATTTAGCATATTTGCA 360
QY 361 GAAGGAAGAGTGTGCAAAATAGCTTTTATCTTCTAGCATTTTTTACTACTATATGG 420
DB 361 GAAGGAAGAGTGTGCAAAATAGCTTTTATCTTCTAGCATTTTTTACTACTATATGG 420
QY 421 CATGATCTATGTTTTGGTGGCTTTAGAACAAACACAGAAAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTTGGTGGCTTTAGAACAAACACAGAAAGAAATGGTCCAGTTAAGT 480
QY 481 GCATCAAAAAGCCACCAAAATGAAGGATCTATCCAGCAGATCTCTGCCAAGGTAGC 540
DB 481 GCATCAAAAAGCCACCAAAATGAAGGATCTATCCAGCAGATCTCTGCCAAGGTAGC 540
QY 541 CTGTGCAATCTGATCAGTTACTTTTAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGCAATCTGATCAGTTACTTTTAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTGTGAAAGACATGTTTTTCAATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTGTGTGAAAGACATGTTTTTCAATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGATATAAATTAATAAATGAATGATCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
DB 661 TACGATATAAATTAATAAATGAATGATCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCATAAATCCTCTGATGATGATTAATTAATCTAGCTGTCTAGTACATGG 780
DB 721 TTAAGGAACAGCATAAATCCTCTGATGATGATTAATTAATCTAGCTGTCTAGTACATGG 780
QY 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTTCATTGAAACAGTATCTTAA 840

Db 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCAATTTGGTTTCATTTGAAACAGTAICTAA 840
Qy 841 TTATAAATTAGCTGTAGATATACAGGTGCTTTCTGATGAAGTGAATAATGATATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATACAGGTGCTTTCTGATGAAGTGAATAATGATATATCTGACTAG 900
Qy 901 TGGGAAACTTTCATGGGTTTCTCTCATCTGCTGATGCGAATGATATATATGATGATCAATTTAC 960
Db 901 TGGGAAACTTTCATGGGTTTCTCTCATCTGCTGATGCGAATGATATATATGATGATCAATTTAC 960
Qy 961 AAAAATAAAGCGGGAATTTTCCCTTCGGTTGAATATATCCCTGTATATTTGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGGTTGAATATATCCCTGTATATTTGATGAAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGATTAATAATATACATTTGCTTTAATCTTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGATTAATAATATACATTTGCTTTAATCTTTAAGCATA 1080
Qy 1081 AGTAAACATGATATAAATAATATATGCTGATGCTGATGCTGATGCTGATGCTGATGCTGAT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGATGCTGATGCTGATGCTGATGCTGATGCTGAT 1140
Qy 1141 TTAATGCTGTTTATTTTGAAGACATTAATTAATAATATGCTGATGCTGATGCTGATGCTGAT 1200
Db 1141 TTAATGCTGTTTATTTTGAAGACATTAATTAATAATATGCTGATGCTGATGCTGATGCTGAT 1200
Qy 1201 TTCTAATCTGCTGTTGTAAGATTAATTTAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGCTGTTGTAAGATTAATTTAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db 1261 GAATGAGAGAAATTTGATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 91
ADD85550 standard; cDNA; 1333 BP.
ID ADD85550;
AC ADD85550;
XX 29-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO181 cDNA.
XX human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
XX vulnary; antiarthritic; pericyte cell proliferation;
XX pericyte cell differentiation; chondrocyte cell proliferation;
XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX (TNF)-alpha release; dermal fibroblast cell proliferation;
XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX colon tumour; breast tumour; prostate tumour; rectal tumour;
XX liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
XX Homo sapiens.
XX OS
XX US2003100721-A1.
XX 29-MAY-2003.
XX 13-AUG-2002; 2002US-00219473.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008971/01.
DR P-PSDB; ADD85551.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.
XX
PS Claim 2; SEQ ID NO 119; 308bp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO329, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCACACGCTCCGATGGGCTTCAGCTTCGCGCCCTTCCTGCTACATGCTGGCGCTCTGCT 60
Db 1 GCCACACGCTCCGATGGGCTTCAGCTTCGCGCCCTTCCTGCTACATGCTGGCGCTCTGCT 60
Qy 61 CACTGCCGCGCTCATCTTCTTCGCGCCATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTTCGCGCCATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
Qy 121 TGATTACAGGATCCCTATAGACCACTGTAATACCTGTAATCCCTTGTACTCCCAAGATA 180
Db 121 TGATTACAGGATCCCTATAGACCACTGTAATACCTGTAATCCCTTGTACTCCCAAGATA 180
Qy 181 CCTCATCCACGCTTTCTTCTTGTGTGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACATGG 240
Db 181 CCTCATCCACGCTTTCTTCTTGTGTGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACATGG 240
Qy 241 TCTCAATATGCCCTCTTTGGGCAATATCATATTTGGAGGATATATGATGACACCATGATGAG 300

Db 241 TCTCAATATGCCCTCTTGGCATATCAATTTGGAGTATATAGAGTACGACGATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACCAACCATATGAATGAGATATCTAGCATATTTGCA 360
Db 301 TGGCCAGGACTCTATGACCCCTACCAACCATATGAATGAGATATCTAGCATATTTGCA 360
QY 361 GAAGGAAGATGGTGCATATGCTTTTATCTCTAGCATATTTTACTACCTATATGG 420
Db 361 GAAGGAAGATGGTGCATATGCTTTTATCTCTAGCATATTTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GATGCAAAAGCCACCAATGAAGGATCTTATCAGCAAGATCTGTGCAAGATGAGC 540
Db 481 GATGCAAAAGCCACCAATGAAGGATCTTATCAGCAAGATCTGTGCAAGATGAGC 540
QY 541 CTGTGMACTCATGATGATCTTAAATAAGTCACTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGMACTCATGATGATCTTAAATAAGTCACTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGACATC 720
Db 661 TAGCTATAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGACATC 720
QY 721 TTAAGGAACAGCATATCTCTGATGATGATTAATTAATTAATGATGATGATGATG 780
Db 721 TTAAGGAACAGCATATCTCTGATGATGATTAATTAATTAATGATGATGATGATG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTTCAATGAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTTCAATGAACAGTATCTAA 840
QY 841 TTATAAATTAAGCTATGATATGAGGCTCTGATGATGATGATGATGATGATGATG 900
Db 841 TTATAAATTAAGCTATGATATGAGGCTCTGATGATGATGATGATGATGATGATG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGATGATGATGATGATGATGATGATG 960
Db 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGATGATGATGATGATGATGATGATG 960
QY 961 AAAAAATAAAGCGGAATTTCCCTTGGTGTGAATATTTATCCCTGTATTTGATGAAT 1020
Db 961 AAAAAATAAAGCGGAATTTCCCTTGGTGTGAATATTTATCCCTGTATTTGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATCTGCTTTAAATTTCTTAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATCTGCTTTAAATTTCTTAAGCAT 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGATTAATTTGCAAGATGCAITTTAAAGCTAT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGATTAATTTGCAAGATGCAITTTAAAGCTAT 1140
QY 1141 TTAATGTTGTTTATTTGTAAGACATCTTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db 1141 TTAATGTTGTTTATTTGTAAGACATCTTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
QY 1201 TTCTATCTGCTGTAAGATTTCTTAAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTATCTGCTGTAAGATTTCTTAAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGTAATACCATCTGCTGTTTCTTTAGTGAATACATAAATACTCT 1320
Db 1261 GAATGAGAGAAATTTGTAATACCATCTGCTGTTTCTTTAGTGAATACATAAATACTCT 1320
QY 1321 GAAATTAAGACTC 1333
|||||

Db 1321 GAAATTAAGACTC 1333
RESULT 92
ADE05099
ID ADE05099 standard; cDNA; 1333 BP.
XX
AC ADE05099;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #60.
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; INF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100726-A1.
XX
PD 29-MAY-2003.
XX
PF 26-AUG-2002; 2002US-00227878.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 15-SEP-2000; 2000US-0232887P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
WPI: 2004-008976/01.
P-PSDB; ADE05100.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, or for preparing a medicament for treating a condition
that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
cancer.
XX
PS Claim 2; Fig 119; 308pp; English.
XX
CC The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCACGGCTCCGATGGGTTACGTTCCGGCGCTTCGTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCACGGCTCCGATGGGTTACGTTCCGGCGCTTCGTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCCCGCTCATCTCTTCGCGCATTTGGCAGATATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCCGCTCATCTCTTCGCGCATTTGGCAGATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACAGCTGAATACCTGTAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAGAAATCCTATAGACAGCTGAATACCTGTAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCTCTTTGGCATATCATATTGGAGGTATATGATGACCAAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTTGGCATATCATATTGGAGGTATATGATGACCAAGTATGAG 300

QY 301 TGGCCAGAGCTCTATGACCCCTACACCATCATGATCAGATATCTTAGCATATTGTCA 360
DB 301 TGGCCAGAGCTCTATGACCCCTACACCATCATGATCAGATATCTTAGCATATTGTCA 360

QY 361 GAAGGAAGATGGTGCATATGCTTTTCTTCTAGCATTTTCTTACTACTATATGG 420
DB 361 GAAGGAAGATGGTGCATATGCTTTTCTTCTAGCATTTTCTTACTACTATATGG 420

QY 421 CATGATCTATGTTTTGGTAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTTGGTAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480

QY 481 GCATCAAAAGCCACCAATGAAGGATCTTATCCAGCAGATCTGTCCAGAGTAGC 540
DB 481 GCATCAAAAGCCACCAATGAAGGATCTTATCCAGCAGATCTGTCCAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGGAAGACAGCTTTTTCATATGTTATCTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACAGCTTTTTCATATGTTATCTCAGATAAGATTTTAAATGGTAT 660

QY 661 TACGTATAAATTAATATAAATGATTAATGATGATGATGATGATGATGATGATGATG 720
DB 661 TACGTATAAATTAATATAAATGATTAATGATGATGATGATGATGATGATGATGATG 720

QY 721 TTAAGGAACAGCATAATCCTCTGATGATGATGATGATGATGATGATGATGATGATG 780
DB 721 TTAAGGAACAGCATAATCCTCTGATGATGATGATGATGATGATGATGATGATGATG 780

QY 781 GAAGCTTTTGTATAGGAACCTGTAGGGGTATTTTGGTTCATTTGAACAGATATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTGTAGGGGTATTTTGGTTCATTTGAACAGATATCTAA 840

QY 841 TTATAAATTAGCTGTAGATATCAGGTCTTCTGATCAAGTGAATAATGATATCTGACTAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGTCTTCTGATCAAGTGAATAATGATATCTGACTAG 900

QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGATGATGATGATGATGATGATGATGATGAT 960
DB 901 TGGGAACCTTCATGGGTTTCTCTCATCTGATGATGATGATGATGATGATGATGATGAT 960

QY 961 AAAAAAAGGGGAAATTTTCCCTTGGTGAATATATCCCTGATATGATGATGATGAT 1020
DB 961 AAAAAAAGGGGAAATTTTCCCTTGGTGAATATATCCCTGATATGATGATGATGATGAT 1020

QY 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATATATCTTGTCTTAAATCTTAAAGCATA 1080
DB 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATATATCTTGTCTTAAATCTTAAAGCATA 1080

QY 1081 AGTAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGAAATGCATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGAAATGCATTTAAAGCTATT 1140

QY 1141 TTAATGCTGTTTTTATTGTTAAGACATCTATTATTAAGAAATGGTTATTATGCTTACTG 1200
DB 1141 TTAATGCTGTTTTTATTGTTAAGACATCTATTATTAAGAAATGGTTATTATGCTTACTG 1200

QY 1201 TTCTAAATCTGCTGTAAAGGTATTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
DB 1201 TTCTAAATCTGCTGTAAAGGTATTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260

QY 1261 GAATGAGAGAAATTTGTATACCATCTCTGCTGTTTCTTGTAGTGAATACATAAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGTATACCATCTCTGCTGTTTCTTGTAGTGAATACATAAAACTCT 1320

QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 93
ADD75312 standard; cDNA; 1333 BP.

ID AC ADD75312; XX
AC ADD75312; XX
DT 29-JAN-2004 (first entry) XX
DE Human PRO polynucleotide #60. XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; XX
KW tumour; cancer; lung; colon; breast; prostate; blood; chondrocyte cell; XX
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; XX
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder; XX
KW arthritis; sports injury; cytostatic; antiarthritic. XX
OS Homo sapiens. XX
PN US2003100714-A1. XX
PD 29-MAY-2003. XX
PF 13-AUG-2002; 2002US-00219071. XX
PX 01-JUN-2001; 2001WO-US017800. XX
PR 29-JUN-2001; 2001WO-US021066. XX
PR 09-APR-2002; 2002US-00119480. XX
PX (GETH) GENENTECH INC. XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ; XX
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI; XX
XX WPI; 2004-008964/01. XX
DR P-PSDB; ADD75313. XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a PT
PT medicament for treating a condition that is responsive to the PRO PT
PT polypeptide or anti-PRO antibody, e.g. cancer. XX
XX Claim 2; Fig 119; 308pp; English. XX
XX The invention relates to human PRO polypeptides (secreted and CC
CC transmembrane polypeptides) and the PRO polynucleotides encoding them. CC
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals, CC
CC diagnostics, biosensors or bioeffectors. They are particularly useful for CC
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour, XX

CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent can also be obtained in electronic
CC format directly from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306; Mismatches 0; Gaps 0;
Matches 1333; Conservative 0; Indels 0;

QY 1 GCCACGGCTCCGATGGCGTTCACGTTGCGGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGGCTCCGATGGCGTTCACGTTGCGGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTCGCCATTGGCACATTATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTCGCCATTGGCACATTATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACAGAGTGAATACCTGTAATCCCTGTGACTCCCAAGATGA 180
DB 121 TGATTACAGAAATCCTATAGACAGAGTGAATACCTGTAATCCCTGTGACTCCCAAGATGA 180
QY 181 CTTCTATCCACGGCTTCTTCTGTGTCATGTTTCTTTGTGCGAGAGTGGCTTACACTGGG 240
DB 181 CTTCTATCCACGGCTTCTTCTGTGTCATGTTTCTTTGTGCGAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACGAGTGAAGTGA 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACGAGTGAAGTGA 300
QY 301 TGGCCCGAGGACTCTATGACCTACCAACCATCATGAATGAGATATCTAGCATATTGTCA 360
DB 301 TGGCCCGAGGACTCTATGACCTACCAACCATCATGAATGAGATATCTAGCATATTGTCA 360
QY 361 GAAGGAAGGATGGTGAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTATG 420
DB 361 GAAGGAAGGATGGTGAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTATG 420
QY 421 CATGATCTATGTTTCTGAGGCTCTTAGACACACACAGAAATTTGGTCCAGTTAAAGT 480
DB 421 CATGATCTATGTTTCTGAGGCTCTTAGACACACACAGAAATTTGGTCCAGTTAAAGT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGG 540
DB 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGG 540
QY 541 CTGTGGAAATCTGATCAGTTACTTTTAAATAAAGTACCTTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAAATCTGATCAGTTACTTTTAAATAAAGTACCTTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGGGAAGACTGTTTCAATGTTTATCTTACTCAGATAAGATTTTAAATGTTAT 660
DB 601 TTTTGTCTTGGGAAGACTGTTTCAATGTTTATCTTACTCAGATAAGATTTTAAATGTTAT 660
QY 661 TACGTATAAATTAATAAATAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720

DB 661 TAGCTATAAATTAATAAATAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATTAATTAATTAATTAATTA 780
DB 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATTAATTAATTAATTAATTA 780
QY 781 GAAGCTTTCTTTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTTCAATCAAAACAGATCTAA 840
DB 781 GAAGCTTTCTTTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTTCAATCAAAACAGATCTAA 840
QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATATCTGACTAG 900
DB 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGATGCGATGCGATGATGATGATGATGATGATGATGAT 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGATGCGATGCGATGATGATGATGATGATGATGATGAT 960
QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATGATGATGAT 1020
DB 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATGATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATAATAATAATAATAATAATAATAATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATAATAATAATAATAATAATAATA 1080
QY 1081 AGTAAACATGATATAAAATATATGCTGAATTAATCTGAGAAATGATGATGATGATGATGATGAT 1140
DB 1081 AGTAAACATGATATAAAATATATGCTGAATTAATCTGAGAAATGATGATGATGATGATGATGAT 1140
QY 1141 TTAATGTTGTTTATTTGTAAGACATTAATTAAGAAATTTGTTTATTTATTTATTTATTTAT 1200
DB 1141 TTAATGTTGTTTATTTGTAAGACATTAATTAAGAAATTTGTTTATTTATTTATTTATTTAT 1200
QY 1201 TTTAAATCTGTGTGTAAGGATTTCTTAAGAAATTTGAGGATTAATTAAGATTTTCAAACT 1260
DB 1201 TTTAAATCTGTGTGTAAGGATTTCTTAAGAAATTTGAGGATTAATTAAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATATACCATCCCTGCTGTTCTTTAGTGCATACATAAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGATATACCATCCCTGCTGTTCTTTAGTGCATACATAAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
RESULT 94
ADD76856
ID ADD76856 standard; cdna; 1333 BP.
XX
AC ADD76856;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
OS Homo sapiens.
XX
PN US2003100715-A1.
XX
PD 29-MAY-2003.

```
XX PF 13-AUG-2002; 2002US-00219074.
XX PR 22-JUN-1999; 99US-0140650P.
XX PR 30-MAY-2000; 2000WO-US014941.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-APR-2002; 2002US-00119480.
XX PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX PR WPI; 2004-008965/01.
XX DR P-PSDB; ADD76857.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
XX PT medicament for treating a condition that is responsive to the PRO
XX PR polypeptide or anti-PRO antibody, e.g. cancer.
XX PS Claim 2; SEQ ID NO 119; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX CC useful for stimulating the proliferation of or gene expression in
XX CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX CC for stimulating the proliferation or differentiation of chondrocyte
XX CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX CC are useful for stimulating the release of tumour necrosis factor (TNF)-
XX CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO411, PRO1309,
XX CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1193, PRO1244, PRO1274, PRO1412,
XX CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
XX CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX CC stimulating the proliferation of normal human dermal fibroblasts cells.
XX CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
XX CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
XX CC are useful for detecting the presence of tumour in a mammal which
XX CC involves comparing the level of expression of the above PRO polypeptides
XX CC in a test sample of cells taken from the mammal, and a control sample of
XX CC normal cells of the same cell type, where a higher level of expression of
XX CC the PRO polypeptides in the test sample as compared to the control sample
XX CC is indicative of the presence of tumour in the mammal. The tumour is lung
XX CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX CC liver tumour. (I) is useful as molecular weight markers, for tissue
XX CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX CC useful for chromosome and gene mapping or gene therapy. (III) is useful
XX CC for generating transgenic animals or knock-out animals which are useful
XX CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
XX CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
XX CC sport injuries). This sequence encodes a human secreted and transmembrane
XX CC PRO polypeptide.
XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Fred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGCTCCGATGGCGCTTCACGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGCTCCGATGGCGCTTCACGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTCGCCAATTTGGCACAATATAGCATTTGATGAGCTGAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTCGCCAATTTGGCACAATATAGCATTTGATGAGCTGAGAC 120
```

Db 1201 TTTAATCTGGTGAAGGATTTCTTAAGAAATTCAGGATTCACAGATTTTCAAACT 1260
 Qy 1261 GAATGAGAGAAAATGTATAACCATCCCTGCTGTTCTTTAGTGCATACATAAACTCT 1320
 Db 1261 GAATGAGAGAAAATGTATAACCATCCCTGCTGTTCTTTAGTGCATACATAAACTCT 1320
 Qy 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333
 RESULT 95
 ADD86624
 ID ADD86624 standard; cDNA; 1333 BP.
 XX
 AC ADD86624;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.
 XX
 KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003100719-A1.
 XX
 PD 29-MAY-2003.
 XX
 PF 14-AUG-2002; 2002US-00219469.
 XX
 PP 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 PI WPI: 2004-008969/01.
 XX P-PSDB; ADD86625.
 DR
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, or for preparing a medicament for treating a condition
 PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
 PT cancer.
 XX
 PS Claim 2; SEQ ID NO 119; 308pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF) -
 CC alpha from human blood. PRO982, PRO357, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1387, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC

CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, or PRO7425 polypeptide are useful for
 CC PRO5723, PRO5725, PRO1154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GCCACGCGTCCGATGGCGTTACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 Db 1 GCCACGCGTCCGATGGCGTTACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 Qy 61 CACTGCGCGCTCATCTCTTCGCGCATTTGCGCATATATAGCATTTGATGAGTCAAGAC 120
 Db 61 CACTGCGCGCTCATCTCTTCGCGCATTTGCGCATATATAGCATTTGATGAGTCAAGAC 120
 Qy 121 TGATTAAGAAGATCCTATAGACCGAGTGTAATACCTCGAATCCCTTGATCCCAAGATA 180
 Db 121 TGATTAAGAAGATCCTATAGACCGAGTGTAATACCTCGAATCCCTTGATCCCAAGATA 180
 Qy 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTTCTTGTGTCAGAGTGGCTTACTGCTGGG 240
 Db 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTTCTTGTGTCAGAGTGGCTTACTGCTGGG 240
 Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACAGTCAATGATGAG 300
 Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACAGTCAATGATGAG 300
 Qy 301 TGGCCCCAGGACTCTATGACCCCTTACAAACCATCATGAATGAGATATTTAGCATATTTGCA 360
 Db 301 TGGCCCCAGGACTCTATGACCCCTTACAAACCATCATGAATGAGATATTTAGCATATTTGCA 360
 Qy 361 GAAGAAGATGGTGCACAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 Db 361 GAAGAAGATGGTGCACAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 Qy 421 CATGATCATGTTTGTGGTGAGCTCTTAGAACACACAGAGAATTTGGTCCAGTTAAGT 480
 Db 421 CATGATCATGTTTGTGGTGAGCTCTTAGAACACACAGAGAATTTGGTCCAGTTAAGT 480
 Qy 481 GCATCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTGCCAAGTAGC 540
 Db 481 GCATCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTGCCAAGTAGC 540
 Qy 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
 Qy 601 TTTTCTGTTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 Db 601 TTTTCTGTTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 Qy 661 TACGTATAAATTAATATAAATGATTAATCCTCTGGTGTGACAGGTTTGAACTTGCACTTC 720

Db 661 TACGATTAATTAATAATAAAGATTAACCTCTGGTGTGACAGGTTTGAACTTGCACTTC 720
 QY 721 TTAAGGAACAGCCATAATCCCTCTGAATGATGCAATTAATTAAGTCTGCTAGTACATG 780
 Db 721 TTAAGGAACAGCCATAATCCCTCTGAATGATGCAATTAATTAAGTCTGCTAGTACATG 780
 QY 781 GAAGCTTTTGTATAGGAAGTCTAGGCTGCTATTTGGTTCATTTGAAACAGTATCTAA 840
 Db 781 GAAGCTTTTGTATAGGAAGTCTAGGCTGCTATTTGGTTCATTTGAAACAGTATCTAA 840
 QY 841 TTATAAATAGCTCTAGATATCAGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
 Db 841 TTATAAATAGCTCTAGATATCAGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
 QY 901 TGGAAACTTCATGGTTTCCATCTGCTGATGCAATGATGATATATATGGAATATCTTAC 960
 Db 901 TGGAAACTTCATGGTTTCCATCTGCTGATGCAATGATGATATATATGGAATATCTTAC 960
 QY 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATGTCATGAAT 1020
 Db 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATGTCATGAAT 1020
 QY 1021 GAGAGATTTCCATATTTCCATCAGATGAATATAATATATATCTTAACTTCTTAAGCAT 1080
 Db 1021 GAGAGATTTCCATATTTCCATCAGATGAATATAATATATATCTTAACTTCTTAAGCAT 1080
 QY 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
 Db 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
 QY 1141 TTAATGCTGTTTATTTGTAAGACATTAATTAATTAAGAAATGCTTATTAATGCTTACTG 1200
 Db 1141 TTAATGCTGTTTATTTGTAAGACATTAATTAATTAAGAAATGCTTATTAATGCTTACTG 1200
 QY 1201 TTCTAACTGCTGTTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 Db 1201 TTCTAACTGCTGTTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAATGATTAACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
 Db 1261 GAATGAGAGAAATGATTAACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
 QY 1321 GAATTAAGACTC 1333
 Db 1321 GAATTAAGACTC 1333

RESULT 96

ADD78092

ID ADD78092 standard; cDNA; 1333 BP.

XX AC ADD78092;

XX AC ADD78092;

DT 29-JAN-2004 (first entry)

XX XX

DE Novel human secreted and transmembrane protein PRO181 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.

OS Homo sapiens.

XX US2003100731-A1.

PN 29-MAY-2003.

XX 29-MAY-2003.

PD 29-MAY-2003.

XX 28-AUG-2002; 2002US-00230234.
 XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen MB, Goddard A, Godowski P; Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI; WPI: 2004-008981/01.
 PR P-PSDB; ADD78093.

XX New PRO polypeptide and nucleic acid useful for gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

XX Claim 2; SEQ ID NO 119; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO331, PRO1083, PRO840, PRO1080, PRO1478, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1317, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4322, PRO9940, PRO6078, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells.

XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCTTACGTTTCGGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
 Db 1 GCCACGCGTCCGATGGCTTACGTTTCGGCCCTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCGCAATTTGCAATTATAGCATTTGATGAGCTGAAGAC 120
 Db 61 CACTGCGCGCTCATCTTCTTCGCAATTTGCAATTATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAAGAAATCCTATAGACCAAGTGTAAATACCTCGAATCCCTTGTACCCAGAGTA 180
 Db 121 TGATTACAAGAAATCCTATAGACCAAGTGTAAATACCTCGAATCCCTTGTACCCAGAGTA 180

Db 121 TGATTACAGAAATCCTATAGACCAGTGTAAATACCTCGAATCCCTTGTTACTCCACAGTA 180
Qy 181 CCTCATCCACGCTTCTTCTGTGTCAGTCTTCTTGTGTCAGACAGAGTGCGCTTACACTGGG 240
Db 181 CCTCATCCACGCTTCTTCTGTGTCAGTCTTCTTGTGTCAGACAGAGTGCGCTTACACTGGG 240
Qy 241 TCTCAATATGCCCCTCTTGGCATATCAATTTGGAGGTATATGATGACACAGTGTATGAG 300
Db 241 TCTCAATATGCCCCTCTTGGCATATCAATTTGGAGGTATATGATGACACAGTGTATGAG 300
Qy 301 TGGCCAGGACTCTATGACCCCTTACACCATCATGAATCAGATATTTCTAGCATATTTGTCA 360
Db 301 TGGCCAGGACTCTATGACCCCTTACACCATCATGAATCAGATATTTCTAGCATATTTGTCA 360
Qy 361 GAAGGAAGATGGTGCAGAAATAGCTTTTATTTCTTCTAGCATATTTTCTACTACCTATATGG 420
Db 361 GAAGGAAGATGGTGCAGAAATAGCTTTTATTTCTTCTAGCATATTTTCTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGCTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGCTCCAGTTAAGT 480
Qy 481 GCATCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATGAGC 540
Db 481 GCATCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATGAGC 540
Qy 541 CTGTGGAAATCTGATCAGTACTTTTAAAAAATGACCTCTTATTTTAAATGTTCCACAT 600
Db 541 CTGTGGAAATCTGATCAGTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTCTTGTGAAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTTGTGAAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATATAAATGATTAATCCTGTGGTGTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGTATAAATTAATATAAATGATTAATCCTGTGGTGTGACAGGTTTGAACCTTGCACTTC 720
Qy 721 TTAAGGAACAGCATATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
Db 721 TTAAGGAACAGCATATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
Qy 781 GAAGCTTTTGTATATAGGAACCTGTAGGGCTCATTTTGGTTTCAATTTGAACAGATCTAA 840
Db 781 GAAGCTTTTGTATATAGGAACCTGTAGGGCTCATTTTGGTTTCAATTTGAACAGATCTAA 840
Qy 841 TTATAAATTAAGCTGTAGATATACAGGTCCTCTGATGAAGTGAATGATATCTGACTAG 900
Db 841 TTATAAATTAAGCTGTAGATATACAGGTCCTCTGATGAAGTGAATGATATCTGACTAG 900
Qy 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATATGATACATTTAC 960
Qy 961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATTAATTAATCCCTGTATATTCATGAAT 1020
Db 961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATTAATTAATCCCTGTATATTCATGAAT 1020
Qy 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAAATAATATCTGCTTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAAATTTCTTAAGCATA 1080
Qy 1081 AGTAACATCATATAAATAATATGCTGAATTTCTGTGAAGATGCAATTAAGCTATT 1140
Db 1081 AGTAACATCATATAAATAATATGCTGAATTTCTGTGAAGATGCAATTAAGCTATT 1140
Qy 1141 TTAATATGTTTTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTATTATCTTACTG 1200
Db 1141 TTAATATGTTTTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTATTATCTTACTG 1200
Qy 1201 TTCTAATCTGGTGAAGTATTTTAAAGATTTGAGGATTTGAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGTATTTTAAAGATTTGAGGATTTGAGTACTACAGATTTTCAAACT 1260

Qy 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTCTCTTTAGTCAATAAATACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTCTCTTTAGTCAATAAATACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 97
ADE89756
ID ADE89756 standard; cDNA; 1333 BP.
XX
AC ADE89756;
XX
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO181.
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
vulnary; auditory; tumour growth; retinal; disorder;
sports-related joint problem; articular cartilage defects;
osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003130181-Al.
XX
PD 10-JUL-2003.
XX
PF 16-OCT-2001; 2001US-00978375.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.

PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081953P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0084396P.
PR 29-APR-1998; 98US-0084999P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100308P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.

PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003585.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (ASHK/) ASHENNAZI A J.
PA (BAKE/) BAKER K P.
PA (BOTS/) BOTSTEIN D.
PA (DESN/) DESNOYERS L.
PA (EATO/) EATON D L.
PA (FEER/) FERRARA N.
PA (FILY/) FILVAROFF E.
PA (FONG/) FONG S.
PA (GAOW/) GAO W.
PA (GERB/) GERBER H.
PA (GERR/) GERRITSEN M E.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P J.
PA (GIRM/) GIRMALDI J C.
PA (GURN/) GURNEY A L.
PA (HILL/) HILLAN K J.
PA (KLJA/) KLJAVIN I J.
PA (KUOS/) KUO S S.
PA (NAPI/) NAPIER M A.
PA (PANJ/) PAN J.
PA (PAON/) PAONI N F.
PA (ROYM/) ROY M A.
PA (SHEL/) SHELTON D L.
PA (STEW/) STEWART T A.
PA (TUMA/) TUMAS D.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred.No. 9.6e-306; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0;
QY 1 GCCACGCGTCCGATCGCGTTTCACCTTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
|||||

Db 1 GCCACGGCTCGATGGCGTTCACTTCGGCGCCCTTCGTACATGCTGGCGCTGCTGCT 60
Qy 61 CACTCGCGCGCTCATCTCTCTTCGCCCATTTGGCACATTTAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTCGCGCGCTCATCTCTTCGCCCATTTGGCACATTTAGCATTTGATGAGCTGAAGAC 120
Qy 121 TGAATCAAGAATCCATATAGACACAGTGAATACCCCTGATCCCTTGTACTCCCAAGATA 180
Db 121 TGAATCAAGAATCCATATAGACACAGTGAATACCCCTGATCCCTTGTACTCCCAAGATA 180
Qy 181 CCTCATCCACGCTTCTCTCTGCTGATGTTCTTTGTGCGACGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCACGCTTCTCTCTGCTGATGTTCTTTGTGCGACGAGTGGCTTACACTGGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
Qy 301 TGGCCGAGGACTATATGACCCCTACACCATCATCATGATGAGATATTTCTAGCATATTTGCA 360
Db 301 TGGCCGAGGACTATATGACCCCTACACCATCATCATGATGAGATATTTCTAGCATATTTGCA 360
Qy 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATTTTCTAGCATTTTCTAGCATATGG 420
Db 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATTTTCTAGCATTTTCTAGCATATGG 420
Qy 421 CATGATCTATGTTTTCGTGAGCTCTTGAACAACACACAGAGAATTTGTCAGTTAAGT 480
Db 421 CATGATCTATGTTTTCGTGAGCTCTTGAACAACACACAGAGAATTTGTCAGTTAAGT 480
Qy 481 CATGCAAAAGCCACCAATGAGGATTTCTATCCAGCAAGATCTCTGTCAGAGTAGG 540
Db 481 GCATGCAAAAGCCACCAATGAGGATTTCTATCCAGCAAGATCTCTGTCAGAGTAGG 540
Qy 541 CTGTGAACTCATGATGATCTTTTAAATAAGTACTCTCTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGAACTCATGATGATCTTTTAAATAAGTACTCTCTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTCTTGGAAAGCTGTTTTCATATGTTTATATCTAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTTGGAAAGCTGTTTTCATATGTTTATATCTAGATAAGATTTTAAATGGTAT 660
Qy 661 TAGCTATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 720
Db 661 TAGCTATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 720
Qy 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAATTAAT 780
Db 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAATTAAT 780
Qy 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGTTCATTTGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGTTCATTTGAACAGATATCTAA 840
Qy 841 TTAATAATTAAGCTGATAGATCAGGTCCTTCTGATGAAGTGAATAATTAATTAATTAATTAAT 900
Db 841 TTAATAATTAAGCTGATAGATCAGGTCCTTCTGATGAAGTGAATAATTAATTAATTAATTAAT 900
Qy 901 TGGGAACCTTCAATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAATTAAT 960
Db 901 TGGGAACCTTCAATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAATTAAT 960
Qy 961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTAATTAAT 1020
Db 961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTAATTAAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATTAATTAATTAATTAATTAATTAATTAATTAAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATTAATTAATTAATTAATTAATTAATTAATTAAT 1080
Qy 1081 AGTAAACATGATATAAAAAATATATGCTGAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1140
Db 1081 AGTAAACATGATATAAAAAATATATGCTGAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1140

Qy 1141 TTAATGTTTTTTTATTTGTAAGACATTAATTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db 1141 TTAATGTTTTTTTATTTGTAAGACATTAATTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Qy 1201 TTCTAAATCTGCTGCTGTAAGAGTATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAAATCTGCTGCTGTAAGAGTATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
Qy 1261 GAATGAGAGAAAAATTTGTAATACCATCTCTGCTGCTTTTCTTTAGTGAATTAATAAACTCT 1320
Db 1261 GAATGAGAGAAAAATTTGTAATACCATCTCTGCTGCTTTTCTTTAGTGAATTAATAAACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 98

ADD77600

ID ADD77600 standard; cDNA; 1333 BP.

XX AC

XX ADD77600;

XX 29-JAN-2004 (first entry)

XX 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO181 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;

XX humeral; antiarthritic; pericyte cell proliferation;

XX pericyte cell differentiation; chondrocyte cell proliferation;

XX chondrocyte cell differentiation; tumour necrosis factor alpha release;

XX (TNF)-alpha release; dermal fibroblast cell proliferation;

XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;

XX colon tumour; breast tumour; prostate tumour; rectal tumour;

XX liver tumour; tissue typing; chromosome mapping; gene mapping;

XX gene therapy.

XX Homo sapiens.

XX US2003100729-A1.

XX 29-MAY-2003.

XX 28-AUG-2002; 2002US-00230113.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-008979/01.

XX P-PSDB; ADD77601.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful

XX in gene therapy, or for preparing a medicament for treating a condition

XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.

XX cancer.

XX Claim 2; SEQ ID NO 119; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)

XX polypeptide (1). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are

XX useful for stimulating the proliferation of or gene expression in

XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful

XX for stimulating the proliferation or differentiation of chondrocyte

XX cells. PRO231, PRO357, PRO725, PRO155, PRO1306 or PRO1419 polypeptide

XX are useful for stimulating the release of tumour necrosis factor (TNF)-

XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419,

CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1219, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9,6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCACGCGTCCGATGGGTTCACTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGCGTCCGATGGGTTCACTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

Qy 61 CACTGCCGCGTCACTTCCTTGGCCATTTGGCCACATATAGCATTTGATGAGTGAAGAC 120
Db 61 CACTGCCGCGTCACTTCCTTGGCCATTTGGCCACATATAGCATTTGATGAGTGAAGAC 120

Qy 121 TGATTAAGAATCCTATAGACAGTGAATACCTGTAATCCCTTGACTCCACAGATA 180
Db 121 TGATTAAGAATCCTATAGACAGTGAATACCTGTAATCCCTTGACTCCACAGATA 180

Qy 181 CCTCATCAGCGTTCTTCTGTGTCATGTTCTTTGTCAGAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCAGCGTTCTTCTGTGTCATGTTCTTTGTCAGAGAGTGGCTTACACTGGG 240

Qy 241 TCTCAATATGCCCTCTTGGCATATCATTTGGAGGTATATGATAGACAGTGTAGT 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATTTGGAGGTATATGATAGACAGTGTAGT 300

Qy 301 TGGCCAGGACTCTATGACCCCTTACCAACCATCATGATGATGATTTCTAGCATATTGTCA 360
Db 301 TGGCCAGGACTCTATGACCCCTTACCAACCATCATGATGATGATTTCTAGCATATTGTCA 360

Qy 361 GAAGGAAGATGGTGCAATAGCTTTTATCTTCTAGCATTTTATCTACCTATATGG 420
Db 361 GAAGGAAGATGGTGCAATAGCTTTTATCTTCTAGCATTTTATCTACCTATATGG 420

Qy 421 CATGATCTATGTTTGGTGGAGCTTTAGAACACACACAGAGATTTGGTCCAGTTAGT 480
Db 421 CATGATCTATGTTTGGTGGAGCTTTAGAACACACACAGAGATTTGGTCCAGTTAGT 480

Qy 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATGAG 540
Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATGAG 540

Qy 541 CTGTGGATCTGATCAGTTACTTTTAAATAAATGACTTCCTTTATTTTAAATGTTTCCCAT 600
Db 541 CTGTGGATCTGATCAGTTACTTTTAAATAAATGACTTCCTTTATTTTAAATGTTTCCCAT 600

Qy 601 TTTTGTCTGGAAAGACTGTTTTTTCATATGTTATCTCAGATAAGATTTTAAATGCTAT 660
Db 601 TTTTGTCTGGAAAGACTGTTTTTTCATATGTTATCTCAGATAAGATTTTAAATGCTAT 660

Qy 661 TACGTATAAATTAATAAATAAGATTAACCTCTGCTGTTGACAGGTTTGAACCTTGCACCTTC 720
Db 661 TACGTATAAATTAATAAATAAGATTAACCTCTGCTGTTGACAGGTTTGAACCTTGCACCTTC 720

Qy 721 TTAAGGAACGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTCTCTCTAGTACATG 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTCTCTCTAGTACATG 780

Qy 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTTCAATTTTAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTTCAATTTTAAACAGATATCTAA 840

Qy 841 TTATAAATTAGCTGTAGATATCAGGTCTCTGATGAAGTGAATAATCTATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTCTCTGATGAAGTGAATAATCTATATCTGACTAG 900

Qy 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATACATTTAC 960

Qy 961 AAAAATAAAGCGGGAATTTCCCTTCCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTCCCTTCCGCTTGAATATATTTCCCTGTATATTTGCATGAAT 1020

Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATATCTTGTCTTAAATCTTAAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATATCTTGTCTTAAATCTTAAAGCATA 1080

Qy 1081 AGTAAACATGATATAAATAATATATGCTGTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140

Qy 1141 TTAATCTGTTTTTATTTTGAAGACATTTTAAAGAAATTTGTTATTTATGCTTACTG 1200
Db 1141 TTAATCTGTTTTTATTTTGAAGACATTTTAAAGAAATTTGTTATTTATGCTTACTG 1200

Qy 1201 TTCTAAATCTGCTGTAAGGATTTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAAATCTGCTGTAAGGATTTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260

Qy 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTTCTTTAGTGAATACATAAATAAATCTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTTCTTTAGTGAATACATAAATAAATCTCT 1320

Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 99
ADD77846
ID ADD77846 standard; cdna; 1333 BP.
XX AC ADD77846;
XX DT 29-JAN-2004 (first entry)
XX XX
DE Novel human secreted and transmembrane protein PRO181 cdna.
XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.

XX Homo sapiens.
XX OS
XX PN US2003100730-A1.
XX PD 29-MAY-2003.
XX PF 28-AUG-2002; 2002US-00230183.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021056.
XX PR 09-APR-2002; 2002US-00119480.
XX PA (GENTH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX DR P-PSDB; ADD77847.
XX WPI; 2004-008980/01.
XX PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.
XX PS Claim 2; SEQ ID NO 119; 308pp; English.
XX CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080.
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX 1 GCCACGCGTCCGATGGCGTTCAGTTCGGCGCTTCGTACATGCTGGCGTGTGCT 60
DB 1 GCCACGCGTCCGATGGCGTTCAGTTCGGCGCTTCGTACATGCTGGCGTGTGCT 60

QY 61 CACTGCCGCGCTCATCTTCTTCGCCATTGSCACATTATAGCATTTGATGGCTGAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTCGCCATTGSCACATTATAGCATTTGATGGCTGAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACCAGAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAAGAAATCCTATAGACCAGAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCACGCTTCTTCTGTGTCATGTTTCTTTGTGACGAGAGTGGCTTACCTGGG 240
DB 181 CCTCATCCACGCTTCTTCTGTGTCATGTTTCTTTGTGACGAGAGTGGCTTACCTGGG 240
QY 241 TCTCAATATGCCCTCTTGTGTCATGTTTCTTTGTGAGGTTATATAGTACACAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGTGTCATGTTTCTTTGTGAGGTTATATAGTACACAGTATGAG 300
QY 301 TGGCCCAAGGACTCTATGACCCCTACAACCATCATGAATGCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCCAAGGACTCTATGACCCCTACAACCATCATGAATGCAGATATTTCTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATCTTTTGTGAGCTCTTAGAACAAACACACAGAAATTCGTCAGTTAAGT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACAAACACACAGAAATTCGTCAGTTAAGT 480
QY 481 GCATCAAAAAAGCCACCAAAATGAAGGATTTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
DB 481 GCATCAAAAAAGCCACCAAAATGAAGGATTTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCATTC 720
DB 661 TACGTATAAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCATTC 720
QY 721 TTAAGGAACAGCCATAATCCTCTGATGATGCAATTAATTAATTAATTAATTAATTAATTA 780
DB 721 TTAAGGAACAGCCATAATCCTCTGATGATGCAATTAATTAATTAATTAATTAATTAATTA 780
QY 781 GAAGCTTTTGTTTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGAAACAGATATCTAA 840
DB 781 GAAGCTTTTGTTTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGAAACAGATATCTAA 840
QY 841 TTATAAATAGCTGTAGATATACAGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
DB 841 TTATAAATAGCTGTAGATATACAGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTGATGTCGATGATATATATGATACATTTAC 960
DB 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTGATGTCGATGATATATATGATACATTTAC 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGTTGAAATATATCCCTGTATATTTGCAATGAT 1020
DB 961 AAAAAATAAAGCGGGAATTTTCCCTTCGTTGAAATATATCCCTGTATATTTGCAATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATACTTCTTTTAACTTTAGACATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATACTTCTTTTAACTTTAGACATA 1080
QY 1081 AGTAAACATGATATAAATAATATATCTGATTAATTTGTAAGATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAATAATATATCTGATTAATTTGTAAGATGCAATTTAAAGCTATT 1140

QY 1141 TTAATGCTGTTTATTTGTAAGACATTAATTAAGAAATGGTATTATGCTTACTG 1200
 Db 1141 TTAATGCTGTTTATTTGTAAGACATTAATTAAGAAATGGTATTATGCTTACTG 1200
 QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGACGCTACTACAGATTTTCAAACT 1260
 Db 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGACGCTACTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAATGTATAACCATCTGCTGCTTTAGTGCATACAAATAAACTCT 1320
 Db 1261 GAATGAGAGAAATGTATAACCATCTGCTGCTTTAGTGCATACAAATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333
 RESULT 100
 ADD85304
 ID ADD85304 standard; cDNA; 1333 BP.
 XX AC ADD85304;
 XX DT 29-JAN-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO181 cDNA.
 XX KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; Gene mapping;
 KW gene therapy.
 XX OS Homo sapiens.
 XX PN US2003100725-A1.
 XX PD 29-MAY-2003.
 XX PF 26-AUG-2002; 2002US-00227876.
 XX PR 15-SEP-2000; 2000US-0232887P.
 XX PR 01-JUN-2001; 2001WO-US017800.
 XX PR 29-JUN-2001; 2001WO-US021066.
 XX PR 09-APR-2002; 2002US-00119480.
 XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2004-008975/01.
 XX P-PSDB; ADD85305.
 XX PT New secreted and transmembrane PRO polypeptide useful for preparing a
 PT medicament for treating a condition that is responsive to the PRO
 PT polypeptide or anti-PRO antibody, e.g. cancer.
 XX PS Claim 2; SEQ ID NO 119; 308pp; English.
 XX CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO382, PRO1160, PRO187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO1083, PRO840, PRO1080,

CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO3333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGCGTCCGATGGGCTTCACTTCGCGCCCTTCTGTACATGCTGGCGCTGCTGCT 60
 Db 1 GCCACGCGTCCGATGGGCTTCACTTCGCGCCCTTCTGTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCATTTGATGAGTCAAGAC 120
 Db 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCATTTGATGAGTCAAGAC 120
 QY 121 TGATTTACAAGAAATCCTATAGACCACTGTAATAACCTGAAATCCCTTGTACTCCCAAGATA 180
 Db 121 TGATTTACAAGAAATCCTATAGACCACTGTAATAACCTGAAATCCCTTGTACTCCCAAGATA 180
 QY 181 CTTATCCACGCTTCTTCTGTGTGTCATGTTCTTTGTGCGACGAGTGGCTTACACTGGG 240
 Db 181 CTTATCCACGCTTCTTCTGTGTGTCATGTTCTTTGTGCGACGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACAGCATGATGAG 300
 Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACAGCATGATGAG 300
 QY 301 TGGCCGAGGACTCTATAGACCCCTTACCAACCATCATGATGAGATATTTAGCATATTTGCA 360
 Db 301 TGGCCGAGGACTCTATAGACCCCTTACCAACCATCATGATGAGATATTTAGCATATTTGCA 360
 QY 361 GAAGAAAGGATGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTACTTACTATATGG 420
 Db 361 GAAGAAAGGATGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTACTTACTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACAGAGAAATTTGGTCCAGTTAAGT 480
 Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACAGAGAAATTTGGTCCAGTTAAGT 480
 QY 481 GCATCAAAAAGCCCAAAATGAAGGGATTCTTACCAAGATCTCTTCCAAAGAGTAGC 540
 Db 481 GCATCAAAAAGCCCAAAATGAAGGGATTCTTACCAAGATCTCTTCCAAAGAGTAGC 540
 QY 541 CTGTGGATCTGATCAGTACTTTTAAAAAATGATCTCTTATTTTAAATGTTTCCCAT 600
 Db 541 CTGTGGAAATCTGATCAGTACTTTTAAAAAATGATCTCTTATTTTAAATGTTTCCCAT 600

241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGATGACCACTGATGAG 300
241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGATGACCACTGATGAG 300
301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATCAGATATTTCTAGCATATTTGTC 360
301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATCAGATATTTCTAGCATATTTGTC 360
361 GAAGGAAGATGGTGGCAAAATGAGCTTTTATCTTCTAGCATATTTTCTACCTATATGG 420
361 GAAGGAAGATGGTGGCAAAATGAGCTTTTATCTTCTAGCATATTTTCTACCTATATGG 420
421 CATGATCTATGTTTGGTGGAGCTCTTGAACACACACAGAGAAATGCTCCAGTTAAGT 480
421 CATGATCTATGTTTGGTGGAGCTCTTGAACACACACAGAGAAATGCTCCAGTTAAGT 480
481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCAAGAGTAGC 540
481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCAAGAGTAGC 540
541 CTGTGGAATCTGATCAGTATCTTTAAAAAATGACTCTCTATTTTAAATGTTTCCAT 600
541 CTGTGGAATCTGATCAGTATCTTTAAAAAATGACTCTCTATTTTAAATGTTTCCAT 600
601 TTTTCTGTTGGAAGAGCTTTTTCATATGTTTATCTAGTAAAGATTTTAAATGTTAT 660
601 TTTTCTGTTGGAAGAGCTTTTTCATATGTTTATCTAGTAAAGATTTTAAATGTTAT 660
661 TACGTATAAATTAATATAAATGATTTTACCTCTGGTGGTGGACAGGTTTGAACCTTGC 720
661 TACGTATAAATTAATATAAATGATTTTACCTCTGGTGGTGGACAGGTTTGAACCTTGC 720
721 TTAAGGAACAGCCATTAATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATG 780
721 TTAAGGAACAGCCATTAATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATG 780
781 GAAGCTTTTGTATAGGAAGCTTTGAGGCTCATTTTGGTTTCAATGAACAGATCTTAA 840
781 GAAGCTTTTGTATAGGAAGCTTTGAGGCTCATTTTGGTTTCAATGAACAGATCTTAA 840
841 TTAATAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTAAATGATATCTGACTAG 900
841 TTAATAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTAAATGATATCTGACTAG 900
901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGATGATATATATGATGATATTTAC 960
901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGATGATATATATGATGATATTTAC 960
961 AAAAAATAAAGGCGGAATTTTCCCTTCCCTTGAATATATCTCTGATATATGATGAT 1020
961 AAAAAATAAAGGCGGAATTTTCCCTTCCCTTGAATATATCTCTGATATATGATGAT 1020
1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGTTTAAATTTCTTAAGCATA 1080
1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGTTTAAATTTCTTAAGCATA 1080
1081 AGTAACATGATATAAATAATATGATGATGATGATGATGATGATGATGATGATGAT 1140
1081 AGTAACATGATATAAATAATATGATGATGATGATGATGATGATGATGATGATGAT 1140
1141 TTAATGTTGTTTATTTGTAAGACATTTCTTAAAGAAATTTGGTTATTTATCTTACTG 1200
1141 TTAATGTTGTTTATTTGTAAGACATTTCTTAAAGAAATTTGGTTATTTATCTTACTG 1200
1201 TTTAATCTCGTGAAGTATTTCTTAAGAAATTTGCAAGTATCTACAGATTTTCAAACT 1260
1201 TTTAATCTCGTGAAGTATTTCTTAAGAAATTTGCAAGTATCTACAGATTTTCAAACT 1260
1261 GAATGAGAGAAATTTGATACCATCTGCTGTTTCTTTAGTCAATACATTAATCTCT 1320
1261 GAATGAGAGAAATTTGATACCATCTGCTGTTTCTTTAGTCAATACATTAATCTCT 1320
1321 GAAATTAAGACTC 1333

Db 1321 GAAATTAAGACTC 1333
RESULT 102
ADD74574
ID ADD74574 standard; cDNA; 1333 BP.
XX ADD74574;
AC ADD74574;
DT 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #60.
XX Human; PRO: gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.
XX Homo sapiens.
OS US2003100713-A1.
PN 29-MAY-2003.
PD 13-AUG-2002; 2002US-00219065.
PF 25-JUL-2000; 2000US-0220638P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI: 2004-008963/01.
DR P-PSDB; ADD74575.
XX New secreted and transmembrane PRO polypeptide useful for preparing a
medicament for treating a condition that is responsive to the PRO
polypeptide or anti-PRO antibody, e.g. cancer.
PS Claim 2; Fig 119; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent can also be obtained in electronic
format directly from USPTO at seqdata.uspto.gov/sequence.html.

XX	Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;	
SQ	Query Match 100.0%; Score 1333; DB 10; Length 1333;	
	Best Local Similarity 100.0%; Pred. No. 9.6e-306;	
	Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 GCGCCGCGTCGATGGGCTTACGCTTGGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60	
Db	1 GCGCCGCGTCGATGGGCTTACGCTTGGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60	
QY	61 CACTGCGCGCTCCTCTTGGCCATTTGGCACAATTATAGCAATTGATGAGCTCAAGAC 120	
Db	61 CACTGCGCGCTCCTCTTGGCCATTTGGCACAATTATAGCAATTGATGAGCTCAAGAC 120	
QY	121 TGATTACAGAATCCTATAGACAGGATTAATACCCCTGATCCCTTGTACTCCAGAGTA 180	
Db	121 TGATTACAGAATCCTATAGACAGGATTAATACCCCTGATCCCTTGTACTCCAGAGTA 180	
QY	181 CTTCTCCAGCTTCTTCTGTGTCATGTTCTTTGTGCGACGAGTGGCTTACACTGGG 240	
Db	181 CTTCTCCAGCTTCTTCTGTGTCATGTTCTTTGTGCGACGAGTGGCTTACACTGGG 240	
QY	241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACCAAGTATGATG 300	
Db	241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACCAAGTATGATG 300	
QY	301 TGGCCCGAGGACTCTATGACCTTACCAACCATCATGATGATGATGATGATGATGATG 360	
Db	301 TGGCCCGAGGACTCTATGACCTTACCAACCATCATGATGATGATGATGATGATGATG 360	
QY	361 GAAGGAAGGATGCGAATGATGCTTTTATCTTCTAGCAATTTTCTAGCTATGATG 420	
Db	361 GAAGGAAGGATGCGAATGATGCTTTTATCTTCTAGCAATTTTCTAGCTATGATG 420	
QY	421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480	
Db	421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480	
QY	481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGATGAGC 540	
Db	481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGATGAGC 540	
QY	541 CTGTGGAATCTGATCAGTACTTTTAAAGATGACTCCTTATTTTAAAGTGTTCACAT 600	
Db	541 CTGTGGAATCTGATCAGTACTTTTAAAGATGACTCCTTATTTTAAAGTGTTCACAT 600	
QY	601 TTTTGTCTTGTGAAAGACTCTTTTTCATATGTTATCTACATGATGATGATGATGATG 660	
Db	601 TTTTGTCTTGTGAAAGACTCTTTTTCATATGTTATCTACATGATGATGATGATGATG 660	
QY	661 TAGCTATAAATTAATAAATGATTAACCTCTGCTGTTGACAGTTTGAACCTTGCATTC 720	
Db	661 TAGCTATAAATTAATAAATGATTAACCTCTGCTGTTGACAGTTTGAACCTTGCATTC 720	
QY	721 TTAAGGAACGCTATCTCTCAATGATGATTAATTAATCTGCTGCTGCTGCTGCTGCTG 780	
Db	721 TTAAGGAACGCTATCTCTCAATGATGATTAATTAATCTGCTGCTGCTGCTGCTGCTG 780	
QY	781 GAAGCTTTTGTATAGGAATCTTGTAGGCTCAATTTGGTTTCAATGAAACAGTATCTAA 840	
Db	781 GAAGCTTTTGTATAGGAATCTTGTAGGCTCAATTTGGTTTCAATGAAACAGTATCTAA 840	
QY	841 TTATAAATAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900	
Db	841 TTATAAATAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900	
QY	901 TGGGAACCTCATGGTTTCTCTCATGATGATGATGATGATGATGATGATGATGATGATG 960	
Db	901 TGGGAACCTCATGGTTTCTCTCATGATGATGATGATGATGATGATGATGATGATGATG 960	
QY	961 AAAAATAAAAGCGGGAATTTTCCCTTCTGATATATATCCCTGATATATGATGATGAT 1020	

Db	961 AAAAATAAAAGCGGGAATTTTCCCTTCTGATATATATCCCTGATATATGATGATGAT 1020	
QY	1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATATTTTAAATTTCTTAAGCATA 1080	
Db	1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATATTTTAAATTTCTTAAGCATA 1080	
QY	1081 AGTAAACATGATATAAAATATATGCTGAAATTTACTTTGTGAAGAATGCAATTTAAAGCTATT 1140	
Db	1081 AGTAAACATGATATAAAATATATGCTGAAATTTACTTTGTGAAGAATGCAATTTAAAGCTATT 1140	
QY	1141 TTAATGTTTATTTTGAAGCAATTAATTAAGAAATGTTGTTATTTATGCTTACTG 1200	
Db	1141 TTAATGTTTATTTTGAAGCAATTAATTAAGAAATGTTGTTATTTATGCTTACTG 1200	
QY	1201 TTCTAATCTGTTGTTAAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260	
Db	1201 TTCTAATCTGTTGTTAAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260	
QY	1261 GAATGAGAGAAAATTTGTTATTAACCATCTCTGCTTCTTTAGTGCATTAACAATAAACTCT 1320	
Db	1261 GAATGAGAGAAAATTTGTTATTAACCATCTCTGCTTCTTTAGTGCATTAACAATAAACTCT 1320	
QY	1321 GAAATTAAGACTC 1333	
Db	1321 GAAATTAAGACTC 1333	

RESULT 103
ADD77102

ID ADD77102 standard; cdNA; 1333 BP.

XX ADD77102;

XX 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO181 cdNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
XX vulnery; antiarthritic; pericyte cell proliferation;
XX pericyte cell differentiation; chondrocyte cell proliferation;
XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX (TNF)-alpha release; dermal fibroblast cell proliferation;
XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX colon tumour; breast tumour; prostate tumour; rectal tumour;
XX liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.

XX Homo sapiens.

XX US2003100716-A1.

XX 29-MAY-2003.

XX 13-AUG-2002; 2002US-00219077.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KD, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-008966/01.

XX P-PSDB; ADD77103.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX cancer.

XX Claim 2; SEQ ID NO 119; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGTCCGATGGCGTTCAGTTCCGCGCTCTGCTACATGCTGGCGCTGCTGCT 60
 DB |||||
 QY 1 GCCACGGTCCGATGGCGTTCAGTTCCGCGCTCTGCTACATGCTGGCGCTGCTGCT 60
 DB |||||
 QY 61 CACTGCCGGCTCATCTCTCGCCATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
 DB |||||
 QY 61 CACTGCCGGCTCATCTCTCGCCATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
 DB |||||
 QY 121 TGATTAACAAGATCTATAGACAGTGTATACCCCTGAATCCCTGTACTCCAGAGTA 180
 DB |||||
 QY 121 TGATTAACAAGATCTATAGACAGTGTATACCCCTGAATCCCTGTACTCCAGAGTA 180
 DB |||||
 QY 181 CTTCTACACAGCTTTCTCTGTCATGTTCTTTGTGCGAGCAGTGGCTTACACTGGG 240
 DB |||||
 QY 181 CTTCTACACAGCTTTCTCTGTCATGTTCTTTGTGCGAGCAGTGGCTTACACTGGG 240
 DB |||||
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
 DB |||||
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
 DB |||||
 QY 301 TGGCCACAGACTCTATGACCTCAACCATCATGAATGAGATATTTCTAGCATATTTGTC 360
 DB |||||
 QY 301 TGGCCACAGACTCTATGACCTCAACCATCATGAATGAGATATTTCTAGCATATTTGTC 360
 DB |||||
 QY 361 GAAGGAAGATGTCGAATATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 DB |||||
 QY 361 GAAGGAAGATGTCGAATATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 DB |||||
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
 DB |||||

Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAGATCCCTGTCCAAGTAGC 540
 Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAGATCCCTGTCCAAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGATCCCTTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGATCCCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTGTGGAAGACTGTTTTCATATGTTATATCATAGTAATGAAGATTTTAAATGGTAT 660
 Db 601 TTTTGTGTGGAAGACTGTTTTCATATGTTATATCATAGTAATGAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATAAATGATTAATCCTCTGGTGTGACAGGTTGAACTTGCACATTC 720
 Db 661 TACGTATAAATTAATAAATGATTAATCCTCTGGTGTGACAGGTTTGAACCTTGCACATTC 720
 QY 721 TTAAGGAACAGCCATAATCCCTCTGAATGATGATTAATTAATCTGACTGCTTAGTACATTTG 780
 Db 721 TTAAGGAACAGCCATAATCCCTCTGAATGATGATTAATTAATCTGACTGCTTAGTACATTTG 780
 QY 781 GAAGCTTTTGTATAGGAAGCTTTGAGGGCTCAITTTGGTTCATTGGAACAGTATCTAA 840
 Db 781 GAAGCTTTTGTATAGGAAGCTTTGAGGGCTCAITTTGGTTCATTGGAACAGTATCTAA 840
 QY 841 TTATAAATAGCTGTAGATATACAGTCTCTGATGAAGTGAATGATAATGATATCTGACTAG 900
 Db 841 TTATAAATAGCTGTAGATATACAGTCTCTGATGAAGTGAATGATAATGATATCTGACTAG 900
 QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATATATGGAATACATTTAC 960
 Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATATATGGAATACATTTAC 960
 QY 961 AAAATAAAAAAGCGGGAATTTCCCTCGCTTGAATATATCCCTGTATATGTCATGAT 1020
 Db 961 AAAATAAAAAAGCGGGAATTTCCCTCGCTTGAATATATCCCTGTATATGTCATGAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATCTGCTTAAATTTCTTAAGCATA 1080
 Db 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATCTGCTTAAATTTCTTAAGCATA 1080
 QY 1081 AGTAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
 Db 1081 AGTAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
 QY 1141 TTAATGTGTTTTTATTTTGAAGACATTAATTATTAAGAAATTTGGTTATATGCTTACTG 1200
 Db 1141 TTAATGTGTTTTTATTTTGAAGACATTAATTATTAAGAAATTTGGTTATATGCTTACTG 1200
 QY 1201 TTCTAATCTGGTGTGTAAGGTTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACT 1260
 Db 1201 TTCTAATCTGGTGTGTAAGGTTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATCAGAGAAAATTTGATTAACCATTCCTGCTGTTCCCTTTAGTGAATACATAAAACTCT 1320
 Db 1261 GAATCAGAGAAAATTTGATTAACCATTCCTGCTGTTCCCTTTAGTGAATACATAAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 104

ADD85796
 ID ADD85796 standard; cDNA; 1333 BP.

XX
 AC ADD85796;

XX
 DT 29-JAN-2004 (first entry)

XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.

KW human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
XX US2003100720-A1.
XX
XX 29-MAY-2003.
XX
XX 14-AUG-2002; 2002US-00219471.
XX
XX 18-NOV-1998; 98US-0108849P.
PR 01-SEP-1999; 99WO-US020111.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI
XX WPI; 2004-008970/01.
DR P-PSDB; ADD85797.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
XX Claim 2; SEQ ID NO 119; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO2114,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCCCTTCTGTACATCTGCTGGCGCTCTGCT 60
DB |||||
QY 61 CACTGCCGCGCTCATCTTCTTGGCCATTGGCACATTATAGCATTTGATAGCTGAAGAC 120
DB |||||
QY 61 CACTGCCGCGCTCATCTTCTTGGCCATTGGCACATTATAGCATTTGATAGCTGAAGAC 120
DB |||||
QY 121 TGAATTACAGAAATCCTATAGACCAAGTAAATACCTGATCCCTTTGACTCCCAAGATA 180
DB |||||
QY 121 TGAATTACAGAAATCCTATAGACCAAGTAAATACCTGATCCCTTTGACTCCCAAGATA 180
DB |||||
QY 181 CCTCATCCACGCTTCTTCTGTGTCTCATGTTCTTTGTGCGAGCAGAGTGGCTTACACTGG 240
DB |||||
QY 181 CCTCATCCACGCTTCTTCTGTGTCTCATGTTCTTTGTGCGAGCAGAGTGGCTTACACTGG 240
DB |||||
QY 241 TCTCAATATGCCCTCTTGGCCATATATATTTGGAGGTATATAGTAGACAGTGTAGAG 300
DB |||||
QY 241 TCTCAATATGCCCTCTTGGCCATATATATTTGGAGGTATATAGTAGACAGTGTAGAG 300
DB |||||
QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGTATTTCTAGCATATTTTCTAC 360
DB |||||
QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGTATTTCTAGCATATTTTCTAC 360
DB |||||
QY 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTACCTATATGG 420
DB |||||
QY 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTACCTATATGG 420
DB |||||
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAGATTTGGTCCAGTTAAGT 480
DB |||||
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAGATTTGGTCCAGTTAAGT 480
DB |||||
QY 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGAGTAGC 540
DB |||||
QY 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGAGTAGC 540
DB |||||
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTTTAAATGTTTCCACAT 600
DB |||||
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTTTAAATGTTTCCACAT 600
DB |||||
QY 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB |||||
QY 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB |||||
QY 661 TAGCTATAAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAACCTGCACTTC 720
DB |||||
QY 661 TAGCTATAAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAACCTGCACTTC 720
DB |||||
QY 721 TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATGATGATGATGATGATGATG 780
DB |||||
QY 721 TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATGATGATGATGATGATGATG 780
DB |||||
QY 781 GAAGCTTTTGTATAGGAGCTTTAGGAGCTCATTTTGGTTCATTTGATGAACAGTATCTAA 840
DB |||||
QY 781 GAAGCTTTTGTATAGGAGCTTTAGGAGCTCATTTTGGTTCATTTGATGAACAGTATCTAA 840
DB |||||
QY 841 TTAATAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATCTGACTAG 900
DB |||||
QY 841 TTAATAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATCTGACTAG 900
DB |||||
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGTCGATGATGATGATGATGATGATG 960
DB |||||
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGTCGATGATGATGATGATGATGATG 960
DB |||||
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGTTGAATATTTATCTCTGATATTTCTGATGATG 1020
DB |||||

Db 961 AAAATAAAGCGGAATTTCCCTCGCTTGAATATATCCCTGATATATGTCATGAAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGAGATATAAATAATACATGCTTTAATCTTAAAGCATTA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGATATAAATAATACATGCTTTAATCTTAAAGCATTA 1080
Qy 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTGTGAAGAAATGCATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTGTGAAGAAATGCATTTAAAGCTATT 1140
Qy 1141 TTAATGCTGTTTTATTTTGAAGACATTTACTTATTAAGAAATGCTTATATGCTTACTG 1200
Db 1141 TTAATGCTGTTTTATTTTGAAGACATTTACTTATTAAGAAATGCTTATATGCTTACTG 1200
Qy 1201 TTTAAATCTGTTGTAAGGATTTCTTAAAGAAATTTGAGGTAATGACATTTTCAAACT 1260
Db 1201 TTTAAATCTGTTGTAAGGATTTCTTAAAGAAATTTGAGGTAATGACATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAAATTTGTATAACCATCTGCTGTTCTTTTGTGCAATACATAAACTCT 1320
Db 1261 GAATGAGAGAAAATTTGTATAACCATCTGCTGTTCTTTTGTGCAATACATAAACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 105
ADE05345
ID ADE05345 standard; cDNA; 1333 BP.
XX
AC ADE05345;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #60.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100723-A1.
XX
PD 29-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219482.
XX
PR 26-JUL-2000; 2000US-0220893P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GENE) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI P-PSDB; ADE05346.
DR WPI: 2004-008973/01.
DR
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.
XX
PS Claim 2; Fig 119; 308pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.

CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumour, rectal tumour, colon tumour, breast tumour,
CC prostate tumour, lung tumour, liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers, and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.

XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

	Query Match	100.0%;	Score 1333;	DB 10;	Length 1333;
	Best Local Similarity	100.0%;	Pred. No. 9.6e-306;		
	Matches 1333;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	GCCACGCGTCCGATGGCGTTACGTTGCGGGCTTCTGTACATGCTGGCGCTGCTGCT	60		
Db	1	GCCACGCGTCCGATGGCGTTACGTTGCGGGCTTCTGTACATGCTGGCGCTGCTGCT	60		
Qy	61	CACGCGCGCTCATCTTCTGCGCATTGCGCATATAGCATTTGATGAGCTGAAGAC	120		
Db	61	CACGCGCGCTCATCTTCTGCGCATTGCGCATATAGCATTTGATGAGCTGAAGAC	120		
Qy	121	TGATTACAGAAATCCTATAGACAGTGTAAATACCTGTAATCCCTTGCTACTCCAGAGTA	180		
Db	121	TGATTACAGAAATCCTATAGACAGTGTAAATACCTGTAATCCCTTGCTACTCCAGAGTA	180		
Qy	181	CCTCATCCACGCTTCTTCTGTGTCACTGTTTGTGTCAGAGTGGCTTACACTGGG	240		
Db	181	CCTCATCCACGCTTCTTCTGTGTCACTGTTTGTGTCAGAGTGGCTTACACTGGG	240		
Qy	241	TCTCAATATGCCCCCTCTGTCGATATCATATTTGGAGGTATATGATAGCAGTCAATGAG	300		
Db	241	TCTCAATATGCCCCCTCTGTCGATATCATATTTGGAGGTATATGATAGCAGTCAATGAG	300		
Qy	301	TGGCCCGAGGACTCTATGACCCCTTACAAACCATCATGTAATTCATGATATTTGCA	360		
Db	301	TGGCCCGAGGACTCTATGACCCCTTACAAACCATCATGTAATTCATGATATTTGCA	360		
Qy	361	GAAGGAAGATGCTGCAAAATTTAGCTTTTAACTTCTTCTAGCATTTTCTTACTATATGG	420		
Db	361	GAAGGAAGATGCTGCAAAATTTAGCTTTTAACTTCTTCTAGCATTTTCTTACTATATGG	420		
Qy	421	CATGATCTATGTTTGTGTCGCTTTAGAACCAACACAGAGAAATTTGCTCCAGTTAAGT	480		
Db	421	CATGATCTATGTTTGTGTCGCTTTAGAACCAACACAGAGAAATTTGCTCCAGTTAAGT	480		
Qy	481	GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGC	540		
Db	481	GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGC	540		
Qy	541	CTGTGGAATCTGATCAGTACCTTTTAAATAAGCTCTTCTTAAATGTTTCCACAT	600		
Db	541	CTGTGGAATCTGATCAGTACCTTTTAAATAAGCTCTTCTTAAATGTTTCCACAT	600		
Qy	601	TTTTGCTGTTGGAAGACTGTTTTTCTATATGTTTATCTCAGATAAAGATTTTAAATGGTAT	660		
Db	601	TTTTGCTGTTGGAAGACTGTTTTTCTATATGTTTATCTCAGATAAAGATTTTAAATGGTAT	660		

Db 301 TGGCCAGGACTCTATGACCTCAACCAATCATGATGACATATTTCTAGCATATTGTCA 360
Qy 361 GAGGAAGAGTGGGCAAAATAGCTTTTATCTTCTAGCAATTTTCTACTACCTATATGG 420
Db 361 GAGGAAGAGTGGGCAAAATAGCTTTTATCTTCTAGCAATTTTCTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTGTGTAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTAAGT 480
Db 421 CATGATCTATGTTTGTGTAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTCCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCCAT 600
Db 541 CTGTGGAATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCCAT 600
Qy 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTGTTGACAGGTTTGAACCTTGCAC 720
Db 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTGTTGACAGGTTTGAACCTTGCAC 720
Qy 721 TTAAGGAACACCAATATCCTCTGAATGATGATTAATCTGACTGTCCTAGTACATTTG 780
Db 721 TTAAGGAACACCAATATCCTCTGAATGATGATTAATCTGACTGTCCTAGTACATTTG 780
Qy 781 GAAGCTTTGTTTATAGAACTGTTGAGGCTTCATTTTGGTTTTCATTTGAAACAGATCTAA 840
Db 781 GAAGCTTTGTTTATAGAACTGTTGAGGCTTCATTTTGGTTTTCATTTGAAACAGATCTAA 840
Qy 841 TTATAAATAGCTGTAGATATCAGTGTCTCTGATGAAGTGAAGTGAATATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGTGTCTCTGATGAAGTGAAGTGAATATATCTGACTAG 900
Qy 901 TGGGAACCTTCATGGTTTCTCATCTGCTGATGATGATTAATATATGATATGATATTTAC 960
Db 901 TGGGAACCTTCATGGTTTCTCATCTGCTGATGATGATTAATATATGATATGATATTTAC 960
Qy 961 AAAAAATAAAGCGGAAATTTTCCCTCGCTTGAATATATTCCTGTATATTTGATGAT 1020
Db 961 AAAAAATAAAGCGGAAATTTTCCCTCGCTTGAATATATTCCTGTATATTTGATGAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATCTTTAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATCTTTAAGCAT 1080
Qy 1081 AGTAAACATGATATAAATAATATCTGCAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATCTGCAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
Qy 1141 TTAATGATGTTTATTTTGAAGCATTTACTTATTAAGAAATGAGTATATGCTTACTG 1200
Db 1141 TTAATGATGTTTATTTTGAAGCATTTACTTATTAAGAAATGAGTATATGCTTACTG 1200
Qy 1201 TTTAATCTGGTGTAAAGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTTAATCTGGTGTAAAGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATGATTAACATCTGCTGCTTCTTTAGTGCATATCAATTAACATCT 1320
Db 1261 GAATGAGAGAAATGATTAACATCTGCTGCTTCTTTAGTGCATATCAATTAACATCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 107
AAX90853

AAAX90853 standard; DNA; 1378 BP.
AAX90853;
17-JAN-2000 (first entry)
cDNA clone pk65_4.
clone pk65_4; pk65_4 protein; human foetal kidney cDNA library;
secreted protein; gene therapy; cytokine; nutritional activity;
tissue growth; cell proliferation; immune stimulation;
immune suppression; hematopoiesis regulation; tumour inhibition; ds.
Homo sapiens.
Key Location/Qualifiers
CDS 44..478
/*tag= a
/product= "pk65_4 protein"
WO9950405-A1.
07-OCT-1999.
30-MAR-1999; 99WO-US006946.
31-MAR-1998; 98US-0080110P.
29-MAR-1999; 99US-00280591.
(GEMY) GENETICS INST INC.
Jacobs K, McCoy JM, Lavallie ER, Collins-Racie LA, Evans C;
Merberg D, Treacy M, Agostino MJ, Steininger RJ;
WPI; 1999-610849/52.
P-PSDB; AY28813.
Polynucleotides encoding secreted human proteins, derived from human
adult brain, human fetal brain, human fetal kidney, and human adult blood
cDNA libraries.
Claim 20; Page 104-105; 122pp; English.
The present nucleotide sequence comprises the full-length protein-coding
sequence of clone pk65_4. pk65_4 was isolated from a human foetal kidney
cDNA library using methods specific for secreted protein cDNAs. This can
be used in gene therapy. The polynucleotide and protein may effect
nutritional activity, cytokine and cell proliferation, immune stimulation
or suppression, hematopoiesis regulation, tissue growth, tumour
inhibition etc
Sequence 1378 BP; 411 A; 258 C; 252 G; 457 T; 0 U; 0 Other;
Query Match 99.1%; Score 1321.4; DB 2; Length 1378;
Best Local Similarity 99.5%; Pred. No. 5.5e-303;
Matches 1325; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
Qy 3 CCACGGCTCCGATCGCTTCACGTTCCGGCTTCTGCTACATCGTGGCTGCTGCTCA 62
Db 33 CCTCCCAAGCATGCGTTTACGTTCCGGCTTCTGCTACATCGTGGCTGCTGCTCA 92
Qy 63 CTGCGCGCTCATCTTCTTCCGCCATTTGGCACATTTAGCATTTTGAGCTGAAGACTG 122
Db 93 CTGCGCGCTCATCTTCTTCCGCCATTTGGCACATTTAGCATTTTGAGCTGAAGACTG 152
Qy 123 ATTACAGAATCTTATAGACCAAGTGAATACCCCTGAATCCCTTGTACTCCAGATACC 182
Db 153 ATTACAGAATCTTATAGACCAAGTGAATACCCCTGAATCCCTTGTACTCCAGATACC 212
Qy 183 TCATCCACGCTTCTTCTGCTCATGTTTCTTTGTCAGCAGAGTGGCTTACACTGGGTC 242
Db 213 TCATCCACGCTTCTTCTGCTCATGTTTCTTTGTCAGCAGAGTGGCTTACACTGGGTC 272

243 TCAATATGCCCCCTCTGGCATATCATATTTGGAGGTATATGAGTATAGACACAGTGATGAGTG 302
Db |||||
273 TCAATATGCCCCCTCTGGCATATCATATTTGGAGGTATATGAGTATAGACACAGTGATGAGTG 332
Qy
303 GCCCAGGACTCTATGACCCCTCAACACATCATCAATGAGTATGATATCTAGCATATCTCAGA 362
Db |||||
333 GCCCAGGACTCTATGACCCCTCAACACATCATCAATGAGTATGATATCTAGCATATCTCAGA 392
Qy |||||
363 AGGAAGGATGGTGCAAAATTTAGCTTTTATCTCTTAGCAATTTTCTTACCTATATAGCA 422
Db |||||
393 AGGAAGGATGGTGCAAAATTTAGCTTTTATCTCTTAGCAATTTTCTTACCTATATAGCA 452
Qy |||||
423 TGATCTATGTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 482
Db |||||
453 TGATCTATGTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 512
Qy |||||
483 ATGCAAAAGCCACCAAAATGAAGGATCTTATCCAGCAAGATCTCTGCTCCAGAGTAGCT 542
Db |||||
513 ATGCAAAAGCCACCAAAATGAAGGATCTTATCCAGCAAGATCTCTGCTCCAGAGTAGCT 572
Qy |||||
543 GTGGAATCTGATCAGTTACTTTAAATAATGATCTCTTATTTTAAATGTTTCCCAATTT 602
Db |||||
573 GTGGAATCTGATCAGTTACTTTAAATAATGATCTCTTATTTTAAATGTTTCCCAATTT 632
Qy |||||
603 TTGCTTGTGGAAGACTGTTTCAATATGTTATCTCAGATTAAGATTTTAAATGTTATTA 662
Db |||||
633 TTGCTTGTGGAAGACTGTTTCAATATGTTATCTCAGATTAAGATTTTAAATGTTATTA 692
Qy |||||
663 CGTATAAATTAATATAAATGATTTACTCTCTGGTGTGACAGGTTTGAATCTGACATCTCT 722
Db |||||
693 CGTATAAATTAATATAAATGATTTACTCTCTGGTGTGACAGGTTTGAATCTGACATCTCT 752
Qy |||||
723 AAGGAACAGCCATTAATCTCTGATGATGATTAATTAATGATCTGCTGATGATGATGA 782
Db |||||
753 AAGGAACAGCCATTAATCTCTGATGATGATTAATTAATGATCTGCTGATGATGATGA 812
Qy |||||
783 AGCTTTTGTGTTAGAACTTTGAGGCTCAATTTTGGTTCATTTGAACAGTATCTAAAT 842
Db |||||
813 AGCTTTTGTGTTAGAACTTTGAGGCTCAATTTTGGTTCATTTGAACAGTATCTAAAT 872
Qy |||||
843 ATAAATAGCTGTAGATATCAGTGTCTCTGATGAGTGAATGATATCTGATGATGATG 902
Db |||||
873 ATAAATAGCTGTAGATATCAGTGTCTCTGATGAGTGAATGATATCTGATGATGATG 932
Qy |||||
903 GGAACCTGATGAGGTTTCCATCTGATGATGATGATTAATATGATGATGATTAACAA 962
Db |||||
933 GGAACCTGATGAGGTTTCCATCTGATGATGATGATTAATATGATGATGATTAACAA 992
Qy |||||
963 AAATAAAAGCGGAAATTTTCCCTGCTGATGATTAATTTCCCTGATGATGATGATGATG 1022
Db |||||
993 AAATAAAAGCGGAAATTTTCCCTGCTGATGATTAATTTCCCTGATGATGATGATGATG 1052
Qy |||||
1023 GAGATTTCCCATATTTCCATCAGAGTAAATATATCTGCTTTAAATTTTAAAGCATAAG 1082
Db |||||
1053 GAGATTTCCCATATTTCCATCAGAGTAAATATATCTGCTTTAAATTTTAAAGCATAAG 1112
Qy |||||
1083 TAAACATGATATAAATAATATGCTGATGATGATGATGATGATGATGATGATGATGATG 1142
Db |||||
1113 TAAACATGATATAAATAATATGCTGATGATGATGATGATGATGATGATGATGATGATG 1172
Qy |||||
1143 AAATGCTGTTTTTATTTGTAAGACATTAATTAAGAAATTTGTTATATGCTTACTGTT 1202
Db |||||
1173 AAATGCTGTTTTTATTTGTAAGACATTAATTAAGAAATTTGTTATATGCTTACTGTT 1232
Qy |||||
1203 CTAATCTGCTGTAAGAGTATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACTGA 1262
Db |||||
1233 CTAATCTGCTGTAAGAGTATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACTGA 1292
Qy |||||
1263 ATGAGAAATTTGATATAACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1322
Db |||||
1293 ATGAGAAATTTGATATAACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1352
Qy |||||
1323 AATTAAGACTC 1333

Db 1353 AATTAAGACTC 1363

RESULT 108

ABK36005

ID ABK36005 standard; cDNA; 1432 BP.

XX AC ABK36005;

XX DT 08-MAY-2002 (first entry)

XX DE cDNA sequence #336 encoding novel human secreted protein.

XX KW Human secreted protein; hyperproliferative disorder; autoimmune disorder;
XX KW immune deficiency disorder; blood disorder; inflammatory disorder;
XX KW infectious disorder; allergic condition; neurodegenerative disorder;
XX KW liver fibrosis; coagulation disorder; gene therapy; antimicrobial;
XX KW tumour; cancer; hepatotropic; immunosuppressive; antirheumatic; gene; ss.

XX OS Homo sapiens.

XX PN WO200177289-A2.

XX XX 18-OCT-2001.

XX PF 29-MAR-2001; 2001WO-US010232.

XX PR 06-APR-2000; 2000US-0195605P.

XX XX (GEMY) GENETICS INST INC.

XX PI Jacobs K, McCooy JM, Lavallie ER, Collins-Racie LA, Evans C;

XX PI Merberg D, Treacy M, Agostino M, Bowman MR, Spaulding V, Mong GG;

XX PI Clark HF, Fechtel K, Howes SH, Resnick RJ, Gulukota K, Graham JR;

XX DR WPI; 2002-179322/23.

XX XX Six hundred and twenty three polynucleotides derived from a variety of
XX PT human tissue sources which encode secreted proteins, useful for treating
XX PT immune deficiencies and disorders such as autoimmune disorders.

XX PS Claim 1; Page 296; 393pp; English.

XX CC The present invention relates to the isolation of novel cDNA sequences
XX CC which encode human secreted proteins. The cDNA sequences have been
XX CC derived from a variety of human tissues. The invention also provides a
XX CC method for producing proteins from these polynucleotide sequences. The
XX CC proteins are useful for identifying compounds that modulate their
XX CC activity and production. The sequences of the invention are useful for
XX CC treating diseases such as hyperproliferative disorders (e.g. cancer),
XX CC immune deficiency disorders (e.g. severe combined immunodeficiency
XX CC (SCID)), autoimmune disorders (e.g. multiple sclerosis), blood disorders
XX CC (e.g. thrombocytopenia), inflammatory disorders (e.g. arthritis),
XX CC infectious disorders (e.g. hepatitis), allergic conditions (e.g. asthma),
XX CC neurodegenerative disorders (e.g. Alzheimer's disease), liver fibrosis,
XX CC coagulation disorders (e.g. haemophilia) and tumours. The polynucleotide
XX CC sequences of the invention are also useful in gene therapy. ABK3610-
XX CC ABK36232 represent the cDNA sequences of the invention that encode for
XX CC novel human secreted proteins

SQ Sequence 1432 BP; 404 A; 276 C; 281 G; 471 T; 0 U; 0 Other;

Query Match 99.1%; Score 1321.4; DB 6; Length 1432;

Best Local Similarity 99.5%; Pred. No. 5.5e-303;

Matches 1325; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3 CCACGGCTCCGATGGGGTTACGTTCCGGGCTTCTGCTACATGCTGGGCTGCTCTCA 62

Db 102 CTTCCCAAGCATGGGGTTACGTTCCGGGCTTCTGCTACATGCTGGGCTGCTCTCA 161

Qy 63 CTGCCGGCTCATCTTCTTCCGCAATTTGGCATTATAGCATTTGATGAGTGAAGACTG 122

Db 162 CTGCGGGCTCATCTTCTTCGCCATTTGGCACATTATAGCATTTGATGAGCTGAAGACTG 221
Qy 123 ATTACAGAAATCCTATAGACCAGTGTAAATACCCCTGAATCCCTTGTACTCCGAGTACC 182
Db 222 ATTACAGAAATCCTATAGACCAGTGTAAATACCCCTGAATCCCTTGTACTCCGAGTACC 281
Qy 183 TCATCCACGCTTCTTCTGTCGTCATGTTCTTTGTCGAGCAGAGTGGCTTACACTGGGTC 242
Db 282 TCATCCACGCTTCTTCTGTCGTCATGTTCTTTGTCGAGCAGAGTGGCTTACACTGGGTC 341
Qy 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAGTG 302
Db 342 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAGTG 401
Qy 303 GCCCAGAGCTATAGACCCCTACACCATCATGAAATGAGATATTTCTAGCATATTTGTGAGA 362
Db 402 GCCCAGAGCTATAGACCCCTACACCATCATGAAATGAGATATTTCTAGCATATTTGTGAGA 461
Qy 363 AGGAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCA 422
Db 462 AGGAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCA 521
Qy 423 TGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGTGC 482
Db 522 TGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGTGC 581
Qy 483 ATGCAAAAGCCACAAATGAGGATCTTATCCAGAGAGTCTCTGTCACAGAGTAGGCT 542
Db 582 ATGCAAAAGCCACAAATGAGGATCTTATCCAGCAAGATCTCTGTCACAGAGTAGGCT 641
Qy 543 GTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACATTT 602
Db 642 GTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACATTT 701
Qy 603 TTGCTTGTGAAAGACTCTTTTATGTTTACTTACTCAGATAAAGATTTTAAATGTTA 662
Db 702 TTGCTTGTGAAAGACTCTTTTATGTTTACTTACTCAGATAAAGATTTTAAATGTTA 761
Qy 763 AGTATTAATTAATAAATGATTAACCTCTGTTGTCAGGTTTGAACCTTGCATCTTT 722
Db 762 CGTATAAATTAATAAATGATTAACCTCTGTTGTCAGGTTTGAACCTTGCATCTTT 821
Qy 723 AAGGAACAGCCATATCTCTGAATGATGCTTAAATTAATTAATTAATTAATTAATTA 782
Db 822 AAGGAACAGCCATATCTCTGAATGATGCTTAAATTAATTAATTAATTAATTAATTA 881
Qy 783 AGCTTTTGTATAGAACTTTGTAGGCTCAFTTTTGGTTTCATCGAAACAGTATCTAAT 842
Db 882 AGCTTTTGTATAGAACTTTGTAGGCTCAFTTTTGGTTTCATCGAAACAGTATCTAAT 941
Qy 843 ATAAATTAAGCTAGATATCAGTCTTCTGATGAAGTGAATGCTATATCTGACTGTG 902
Db 942 ATAAATTAAGCTAGATATCAGTCTTCTGATGAAGTGAATGCTATATCTGACTGTG 1001
Qy 903 GAAACATTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGATATGATTA 962
Db 1002 GAAACATTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGATATGATTA 1061
Qy 963 AAATAAAGCGGGAATTTCCCTTGGCTTGAATTAATTAATTAATTAATTAATTAATTA 1022
Db 1062 AAATAAAGCGGGAATTTCCCTTGGCTTGAATTAATTAATTAATTAATTAATTAATTA 1121
Qy 1023 GAGATTTCCCATATTTCCCATCAGAGTAATAATATATCTGCTTTAACTTTAAAGCATAG 1082
Db 1122 GAGATTTCCCATATTTCCCATCAGAGTAATAATATATCTGCTTTAACTTTAAAGCATAG 1181
Qy 1083 TAAACATGATATAAAATATATGCTGAATTAATTAATTAATTAATTAATTAATTAATTA 1142
Db 1182 TAAACATGATATAAAATATATGCTGAATTAATTAATTAATTAATTAATTAATTAATTA 1241
Qy 1143 AAATGTTTATTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTAATGCTTACTGTT 1202
Db 1242 AAATGTTTATTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTAATGCTTACTGTT 1301

Qy 1203 CTAATCTGGTGAAGGTAATCTTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACCTGA 1262
Db 1302 CTAATCTGGTGAAGGTAATCTTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACCTGA 1361
Qy 1263 ATGAGAGAAATTTGTATTAACCATCTCTGCTCTCTTTAGTGCATTAACAATAAAACCTCTGA 1322
Db 1362 ATGAGAGAAATTTGTATTAACCATCTCTGCTCTCTTTAGTGCATTAACAATAAAACCTCTGA 1421
Qy 1323 AATTAAGACTC 1333
Db 1422 AATTAAGACTC 1432

RESULT 109
AAZ30544
ID AAZ30544 standard; DNA; 1391 BP.
XX
AC AAZ30544;
XX
DT 18-JAN-2000 (first entry)
XX
Human cornichon gene.
XX
Human; cornichon; differentiation; body plan; metazoan; oogenesis;
KW embryogenesis; dorsalization; oocyte; dorsal-ventral axis; bicoid;
KW anterior-posterior axis; microtubule; cytoskeleton; oskar; diagnosis;
KW developmental disorder; hereditary neuropathy; seizure disorder;
KW reproductive disorder; immunological disorder; neoplastic disorder;
KW cancer; infection; spina bifida; cataract; ss.
XX
Homo sapiens.
XX
US9568744-A.
XX
PD 19-OCT-1999.
XX
PF 14-OCT-1997; 97US-00950168.
XX
PR 14-OCT-1997; 97US-00950168.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Hillman JL, Shah P, Corley NC;
XX
DR WPI; 1999-590398/50.
DR P-PSDB; AAY41306.
XX
Isolated nucleic acids encoding human cornichon molecules, useful in the recombinant production of cornichon proteins and in the prevention, diagnosis and treatment of developmental, reproductive, immunological and neoplastic disorders.
XX
Claim 4; Fig 1; 28pp; English.
XX
This sequence represents the human cornichon (CORN) gene (I). CORN is involved in the differentiation and determination of body plan in metazoans during oogenesis and embryogenesis. It is involved in controlling the correct dorsalization of the oocyte (i.e. determining the dorsal-ventral axis) and is essential in the correct induction of the anterior-posterior axis. In this case, CORN is implicated in the formation of correctly polarized microtubule cytoskeletons, which are required for proper localization of the anterior and posterior determinant genes (bicoid and oskar) and for the asymmetric positioning of the oocyte nucleus (see Roth et al., Cell (1995)). (I) may be used for the diagnosis, prevention and treatment of disorders associated with inappropriate expression and/or activity of CORN proteins. These disorders include developmental disorders (e.g. anemia, Cushing's syndrome, epilepsy and achondroplastic dwarfism), hereditary neuropathies (e.g. Charcot-Marie-Tooth disease), seizure disorders (e.g. Sydenham's chorea and cerebral palsy), reproductive disorders (e.g. infertility, disorders of prolactin production, tumors and disruptions of the menstrual cycle), immunological disorders (e.g. acquired immune

CC deficiency syndrome (AIDS), Addison's disease and asthma), neoplastic
CC disorders (e.g. adenocarcinoma, leukemia, cancers of the breast, lung,
CC testis, ovaries and prostate and melanomas), complications of cancers,
CC bacterial, viral, parasitic, protozoal, helminthic and fungal infections
CC and other disorders such as spina bifida and cataracts
XX
SQ Sequence 1391 BP; 402 A; 266 C; 259 G; 464 T; 0 U; 0 Other;

Query Match 98.8%; Score 1316.8; DB 2; Length 1391;
Best Local Similarity 99.5%; Pred. No. 6.7e-302;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 CCACGCGTCCGATGCGTTCACGTTCCGCGGCTCTGCTACATGCTGCGCTGCTGCTCA 62
Db |||||
QY 63 CCTCCCGACGCCGCTGCTACGTTCCGCGGCTTCTGCTACATGCTGCGCTGCTGCTCA 122
Db |||||
QY 63 CTGCGCGCTCATCTCTTCTGCGCAATTGGGCACATTATAGCAATTTGATGAGCTGAAGACTG 122
Db |||||
QY 123 CTGCGCGCTCATCTCTTCTGCGCAATTGGGCACATTATAGCAATTTGATGAGCTGAAGACTG 182
Db |||||
QY 123 ATTACAGAAATCTATAGACCGAGTGAATACCGTGAATCCCGTGTACTCCAGAGTACC 182
Db |||||
QY 183 ATTACAGAAATCTATAGACCGAGTGAATACCGTGAATCCCGTGTACTCCAGAGTACC 242
Db |||||
QY 183 TCATCCAGCTTCTCTGCTGTCATGTTCTTGTGCGAGCAGAGTGGCTTACACTGGGTC 242
Db |||||
QY 243 TCATCCAGCTTCTCTGCTGTCATGTTCTTGTGCGAGCAGAGTGGCTTACACTGGGTC 302
Db |||||
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGTG 302
Db |||||
QY 303 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGTG 362
Db |||||
QY 303 GCCCAGGACTATGACCCCTCAACCATCATGAATGCGAGATTTCTAGCATATTTGTCAGA 362
Db |||||
QY 363 GCCCAGGACTATGACCCCTCAACCATCATGAATGCGAGATTTCTAGCATATTTGTCAGA 422
Db |||||
QY 363 AGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCA 422
Db |||||
QY 423 AGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCA 482
Db |||||
QY 423 TGATCTATGTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 482
Db |||||
QY 483 TGATCTATGTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 542
Db |||||
QY 483 ATGCAAAAGCCACCAATGAGGATTTCTATCCAGCAGATCCCTCCAGAGTACCT 542
Db |||||
QY 543 ATGCAAAAGCCACCAATGAGGATTTCTATCCAGCAGATCCCTCCAGAGTACCT 602
Db |||||
QY 543 GTGGAACTCTGATCAGTTACTTTTAAATAATGACTCTCTTATTTTAAATGTTTTCCACATTT 602
Db |||||
QY 603 GTGGAACTCTGATCAGTTACTTTTAAATAATGACTCTCTTATTTTAAATGTTTTCCACATTT 662
Db |||||
QY 603 TTGCTTTGGAAAGACTGTTTTTATATGTTATATCTAGTAAAGATTTTAAATGTTATTA 662
Db |||||
QY 663 TTGCTTTGGAAAGACTGTTTTTATATGTTATATCTAGTAAAGATTTTAAATGTTATTA 722
Db |||||
QY 663 CGTATAAATTAATATAAATGATTAATCTCTGTTGTTGACAGTTTGAATCTGCACTTTT 722
Db |||||
QY 723 CGTATAAATTAATATAAATGATTAATCTCTGTTGTTGACAGTTTGAATCTGCACTTTT 782
Db |||||
QY 723 AAGGAACAGCCATAATCCCTCGAATGATGATTAATTTACTGACTGTCTTAGTACATTGA 782
Db |||||
QY 783 AAGGAACAGCCATAATCCCTCGAATGATGATTAATTTACTGACTGTCTTAGTACATTGA 842
Db |||||
QY 783 AGCTTTTGTGTTATAGGAATCTGTAGGCTCAATTTTGGTTTCAATGAAACAGTATCTAAT 842
Db |||||
QY 843 AGCTTTTGTGTTATAGGAATCTGTAGGCTCAATTTTGGTTTCAATGAAACAGTATCTAAT 902
Db |||||
QY 843 ATAAATTTAGCTGTAGATATCATGCTGCTCTGATGAAGTGAATATATCTGACTAGTG 902
Db |||||
QY 903 ATAAATTTAGCTGTAGATATCATGCTGCTCTGATGAAGTGAATATATCTGACTAGTG 962
Db |||||
QY 903 GGAAACTTTCATGGGTTTTCTCTCATCTGTCATGTCGATGATTAATATATGATATTTACAA 962
Db |||||

Db 963 GGAAACTTTCATGGGTTTTCTCTCATCTGTCATGTCGATGATTAATATGATATTTACAA 1022
QY 963 AAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATGATGATGAATGA 1022
Db 1023 AAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATGATGATGAATGA 1082
QY 1023 GAGATTTCCCATATTTCCATCAGATTAATAATATATCTGCTTTAAATCTTAAGCATAAAG 1082
Db 1083 GAGATTTCCCATATTTCCATCAGATTAATAATATATCTGCTTTAAATCTTAAGCATAAAG 1142
QY 1083 TAAACATGATATAAAATATATGCTGAATTAATCTTGTGAAGAAATGCAATTTAAAGCTATTTT 1142
Db 1143 TAAACATGATATAAAATATATGCTGAATTAATCTTGTGAAGAAATGCAATTTAAAGCTATTTT 1202
QY 1143 AAATGTGTTTTTATTTGTAAGACATATCTTAATTAAGAAATTTGGTTATATGCTTACTGTT 1202
Db 1203 AAATGTGTTTTTATTTGTAAGACATTAATTTAAGAAATTTGGTTATATGCTTACTGTT 1262
QY 1203 CTAACTGTGGTAAAGTATTTCTTAAGAAATTTGCAGTACTACAGATTTTCAAAACTGA 1262
Db 1263 CTAACTGTGGTAAAGTATTTCTTAAGAAATTTGCAGTACTACAGATTTTCAAAACTGA 1322
QY 1263 ATGAGAGAAATTTGTATAACCATCTGCTGCTTCTTAGTGCATTAACAATAAACTCTGA 1322
Db 1323 ATGAGAGAAATTTGTATAACCATCTGCTGCTTCTTAGTGCATTAACAATAAACTCTGA 1382
QY 1323 AATTAAGA 1330
Db 1383 AATTAAGA 1390

RESULT 110
AAD31079
ID AAD31079 standard; cDNA; 1391 BP.
XX AC AAD31079;
XX AC AAD31079;
DT 18-JUN-2002 (first entry)
XX Human cornichon protein (CORN) cDNA.
DE Human cornichon protein; CORN; Cushing's syndrome; muscular dystrophy;
KW developmental disorder; neoplastic; seizure; reproductive; immunological;
KW tubular acidosis; anaemia; polycystic ovary; autoimmune disorder; tumour;
KW breast cancer; prostate; testis; epilepsy; neuropathy; Addison's disease;
KW ulcerative colitis; spermatogenesis; hypothyroidism; cataract; arthritis;
KW infertility; galactorrhea; gynaecomastia; diabetes mellitus; fungicide;
KW dermatitis; acquired immunodeficiency syndrome; AIDS; glomerulonephritis;
KW atherosclerosis; allergy; asthma; bronchitis; Crohn's disease; auditory;
KW gout; Graves' disease; multiple sclerosis; haemodialysis; anticonvulsant;
KW trauma; drug screening; ophthalmological; cytostatic; immunosuppressive;
KW synecological; antiulcer; nephrotropic; neuroprotective; antihelminthic;
KW antibacterial; tranquilizer; osteoporosis; antiparasitic; protozoacide;
KW vulnerary; virucide; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX
FH Key Location/Qualifiers
CDS 74..508
FT /*tag= a
FT /product= "Human CORN"
XX
PN US6348576-B1.
XX
PD 19-FEB-2002.
XX
PF 02-AUG-1999; 99US-00365705.
XX
PR 14-OCT-1997; 97US-00950168.
XX (INCY-) INCYTE GENOMICS INC.
PA XX

Db 1012 AAATAAAGCGGAATTTCCCTTCGCTGAATATTATCCCTGTATATTCATGAATGA 1071
 QY 1023 GAGATTTCCCATATTTCCCATCAGAGTAATAATATATCTTAAATCTTTAAAGCATTAAG 1082
 Db 1072 GAGATTTCCCATATTTCCCATCAGAGTAATAATATATCTTAAATCTTTAAAGCATTAAG 1131
 QY 1083 TAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGATGCAATTAAGCTATTTT 1142
 Db 1132 TAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATTTT 1191
 QY 1143 AAATGCTGTTTATTTTGAAGACATTTACTTATTAAGAAATTCGTTATTTATGTTACTGTT 1202
 Db 1192 AAATGCTGTTTATTTTGAAGACATTTACTTATTAAGAAATTCGTTATTTATGTTACTGTT 1251
 QY 1203 CTAATCTGCTGTAAGAGTATTTCTTAAAGAAATTCGAGTACTACAGATTTTCAAAACTGA 1262
 Db 1252 CTAATCTGCTGTAAGAGTATTTCTTAAAGAAATTCGAGTACTACAGATTTTCAAAACTGA 1311
 QY 1263 ATGAGAGAAATTTGATTAACCACTCTGCTGTTCCCTTTAGTGAATTAACCACTCTGA 1322
 Db 1312 ATGAGAGAAATTTGATTAACCACTCTGCTGTTCCCTTTAGTGAATTAACCACTCTGA 1371
 QY 1323 AATTAA 1328
 Db 1372 AATTAA 1377

RESULT 113

AAZ36228

ID AAZ36228 standard; cDNA; 1320 BP.

XX AC AAZ36228;

XX DT 22-FEB-2000 (first entry)

XX DE cDNA encoding a bone marrow secreted protein designated hCornichin.

XX KW Bone marrow secreted protein; bone marrow stromal cell; cytokine;
 KW cell proliferation; cell differentiation; hematopoiesis; anaemia;
 KW myeloid cell deficiency; lymphoid cell deficiency; myeloid cell;
 KW erythroid progenitor cell; colony stimulating factor; granulocyte;
 KW monocyte; macrophage; myelo-suppression; megakaryocyte; platelet;
 KW platelet disorder; thrombocytopenia; hematopoietic stem cell;
 KW stem cell disorder; aplastic anaemia; bone differentiation;
 KW paroxysmal nocturnal hemoglobinuria; bone growth; cartilage; tendon;
 KW ligament; nerve; wound healing; tissue repair; burn; incision; ulcer;
 KW bone fracture; cartilage damage; artificial joint; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers
 XX CDS 2..430

FT /*tag= a
 FT /product= "bone marrow secreted protein"
 FT /notes= "no ATG start codon given"

FT sig_peptide 2..85

FT polyA_signal 1292..1297

FT /*tag= c

XX WO9933979-A2.

XX PN 08-JUL-1999.

XX PD 18-DEC-1998;

XX PF 98WO-US0207008.

XX PR 30-DEC-1997;

XX PR 97US-0068958P.

XX PR 24-SEP-1998;

XX PR 98US-0101603P.

XX PR 30-SEP-1998;

XX PR 98US-0102540P.

XX PA (CHIR) CHIRON CORP.

XX

PI Lin H, Cao L;
 XX WPI; 2000-038344/03.
 DR P-PSDB; AAY53622.
 XX New isolated human polynucleotide and secreted proteins can induce
 PT production of other cytokines in certain cell populations.
 PT Claim 11; Page 70; 120pp; English.
 PS
 XX AAZ36228-49 encode bone marrow secreted proteins of human bone marrow
 CC stromal cells. The proteins can exhibit cytokine, cell proliferation, or
 CC cell differentiation activity (either inducing or inhibiting). They can
 CC be used to support colony forming cells or factor-dependent cell lines,
 CC to regulate hematopoiesis, and to treat myeloid or lymphoid cell
 CC deficiencies. In addition, they may be used to support the growth and
 CC proliferation of erythroid progenitor cells, and to treat various
 CC anaemias. They can have colony stimulating factor (CSF) activity and can
 CC be used to support the growth and proliferation of myeloid cells such as
 CC granulocytes, monocytes or macrophages, to prevent or treat myelo-
 CC suppression, to support the growth and proliferation of megakaryocytes
 CC and platelets, thereby allowing prevention or treatment of platelet
 CC disorders such as thrombocytopenia, to support the growth and
 CC proliferation of hematopoietic stem cells, either in place of or in
 CC conjunction with platelet transfusions, to treat stem cell disorders,
 CC such as aplastic anaemia and paroxysmal nocturnal hemoglobinuria, or to
 CC repopulate the stem cell compartment after irradiation or chemotherapy.
 CC They can be used for growth or differentiation of bone, cartilage,
 CC tendon, ligament, or nerve tissue, as well as for wound healing and
 CC tissue repair and replacement, and in the treatment of burns, incisions
 CC and ulcers, to induce cartilage and/or bone growth in circumstances where
 CC bone is not normally formed and thus have an application in healing bone
 CC fractures and cartilage damage or defects, prophylactic use in fracture
 CC reduction and also in the improved fixation of artificial joints
 XX
 SQ Sequence 1320 BP; 396 A; 232 C; 242 G; 450 T; 0 U; 0 Other;

Query Match 98.5%; Score 1313.4; DB 3; Length 1320;
 Best Local Similarity 99.9%; Pred. No. 4.2e-301;
 Matches 1314; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 19 GTTCACGTTTCGGCGCTTCTGCTACATGCTGGCGTGTGCTACTCGCGGCTCATCTT 78
 Db 1 GTTCACGTTTCGGCGCTTCTGCTACATGCTGGCGTGTGCTACTCGCGGCTCATCTT 60
 QY 79 CTTCCCATTTGGCACATATAGCATTTTGTAGAGCTGAAGACTGATTACAGAACTCTAT 138
 Db 61 CTTCCCATTTGGCACATTTATAGCATTTTGTAGAGCTGAAGACTGATTACAGAACTCTAT 120
 QY 139 AGACCAAGTGTATACCTGGAATCCCTTGTACTCCAGAGTACCTCATCCAGCTTCTT 198
 Db 121 AGACCAAGTGTATACCTGGAATCCCTTGTACTCCAGAGTACCTCATCCAGCTTCTT 180
 QY 199 CTGTGTCATGTTTCTTTGTGAGAGAGTGGGTTACATGGGTCTCAATATGCCCTCTT 258
 Db 181 CTGTGTCATGTTTCTTTGTGAGAGAGTGGGTTACATGGGTCTCAATATGCCCTCTT 240
 QY 259 GGCATATCATATTTTCGAGGTATATCAGTAGACCACTGATGAGTGGCCAGGACTCTATGA 318
 Db 241 GGCATATCATATTTTCGAGGTATATGAGTAGACCACTGATGAGTGGCCAGGACTCTATGA 300
 QY 319 CCCTACACCATCATGCAATGCAATATTTCTAGCATATTTGTACAGAGGAGGATGGTGCAA 378
 Db 301 CCCTACACCATCATGCAATGCAATATTTCTAGCATATTTGTACAGAGGAGGATGGTGCAA 360
 QY 379 ATTAGCTTTTATCTTTCTAGCATTTTCTTTTATCTACCTATATGGCATGATCTATGTTGGT 438
 Db 361 ATTAGCTTTTATCTTTCTAGCATTTTCTTTTATCTACCTATATGGCATGATCTATGTTGGT 420
 QY 439 GAGCTCTTAGACCAACACACAGAAATTTGGTCCAGTTTAAAGTGCATGCAAAAAGCACCACCA 498
 Db 421 GAGCTCTTAGACCAACACACAGAAATTTGGTCCAGTTTAAAGTGCATGCAAAAAGCACCACCA 480

QY 499 AATGAAGGAACTCTATCCAGCAAGATCCTGTCCAGAGTAGCCTGTGGAACTCTGATCAGT 558
DB |||||
QY 481 AATGAAGGAACTCTATCCAGCAAGATCCTGTCCAGAGTAGCCTGTGGAACTCTGATCAGT 540
DB |||||
QY 559 TACTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACATTTTGTGTTGGAAGAC 618
DB |||||
QY 541 TACTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACATTTTGTGTTGGAAGAC 600
DB |||||
QY 619 TGTTTTTCATATGTTATCTACAGATAAGATTTTAAATGTTTATGTTATTAATTAATATA 678
DB |||||
QY 601 TGTTTTTCATATGTTATCTACAGATAAGATTTTAAATGTTTATGTTATTAATTAATATA 660
DB |||||
QY 679 AAATGATTACCTCTGCTGTGTTGACAGGTTTGAACCTTGCACCTTCTTAAGGAACAGCCATAAT 738
DB |||||
QY 661 AAATGTTTACCTCTGCTGTGTTGACAGGTTTGAACCTTGCACCTTCTTAAGGAACAGCCATAAT 720
DB |||||
QY 739 CCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTTGGAAGCTTTTGTATAGG 798
DB |||||
QY 721 CCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTTGGAAGCTTTTGTATAGG 780
DB |||||
QY 799 AACTTGTAGGCTCAATTTTGGTTTTCATTGAACAGCTATCTAATTAATTAATAGCTGTAGA 858
DB |||||
QY 781 AACTTGTAGGCTCAATTTTGGTTTTCATTGAACAGCTATCTAATTAATTAATAGCTGTAGA 840
DB |||||
QY 859 TATCAGGTGCTTCTGATGAAGTGAATAATGTTATATCTGACTAGTGGGAACCTTCATGGGT 918
DB |||||
QY 841 TATCAGGTGCTTCTGATGAAGTGAATAATGTTATATCTGACTAGTGGGAACCTTCATGGGT 900
DB |||||
QY 919 TCCTCATCTGTCATGTCGATGATTAATTAATGATGATTAATTAATTAATTAATTAATTAATTAAT 978
DB |||||
QY 901 TCCTCATCTGTCATGTCGATGATTAATTAATGATGATTAATTAATTAATTAATTAATTAATTAAT 960
DB |||||
QY 979 TTTTCCCTTCCGCTTCAATTAATTAATCCCTGTATATTCATGAATGAGAGATTTTCCCATATTT 1038
DB |||||
QY 961 TTTTCCCTTCCGCTTCAATTAATTAATCCCTGTATATTCATGAATGAGAGATTTTCCCATATTT 1020
DB |||||
QY 1039 CCATCAGAGTAAATAATFACCTTGCTTTAAATCTTAAAGCAATGAATGAATGAATGAATGAATGAAT 1098
DB |||||
QY 1021 CCATCAGAGTAAATAATFACCTTGCTTTAAATCTTAAAGCAATGAATGAATGAATGAATGAATGAAT 1080
DB |||||
QY 1099 ATATATGCTGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1158
DB |||||
QY 1081 ATATATGCTGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1140
DB |||||
QY 1159 GTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1218
DB |||||
QY 1141 GTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
DB |||||
QY 1219 GGTATCTTTAAGAAATTTGAGGATCTACAGATTTTCAAAATCTGAATGAGAGAAATTTGTA 1278
DB |||||
QY 1201 GGTATCTTTAAGAAATTTGAGGATCTACAGATTTTCAAAATCTGAATGAGAGAAATTTGTA 1260
DB |||||
QY 1279 TAAACCATCTGCTGCTTTTGTAGTGCATACATTAATTAATTAATTAATTAATTAATTAATTAAT 1333
DB |||||
QY 1261 TAAACCATCTGCTGCTTTTGTAGTGCATACATTAATTAATTAATTAATTAATTAATTAATTAAT 1315
DB |||||

RESULT 114

AAK94250

ID AAK94250 standard; cDNA; 1321 BP.

XX AC AAK94250;

XX AC AAK94250;

XX DT 06-NOV-2001 (first entry)

XX DE Human full-length cDNA, SEQ ID NO: 2858.

XX KW Human; full length cDNA; cDNA synthesis; oligo-capping; ss.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

XX OS Homo sapiens.

PD 05-SEP-2001.
XX 07-JUL-2000; 2000EP-00114089.
XX 08-JUL-1999; 99JP-00194486.
PR 11-JAN-2000; 2000JP-00118774.
PR 02-MAY-2000; 2000JP-00183765.
XX (HELI-) HELIX RES INST.
XX Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsubo T, Koga H;
XX WPI; 2001-524255/58.
DR P-PSDB; AAM93330.
XX 830 Primers useful for synthesizing full length cDNA clones and their use
PT in genetic manipulation.
XX Claim 8; SEQ ID NO 2858; 1380pp + Sequence Listing; English.
XX The invention relates to primers for synthesizing full length cDNA
CC clones. 830 cDNA molecules encoding a human protein have been isolated
CC and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have
CC been determined. Primers for synthesizing the full length cDNA are useful
CC for clarifying the function of the protein encoded by the cDNA. The full
CC length clones were obtained by construction of full length enriched cDNA
CC libraries that were synthesised by the oligo-capping method. The primers
CC enable the production of the full length cDNA easily without any special
CC methods. The present sequence is a full length human cDNA of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in CD-ROM format directly
CC from EPO
XX
SQ Sequence 1321 BP; 391 A; 238 C; 243 G; 449 T; 0 U; 0 Other;

Query Match 98.4%; Score 1311.8; DB 4; Length 1321;
Best Local Similarity 99.8%; Pred. No. 1e-300;
Matches 1313; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 12 CGATGGCCTTACGTTTCGCGGCTTCTCTACATGCTGGCGCTGTCTACTGCGGCG 71
DB |||||
QY 7 CCATGGCCTTACGTTTCGCGGCTTCTCTACATGCTGGCGCTGTCTACTGCGGCG 66
DB |||||
QY 72 TCATCTTCTTCGCAATTTGGCACAATTATAGCATTTTGTAGCTGAAGACTGATTACAAGA 131
DB |||||
QY 67 TCATCTTCTTCGCAATTTGGCACAATTATAGCATTTTGTAGCTGAAGACTGATTACAAGA 126
DB |||||
QY 132 ATCCTATAGACAGTGAATACCCCTGAAATCCCTTGTACTCCAGAGTACCTCATCCACG 191
DB |||||
QY 127 ATCCTATAGACAGTGAATACCCCTGAAATCCCTTGTACTCCAGAGTACCTCATCCACG 186
DB |||||
QY 192 CTTTCTTCTGTGTCATGTTTCTTTGTGCGAGAGTGGCTTACACTGGTCTCATATGC 251
DB |||||
QY 187 CTTTCTTCTGTGTCATGTTTCTTTGTGCGAGAGTGGCTTACACTGGTCTCATATGC 246
DB |||||
QY 252 CCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAGTGGCCCGAGAC 311
DB |||||
QY 247 CCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAGTGGCCCGAGAC 306
DB |||||
QY 312 TCTATGACCCCTACAAACCATCATGATGAGATATTTCTAGCATATTTGTGAGAGGAGAT 371
DB |||||
QY 307 TCTATGACCCCTACAAACCATCATGATGAGATATTTCTAGCATATTTGTGAGAGGAGAT 366
DB |||||
QY 372 GGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTATATATGCGATGATCTATG 431
DB |||||
QY 367 GGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTATATATGCGATGATCTATG 426
DB |||||
QY 432 TTTTGGTGAGCTCTTAGAACAACACACAGAGAAATTTGTCAGTTTAACTGATGCAAAA 491
DB |||||
QY 427 TTTTGGTGAGCTCTTAGAACAACACACAGAGAAATTTGTCAGTTTAACTGATGCAAAA 486
DB |||||
QY 492 GCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGCCTGTGGAATCT 551
DB |||||

Db 487 GCCACCAATGAAGGATCTTATCCAGCAAGATCTGTCCAAAGTAGCTGTGAACT 546
QY 552 GATCAGTTACTTTAAATAAGTACTCTTATTTTAAATGTTTCCACATTTTGTGTG 611
Db 547 GATCAGTTACTTTAAATAAGTACTCTTATTTTAAATGTTTCCACATTTTGTGTG 606
QY 612 GAAAGACTGTTTTCATATCTTATCTACATGATAAGATTTTAAATGGTATTACGTATAAT 671
Db 607 GAAAGACTGTTTTCATATCTTATCTACATGATAAGATTTTAAATGGTATTACGTATAAT 666
QY 672 TAAATATAATGATTAACCTCTGGTGTGACAGTTTGAACCTTGACCTTTTAAAGAACAG 731
Db 667 TAAATATAATGATTAACCTCTGGTGTGACAGTTTGAACCTTGACCTTTTAAAGAACAG 726
QY 732 CCAATATCTCTGAATGATGATTAATTAATCTGACTGTCTGCTAGTACATGCGAAGCTTTTGT 791
Db 727 CCAATATCTCTGAATGATGATTAATTAATCTGACTGTCTGCTAGTACATGCGAAGCTTTTGT 786
QY 792 TTAAGGAACCTGTAGGGCTCAATTTTGGTTTCATTGAAACAGTATCTAATTATAAATTAG 851
Db 787 CTAATAGGAACCTGTAGGGCTCAATTTTGGTTTCATTGAAACAGTATCTAATTATAAATTAG 846
QY 852 CTGTAGATATGAGTCTCTCTGATGAGTGAAGTGAATAATGTAATCTGACTAGTGGAACTTTC 911
Db 847 CTGTAGATATGAGTCTCTCTGATGAGTGAAGTGAATAATGTAATCTGACTAGTGGAACTTTC 906
QY 912 ATGGGTTTCTCATCTGCTCATGTCGATGATTAATATATGATGATACATTTTACAAAATAAAA 971
Db 907 ATGGGTTTCTCATCTGCTCATGTCGATGATTAATATATGATGATACATTTTACAAAATAAAA 966
QY 972 GCGGGAATTTCCCTTCGCTTGAATATTAATTCCTGCTGATATTCGATGATGAGAGATTTCC 1031
Db 967 GCGGGAATTTCCCTTCGCTTGAATATTAATTCCTGCTGATATTCGATGATGAGAGATTTCC 1026
QY 1032 CATATTTCCATCAGAGTATAAATATATCTGTTTAAATTTCTTAAGCATTAAGTAAACATGA 1091
Db 1027 CATATTTCCATCAGAGTATAAATATATCTGTTTAAATTTCTTAAGCATTAAGTAAACATGA 1086
QY 1092 TATAAAATATATGCTGAATTTACTCTGGAAGTATGATTTAAAGCTATTTTAAATGTTT 1151
Db 1087 TATAAAATATATGCTGAATTTACTCTGGAAGTATGATTTAAAGCTATTTTAAATGTTT 1146
QY 1152 TTTATTTGTAAGACATTAATTAAGAAATGGTTTATTTATGCTTTACTGTTCTTAATCTGG 1211
Db 1147 TTTATTTGTAAGACATTAATTAAGAAATGGTTTATTTATGCTTTACTGTTCTTAATCTGG 1206
QY 1212 TGGTAAAGTATTTCTTAAGAAATGGTGTGAGTATCTACAGATTTTCAAACTGAATGAGAA 1271
Db 1207 TGGTAAAGTATTTCTTAAGAAATGGTGTGAGTATCTACAGATTTTCAAACTGAATGAGAA 1266
QY 1272 AATTGTATAACCATCTGCTGTTTCTTTAGTGAATACAAATAAACTCTGAAAT 1326
Db 1267 AATTGTATAACCATCTGCTGTTTCTTTAGTGAATACAAATAAACTCTGAAAT 1321

RESULT 115

ABK35858

ID ABK35858 standard; cDNA; 2916 BP.

XX

AC ABK35858;

XX

DT 08-MAY-2002 (first entry)

XX

DE cDNA sequence #249 encoding novel human secreted protein.

XX

KW Human secreted protein; hyperproliferative disorder; autoimmune disorder;
KW immune deficiency disorder; blood disorder; inflammatory disorder;
KW infectious disorder; allergic condition; neurodegenerative disorder;
KW liver fibrosis; coagulation disorder; gene therapy; antimicrobial;
KW tumour; cancer; hepatotropic; immunosuppressive; antirheumatic; gene; ss.

XX

OS Homo sapiens.

XX WO200177289-A2.
PN
XX 18-OCT-2001.
PD
XX 29-MAR-2001; 2001WO-US010232.
PF
XX 06-APR-2000; 2000US-0195605P.
PR
XX (GENY) GENETICS INST INC.
PA
XX Jacobs K, Mc Coy JM, Lavallie ER, Collins-Racie LA, Evans C;
PI Merberg D, Treacy M, Agostino MJ, Bowman MR, Spaulding V, Wong GG;
PI Clark HF, Fechtel K, Howes SH, Resnick RJ, Gulukota K, Graham JR;
PI WPI; 2002-179322/23.
DR
XX Six hundred and twenty three polynucleotides derived from a variety of
PT human tissue sources which encode secreted proteins, useful for treating
PT immune deficiencies and disorders such as autoimmune disorders.
PS Claim 1; Page 223; 393pp; English.
XX
CC The present invention relates to the isolation of novel cDNA sequences
CC which encode human secreted proteins. The cDNA sequences have been
CC derived from a variety of human tissues. The invention also provides a
CC method for producing proteins from these polynucleotide sequences. The
CC proteins are useful for identifying compounds that modulate their
CC activity and production. The sequences of the invention are useful for
CC treating diseases such as hyperproliferative disorders (e.g. cancer),
CC immune deficiency disorders (e.g. severe combined immunodeficiency
CC (SCID)), autoimmune disorders (e.g. multiple sclerosis), blood disorders
CC (e.g. thrombocytopenia), inflammatory disorders (e.g. arthritis),
CC infectious disorders (e.g. hepatitis), allergic conditions (e.g. asthma),
CC neurodegenerative disorders (e.g. Alzheimer's disease), liver fibrosis,
CC coagulation disorders (e.g. haemophilia), and tumours. The polynucleotide
CC sequences of the invention are also useful in gene therapy. ABK35610-
CC ABK36232 represent the cDNA sequences of the invention that encode for
CC novel human secreted proteins
XX
SQ Sequence 2916 BP; 894 A; 517 C; 579 G; 926 T; 0 U; 0 Other;

Query Match 97.6%; Score 1301.4; DB 6; Length 2916;

Best Local Similarity 99.8%; Pred. NO. 3.8e-298;

Matches 1313; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 16 GCGGTTCAAGTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCTCACTCGCGGCTCAT 75

Db 1 GCGGTTCAAGTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCTCACTCGCGGCTCAT 60

QY 76 CTTCTTCGCCATTTGGCCATTTATAGCATTTTATGAGCTGAAGCTGATTACAAGATCC 135

Db 61 CTTCTTCGCCATTTGGCCATTTATAGCATTTTATGAGCTGAAGCTGATTACAAGATCC 120

QY 136 TATAGCAGGTGTAATACCTGATCCCTTGTACTCCAGAGTACCTCATCCAGCTTT 195

Db 121 TATAGCAGGTGTAATACCTGATCCCTTGTACTCCAGAGTACCTCATCCAGCTTT 180

QY 196 CTTCTGTCTCATGTTTCTTTGTGAGCAGAGTGGCTTACACTGGTCTCAATATGCCCT 255

Db 181 CTTCTGTCTCATGTTTCTTTGTGAGCAGAGTGGCTTACACTGGTCTCAATATGCCCT 240

QY 256 CTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAGTGGCCCGGAGCTCTA 315

Db 241 CTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAGTGGCCCGGAGCTCTA 300

QY 316 TGACCTTCAACCATCATGAATGCGATTTCTAGCATATTTGTGAGAAGAGATGTGTG 375

Db 301 TGACCTTCAACCATCATGAATGCGATTTCTAGCATATTTGTGAGAAGAGATGTGTG 360

QY 376 CAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGCGATGATCTATGTTT 435

Db 361 CAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGCGATGATCTATGTTT 420

QY 436 GGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGTGCATGCAAAAAGCCA 495
 Db |||||
 QY 421 GGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGTGCATGCAAAAAGCCA 480
 Db |||||
 QY 496 CCAATAGAGGATTTCTATCCAGCAGAGATCTGTCCAGAGTAGCTGTGAATCTGATC 555
 Db |||||
 QY 481 CCAATAGAGGATTTCTATCCAGCAGAGATCTGTCCAGAGTAGCTGTGAATCTGATC 540
 Db |||||
 QY 556 AGTTACTTTAAATAAGACTCCTTAATTTTAAATGTTTCCACATTTTGTGTTGGAAA 615
 Db |||||
 QY 541 AGTTACTTTAAATAAGACTCCTTAATTTTAAATGTTTCCACATTTTGTGTTGGAAA 600
 Db |||||
 QY 616 GACTGTTTTATATGTTTACTCAGATAAGATTTTAAATGTTTAAATGTTTAAATTTAT 675
 Db |||||
 QY 601 GACTGTTTTATATGTTTACTCAGATAAGATTTTAAATGTTTAAATGTTTAAATTTAT 660
 Db |||||
 QY 676 ATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTCTTAAGGAACAGCCAT 735
 Db |||||
 QY 661 ATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTCTTAAGGAACAGCCAT 720
 Db |||||
 QY 736 AATCTCTGAATGATGATTAATTAATGACTGCTCTAGTACATTTGGAAGCTTTTGTAT 795
 Db |||||
 QY 721 AATCTCTGAATGATGATTAATTAATGACTGCTCTAGTACATTTGGAAGCTTTTGTAT 780
 Db |||||
 QY 796 AGGAACCTTGTAGGGCTCAATTTTGGTTTCATTTGAAACAGTATCTAATTAATTAAGCTGT 855
 Db |||||
 QY 781 AGGAACCTTGTAGGGCTCAATTTTGGTTTCATTTGAAACAGTATCTAATTAATTAAGCTGT 840
 Db |||||
 QY 856 AGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAGTGGAACTTCATGG 915
 Db |||||
 QY 841 AGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAGTGGAACTTCATGG 900
 Db |||||
 QY 916 GTTTCCTCATCTGATGCGATGATTAATATGATGATCATTTTACAAAATAAAGGCG 975
 Db |||||
 QY 901 G-TTCCCTCATCTGATGCGATGATTAATATGATGATCATTTTACAAAATAAAGGCG 959
 Db |||||
 QY 976 GAATTTTCCCTTGGCTTGAATATTAATTCCTGTATATGCAATGAAGAGAGATTTCCCAT 1035
 Db |||||
 QY 960 GAATTTTCCCTTGGCTTGAATATTAATTCCTGTATATGCAATGAAGAGATTTCCCAT 1019
 Db |||||
 QY 1036 TTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGCATTAAGTAACATGATATA 1095
 Db |||||
 QY 1020 TTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGCATTAAGTAACATGATATA 1079
 Db |||||
 QY 1096 AAAAAATATGCTGAATTAATCTTGTGAAGATGCAATTAAGCATTAATTAATGTTTATA 1155
 Db |||||
 QY 1080 AAAAAATATGCTGAATTAATCTTGTGAAGATGCAATTAAGCATTAATTAATGTTTATA 1139
 Db |||||
 QY 1156 TTTGTAAGACATTAATTAAGAAATTTGGTTATTAATGCTTACTGTTCTTAATCTGTTGCT 1215
 Db |||||
 QY 1140 TTTGTAAGACATTAATTAAGAAATTTGGTTATTAATGCTTACTGTTCTTAATCTGTTGCT 1199
 Db |||||
 QY 1216 AAAGTATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAACTGAATGAGAGAAATTT 1275
 Db |||||
 QY 1200 AAAGTATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAACTGAATGAGAGAAATTT 1259
 Db |||||
 QY 1276 GTATAACCATCTGCTGTTTCTTTAGTGCATACAAATAAACTCTGAAATTAAGA 1330
 Db |||||
 QY 1260 GTATAACCATCTGCTGTTTCTTTAGTGCATACAAATAAACTCTGAAATTAAGA 1314
 Db |||||

RESULT 116
 ABX10419

ID ABX10419 standard; DNA; 1398 BP.

XX AC ABX10419;

XX AC ABX10419;

DT 28-JAN-2003 (first entry)

XX DE DNA encoding protein differentially regulated in prostate cancer #88.

XX KW Prostate cancer; gene expression; differential regulation;

KW molecular marker; drug target; cancer detection; cancer diagnosis;
 KW cancer staging; cancer grading; cancer assessing; cancer monitoring;
 KW gene; ds.

OS Homo sapiens.

XX WO200281638-A2.

XX 17-OCT-2002.

XX 08-APR-2002; 2002WO-US010824.

XX 06-APR-2001; 2001US-0281731P.

XX 06-APR-2001; 2001US-0281732P.

XX (ORIG-) ORIGENE TECHNOLOGIES INC.

XX Sun Z, Jay G;

XX WPI; 2003-058520/05.

PT Novel genes which are differentially regulated in prostate cancer, useful
 PT for diagnosing prostate cancer in prostate tissue sample and assessing
 PT therapeutic or preventive intervention in prostate cancer patients.

XX Claim 1; Page 177-178; 416pp; English.

CC The invention describes genes (I) which are differentially regulated in
 CC prostate cancer. (I) Is useful for diagnosing a prostate cancer in a
 CC sample comprising prostate tissue, which involves determining the number
 CC of target genes which are differentially-regulated in the sample, where
 CC the number is indicative of the probability that the sample comprises
 CC prostate cancer. (I) Is useful for assessing a therapeutic or preventive
 CC intervention in a subject having a prostate cancer, which involves
 CC determining the expression levels in a sample comprising prostate tissue
 CC of target genes which are differentially-regulated in prostate cancer.
 CC Preferably, the expression levels of at least 10 genes are determined.
 CC (I) is also useful for identifying agents that modulate a biological
 CC activity of a polypeptide differentially-regulated in prostate cancer
 CC cells, which involves contacting a polypeptide differentially-regulated
 CC in prostate cancer cells with a test agent under conditions effective for
 CC the test agent to modulate a biological activity of the polypeptide, and
 CC determining whether the test agent modulates the biological activity. (I)
 CC is useful as molecular markers, as drug targets, and for detecting,
 CC diagnosing, staging, grading, assessing, monitoring, prognosticating,
 CC preventing or treating, determining predisposition to diseases and
 CC conditions especially relating to prostate cancer. (I) and its expression
 CC products are used in the diagnostic test to assay for presence of cancer
 CC e.g., in tissue sections, in biopsy sample, in total RNA, in lymph, in
 CC blood etc. (I) is useful for assessing cancer e.g., to determine the type
 CC of cancer, its stage of development, the nature of genetic defect, etc.
 CC The polypeptide encoded by (I) can be used as target for therapy or drug
 CC discovery. (I) can also be used for expressing the polypeptide and thus
 CC for searching specific binding partners of the polypeptide. (I) is useful
 CC in therapeutic applications to treat prostate cancer. The identification
 CC of specific genes, and groups of genes, expressed in pathways
 CC physiologically relevant to prostate cancer permits the definition of
 CC functional and disease pathways and the delineation of targets in these
 CC pathways which are useful in diagnostic, therapeutic, and clinical
 CC applications. This sequence encodes a protein differentially regulated in
 CC prostate cancer

XX SQ Sequence 1398 BP; 419 A; 262 C; 255 G; 459 T; 0 U; 3 Other;

Query Match 95.9%; Score 1277.8; DB 7; Length 1398;

Best Local Similarity 98.8%; Pred. No. 1.2e-292;

Matches 1319; Conservative 0; Mismatches 9; Indels 7; Gaps 3;

QY 3 CCAGCGCTCCAGTGGCTTACGTTCCGGGCTTCTGCTACATGCTGCGCTGCTGCTCA 62

Db 46 CCTCCCGAGCCATGGCGTTACGTTCCGGGCTTCTGCTACATGCTGCGCTGCTGCTCA 105

QY 63 CTGCGCGCTCATCTTCTTCGCCATTTGGCACATTATAGCATTTTGTAGCTGAAGACTG 122

106 CTGCGCGCTCATCTTCTGCGCAATTTGGACATATATAGATTTGATGAGCTGAGACTG 165
123 ATTCAGAAATCCCTATAGACAGAGTGTAATACCCCTGAATCCCTTGTTACTCCAGAGTACC 182
166 ATTCAGAAATCCCTATAGACAGAGTGTAATACCCCTGAATCCCTTGTTACTCCAGAGTACC 225
183 TCATCCAGCTTCTTCTGTCGTCATGTTCTTTCTGTCAGCAGAGTGCTTACACTGGTC 242
226 TCATCCAGCTTCTTCTGTCGTCATGTTCTTTCTGTCAGCAGAGTGCTTACACTGGTC 285
243 TCATATATGCCCCCTCTGGCATATCATATTTGGAGGTATATGAGTACCCAGTGCATGAGTG 302
286 TCATATATGCCCCCTCTGGCATATCATATTTGGAGGTATATGAGTACCCAGTGCATGAGTG 345
303 GCCCAGAGCTATGAGCCCTACACCATCATGATGAGATATCTAGCATATTTGTGAGA 362
346 GCCCAGAGCTATGAGCCCTACACCATCATGATGAGATATCTAGCATATTTGTGAGA 405
363 AGGAAGGATGGTGCAAAATAGCTTTTATCTCTAGCATATTTTCTAGCATATTTTCTAGCATATTTGCA 422
406 AGGAAGGATGGTGCAAAATAGCTTTTATCTCTAGCATATTTTCTAGCATATTTTCTAGCATATTTGCA 465
423 TGATCTATGTTTGGTGAGCTCTTAGAAACACACAGAGAAATTTGGTCCAGTTAAGCGC 482
466 TGATCTATGTTTGGTGAGCTCTTAGAAACACACAGAGAAATTTGGTCCAGTTAAGCGC 525
483 ATGCAAAAGCCCAATCAAGGATCTCTCCAGCAAGATCTGTCAGAGTAGCTT 542
526 ATGCAAAAGCCCAATCAAGGATCTCTCCAGCAAGATCTGTCAGAGTAGCTT 585
543 GTGGAATCTGATCAGTTTACCTTTAAATGACCTCTTATTTTAAATGTTTCCACATTT 602
586 GTGGAATCTGATCAGTTTACCTTTAAATGACCTCTTATTTTAAATGTTTCCACATTT 645
603 TTGCTTGTGAAAGACCTGTTTTT-CATATGTTTACTCAGATAAGATTTTAAATGTTT 661
646 TTGCTTGTGAAAGACCTGTTTTTCCATATGTTTACTCAGATAAGATTTTAAATGTTT 705
662 ACCTATATAATTAATAAATGATTAATCTCTGTTGTTGACAGGTTTGAATCTGACTTCT 721
706 ACCTATATAATTAATAAATGATTAATCTCTGTTGTTGACAGGTTTGAATCTGACTTCT 765
722 TAAGAAACCCCAATATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTTG 781
766 TAAGAAACCCCAATATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTTG 825
782 AAGCTTTTGTATAGAACTTGTAGGCTCATTTTGGTTTCATTTGAAACAGATATCTAAT 841
826 AAGCTTTTGTATAGAACTTGTAGGCTCATTTTGGTTTCATTTGAAACAGATATCTAAT 885
842 TATAAATTAGCTGTAGATATCAGTCTCTGATGAAGTCAAAATGATATCTGACTAGT 901
886 TATAAATTAGCTGTAGATATCAGTCTCTGATGAAGTCAAAATGATATCTGACTAGT 945
902 GGAACCTTCAAGGTTTCTCTCTCTGTCATGTCGATGATTAATATGAGTACATTTACA 961
946 GGAACCTTCAAGGTTTCTCTCTCTGTCATGTCGATGATTAATATGAGTACATTTACA 1005
962 AAAAT-----AAAAAGCGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATTTGCAAT 1016
1006 AAAATAAAAAAGCGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATTTGCAAT 1065
1017 GAATGAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAAAT-CTTAA 1075
1066 GAATGAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAAATNNNTAA 1125
1076 GCATAGTAACATGATATAAAATATATCTGATTAATTTGTGAAGATGCAATTTAAAG 1135
1126 GCATAGTAACATGATATAAAATATATCTGATTAATTTGTGAAGATGCAATTTAAAG 1185
1136 CTATTTTAAATGTTTATTTTGTAGACATTTACTTATTAAGAAATGTTTATTTAGCT 1195

1186 CTATTTTAAATGTTTATTTTATTTGTAAGACATTTACTTATTAAGAAATGTTTATTTAGCT 1245
1196 TACTGTTCTAATCTGTTGTAAGAGTATTTCTTAAAGAAATTTGAGGTAATACAGATTTTCA 1255
1246 TACTGTTCTAATCTGTTGTAAGAGTATTTCTTAAAGAAATTTGAGGTAATACAGATTTTCA 1305
1256 AAACCTGAATGAGAGAAATTTGTAATACCATCTCTGTTCTTCTTGTAGTCAATACATAA 1315
1306 AAACCTGAATGAGAGAAATTTGTAATACCATCTCTGTTCTTCTTGTAGTCAATACATAA 1365
1316 ACTCTGAAATTAAGA 1330
1366 ACTTGAATTAAGA 1380

RESULT 117
ADD78291
ID ADD78291 standard; DNA; 1360 BP.
XX
AC ADD78291;
XX
DT 29-JAN-2004 (first entry)
XX
Human CGDD-33 coding sequence.
XX
DE
XX
KW Anabolic; Hypertensive; Respiratory; Anti-HIV; Antiallergic;
KW Neuroprotective; Ophthalmic; Antianemic; Antiarteriosclerotic;
KW Antiinflammatory; Ophthalmological; Muscular; Hepatotropic;
KW Neuroprotective; Antispasmodic; Anticonvulsant; Virucide; Antibacterial;
KW Fungicide; Antiparasitic; Protozoacide; Antihelminthic; Cytostatic;
KW Cerebroprotective; Antiparkinsonian; Antipsoriatic; Anticancer;
KW Antidiabetic; Antiarthritic; Antirheumatic; Osteopathic; Gene therapy;
KW human; cell growth; cell differentiation; cell death; CGDD;
KW cell proliferative disorder; cancer; developmental disorder;
KW neurological disorder; autoimmune disorder; inflammatory disorder;
KW infection; reproductive disorder; gene; ds.
XX
OS Homo sapiens.
XX
PN WO2003077875-A2.
XX
PD 25-SEP-2003.
XX
PF 14-MAR-2003; 2003WO-US008310.
XX
PR 15-MAR-2002; 2002US-0364494P.
PR 29-MAR-2002; 2002US-0369129P.
PR 12-APR-2002; 2002US-0372511P.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Kable AE, Tran UK, Hafalia AJA, Burford N, Honchell CD,
PI Lehr-Watson PM, Duggan BM, Ramkumar J, Griffin JA, Richardson TW,
PI Elliott VS, Jiang X, Jackson AA, Marquis JP, Chawla NK, Khare R,
PI Becha SD, Lee SY, Swarnakar A, Yue H, Warren BA, Baughn MR, Lal PG,
PI Lee S, Ho A, Gandhi AR, Yao MG,
XX
DR WPI; 2003-779081/73.
DR P-PSDB; ADD78252.
XX
PT New polypeptides and polynucleotides associated with cell growth,
PT differentiation and death, useful for diagnosing, treating or preventing
PT e.g. developmental, neurological, autoimmune, inflammatory or
PT reproductive disorders.
XX
PS Claim 5; SEQ ID NO 72; 320pp; English.
XX
CC The present invention relates to novel human proteins (I; ADD78220-
CC ADD78258) and their coding sequences (II; ADD78259-ADD78297), which are
CC associated with cell growth, differentiation and death, referred to as
CC CGDD-n proteins, where n is a number from 1 to 39. The CGDD proteins and
CC their coding sequences are useful for diagnosing, treating or preventing
CC cell proliferative disorders (e.g. cirrhosis, hepatitis,

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 14, 2004, 16:07:07 ; Search time 114 Seconds
(without alignments)
6489.031 Million cell updates/sec

Title: US-09-978-298A-321
Perfect score: 1333
Sequence: 1 gccacgcgtccgatggcgt.....aaactctgaaattaagactc 1333

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 682709 seqs, 277475446 residues

Total number of hits satisfying chosen parameters: 3

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database : Issued Patents NA: *
1: /cgn2_6/prodata/2/ina/5A COMB seq: *
2: /cgn2_6/prodata/2/ina/5B COMB seq: *
3: /cgn2_6/prodata/2/ina/6A COMB seq: *
4: /cgn2_6/prodata/2/ina/6B COMB seq: *
5: /cgn2_6/prodata/2/ina/PCUTUS COMB seq: *
6: /cgn2_6/prodata/2/ina/backfiles1.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Match	Length	ID	Description
1	1316.8	98.8	1391	2	US-08-950-168-2
2	1316.8	98.8	1391	4	US-09-365-705-2
3	1316.4	98.8	1404	4	US-09-257-179-34

SUMMARIES

ALIGNMENTS

RESULT 1
US-08-950-168-2
; Sequence 2, Application US/08950168
; Patent No. 5968744
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Corley, Neil C.
; APPLICANT: Shah, Purvi
; TITLE OF INVENTION: HUMAN CORNICHON PROTEIN
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/950,168
FILING DATE: Herewith
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0401 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-855-0555
TELEFAX: 650-845-4166
TELEX:
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 1391 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: BLADNOT04
CLONE: 1318847
US-08-950-168-2

Query Match 98.8%; Score 1316.8; DB 2; Length 1391;
Best Local Similarity 99.5%; Pred. No. 0;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 CCACGGCTCCGATGGCGTTACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTCTCA 62
DB 63 CCTCCCCAGCCATGGCGTTACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTCTCA 122

QY 63 CTGCGCGCTCATCTTCTTCCGCAATTTGGCATTATAGCATTTGATGAGCTGAAGACTG 122
DB 123 CTGCGCGCTCATCTTCTTCCGCAATTTGGCATTATAGCATTTGATGAGCTGAAGACTG 182

QY 123 ATTACAAGAAATCCTATAGACCAAGTGTATACCCCTGAATCCCTGTGCTACCTCCAGAGTACC 182
DB 183 ATTACAAGAAATCCTATAGACCAAGTGTATACCCCTGAATCCCTGTGCTACCTCCAGAGTACC 242

QY 183 TCATCCACGCTTCTTCTGCTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGGTC 242
DB 243 TCATCCACGCTTCTTCTGCTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGGTC 302

QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGCATGAGTG 302
DB 303 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGCATGAGTG 362

QY 303 GCCCAGGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTTAGCATATTTGTCAGA 362
DB 363 GCCCAGGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTTAGCATATTTGTCAGA 422

QY 363 AGGAGGATGGTGCATAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCA 422
DB 423 AGGAGGATGGTGCATAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGGCA 482

QY 423 TGAATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGTGC 482
DB 483 TGAATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGTGC 542

QY 483 ATGCAAAAAGCCACCAAAATGAAGGATTTATCCAGCAAGATCCTCTCCAGAGTAGCCCT 542
DB 543 ATGCAAAAAGCCACCAAAATGAAGGATTTATCCAGCAAGATCCTCTCCAGAGTAGCCCT 602

QY 543 GTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACATTT 602
DB 603 GTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACATTT 662

QY 603 TTGCTGTGGAAAGACGTGTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTATTA 662
Db 663 TTGCTGTGGAAAGACGTGTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTATTA 722
QY 663 CGTATAAATTAATAAATAAAGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTTCTT 722
Db 723 CGTATAAATTAATAAATAAAGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTTCTT 782
QY 723 AAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATCTGACGTGCTCTAGTACATTGGA 782
Db 783 AAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATCTGACGTGCTCTAGTACATTGGA 842
QY 783 AGCTTTTGTATAGGAACCTGTTAGGGCTCAATTTGGTTTCATTTGAACAGATNCTAAT 842
Db 843 AGCTTTTGTATAGGAACCTGTTAGGGCTCAATTTGGTTTCATTTGAACAGATNCTAAT 902
QY 843 ATAAATAGCTGTAGATATCAGGTGCTCTCTGATGAAGTGAATAATGATATCTGACTAGTG 902
Db 903 ATAAATAGCTGTAGATATCAGGTGCTCTCTGATGAAGTGAATAATGATATCTGACTAGTG 962
QY 903 GGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATATATGATGATACATTACAA 962
Db 963 GGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATATATGATGATACATTACAA 1022
QY 963 AAATAAAGCGGGAATTTCCCTTCGCTTGAATTAATTAATCCCTGTATATTCGATCAATGA 1022
Db 1023 AAATAAAGCGGGAATTTCCCTTCGCTTGAATTAATTAATCCCTGTATATTCGATCAATGA 1082
QY 1023 GAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTGAATTTCTTAAGCATAAAG 1082
Db 1083 GAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTGAATTTCTTAAGCATAAAG 1142
QY 1083 TAAACATGATATAAATAATATATGCTGAATTAATCTGCTGAAGTAATGATTAAGCATAAAG 1142
Db 1143 TAAACATGATATAAATAATATATGCTGAATTAATCTGCTGAAGTAATGATTAAGCATAAAG 1202
QY 1143 AAATGCTGTTTTATTTGTAAGACATTAATTAATTAAGTAATGCTTATTAATGCTTACTGTT 1202
Db 1203 AAATGCTGTTTTATTTGTAAGACATTAATTAATTAAGTAATGCTTATTAATGCTTACTGTT 1262
QY 1203 CTAATCTGGTGAAGGTATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACTGA 1262
Db 1263 CTAATCTGGTGAAGGTATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACTGA 1322
QY 1263 ATGAGAAATATGATTAACCATCTGCTGTTTCTTATGTCGAATTAAGCATAAAGCATCTGA 1322
Db 1323 ATGAGAAATATGATTAACCATCTGCTGTTTCTTATGTCGAATTAAGCATAAAGCATCTGA 1382
QY 1323 AATTAAGA 1330
Db 1383 AATTAAGA 1390

RESULT 2

US-09-365-705-2

; Sequence 2, Application US/09365705

; Patent No. 6348576

GENERAL INFORMATION:

; APPLICANT: Hillman, Jennifer L.

; Corley, Neil C.

; Shah, Purvi

; TITLE OF INVENTION: HUMAN CORNICHON PROTEIN

; NUMBER OF SEQUENCES: 3

CORRESPONDENCE ADDRESS:

; ADDRESSEE: Incyte Pharmaceuticals, Inc.

; STREET: 3174 Porter Drive

; CITY: Palo Alto

; STATE: CA

; COUNTRY: USA

; ZIP: 94304

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION NUMBER: US/09/365,705
; FILING DATE: 02-Aug-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/950,168
; FILING DATE: 14-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy J.
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0401 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-855-0555
; TELEFAX: 650-845-4166
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1391 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: BLADNOT04
; CLONE: 1318847
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-365-705-2

Query Match 98.8%; Score 1316.8; DB 4; Length 1391;
Best Local Similarity 99.5%; Pred. No. 0;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 3 CCACGGCTCCGATGGCGTTCACGTTCCGGCGCTTCGCTACATGCTGGCGCTGCTGCTCA 62
Db 63 CCTCCCGAGCATGGCGTTCACGTTCCGGCGCTTCGCTACATGCTGGCGCTGCTGCTCA 122
QY 63 CTGCGCGGCTCATCTCTTCGCCATTTCGGCACATTATAGCATTTGATGAGCTGAAGACTG 122
Db 123 CTGCGCGGCTCATCTCTTCGCCATTTCGGCACATTATAGCATTTGATGAGCTGAAGACTG 182
QY 123 ATTAACAAGATCCATATAGACCCAGTGTAAATACCCCTGTAATCCCTTGTACTCCAGAGTACC 182
Db 183 ATTAACAAGATCCATATAGACCCAGTGTAAATACCCCTGTAATCCCTTGTACTCCAGAGTACC 242
QY 183 TCATCCAGGCTTCTCTCTGCTGATGTTCTTTGTCAGCAGAGTGGCTTACATGGGTC 242
Db 243 TCATCCAGGCTTCTCTCTGCTGATGTTCTTTGTCAGCAGAGTGGCTTACATGGGTC 302
QY 243 TCAATATGCCCTCTTCGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGATG 302
Db 303 TCAATATGCCCTCTTCGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGATG 362
QY 303 GCCCAGGACTCTATGACCCCTACAAACCATCATGAATGCAGATATTCTAGCATATTGTCAGA 362
Db 363 GCCCAGGACTCTATGACCCCTACAAACCATCATGAATGCAGATATTCTAGCATATTGTCAGA 422
QY 363 AGGAAGGATGGTGCATAATAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGSCA 422
Db 423 AGGAAGGATGGTGCATAATAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGSCA 482
QY 423 TGATCTATGTTTGGTGGAGCTCTTTAGAACCAACACACAGAGAAATGGTCCAGTTAAGTGC 482
Db 483 TGATCTATGTTTGGTGGAGCTCTTTAGAACCAACACACAGAGAAATGGTCCAGTTAAGTGC 542
QY 483 ATGCAAAAAGCCACCAATGAAGGATTCATATCCAGCAGAGATCTCTGTCGAAGTAGCCT 542
Db 543 ATGCAAAAAGCCACCAATGAAGGATTCATATCCAGCAGAGATCTCTGTCGAAGTAGCCT 602
QY 543 GTGGAACTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACATTT 602
Db 603 GTGGAACTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACATTT 662
QY 603 TTGCTGTGGAAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTATTA 662

Db 663 TTGCTTGTGGAAGACGCTTTTCATATCTATATCTCAGATAAAGATTTAAATGGTATTA 722
QY 663 CGTATAAATTAATATAAATGATTACCTCTGGTGTGACAGTTTGAACCTTGGCACTTTCT 722
Db 723 CGTATAAATTAATATAAATGATTACCTCTGGTGTGACAGTTTGAACCTTGGCACTTTCT 782
QY 723 AAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATGATGCTGCTAGTACATTTGA 782
Db 783 AAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATGATGCTGCTAGTACATTTGA 842
QY 783 AGCTTTTGTATAGGAACCTTGTAGGCTCAATTTTGGTTTCATTTGAAACAGTATCTAATT 842
Db 843 AGCTTTTGTATAGGAACCTTGTAGGCTCAATTTTGGTTTCATTTGAAACAGTATCTAATT 902
QY 843 ATAAATTAAGCTGATAGATCAGGCTCTCTGATGAAGTGAATTAATTAATGATGCTAGTG 902
Db 903 ATAAATTAAGCTGATAGATCAGGCTCTCTGATGAAGTGAATTAATTAATGATGCTAGTG 962
QY 903 GGAAACTTCATGGGTTTCCCTCATCTGTCATGTCGATGCAATTAATTAATGATGCTAGTG 962
Db 963 GGAAACTTCATGGGTTTCCCTCATCTGTCATGTCGATGCAATTAATTAATGATGCTAGTG 1022
QY 963 AAATAAAGGCGGAATTTCCCTTCGCTTGAATTAATTAATGATGCTAGTG 1022
Db 1023 AAATAAAGGCGGAATTTCCCTTCGCTTGAATTAATTAATGATGCTAGTG 1082
QY 1023 GAGATTTCCCATATTTCCATCAGAGTAAATTAATTAATGATGCTAGTG 1082
Db 1083 GAGATTTCCCATATTTCCATCAGAGTAAATTAATTAATGATGCTAGTG 1142
QY 1083 TAAACATGATATAAATAATATATGCTGAATTAATTAATGATGCTAGTG 1142
Db 1143 TAAACATGATATAAATAATATATGCTGAATTAATTAATGATGCTAGTG 1202
QY 1143 AAATGTGTTTATTTGTAAGACATTAATTAATTAATGATGCTAGTG 1202
Db 1203 AAATGTGTTTATTTGTAAGACATTAATTAATTAATGATGCTAGTG 1262
QY 1203 CTAACTGGTGTAAAGTATTTCTTAAGATTTGAGTACTACAGATTTTCAAACTGA 1262
Db 1263 CTAACTGGTGTAAAGTATTTCTTAAGATTTGAGTACTACAGATTTTCAAACTGA 1322
QY 1263 ATGAGAAAATTTGTAATACCATCTGCTGTTTCTTAAATTAATTAATGATGCTAGTG 1322
Db 1323 ATGAGAAAATTTGTAATACCATCTGCTGTTTCTTAAATTAATTAATGATGCTAGTG 1382
QY 1323 AATTAAGA 1330
Db 1383 AATTAAGA 1390

RESULT 3

US-09-257-179-34
; Sequence 34, Application US/09257179
; Patent No. 6410709
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: 29 Human Secreted Proteins
; FILE REFERENCE: PZO15PI
; CURRENT APPLICATION NUMBER: US/09/257,179
; CURRENT FILING DATE: 1999-02-25
; EARLIER APPLICATION NUMBER: PCT/US98/17709
; EARLIER FILING DATE: 1998-08-27
; EARLIER APPLICATION NUMBER: 60/056,270
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,271
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,247
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,073
; EARLIER FILING DATE: 1997-08-29
; NUMBER OF SEQ ID NOS: 128

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 34

; LENGTH: 1404

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: SITE

; LOCATION: (36)

; OTHER INFORMATION: n equals a,t,g, or c

US-09-257-179-34

Query Match 98.8%; Score 1316.4; DB 4; Length 1404;
Best Local Similarity 99.5%; Pred. No. 0;
Matches 1320; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 3 CCACGGCTCCAGTGGGCTTCAAGTTCCGGGCTCTCTGCTACATGCTGGCGCTGCTGCTCA 62
Db 52 CCTCCAGCCATGGCGTTTCAAGTTCCGGGCTCTCTGCTACATGCTGGCGCTGCTGCTCA 111
QY 63 CTGCGGCTCATCTTCTTCCGCAATTTGGCACATTTAGCATTTGATGAGCTGAAGACTG 122
Db 112 CTGCGGCTCATCTTCTTCCCAATTTGGCACATTTAGCATTTGATGAGCTGAAGACTG 171
QY 123 ATTACAAGATCCCTATAGACCAAGTGAATACCCCTGAATCCCTTGTACTCCCAAGTACC 182
Db 172 ATTACAAGATCCCTATAGACCAAGTGAATACCCCTGAATCCCTTGTACTCCCAAGTACC 231
QY 183 TCATCCAGCTTCTTCTGCTCATGTTCTTTGTCAGCAGAGTGGCTTACATCTGGGTC 242
Db 232 TCATCCAGCTTCTTCTGCTCATGTTCTTTGTCAGCAGAGTGGCTTACATCTGGGTC 291
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGTATATGAGTATGAGTATGAGTATGAGT 302
Db 292 TCAATATGCCCTCTTGGCATATCATATTTGGAGTATATGAGTATGAGTATGAGTATGAGT 351
QY 303 GCCCAGACTCTATGACCCCTACAACCATCATCAATGAGATATTTCTAGCATTTTGTCTAGA 362
Db 352 GCCCAGACTCTATGACCCCTACAACCATCATCAATGAGATATTTCTAGCATTTTGTCTAGA 411
QY 363 AGGAAGATGCTGCAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTTCTAGCAT 422
Db 412 AGGAAGATGCTGCAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTTCTAGCAT 471
QY 423 TGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAAGTC 482
Db 472 TGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAAGTC 531
QY 483 ATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAGAGTAGCCT 542
Db 532 ATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAGAGTAGCCT 591
QY 543 GTGGAATCTGATCAGTTACTTTAAATAATGATCTTTTAAATGTTTAAATGTTTCCACATTT 602
Db 592 GTGGAATCTGATCAGTTACTTTAAATAATGATCTTTTAAATGTTTAAATGTTTCCACATTT 651
QY 603 TTGCTTGTGAAAGACTGTTTTCATATGTTTATCTACAGATAAAGATTTAAATGTTTAA 662
Db 652 TTGCTTGTGAAAGACTGTTTTCATATGTTTATCTACAGATAAAGATTTAAATGTTTAA 711
QY 663 CGTATAAATTAATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTCTT 722
Db 712 CGTATAAATTAATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTCTT 771
QY 723 AAGGAACAGCCATATCTCTGATGATGCAATTAATTAATGATGCTGCTAGTACATTTGA 782
Db 772 AAGGAACAGCCATATCTCTGATGATGCAATTAATTAATGATGCTGCTAGTACATTTGA 831
QY 783 AGCTTTTGTATAGGAACCTTGTAGGCTCAATTTTGGTTTCTTCAATTTGAAACAGTATCTA 842
Db 832 AGCTTTTGTATAGGAACCTTGTAGGCTCAATTTTGGTTTCTTCAATTTGAAACAGTATCTA 891
QY 843 ATAAATTAAGCTGATATCAGGCTTCTGATGAAGTGAATGATATCTAGTACTAGT 902

Db 892 ATAAATTAGCTGTAGATATCAGCTGCTCTCTGATGAGTGAATGTATATCTGACTAGTG 951
QY 903 GGAACTTTCATGGTTTCCCTCATCTCTCATGTCGATGATATATATGATACATTACAA 962
Db 952 GGAACTTTCATGGTTTCCCTCATCTCTCATGTCGATGATATATATGATACATTACAA 1011
QY 963 AAATAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAATGA 1022
Db 1012 AAATAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAATGA 1071
QY 1023 GAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTGGCTTTAAATCTTAAGCATAAG 1082
Db 1072 GAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTGGCTTTAAATCTTAAGCATAAG 1131
QY 1083 TAAACATGATATAAAATATATGCTGAATTTCTTGTGAAGATGCAATTTAAAGCTATTTT 1142
Db 1132 TAAACATGATATAAAATATATGCTGAATTTCTTGTGAAGATGCAATTTAAAGCTATTTT 1191
QY 1143 AAATGTGTTTTTATTTGTGAAGACATTACTTATTAGAAATTTGGTTATTTATGCTTACTGTT 1202
Db 1192 AAATGTGTTTTTATTTGTGAAGACATTACTTATTAGAAATTTGGTTATTTATGCTTACTGTT 1251
QY 1203 CTAATCTGTGTGTAAGGTATTTCTTAAGAAATTTGCGAGGTACTACAGATTTTCAAAACTGA 1262
Db 1252 CTAATCTGTGTGTAAGGTATTTCTTAAGAAATTTGCGAGGTACTACAGATTTTCAAAACTGA 1311
QY 1263 ATCAGAGAAAATTTGTATAACCATCTCTGCTGTTCCCTTTAGTGCATATACATTAACCTCTGA 1322
Db 1312 ATGAGAGAAAATTTGTATAACCATCTCTGCTGTTCCCTTTAGTGCATATACATTAACCTCTGA 1371
QY 1323 AATTAA 1328
Db 1372 AATTAA 1377

Search completed: June 14, 2004, 18:58:03
Job time : 117 secs